Medical Knowledge Self-Assessment Program
Cumulative Index
速
Cumulative Index
Cumulative Index
Editor-in-Chief Patrick C. Alguire, MD, FACP1 Senior Vice President, Medical Education American College of Physicians Philadelphia, Pennsylvania
Deputy Editor-in-Chief
Temple University Medical School Philadelphia, Pennsylvania Howard H. Weitz, MD, FACP1 Professor of Medicine Director, Jefferson Heart Institute Director, Division of Cardiology Jefferson Medical College of Thomas Jefferson University Philadelphia, Pennsylvania
Philip A. Masters, MD, FACP1 Senior Medical Associate for Content Development American College of Physicians Philadelphia, Pennsylvania
ACP Principal Staff
Senior Medical Associate for Content Development
D. Theresa Kanya, MBA1 Vice President, Medical Education
Cynthia D. Smith, MD, FACP2 American College of Physicians Philadelphia, Pennsylvania
Sean McKinney1 Director, Self-Assessment Programs Margaret Wells1 Managing Editor
Associate Editors MACP2
Virginia U. Collier, MD, Hugh R. Sharp, Jr. Chair of Medicine Christiana Care Health System Newark, Delaware Professor of Medicine Jefferson Medical College of Thomas Jefferson University Philadelphia, Pennsylvania 1
Richard S. Eisenstaedt, MD, FACP Professor of Medicine Temple University School of Medicine Chair, Department of Medicine Abington Memorial Hospital Abington, Pennsylvania Jack Ende, MD, MACP1 Professor of Medicine University of Pennsylvania Chief, Department of Medicine Penn Presbyterian Medical Center Philadelphia, Pennsylvania 1
Thomas Fekete, MD, FACP Professor of Medicine Section of Infectious Diseases
ii
Patrick C. Alguire, MD, FACP1 Senior Vice President, Medical Education
Valerie Dangovetsky1 Program Administrator Becky Krumm1 Senior Staff Editor Ellen McDonald, PhD1 Senior Staff Editor Katie Idell1 Senior Staff Editor Randy Hendrickson1 Production Administrator/Editor Megan Zborowski1 Staff Editor Linnea Donnarumma1 Assistant Editor John Haefele1 Assistant Editor Developed by the American College of Physicians _______________________________________________________________________ 1. Has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. 2. Has disclosed relationships with entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. See below.
Conflicts of Interest
ABIM Maintenance of Certification
The following committee members, reviewers, and ACP staff members have disclosed relationships with commercial companies:
Check the MKSAP Resource Site (mksap.acponline.org) for the latest information on how MKSAP tests can be used to apply to the American Board of Internal Medicine for MOC points.
Virginia U. Collier, MD, MACP Stock Options/Holdings Celgene, Pfizer, Merck, Schering-Plough, Abbott, Johnson and Johnson, Medtronic, McKesson, Amgen Cynthia D. Smith, MD, FACP Stock Options/Holdings Merck and Company
Acknowledgments The American College of Physicians (ACP) gratefully acknowledges the special contributions to the development and production of the 16th edition of the Medical Knowledge Self-Assessment Program® (MKSAP® 16) made by the following people: Graphic Services: Michael Ripca (Technical Administrator/Graphics Designer) and Willie-Fetchko Graphic Design (Graphic Designer). Production/Systems: Dan Hoffmann (Director, Web Services & Systems Development), Neil Kohl (Senior Architect), and Scott Hurd (Senior Systems Analyst/Developer). MKSAP 16 Digital: Under the direction of Steven Spadt, Vice President, ACP Digital Products & Services, the digital version of MKSAP 16 was developed within the ACP’s Digital Product Development Department, led by Brian Sweigard (Director). Other members of the team included Sean O’Donnell (Senior Architect), Dan Barron (Senior Systems Analyst/Developer), Chris Forrest (Senior Software Developer/Design Lead), Jon Laing (Senior Web Application Developer), Brad Lord (Senior Web Developer), John McKnight (Senior Web Developer), and Nate Pershall (Senior Web Developer). The College also wishes to acknowledge that many other persons, too numerous to mention, have contributed to the production of this program. Without their dedicated efforts, this program would not have been possible.
RCPSC Maintenance of Certification In Canada, MKSAP 16 is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada (RCPSC) and approved by the Canadian Society of Internal Medicine on December 9, 2011. Approval of Part A sections of MKSAP 16 extends from July 31, 2012, until July 31, 2015. Approval of Part B sections of MKSAP 16 extends from December 31, 2012, to December 31, 2015. Fellows of the Royal College may earn three credits per hour for participating in MKSAP 16 under Section 3. MKSAP 16 will enable Fellows to earn up to 75% of their required 400 credits during the 5-year MOC cycle. A Fellow can achieve this 75% level by earning 100 of the maximum of 174 AMA PRA Category 1 Credits™ available in MKSAP 16. MKSAP 16 also meets multiple CanMEDS Roles for RCPSC MOC, including that of Medical Expert, Communicator, Collaborator, Manager, Health Advocate, Scholar, and Professional. For information on how to apply MKSAP 16 CME credits to RCPSC MOC, visit the MKSAP Resource Site at mksap.acponline.org.
The Royal Australasian College of Physicians CPD Program In Australia, MKSAP 16 is a Category 3 program that may be used by Fellows of The Royal Australasian College of Physicians (RACP) to meet mandatory CPD points. Two CPD credits are awarded for each of the 174 AMA PRA Category 1 Credits™ available in MKSAP 16. More information about using MKSAP 16 for this purpose is available at the MKSAP Resource Site at mksap.acponline.org and at www.racp.edu.au. CPD credits earned through MKSAP 16 should be reported at the MyCPD site at www.racp.edu.au/mycpd.
Continuing Medical Education Introducing the MKSAP Resource Site (mksap.acponline.org) The MKSAP Resource Site (mksap.acponline.org) is a continually updated site that provides links to MKSAP 16 online answer sheets for print subscribers; access to MKSAP 16 Digital, Board Basics® 3, and MKSAP 16 Updates; the latest details on Continuing Medical Education (CME) and Maintenance of Certification (MOC) in the United States, Canada, and Australia; errata; and other new information.
The American College of Physicians is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Physicians designates this enduring material, MKSAP 16, for a maximum of 174 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. iii
Learning Objectives The learning objectives of MKSAP 16 are to: • Close gaps between actual care in your practice and preferred standards of care, based on best evidence • Diagnose disease states that are less common and sometimes overlooked and confusing • Improve management of comorbid conditions that can complicate patient care • Determine when to refer patients for surgery or care by subspecialists • Pass the ABIM Certification Examination • Pass the ABIM Maintenance of Certification Examination
Target Audience • General internists and primary care physicians • Subspecialists who need to remain up-to-date in internal medicine • Residents preparing for the certifying examination in internal medicine • Physicians preparing for maintenance of certification in internal medicine (recertification)
Earn ‘Same-Day’ CME Credits Online For the first time, print subscribers can enter their answers online to earn CME credits in 24 hours or less. You can submit your answers using online answer sheets that are provided at mksap.acponline.org, where a record of your MKSAP 16 credits will be available. To earn CME credits, you need to answer all of the questions in a test and earn a score of at least 50% correct. (Number of correct answers divided by the total number of questions.) Take any of the following approaches: 1. Use the printed answer sheet at the back of this book to record your answers. Go to mksap.acponline.org, access the appropriate online answer sheet, transcribe your answers, and submit your test for same-day CME credits. There is no additional fee for this service. 2. Go to mksap.acponline.org, access the appropriate online answer sheet, directly enter your answers, and submit your test for same-day CME credits. There is no additional fee for this service. 3. Pay a $10 processing fee per answer sheet and submit the printed answer sheet at the back of this book by mail or fax, as instructed on the answer sheet. Make sure you calculate your score and fax the answer sheet to 215-3512799 or mail the answer sheet to Member and Customer Service, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106-1572, using the courtesy envelope provided in your MKSAP 16 slipcase. You will need your 10-digit order number and 8-digit ACP ID number, which are iv
printed on your packing slip. Please allow four to six weeks for your score report to be emailed back to you. Be sure to include your email address for a response. If you do not have a 10-digit order number and 8-digit ACP ID number or if you need help creating a username and password to access the MKSAP 16 online answer sheets, go to mksap.acponline.org or email custserv@ acponline.org.
Disclosure Policy It is the policy of the American College of Physicians (ACP) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. To this end, and consistent with the policies of the ACP and the Accreditation Council for Continuing Medical Education (ACCME), contributors to all ACP continuing medical education activities are required to disclose all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Contributors are required to use generic names in the discussion of therapeutic options and are required to identify any unapproved, off-label, or investigative use of commercial products or devices. Where a trade name is used, all available trade names for the same product type are also included. If trade-name products manufactured by companies with whom contributors have relationships are discussed, contributors are asked to provide evidence-based citations in support of the discussion. The information is reviewed by the committee responsible for producing this text. If necessary, adjustments to topics or contributors’ roles in content development are made to balance the discussion. Further, all readers of this text are asked to evaluate the content for evidence of commercial bias and send any relevant comments to mksap_editors@acponline.org so that future decisions about content and contributors can be made in light of this information.
Resolution of Conflicts To resolve all conflicts of interest and influences of vested interests, the ACP precluded members of the content-creation committee from deciding on any content issues that involved generic or trade-name products associated with proprietary entities with which these committee members had relationships. In addition, content was based on best evidence and updated clinical care guidelines, when such evidence and guidelines were available. Contributors’ disclosure information can be found with the list of contributors’ names and those of ACP principal staff listed in the beginning of this book.
Educational Disclaimer The editors and publisher of MKSAP 16 recognize that the development of new material offers many opportunities for error. Despite our best efforts, some errors may persist in print. Drug dosage schedules are, we believe, accurate and in accordance with current standards. Readers are advised, however, to ensure that the recommended dosages in MKSAP 16 concur with the information provided in the product information material. This is especially important in cases of new, infrequently used, or highly toxic drugs. Application of the information in MKSAP 16 remains the professional responsibility of the practitioner. The primary purpose of MKSAP 16 is educational. Information presented, as well as publications, technologies, products, and/or services discussed, is intended to inform subscribers about the knowledge, techniques, and experiences of the contributors. A diversity of professional opinion exists, and the views of the contributors are their own and not those of the ACP. Inclusion of any material in the program does not constitute endorsement or recommendation by the ACP. The ACP does not warrant the safety, reliability, accuracy, completeness, or usefulness of and disclaims any and all liability for damages and claims that may result from the use of information, publications, technologies, products, and/or services discussed in this program.
Publisher’s Information Copyright © 2012 American College of Physicians. All rights reserved. This publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or mechanical, including photocopy, without the express consent of the ACP. MKSAP 16 is for individual use only. Only one account per subscription will be permitted for the purpose of earning CME credits and MOC points/credits and for other authorized uses of MKSAP 16.
19106-1572, or email your request to mksap_editors@acponline.org. MKSAP 16 ISBN: 978-1-938245-00-8 Printed in the United States of America. For order information in the U.S. or Canada call 800523-1546, extension 2600. All other countries call 215351-2600. Fax inquiries to 215-351-2799 or email to custserv@acponline.org.
Errata and Norm Tables Errata for MKSAP 16 will be available through the MKSAP Resource Site at mksap.acponline.org as new information becomes known to the editors. MKSAP 16 Performance Interpretation Guidelines with Norm Tables, available July 31, 2013, will reflect the knowledge of physicians who have completed the selfassessment tests before the program was published. These physicians took the tests without being able to refer to the syllabus, answers, and critiques. For your convenience, the tables will be made available in a printable PDF file at the MKSAP Resource Site at mksap.acponline.org.
Interpretation Key Each of the 11 books of MKSAP 16 is page-numbered individually beginning with number 1. Each entry of the cumulative index consists of the page number on which a particular term appears, followed, in parentheses, by a two-letter code designating the particular book. For example, in the index entry: Amoxicillin for H. pylori infection, 15(GI), 16t(GI) for infective endocarditis prophylaxis, 8(ID)
15(GI) refers to page 15 of the Gastroenterology and Hepatology syllabus; 16t(GI) refers to a table on page 16 of the Gastroenterology and Hepatology syllabus; and 8(ID) refers to page 8 of the Infectious Disease syllabus
Unauthorized Use of This Book Is Against the Law Unauthorized reproduction of this publication is unlawful. The ACP prohibits reproduction of this publication or any of its parts in any form either for individual use or for distribution. The ACP will consider granting an individual permission to reproduce only limited portions of this publication for his or her own exclusive use. Send requests in writing to MKSAP® Permissions, American College of Physicians, 190 North Independence Mall West, Philadelphia, PA
The codes for the books are as follows: CV DM EN GA GIM HO ID NP NR PM RM
= Cardiovascular Medicine = Dermatology = Endocrinology and Metabolism = Gastroenterology and Hepatology = General Internal Medicine = Hematology and Oncology = Infectious Disease = Nephrology = Neurology = Pulmonary and Critical Care Medicine = Rheumatology
v
Cumulative Index
Note: Page numbers followed by f and t denote figures and tables, respectively. Test questions are indicated by Q. Abatacept immunization and, 12(RM), Q58(RM) for rheumatic disease, 13t(RM) for rheumatoid arthritis, 13(RM) ABCDE method, for pigmented lesion diagnosis, 3(DM), 37(DM) ABCD2 score, in stroke, 26(NR), 28(NR), 29t(NR), 38–39(NR), Q86(NR) Abdomen, acute, 90(PM), 92(PM), 92t(PM) Abdominal aortic aneurysms, 96–97(CV), 97t(CV), Q81(CV) screening for, 7t(GIM), 8(GIM), Q151(GIM) surgical repair of, 128(GIM) Abdominal fat pad aspiration, in amyloid light chain amyloidosis, 16(HO), Q40(HO) Abdominal pain in Campylobacter infections, 67(ID) in Clostridium difficile diarrhea, 70(ID) in Escherichia coli diarrhea, 68(ID) in malaria, 61(ID), 62(ID) in pelvic inflammatory disease, 44(ID), Q26(ID) in salmonellosis, 67(ID) in typhoid fever, Q75(ID) Abdominal surgical emergencies, acute, 90(PM), 92(PM), 92t(PM) ABO compatibility, 36–37(HO), 36t(HO), 38–39(HO) Abortifacients, 86(GIM) Abscesses anorectal, 108(GIM) of brain, 6–7(ID), 7t(ID), Q80(ID) colonic, in colorectal cancer, 52(GA) epidural, 65(NR) hepatic, 68(GA) in amebiasis, 72(ID) intra-abdominal, fever of unknown origin in, 53(ID), 54(ID) intrarenal, 30(ID) in methicillin-resistant Staphylococcus aureus infections, 14(ID) pelvic, fever of unknown origin in, 53(ID), 54(ID) perinephric, 30(ID) pulmonary, 7t(ID) spinal epidural, 8(ID), Q66(ID) staphylococcal, 13(ID), 22(DM), 23(DM), 23f(DM) vs. epidermal inclusion cysts, 42(DM) Absence seizures, 14(NR) Absolute neutrophil count (ANC), 4(HO) Absolute risk (AR), 3(GIM), 3t(GIM), Q58(GIM) Absolute risk reduction (ARR), 3(GIM), 3t(GIM), 4(GIM) Acalculous cholecystitis, 72(GA), Q80(GA) Acanthocytes, 5f(NP), 5(NP) in hematuria, 7(NP), Q40(NP) Acantholytic dermatosis (Grover disease), 17(DM), 17f(DM), Q59(DM) Acanthosis, in pityriasis rosea, 14(DM) Acarbose, 8t(EN) colitis and, Q89(GA) Accountable care organizations (ACOs), 6t(GIM) Acebutolol, contraindication in heart failure, 33(CV) ACE inhibitors action mechanism of, 38f(NP) acute kidney injury and, 83(NP) for Alport syndrome, Q59(NP) angioedema and, 85(PM), Q78(PM) in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) cardioprotective effects of, 17(CV), 86(NP) for chronic kidney disease, 83(NP), 85(NP), 86(NP) combined with angiotensin receptor blockers, 85(NP), Q39(NP) calcium channel blockers, 40(NP), 83(NP) contraindications to, 40t(NP), 42(NP) for coronary artery disease, 17(CV) cough and, 37(GIM), Q1(PM), Q81(GIM) for diabetes mellitus prevention, 4t(EN), 6(EN) in type 2 diabetes mellitus, Q71(NP) for focal segmental glomerulosclerosis, 51(NP) for heart failure, 32(CV), 33(CV), 33t(CV), 34(CV), 35–36(CV), 38(CV), Q24(CV), Q36(CV) for hepatitis B virus-associated kidney disease, 56(NP) hyperkalemia and, 21(NP) for immunoglobulin A nephropathy, 57(NP) indications for, 40t(NP) intolerance to, Q102(CV) as lichen planus cause, 11(DM), 12(DM) for lupus nephritis, 60(NP) for membranous glomerulopathy, 52f(NP), Q64(NP) for mitral regurgitation, 80(CV) for peripartum cardiomyopathy, 107(CV) for proteinuric kidney disease, 7(NP) for scleroderma renal crisis, 44(RM), Q42(RM) serum creatinine increase and, Q91(NP) side effects of, 40t(NP) for ST-elevation myocardial infarction, 23(CV), 25(CV), 111(CV) for systemic sclerosis, in pregnancy, 45(RM) teratogenicity of, 43(NP), 78–79(NP), 79t(NP), 81(NP), 108t(CV), 111(CV), Q70(NP), Q97(NP) for thrombotic microangiography, 62(NP) Acetaminophen adverse effects of, 10(RM) chronic kidney disease and, 46(NP) hepatotoxicity of, 57(GA), 58(GA), 65(GA)
for osteoarthritis, 26(RM) overdose of, 90(PM), 91t(PM) for plantar fasciitis, Q167(GIM) in pregnancy, 8(NR), Q53(NR) pyroglutamic acidosis and, 26(NP), Q93(NP) for rheumatic disease, 10(RM) for tension-type headaches, 9(NR) use in cirrhosis, 70(GA) use in liver disease, 35(GIM) use in older patients, 35(GIM), Q144(GIM) Acetazolamide contraindication in salicylate toxicity, Q66(NP) for high-altitude illness prevention, Q52(PM) metabolic acidosis and, Q34(NP) for metabolic alkalosis, Q9(NP) for urine alkalinization, Q34(NP) Acetoacetate, interaction with serum creatinine, 1(NP) N-Acetylcysteine for contrast-induced nephrotoxicity prevention, 69(NP), 90(NP) for drug-induced liver disease, 57(GA), 65(GA) Achalasia, 3–4(GA), 4f(GA), 5f(GA), Q87(GA), Q92(GA) esophageal obstruction and, 3(GA), Q92(GA) Achilles tendon rupture of, 62(GIM) tendinopathy of, 61–62(GIM) Acid-base balance, in pregnancy, 77(NP) Acid-base disorders, 22-33(NP). See also Acidosis; Alkalosis compensation in, 23(NP), 23t(NP) general approach in, 22–23(NP) pH in, 22(NP) primary, 22–23(NP) Acid-fast bacilli smears, 34(ID) Acidosis acute-on-chronic respiratory, 81(PM) metabolic anion gap, 23(NP), 24–27(NP), 24t(NP), Q7(NP), Q57(NP), Q66(NP) in chronic kidney disease, 84–85(NP), Q22(NP) in chronic tubulointerstitial disease, 44t(NP) classification of, 23–30(NP) compensation in, 23t(NP) definition of, 22–23(NP) D-lactic, 24–25(NP), 24t(NP) evaluation of, 23(NP) in HIV/AIDS, 90(ID) lactic, 24t(NP), 32(NP), Q76(NP) lactic, type B, Q93(NP) non-anion gap, 44t(NP) normal anion gap in, 27–30(NP), 28f(NP), Q17(NP) in salicylate toxicity, Q66(NP) pyroglutamic, 26(NP), Q93(NP) renal tubular, 27(NP) evaluation of, 29f(NP) hyperkalemic distal (type 4), 28–29(NP), 29f(NP), 30(NP) hypokalemic distal (type 1), 27–28(NP), 30(NP), Q17(NP), Q45(NP) mixed forms of, 29–30(NP) proximal (type 2), 27(NP), 28t(NP), 29t(NP), 30(NP), Q17(NP), Q76(NP) urine pH in, 3(NP) respiratory, 31–32(NP) causes of, 31t(NP) compensation in, 23t(NP) definition of, 22(NP) treatment of, 32(NP) Acid regurgitation, in esophageal disorders, 2–3(GA) Acid suppression, for short-bowel syndrome, 33–34(GA), Q39(GA) Acinetobacter baumannii infections, 83(DI), 84(ID), 99(ID), 100(ID) carbapenem-resistant, 83(ID) treatment for, 84(ID), 99(ID), 100(ID), Q96(ID) Aclidinium, for chronic obstructive pulmonary disease, 22t(PM) Acne fulminans, 19(DM) Acneiform lesions/acne, 18–21(DM) chemotherapy-related, 58(DM) differential diagnosis of, 19t(DM) in polycystic ovary syndrome, 60(DM) treatment of, 19–21(DM), 19t(DM), 20t(DM) Acne keloidalis nuchae, 77(DM), 77f(DM) Acne vulgaris, 19t(DM) Acquired immunodeficiency syndrome (AIDS). See HIV/AIDS Acquired platelet dysfunction, 52–53(HO) Acquired renal cystic disease, in chronic kidney disease, 92(NP) Acrochordons, 40(DM) Acrodermatitis atrophicans, 4t(RM) Acromegaly, 6t(RM), 24t(EN), 25–26(EN) diabetes mellitus and, 1t(EN), 5(EN) diagnosis of, Q7(EN), Q74(EN) familial, 25(EN) pituitary adenomas and, 24t(EN) sellar masses and, 21(EN) transsphenoidal surgery for, 25(EN), Q83(EN) treatment of, 24t(EN), 25–26(EN), Q83(EN) Acromioclavicular joint, degeneration of, 56(GIM), Q26(GIM) ACTH. See Adrenocorticotropic hormone Actinic cheilitis, 71(DM), 71f(DM), 72f(DM), Q13(DM) Actinic keratoses, 35–36(DM), 35f(DM), 75–76(DM), 75f(DM), Q71(DM) Actinomyces, 25(DM)
1
Cumulative Index
Activated partial thromboplastin time, 43(HO), 44t–45t(HO) in hemophilia, Q8(HO) in heparin dosing, 57t(HO), 59(HO) in thrombocytopenia, 48(HO) Activities of daily living (ADLs), 116–117(GIM), 117t(GIM) Actretin contraindication during pregnancy and lactation, 4t(DM) for lichen planus, 12(DM) for psoriasis, 11(DM) Acupuncture, 35(GIM) Acute abdominal surgical emergencies, 90(PM), 92(PM), 92t(PM) Acute acalculous cholecystitis, 72(GA) Acute aortic disease, 95–96(CV), 95f(CV) Acute chest syndrome, of sickle cell disease, 30–31(HO), 32(HO), Q62(HO) Acute cholecystitis, 71–72(GA) Acute coronary syndromes, 19-28(CV). See also Angina pectoris; Myocardial infarction, non-ST-elevation; Myocardial infarction, ST-elevation chest pain in, 48(GIM), 49(GIM), Q101(GIM) classification of, 19–20(CV) clinical presentation of, 19–20(CV), Q50(CV) diagnosis of, 19f(CV) hospitalization for, 49(GIM) quality of care core measures for, 3(CV) treatment of, 20–26(CV), 28(CV) in women, 30(CV) Acute Dialysis Quality Initiative, 65(NP) Acute disseminated encephalomyelitis, 59(NR) Acute fatty liver of pregnancy, 64t(HO), 68–69(GA), 69t(GA) Acute generalized exanthematous pustulosis (AGEP), 16(DM) Acute hemolytic transfusion reaction, 39–40(HO), 41(HO) Acute inflammatory demyelinating polyneuropathy, 74(PM) Acute Kidney Injury Network (AKIN), 65(NP), 66t(NP) Acute limb ischemia, 101–102(CV), 102t(CV), Q85(CV) Acute mesenteric ischemia, 43–44(GA), 45(GA), Q7(GA) Acute mountain sickness, 69(PM), 70(PM), Q52(PM) Acute myeloid leukemia, 5(HO), Q39(HO) Acute pancreatitis, 23(GA), 23t(GA), 24f(GA), Q54(GA), Q86(GA) Acute Physiologic and Chronic Health Evaluation (APACHE) score, 24(GA), 95(PM) Acute respiratory distress syndrome (ARDS), 70–72(PM) amiodarone and, Q16(PM) Berlin diagnostic criteria for, 70–71(PM) causes of, 71(PM), 71t(PM) diagnosis of, 70–71(PM), Q70(PM) differential diagnosis of, 72(PM) hypercapnic, 72–73(PM) in hyperthermic emergencies, 86(PM) intubation in, 79(PM) management of, 71–72(PM), 71t(PM), Q76(PM), Q82(PM) with mechanical ventilation, 71(PM), 80(PM), Q47(PM) in pneumonia, 34(PM), 71t(PM), 72(PM) sepsis in, 84(PM) tidal volume in, Q103(PM) Acute retroviral syndrome, 86(ID), 86t(ID), Q99(ID) Acute toxic inhalation syndromes, 39(PM), 84–85(PM) Acute tubular necrosis (ATN), 67–68(NP), 68f(NP), 69t(NP) Acyclovir for erythema multiforme, Q33(DM) for herpes simplex encephalitis, 9–10(ID) for herpes simplex virus genital infections, 46t(ID), Q5(ID), Q91(ID) for herpes simplex virus infections, 96(ID) for herpes zoster infections, 96(ID) urinary crystals and, 6(NP) for varicella, 96(ID) Adalimumab for inflammatory bowel disease, 37t(GA) for rheumatic disease, 13t(RM) for rheumatoid arthritis, 20(RM), Q75(RM) for spondyloarthritis, 34(RM) ADAMTS 13 protease, in thrombotic thrombocytopenic purpura, 51(HO), 64(HO) Adaptive servoventilation, 67(PM) Addison disease, 16(EN), 60(DM). See also Adrenal insufficiency, primary Addisonian crisis, 42(EN) Adefovir, for hepatitis B, 55(GA), 55t(GA) Adenocarcinoma ampullary, 73(GA), 74(GA), Q21(GA) endometrial, 46(GA) esophageal, 10(GA), 11–12(GA), Q50(GA) gastric, 20(GA) gastroesophageal junction, 83(HO), Q90(HO) of the head and neck, 88(HO) pancreatic, 26–27(GA), 27f(GA), 27t(GA) pulmonary, 57(PM), 68(HO), 85(HO), 87(HO) imaging of, 6f(PM) in situ, 5(PM), 57–58(PM), 57f(PM), Q99(PM) spiculated, 56f(PM) Adenoid cystic carcinoma, of the head and neck, 88(HO) Adenomas adrenal aldosterone-secreting, 47(EN), 50(EN), 51(EN), 52(EN) benign, 47(EN) cortisol-secreting, 42(EN), 46(EN), 47(EN) Cushing syndrome and, 44f(EN), 44t(EN) hypercortisolism in, Q84(EN) primary hyperaldosteronism in, 51(EN), 52(EN) colorectal, 46(GA), 47(GA), 51–52(GA), Q45(GA) duodenal, 47(GA) gastric, 20(GA) hepatic, 67–68(GA) pituitary, 21–22(EN) acromegaly and, 24t(EN), 25–26(EN) adrenocorticotropic hormone-secreting, 44f(EN), 44t(EN), 46(EN) clinically nonfunctioning, 26(EN) Cushing syndrome in, 44f(EN), 46(EN) effects of, 21–22(EN) follicle-stimulating hormone-secreting, 21(EN), 26(EN) gonadotropin-secreting, 21(EN), 26(EN) growth hormone-secreting, 25(EN) luteinizing hormone-secreting, 21(EN), 26(EN) macroadenomas, 21(EN), 22(EN), 25(EN), 26(EN), Q46(EN)
2
microadenomas, 21(EN), Q32(EN) in multiple endocrine neoplasia type 1, 21(EN), Q32(EN) radiation therapy for, Q57(EN) thyroid-stimulating hormone-secreting, 21(EN), 24t(EN), 26(EN), 29(EN), 30t(EN), Q28(EN) treatment of, 22(EN), 24t(EN) solitary parathyroid, primary hyperparathyroidism and, 61–63(EN), 61t(EN) toxic thyroid, 31–32(EN) Adenosine for arrhythmias, 51t(CV), 52(CV) in stress testing, 5t(CV) for supraventricular tachycardia, Q59(CV) in pregnancy, 108(CV), 108t(CV) Adenosine deaminase, in tuberculous pleural effusion, 45(PM), Q14(PM) Adenosquamous cell carcinoma, cervical, 78(HO) Adenovirus infections, 19(ID) Adhesive capsulitis, 55–56(GIM) Adolescents medical confidentiality for, 26(GIM) sexually active, 18(GIM) Adrenal carcinoma Cushing syndrome in, 46(EN) primary hyperaldosteronism in, 51(EN) Adrenal crisis, in adrenal insufficiency, 42(EN), Q27(EN) Adrenalectomy, laparoscopic, for pheochromocytoma, 50(EN) Adrenal function, physiologic regulation of, 40–41(EN), 40f(EN) Adrenal gland disorders, 40–52(EN) adrenal insufficiency, 40–43(EN) Cushing syndrome, 43–46(EN) incidentalomas, 47–49(EN), 47f(EN), 48f(EN) pheochromocytomas, 49–50(EN) primary hyperaldosteronism, 50–52(EN) Adrenal hyperplasia, bilateral, primary hyperaldosteronism in, 51(EN), 52(EN) Adrenal insufficiency, 40–43(EN) acute, adrenal hemorrhage and, 41t(EN), Q60(EN) causes of, 41(EN), 41t(EN) central (secondary) adrenal crisis in, 42(EN) causes of, 41(EN), 41t(EN), 43(EN) in critical illness, Q48(EN), Q55(EN) in Cushing syndrome, 46(EN) diagnosis of, Q9(EN) management of, Q25(EN) in Sheehan syndrome, 18(EN), Q69(EN) definition of, 41(EN) diagnosis of, 41–42(EN) drug-induced, 39(EN), 41t(EN) hydrocortisone for, 42–43(EN), 42t(EN), Q25(EN), Q27(EN), Q39(EN) hyponatremia in, Q27(NP) perioperative management of, 132–133(GIM) primary adrenal crisis in, 42(EN), Q27(EN) causes of, 41(EN), 41t(EN) hyperkalemia in, 20(EN), 41t(EN) management of, Q39(EN) tertiary, 41(EN) treatment of, 42–43(EN), Q25(EN) Adrenalitis, autoimmune, 41(EN), 41t(EN) Adrenal masses evaluation and management of, 47–49(EN), 47f(EN), 48f(EN) incidental, 26(EN), 47–49(EN), Q2(EN), Q71(EN) Adrenocortical cancer/carcinoma, 47(EN), 52(EN) Adrenocorticotropic hormone (ACTH), 60(DM) adrenal secretion of, 40(EN), 40f(EN) ectopic secretion of, Q84(EN) function of, 40(EN), 40f(EN) hypothalamic secretion of, 17(EN) Adrenocorticotropic hormone deficiency, 16(EN), 20(EN) in lymphocytic hypophysitis, Q40(EN) in pituitary apoplexy, 18(EN), 18t(EN), Q14(EN) in primary adrenal insufficiency, Q39(EN) Adrenocorticotropic hormone-dependent Cushing syndrome, 44f(EN), 44t(EN), 45f(EN), 46(EN) Adrenocorticotropic hormone-secreting pituitary adenomas, 44f(EN), 46(EN) Adrenocorticotropic hormone syndrome, ectopic, 59t(DM) Advanced cardiac life support, 61(CV) Advance directives, 24(GIM) African Americans bone mineral density in, 67(EN) breast cancer in, 69–70(HO) cardiovascular disease in, 1(CV) colorectal cancer in, 45(GA), 49(GA) colorectal cancer screening guidelines for, 49(GA) factor V Leiden in, 53(HO) focal segmental glomerulosclerosis in, 50t(NP), 51(NP) glucose-6-phosphate dehydrogenase deficiency in, 26–27(HO) hair abnormalities in, 66(DM) hypertension management in, 43(NP), Q86(NP) intracranial atherosclerosis in, 27(NR) kidney function measurement in, 1(NP) lupus nephritis in, 60(NP), Q5(NP) neutropenia in, 4(HO), Q57(HO) prostate cancer in, 89(HO) sickle cell syndromes in, 28–31(HO) skin diseases in, 68(DM), 76–78(DM), 77f(DM), 78f(DM) tuberculosis in, 32(ID) African tick typhus, 64(ID) AGEP (acute generalized exanthematous pustulosis), 16(DM) Aggression, in Alzheimer disease, 43(NR), 44(NR) Aging. See also Elderly patients; Geriatric medicine as dementia risk factor, 41(NR) as memory loss risk factor, 41(NR), Q30(NR) Agitated saline contrast study, 9(CV), Q114(CV) Agitation, in Alzheimer disease, 43(NR), 44(NR), 45(NR), Q18(NR) Airflow obstruction in chronic obstructive pulmonary disease, 19(PM), 19t(PM) in diffuse parenchymal lung disease, 30–31(PM) Air pollution asthma and, 7(PM) chronic obstructive pulmonary disease and, 17(PM), 18(PM), 18t(PM)
Cumulative Index
Airspace disease, 19(ID) Air travel in chronic obstructive pulmonary disease, 69(PM), Q98(PM) in pulmonary disease, 69(PM), 70(PM), Q98(PM) thromboembolism and, 47f(PM) Airway hyperresponsiveness, bronchial challenge testing in, 1(PM), 3(PM) Airway inflammation, in asthma, 7(PM) Airway lesions, central, imaging of, 5(PM) Airway obstruction in anaphylaxis, 85(PM) asthma and, 7(PM), 8(PM), 8t(PM), 9f(PM) in chronic obstructive pulmonary disease, 16(PM) flow-volume loops in, 1(PM), 2f(PM), Q22(PM) mechanical, differentiated from asthma, 8t(PM) Airway stenosis, in inhalational injury, 84(PM) Akathisia, 48t(NR) AKI. See Kidney injury, acute Alanine aminotransferase in inflammatory myopathies, 60(RM), 61(RM) in liver disease, 53(GA), 53t(GA) in acute viral hepatitis, 53t(GA), Q5(GA) in alcohol-induced liver disease, 57(GA) in autoimmune hepatitis, 58(GA) in primary biliary cirrhosis, 60(GA) Alastrim, 58(ID) Albumin intravenous for hepatorenal syndrome, 64(GA), Q61(GA) for spontaneous bacterial peritonitis, 63(GA), Q3(GA) serum-ascites albumin gradient, 62–63(GA), Q23(GA) testosterone binding of, 52(EN) thyroid hormone binding of, 27(EN) urine dipstick detection of, 3(NP), 4t(NP), 5(NP) Albumin-creatinine ratio, 16(EN) in chronic kidney disease, Q73(NP) in diabetic nephropathy, Q89(NP) in nephrotic syndrome, Q102(NP) Albuminuria in cardiovascular disease, 2(CV) definition of, 6t(NP) in glomerular disease, 7(NP) measurement of, Q73(NP) Albuterol for asthma, 14(PM) for chronic obstructive pulmonary disease, 22t(PM) use during pregnancy, 16(PM) Alcohol, as topical corticosteroid component, 2(DM), 3(DM) Alcohol dependence, 17(GIM) Alcohol-induced liver disease, 57–58(GA) Alcohol septal ablation, for hypertrophic cardiomyopathy, 45(CV) Alcohol use/abuse beer potomania in, 12(NP) as breast cancer cause, 70(HO) colorectal cancer and, 46(GA), 48(GA) as coronary artery disease risk factor, 12t(CV) as esophageal cancer cause, 82(HO) esophageal carcinoma and, 11(GA) as head and neck cancer cause, 88(HO) hepatitis and, 53t(GA), 57–58(GA), Q18(GA) hypertension management and, 39(NP), 40(NP) hypocalcemia in, Q75(EN) hypoglycemia in, 14(EN), 16(EN) hypoparathyroidism in, 65(EN) insomnia in, 44(GIM), Q153(GIM) interventions for, 18(GIM), Q120(GIM) liver disease and, 57–58(GA) low bone mass in, 68t(EN) methotrexate use and, 11(RM), 12(RM), Q25(RM) as myopathy cause, 77(NR) as neuropathy cause, 70–71(NR) as pancreatic cancer cause, 81(HO) pancreatitis and, 23(GA), 23t(GA), 25(GA), 25t(GA) in physicians, 27(GIM), 27t(GIM) screening for, 7t(GIM), 8(GIM), 9(GIM), 17–18(GIM) Alcohol Use Disorders Identification Test (AUDIT), 17(GIM) Alcohol withdrawal, 89(PM), Q17(PM) Aldolase, in inflammatory myopathies, 60(RM), 61(RM) Aldosterone, adrenal secretion of, 41(EN) Aldosterone. See also Hyperaldosteronism; Hypoaldosteronism in hyperkalemia, 20–21(NP) in hypertension, 35(NP) in metabolic alkalosis, 30–31(NP) urine potassium excretion and, 18(NP) Aldosterone antagonists, 40t(NP) for heart failure, 33t(CV), 34(CV) teratogenicity of, 111(CV) Aldosterone assay, for primary hyperaldosteronism, 51(EN) Aldosterone deficiency, adrenal insufficiency in, 41t(EN), 42(EN) Aldosterone-renin activity ratio in adrenal incidentalomas, Q2(EN) in primary hyperaldosteronism, 51(EN), 52(EN), Q16(EN) Aldosterone-secreting adrenal adenomas, 47(EN), 50(EN), 51(EN), 52(EN) Alendronate with corticosteroids, 10(RM) for osteoporosis, 69(EN), 70(EN), 70t(EN), 71(EN), Q10(EN), Q59(EN) Alkaline phosphatase in liver disease, 53t(GA) in Paget disease of bone, 73(EN) Alkalosis metabolic, 30–31(NP) compensation in, 23t(NP) evaluation of, 30–31(NP), 30f(NP) hypokalemic, 30–31(NP), Q45(NP), Q94(NP), Q104(NP) treatment of, 31(NP), Q9(NP) respiratory, 32–33(NP) anion gap metabolic acidosis and, 37–38(NP), Q57(NP), 37t(NP) causes of, 33t(NP) compensation in, 23t(NP) Alkylating agents
cardiotoxicity of, 104t(CV) as neutropenia cause, 4(HO) Allergen immunotherapy, for asthma, 15(PM) Allergic bronchopulmonary aspergillosis, 40(ID) Allergic contact dermatitis, 5–6(DM), 5f(DM), 6f(DM), 34f(DM), Q4(DM), Q41(DM), Q49(DM) corticosteroid-related, 3(DM) drug-related, 8(DM), 33(DM) irritant, 5(DM) of hand, 7t(DM) vs. acanthosis nigricans, Q15(DM) Allergic reactions allergic bronchopulmonary aspergillosis and, Q20(PM) asthma and, 7–8(PM), 13f(PM), 14(PM), 15(PM) atopy and, 8–10(DM) to β-lactam antibiotics, 17(ID) to drugs, 6(DM), 33(DM). See also Drug reactions to food, 44(DM) to penicillin, Q13(ID) to plants, 6(DM) transfusion-related, 40(HO) urticarial, 15t(DM), 44–45(DM), 44f(DM), 52(DM), Q72(DM) Allopurinol adverse effects of, 15(RM) for gout, 15(RM), 52(RM) interaction with azathioprine, Q68(RM) for tumor lysis syndrome, Q128(HO) for uric acid stones, Q34(NP) All-trans-retinoic acid, for acute myeloid leukemia, 11(HO) All-trans-retinoic acid-induced differentiation syndrome, Q15(HO) Almotriptan, for migraine, 7t(NR) Alopecia, 65–67(DM) in dermatomyositis, 50(DM) nonscarring, 65–66(DM) scarring, 65–67(DM) in systemic lupus erythematosus, 4t(RM), 35(RM) Alopecia areata, 66(DM), 66f(DM), Q55(DM) Alosetron, for irritable bowel syndrome, 42(GA) α-Adrenergic blocking agents, for pheochromocytoma, 50(EN), Q29(EN) α-Blockers, 40t(NP) for benign prostatic hyperplasia, 78(GIM), 78t(GIM), Q70(GIM) for kidney stones, Q79(NP) for pheochromocytoma, 50(EN), Q29(EN) α-Fetoprotein, in testicular cancer, 93(HO), Q117(HO) α1-Antitrypsin deficiency, 53t(GA), 59(GA) chronic obstructive pulmonary disease and, 17(PM), 18(PM), 21(PM), Q93(PM) α1-Antitrypsin replacement therapy, for chronic obstructive pulmonary disease, 25(PM) Alport syndrome, 64–65(NP), Q59(NP) ALT. See Alanine aminotransferase Alteplase, for ST-elevation myocardial infarction, 25t(CV) Alternative and complementary therapies, for asthma, 15(PM) Alveolar ventilation, decreased, 72(PM) Alveolar walls, in chronic obstructive pulmonary disease, 17f(PM) Alveolitis, in diffuse cutaneous systemic sclerosis, Q93(RM) Alzheimer disease, 118(GIM) agitation in, 43(NR), 44(NR), 45(NR), Q18(NR) amyloid plaques in, 43(NR), 44(NR) behavioral changes in, 43(NR), 44(NR), 45(NR) Capgras syndrome in, 43(NR) caregivers for, 43(NR), 44(NR) clinical features of, 43–44(NR) cognitive impairment in, 41(NR), 43(NR), 44(NR) confusion in, 43(NR), Q18(NR) course of, 43(NR) diagnosis of, 42–43(NR) early-onset familial, 43(NR) end-stage, 45(NR) epidemiology of, 43(NR) evaluation of, 41–42(NR) genetic factors in, 43(NR) genetic marker for, 43(NR) Lewy body variant of, 45(NR) living arrangements for, 43(NR) memory loss in, 42(NR) mild cognitive impairment and, 41(NR) palliative care for, 45(NR) pathology of, 43(NR), 44(NR), 45(NR), 46f(NR) prevalence of, 43(NR) progression toward, 41(NR) safety precautions in, 43(NR), 45t(NR) sleep disorders in, 43(NR) treatment of, 44–45(NR), 44t(NR), 45t(NR) urinary incontinence in, 43(NR), 45(NR) Amanita mushroom poisoning, 65(GA), 67t(GA) Amantadine contraindication as influenza A prophylaxis, 95(ID) for multiple sclerosis–related fatigue, 63t(NR), Q49(NR) for Parkinson disease, 50t(NR), 51(NR) Amblyomma americanum, 27(ID) Ambulatory blood pressure monitoring, 35–36(NP), 36f(NP), 37(NP), 42(NP), Q84(NP) in masked hypertension, 36(NP), 42(NP), Q46(NP) in resistant hypertension, Q12(NP) in white coat hypertension, 36(NP), 42(NP), Q23(NP) Ambulatory electrocardiographic monitoring, of arrhythmias, 11–12(CV), 51(CV), Q33(CV), Q117(CV) Ambulatory pH monitoring, esophageal, 6(GA), 7(GA), Q83(GA) Amebiasis, 68(GA), 72(ID) Amenorrhea anorexia nervosa and, 113(GIM) chemotherapy-related, 74(HO) diagnosis and evaluation of, 57(EN), Q3(EN) functional hypothalamic, 57(EN), Q44(EN) in hyperprolactinemia, 22(EN), 23(EN), 24(EN), 57(EN), Q7(EN) in hypothyroidism, 57(EN) in macroprolactinoma, Q64(EN) in polycystic ovary syndrome, 58(EN) primary, 56–57(EN) in primary ovary insufficiency, Q77(EN) secondary, 57(EN), Q3(EN) American Academy of Family Physicians, cancer screening guidelines from, 10(GIM) American Academy of Ophthalmology, 119(GIM)
3
Cumulative Index
American Cancer Society cancer screening guidelines from, 10(GIM) cervical cancer screening guidelines from, 10t(GIM) mammography recommendations from, 9–10(GIM) osteoporosis screening guidelines from, 9(GIM) American College of Cardiology/American Heart Association, 125(GIM), 127(GIM), Q151(GIM), Q168(GIM) American College of Chest Physicians, 36(GIM) lung cancer screening recommendation from, 58(PM), Q27(PM) American College of Gastroenterological Association criteria, for irritable bowel syndrome, 41–42(GA), Q81(GA) American College of Obstetricians and Gynecologists mammography recommendation from, 9(GIM) pelvic pain treatment recommendation from, 92(GIM) American College of Physicians airflow obstruction definition from, 19(PM) cancer screening guidelines from, 10(GIM) chronic obstructive pulmonary disease diagnostic guideline from, 19(PM), Q1(PM) chronic obstructive pulmonary disease pharmacotherapy recommendation from, 21(PM), 23t(PM) clinical practice guidelines from, 4(GIM), 7(GIM) evidence-based medicine resources from, 4(GIM) High-Value Cost-Conscious Care initiative of, 23(GIM) HIV testing guidelines from, 87(ID) low back pain diagnostic testing recommendation from, 51(GIM) position on physician-assisted suicide, 25(GIM), Q83(GIM) American Diabetes Association blood pressure target goal recommendation from, 39(NP), 43(NP), Q29(NP), Q71(NP) diabetes diagnostic guidelines from, 3t(EN) diabetes screening guidelines from, 2(EN), 2t(EN) diabetes screening recommendation from, 70(GIM) urine albumin screening recommendation from, 7(NP), Q73(NP), Q89(NP) American Geriatrics Society, 35(GIM), 117(GIM) American Heart Association blood pressure measurement recommendation from, Q84(NP) infective endocarditis prophylaxis recommendation from, 84(ID), 85(ID) optimal triglyceride levels guidelines from, 63(GIM) quality of care guidelines from, 3(CV) stroke prevention guidelines from, 69(GIM) American Indians cardiovascular disease in, 1(CV) factor V Leiden in, 53(HO) American Lung Association, lung cancer screening recommendation from, 58(PM) American Medical Association alcohol abuse screening recommendation from, 8(GIM) mammography recommendation from, 9(GIM) older driver evaluation recommendation from, 120(GIM) position on physician-assisted suicide, 25(GIM), Q83(GIM) American Society of Addictive Medicine, alcohol abuse screening recommendation from, 8(GIM) American Society of Clinical Oncology, lung cancer screening recommendation from, 58(PM) American Thoracic Society acute respiratory distress syndrome classification recommendation from, 70(PM) idiopathic diffuse parenchymal lung disease classification statement from, 30(PM) American Urological Association hematuria evaluation protocol of, 7(NP), 8f(NP) kidney stone treatment guideline from, 76(NP) American Urological Society, 78(GIM) America Thyroid Association, thyroid cancer treatment guidelines from, 38(EN) Amikacin, for tuberculosis, 35t(ID) Amiloride, for primary hyperaldosteronism, 51–52(EN) Aminoglycosides, 100(ID), 101(ID) Bartter-like syndrome and, 19(NP) for multidrug-resistant organisms, 83–84(ID) nephrotoxicity of, 68t(NP), Q77(NP) Aminophylline, for chronic obstructive pulmonary disease, 22t(PM), Q42(PM) para-Aminosalicylic acid, for tuberculosis, 35t(ID) Aminosalicylates for inflammatory bowel disease, 37–38(GA), 37t(GA) for microscopic colitis, 38(GA) Aminotransferases in acute viral hepatitis, 53t(GA), Q5(GA) in hemochromatosis, 36(HO) in immune-tolerant hepatitis B, Q56(GA) in nonalcoholic steatohepatitis, 53t(GA), 58(GA), Q2(GA) statin-related increase in, 65(GIM), 66t(GIM), 67(GIM), Q158(GIM) Amiodarone adverse effects of, 51–52(CV) for arrhythmias, 51–52(CV), 51t(CV) for atrial fibrillation, Q30(CV) for hypertrophic cardiomyopathy, 43(CV) hypothyroidism-inducing effect of, 33(EN), Q61(EN) in pregnancy, 108(CV), 108t(CV) pulmonary toxicity of, 37(PM), 37t(PM), Q16(PM) for supraventricular tachycardia, in pregnancy, 108(CV) thyrotoxicosis-inducing effect of, 32(EN), 33(EN) Amitriptyline for fibromyalgia, 27(RM) for migraine, 8(NR), 9(NR), Q83(NR) for neuropathic pain, 73(NR) Amlodipine for heart failure, 35(CV), Q120(CV) side effects of, Q44(ID) Ammonium, urinary excretion of, 27(NP), Q45(NP) Amoxicillin for Helicobacter pylori infection, 15(GA) as infective endocarditis prophylaxis, 85t(ID) for Lyme disease, 26t(ID) Amoxicillin-clavulanate, for animal bites, 17(ID) Amphetamines, toxicity of, 90(PM) Amphotericin B for aspergillosis, 40(ID) for blastomycosis, 42(ID) for cryptococcosis, 41(ID) for histoplasmosis, 42(ID), Q30(ID) for mucormycosis, 41(ID) Ampicillin, for bacterial meningitis, Q59(ID) Ampullary adenocarcinoma, 73(GA), 74(GA), Q21(GA) Amputation for acute limb ischemia, 101(CV), 102(CV) in diabetic patients, 16(EN)
4
Amsterdam II criteria, for colorectal cancer screening, 46(GA), 47t(GA) Amylase in pancreatic cystic lesions, 29t(GA) in pancreatitis, 23(GA) Amylinomimetics, 8t(EN) Amyloid-β in Alzheimer disease, 43(NR), 44(NR) Amyloid imaging, in Alzheimer disease, 44(NR) Amyloidosis AA, 54(NP), 55(NP) AH, 54(NP), 55(NP) AL, 54–55(NP), Q35(NP) amyloid light-chain, 13(HO), 14(HO), 16–17(HO), 16f(HO) in ankylosing spondylitis, 29t(RM) bradycardia in, 49(CV) cardiomyopathy in, 46(CV), 47t(CV), Q7(CV) nephrotic syndrome in, 50t(NP), 54–55(NP) in rheumatoid arthritis, 18(RM) Amyloid plaques, in Creutzfeldt-Jakob disease, 12(ID) Amyopathic dermatomyositis, 4t(RM), 59(RM) Amyotrophic lateral sclerosis, 73–74(NR), Q14(NR) ventilatory failure in, 74(PM) Amyotrophy, diabetic, 16(EN), 71(NR), 71t(NR), Q87(NR) Anabolic agents, for osteoporosis, 70(EN), 71(EN), 72(EN), Q10(EN) Anabolic steroid abuse in men, 55(EN) in women, 58–59(EN) Anagrelide, for essential thrombocytopenia, 8(HO) Anakinra, for rheumatic disease, 13t(RM) Anal cancer, 81(HO), Q116(HO) screening for, 10(GIM) Anal fissures, 108(GIM) Analgesic ladder, 29–30(GIM), 29f(GIM), 35(GIM), Q65(GIM) Analgesics nephrotoxicity of, 45t(NP), 46–47(NP), Q68(NP) for osteoarthritis, 25(RM), 26(RM) overdose/toxicity of, 90(PM), 91t(PM) perioperative use of, 126t(GIM) for rheumatic disease, 10(RM) for ST-elevation myocardial infarction, 23(CV) Anaphylactic reactions, to immune globulin therapy, 55(ID), Q86(ID) Anaphylactoid reactions, to omalizumab, 14(PM), Q73(PM) Anaphylaxis, 85(PM), Q19(PM) insect sting-related, 31(DM) transfusion-related, 40(HO), Q3(HO) in urticaria, 44(DM), 45(DM) Anaplasmosis, human granulocytic, 25t(ID), 28(ID), Q87(ID) Anastomotic leaks, after bariatric surgery, 20–21(GA), 21t(GA), Q47(GA) Anchoring heuristic, 21t(GIM), Q12(GIM) Androgen deficiency, 77(GIM), 77t(GIM), Q40(GIM) in aging males, 53(EN) Androgen deprivation therapy, for prostate cancer, 90–91(HO), 92(HO), 93(HO), Q93(HO) Androgen therapy, for primary myelofibrosis, 9(HO) Anemia, 5(EN), 18–36(HO), 19(EN), 20–21(HO), 20f(HO), 24(HO), 41t(EN) after bariatric surgery, 22(GA) in anisopoikilocytosis, 21(HO), Q19(HO) aplastic, 1–3(HO), 2f(HO), 2t(HO), 52(HO), Q2(HO), Q66(HO) in celiac disease, 33t(GA), Q88(GA) of chronic disease, 24(HO) in chronic kidney disease, 89(NP), Q8(NP), Q105(NP) in chronic myelomonocytic leukemia, 6(HO) in colorectal cancer, 42(GA) Cooley, 28(HO) in cyanotic heart disease, Q113(CV) diagnosis of, 18–19(HO), 19f(HO) Fanconi, 2(HO), 10(HO), 52(HO) in folate deficiency, 4(HO) gestational, 62(HO), Q10(HO) hemoglobin A1c in, Q41(EN) hemolytic. See Hemolytic anemia inflammatory, 24(HO), 24t(HO) in systemic lupus erythematosus, Q26(HO) iron-deficiency, 20–21(HO), 20f(HO), 24(HO) in anisopoikilocytosis, 21(HO), Q19(HO) in celiac disease, 33t(GA), Q88(GA) in cyanotic heart disease, Q113(CV) hemoglobin A1c in, Q41(EN) menstrual blood loss-related, 35(HO), Q61(HO) in microangiopathic hemolytic anemia, 34(HO) in pregnancy, 62(HO) in systemic sclerosis, Q88(RM) in Kawasaki disease, 66(RM) of kidney disease, 24–25(HO), Q36(HO) macrocytic, Q72(HO) menstrual blood loss-related, 35(HO), Q61(HO) microangiopathic hemolytic, 43(RM) in microangiopathic hemolytic anemia, 34(HO) microcytic, in thalassemia, Q31(HO) in multiple myeloma, 13(HO) in nephrotic syndrome, 49t(NP) perioperative management of, 131(GIM) pernicious, 22–23(HO), 22f(HO) in polyarteritis nodosa, 66(RM) in polymyalgia rheumatica, 65(RM) in pregnancy, 62(HO) in primary myelofibrosis, 9(HO) in pure red cell aplasia, 3(HO) sickle cell, 31(HO), 55(RM). See also Sickle cell disease in pregnancy, 63(HO) in systemic lupus erythematosus, 37(RM) in thrombocytopenia, 48(HO) in vitamin B12 deficiency, 4(HO) Aneurysms aortic abdominal, 96–97(CV), 97t(CV), Q81(CV) thoracic, 93–94(CV), 94t(CV), Q111(CV) aortic root, in Marfan syndrome, 74(RM) Charcot-Bouchard, 33(NP) in Ehlers-Danlos syndrome, 73–74(RM) intracranial
Cumulative Index
asymptomatic, 36(NR) in autosomal dominant polycystic kidney disease, 63(NP), Q100(NP) in stroke, 33(NR), 34f(NR), 36(NR) treatment of, 38(NR), 88(NR) in polyarteritis nodosa, Q92(NP) renal arteriolar, 66(RM) Angiitis, primary cerebral, 3(NR) Angina, intestinal, 43(GA), 44(GA), 45(GA) Angina pectoris chronic stable, 14–19(CV) diagnosis of, 14(CV) medical therapy for, 14(CV), 16–17(CV), 16f(CV), Q70(CV), Q99(CV) management of, 21f(CV) with coronary revascularization, 16f(CV), 17–19(CV) with pharmacotherapy, 14(CV), 16–17(CV), 16f(CV), Q57(CV), Q68(CV), Q70(CV) post-revascularization, 19(CV) unstable, 19–22(CV), 19f(CV), Q57(CV), Q68(CV) vasospastic (Prinzmetal), 16–17(CV), 19(CV) in women, 30(CV) Angioectasia, 77(GA), 79(GA) aortic stenosis and, Q20(GA) bleeding from, 74(GA) Angioedema, 45(DM), 85(PM), Q78(PM) Angiofibromas, in tuberous sclerosis complex, 63t(NP), 64(NP) Angiofollicular lymph node dysplasia, 48(DM) Angiography computed tomography, in peripheral arterial disease, 99(CV) coronary. See Coronary angiography in gastrointestinal bleeding, 79(GA), 81(GA) magnetic resonance, in peripheral arterial disease, 99(CV) pulmonary, in pulmonary embolism, 49(PM) Angiography, computed tomography. See Computed tomography angiography Angiokeratomas, in Fabry disease, 65(NP) Angiolipomas, 42(DM) Angiomas, cherry, 41(DM), 41f(DM), 75(DM) Angiomyolipomas, in tuberous sclerosis complex, 63t(NP), 64(NP), Q88(NP) Angioplasty for acute limb ischemia, 101–102(CV) for carotid artery stenosis, 38(RN) kidney, for renovascular hypertension, 42(NP), Q58(NP) Angiotensin, conversion to angiotensin I, 40f(EN), 41(EN) Angiotensin-converting enzyme inhibitors. See ACE inhibitors Angiotensin I, 40f(EN), 41(EN) Angiotensin II, 40f(EN), 41(EN) in pregnancy, 77(NP) Angiotensin receptor blockers action mechanism of, 38f(NP) acute kidney injury and, 83(NP) for Alport syndrome, Q59(NP) autosomal dominant polycystic kidney disease and, 63(NP), 64(NP) for chronic kidney disease, 83(NP), 85(NP), 86(NP), Q74(NP) combined with ACE inhibitors, 85(NP), Q39(NP) contraindication in renal artery disease, 42(NP) cough and, Q1(PM) for diabetes mellitus-related cardiovascular disease, 6(EN) in type 2 diabetes mellitus, Q71(NP) for focal segmental glomerulosclerosis, 51(NP) for heart failure, 33(CV), 33t(CV), 34(CV), 35(CV), 38(CV) for hepatitis B virus-associated kidney disease, 56(NP) for immunoglobulin A nephropathy, 57(NP) indications for, 40t(NP) for lupus nephritis, 60(NP) for membranous glomerulopathy, 52f(NP) for proteinuric kidney disease, 7(NP) for scleroderma renal crisis, 44(RM) side effects of, 40t(NP) serum creatinine increase, Q91(NP) teratogenicity, 108t(CV), 111(CV), 43(NP), 78–79(NP), 79t(NP), 81(NP), Q70(NP), Q97(NP) for thrombotic microangiopathy, 62(NP) Animal bites, 16–17(ID) Anion gap delta, 23–24(NP) in metabolic acidosis, 23(NP), 24–30(NP), 24t(NP), 28f(NP), Q7(NP), Q17(NP), Q57(NP), Q66(NP) Anisopoikilocytosis, iron deficiency in, 21(HO), Q19(HO) Ankle rheumatoid arthritis of, 16(RM) sarcoidosis of, 75(RM) sprains of, 61(GIM), Q59(GIM) Ankle-brachial index, 97(CV), 98–99(CV), 99t(CV), Q60(CV), Q116(CV) Ankylosing spondylitis, 27–28(RM) cardiovascular disease and, 2t(CV) characteristic posture in, 28f(RM) clinical features of, 3t(RM), 29(RM), 29t(RM) evaluation of, 9(RM) in inflammatory bowel disease, 36(GA) polyarthritis in, 3t(RM) radiographic findings in, 8t(RM), Q41(RM) spinal involvement in, 28f(RM), Q51(RM) vs. diffuse idiopathic skeletal hyperostosis, 23–24(RM) Ann Arbor Staging System, for lymphoma, 98(HO), 100f(HO) Anorectal abscesses, 108(GIM) Anorectal disorders, 107–108(GIM) Anorectal pain, chronic, 108(GIM) Anorexia, 32(GIM) in lung cancer, 59t(PM) Anorexia nervosa, 113–114(GIM), Q143(GIM) Antacids, magnesium-containing, for constipation, 41(GA) Antecubital fossa, atopic dermatitis of, 8(DM), 9f(DM) Anterior cruciate ligament examination of, 59f(GIM), 59(GIM) injuries to, 59(GIM) Anterior drawer test, 59f(GIM), 59(GIM) Anthracyclines, cardiotoxicity of, 103(CV), 104t(CV), 110(HO) Anthrax as bioterrorism agent, 56t(ID), 57–58(ID) cutaneous, 57f(ID), 57(ID), 58(ID) inhalational, 57f(ID), 57(ID), 58(ID), Q47(ID)
Antianginal agents for acute coronary syndromes, 20(CV) for coronary artery disease, 14(CV), 16–17(CV), 16f(CV) Antiarrhythmics, 51–52(CV), 51t(CV) classes of, 51–52(CV), 51t(CV) creatinine and, 52(CV), Q23(CV) as pericarditis cause, 63t(CV) for premature ventricular contractions, 57(CV) Antibiotic resistance, 33(DM) Antibiotics. See also specific antibiotics for acne, 20–21(DM), 20t(DM) acute interstitial nephritis and, 5(NP) for acute mesenteric ischemia, 44(GA) allergic reactions to, 6(DM) for bacterial meningitis, 3–4(ID), 5–6t(ID) for brain abscess, 7(ID), 7t(ID) for cellulitis, 24–25(DM) for chlamydial reactive arthritis, 34(RM) for chronic obstructive pulmonary disease, 25(PM) as Clostridium difficile infection risk factor, 69(ID) contraindication in stasis dermatitis, 8(DM) for diverticulitis, 43t(GA), Q26(GA) drug interactions of, Q20(CV) as erythema nodosum cause, 55(DM), 56(DM) in heart transplant recipients, Q20(CV) hepatotoxicity of, 57(GA), 70(GA) for infective endocarditis, 81(CV), 82(CV) for inflammatory bowel disease, 37t(GA), 38(GA) for neutropenia, Q124(HO) as neutropenia cause, 4(HO) newer, 97–99(ID) as pericarditis cause, 63t(CV) for rosacea, 22(DM) for septic arthritis, 57(RM) for septic shock, Q66(PM), Q80(PM) skin eruptions due to, 14(DM), 15t(DM), 16(DM), 55(DM), 56(DM). See also Drug reactions for spontaneous bacterial peritonitis, 63(GA), Q3(GA) for wounds, 33(DM) Antibodies, myositis-specific, 60–61(RM), 60t(RM) Antibody tests, in rheumatic disease, 6–7(RM), 7t(RM) Anticentromere antibodies in rheumatic disease, 7t(RM) in systemic sclerosis, 42t(RM) Anticholinergics for asthma, 11(PM), 13–14(PM) for chronic obstructive pulmonary disease, 13(PM), 21(PM), 23(PM), 29(PM) Anticholinergic syndromes, 88t(PM) Anticoagulants. See also Heparin; Warfarin for acute coronary syndromes, 21–22(CV) for atrial fibrillation, 53–54(CV), 53t(CV), Q37(CV) for chronic thromboembolic hypertension, 54(PM) for dural sinus venous thrombosis, 35(NR) for heparin-induced thrombocytopenia, 51(HO) as intracerebral hemorrhage cause, 33(RN) for mitral stenosis, 79(CV) for myocardial infarction, Q25(CV) for pericarditis, 66(CV) perioperative management of, 126t(GIM), 129–130(GIM), 131t(GIM), 132(GIM), Q142(GIM) in pregnancy, 108–111(CV), 110t(CV), Q49(CV) for prosthetic valves, 82–83(CV), Q42(CV) for pulmonary embolism, 49–51(PM), 50t(PM), Q37(PM) for stroke, 26(NR), 37–38(NR), Q17(NR) for superficial venous thrombophlebitis, Q16(HO) for venous thromboembolism, 56–59(HO), 57t(HO), 58t(HO), 59t(HO), Q18(HO) in pregnancy, 66(HO) Anticonvulsants, 18–21(NR), 20t(NR) adverse effects of, 16(NR), 18–19(NR), 19t(NR), 20t(NR), 21(NR) in breastfeeding, 21(NR) dosages of, 21(NR) drug interactions of, 19(NR), 20t(NR), 21(NR), 40(CV), Q20(CV), Q32(NR) in the elderly, Q67(NR) for epilepsy, 18–21(NR), 20t(NR) for fibromyalgia, 27(RM) metabolism of, 20t(NR) monitoring of, 21(NR) for myoclonus, 54(NR) as neutropenia cause, 4(HO) for nonepileptic seizures, 17–18(NR) in pregnancy, 19(NR), 21(NR), Q12(NR) selection of, 19(NR) skin eruptions due to, 14(DM), 16(DM), 62–63(DM) teratogenicity of, 19(NR), 21(NR), 22(NR), Q12(NR) Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis, 30(RM) in rheumatoid arthritis, 7t(RM), 16–17(RM), Q20(RM) Antidepressants, 109(GIM), 110t(GIM), Q56(GIM) for Alzheimer disease, 45(NR) for diabetic neuropathy, 16(EN), Q67(EN) for fibromyalgia, 27(RM) for insomnia, 44(GIM) for irritable bowel syndrome, 42(GA) for multiple sclerosis, 64(NR) for neuropathic pain, 63(NR), 63t(NR), 73(NR) overdose/toxicity of, 91t(PM), Q28(PM) for pain, 35(GIM) perioperative management of, 126t(GIM) as tardive dyskinesia cause, 54(NR) Anti-D immune globulin, for immune (idiopathic) thrombocytopenic purpura, 49(HO), Q45(HO) Antidiuretic hormone. See also Syndrome of inappropriate antidiuretic hormone secretion in diabetes insipidus, 15(NP) non-osmotic secretion of, 12(NP), 13(NP) nonphysiologic secretion of, 10(NP), 12(NP) Antidiuretic hormone deficiency in diabetes insipidus, 20(EN) pituitary adenomas and, Q46(EN) Antidotes, for drug overdose or toxicity, 89t(PM), 90(PM), 91t(PM) Anti-double-stranded DNA antibodies in psoriatic arthritis, 30(RM) in systemic lupus erythematosus, 7t(RM), 39(RM), 39t(RM), Q29(RM)
5
Cumulative Index
Antiemetics, 32(GIM) for gastroparesis, 18(GA) for migraine, 6(NR), Q53(NR) Antiepileptics. See Anticonvulsants Antifreeze poisoning, 89(PM), 89t(PM) Antifungal agents azole, drug interactions of, 73(ID), Q18(ID) for candidiasis, 27(DM) with corticosteroids, 3–4(DM) drug interactions of, 40(CV), Q20(CV) for erythrasma, 25(DM) for mucormycosis, Q65(ID) for onychomycosis, 69(DM) for seborrheic dermatitis, 14(DM) skin eruptions due to, 14(DM), 16(DM) for tinea, 26(DM), 27(DM), Q45(DM) triazole, for histoplasmosis, Q30(ID) Antigens, hypersensitivity pneumonitis and, 35–36(PM), 36t(PM) Anti-glomerular basement membrane antibody disease, 56t(NP), 60(NP) as Goodpasture syndrome, 60(NP), 62(NP) post-kidney transplantation, 65(NP) Antihistamines for bedbug bites, 32(DM), Q1(DM) for insomnia, 44(GIM), 45(GIM) for pruritus, 43(DM) skin eruptions due to, 15t(DM) for systemic sclerosis, 42(RM) for urticaria, 45(DM), Q72(DM) Antihistone antibodies, in drug-induced systemic lupus erythematosus, 7t(RM), 39t(RM) Antihypertensive agents action mechanism of, 38f(NP), 39(NP) choice of, 39(NP) in chronic kidney disease, 83–84(NP), 84f(NP), 86(NP), Q74(NP) as combination therapy, 39–40(NP), 41(NP), Q1(NP), Q74(NP) contraindications to, 40t(NP) for essential hypertension, 39–40(NP), 40t(NP) for hypertensive emergencies, 86t(PM) indications for, 39(NP), 41(NP) as monotherapy, 39(NP), Q1(NP) as pericarditis cause, 63t(CV) for secondary hypertension, 41(NP) side effects of, 40t(NP), Q91(NP) for special populations, 43–44(NP) for stage 2 hypertension, Q1(NP) use in pregnancy, 78–79(NP), 79t(NP) Anti-immunoglobulin E therapy, for asthma, 11(PM), 14(PM) Anti-infective therapy. See also Antibiotics new topics in, 97–102(ID) Anti-inflammatory agents. See also Non-steroidal anti-inflammatory drugs (NSAIDs) for asthma, 11(PM) for chronic obstructive pulmonary disease, 22t(PM) for pericarditis, 66(CV), 66t(CV), 67(CV), Q84(CV) for rheumatic disease, 9–11(RM), 10t(RM) Anti-Jo-1 antibodies in inflammatory myopathies, 60(RM), 60t(RM), Q49(RM) in myositis, 7t(RM) Anti-La/SSB antibodies, Q44(GIM) in rheumatic disease, 7t(RM) in systemic lupus erythematosus, 35t(RM), 39t(RM), 41(RM) Antimalarial agents for cutaneous lupus, 50(DM) for dermatomyositis, 51(DM) as lichen planus cause, 11(DM), 12(DM) for mixed connective tissue disease, 48(RM) for porphyria cutanea tarda, 57(DM), 58(DM) for sarcoidosis, 54(DM), 55(DM) Anti-Mi-2 antibodies, in inflammatory myopathies, 60–61(RM), 60t(RM) Antimicrobial stewardship, 101(ID), Q15(ID) Antimicrobial therapy. See also Antibiotics outpatient, 101(ID) for spinal epidural abscess, 8(ID) Antimotility agents, for travelers’ diarrhea, 64(ID) Anti-myeloperoxidase antibodies in Churg-Strauss syndrome, 67(RM) in microscopic polyangiitis, 67(RM), 68(RM) in rheumatic disease, 7t(RM) Antineutrophil cytoplasmic antibodies in neutropenia, 4(HO) in vasculitis, 67–69(RM), Q39(RM) Antinuclear antibodies in rheumatic disease, 6–7(RM), 7t(RM) in Sjögren syndrome, 46(RM) in systemic lupus erythematosus, 38(RM), 38t(RM), 39t(RM) Antioxidants for chronic obstructive pulmonary disease, 25(PM) for chronic pancreatitis, 26(GA) Antiphospholipid antibodies, in systemic lupus erythematosus, 39t(RM), 40(RM), 41(RM) Antiphospholipid antibody syndrome catastrophic, 55(HO) diagnosis of, 55t(HO), Q17(HO) eye disorders in, 5t(RM) in pregnancy, 108(CV) in systemic lupus erythematosus, 37(RM), 38(RM), 40(RM), 41(RM), Q90(RM) as venous thromboembolism cause, 54–55(HO) Antiplatelet agents for acute coronary syndromes, 20–21(CV) for acute limb ischemia, 101(CV), 102(CV) for aortic atheromas, 96(CV) drug interactions of, 8(GA) for essential thrombocytopenia, 8(HO) perioperative management of, 126t(GIM), 130–131(GIM), 132(GIM) for peripheral arterial disease, 99–100(CV) in pregnancy, 108t(CV) for ST-elevation myocardial infarction, 23(CV), 26(CV) for stroke, 33(NR), 38(NR), Q34(NR) Anti-PM-Scl antibodies, in systemic sclerosis, 42t(RM) Anti-proteinase-3 antibodies in rheumatic disease, 7t(RM) in vasculitis, 67(RM)
6
in Wegener granulomatosis, 68(RM) Antipsychotics for Alzheimer disease, 45(NR) diabetes mellitus and, 1(EN) hyperprolactinemia and, 22(EN), 23t(EN) for Lewy body dementia, 46(NR) Antireflux surgery, 3(GA), 8–9(GA), Q52(GA) Antirejection drugs. See Immunosuppressive agents Antiresorptive agents, for osteoporosis, 69–71(EN), 72(EN) Antiretroviral therapy for acute retroviral syndrome, 86(ID) adverse effects of, 89–90(ID) drug interactions of, 93(ID) dyslipidemia in, 89(ID), Q72(ID) failure of, 93(ID), 94(ID), Q68(ID) in genital herpes infections, Q91(ID) highly-active antiretroviral therapy (HAART), 61(DM), 89(ID) initiation of, 88–89(ID), 92–93(ID), 92t(ID), Q33(ID) in pregnancy, 94(ID), Q54(ID) regimens of, 93(ID), 93t(ID) resistance testing for, 93(ID), 94(ID), Q68(ID) in tuberculosis, 36(ID) Anti-Ro/SSA antibodies, Q44(GIM) in rheumatic disease, 7t(RM) in systemic lupus erythematosus, 35t(RM), 39t(RM), 41(RM) Anti-Scl-70 antibodies in progressive systemic sclerosis, 7t(RM) in systemic sclerosis, 42t(RM) Antiseizure medications. See also Anticonvulsants perioperative management of, 126t(GIM) Antisignal recognition antibodies, in inflammatory myopathies, 60t(RM) Anti-single-stranded DNA antibodies, in systemic lupus erythematosus, 39t(RM) Anti-Smith antibodies, in systemic lupus erythematosus, 7t(RM), 39(RM), 39t(RM) Antisynthetase antibodies, in inflammatory myopathies, 60(RM), 60t(RM) Antithrombin deficiency, 53(HO), 54(HO) acquired, 55(HO) Antithrombin therapy, 31–32(NR), 33(NR), 37–38(NR), Q17(NR) Anti-Th/To antibodies, in systemic sclerosis, 42t(RM) Antithyroglobulin antibodies, 28(EN) Antithyroid drugs, 30(EN), 31(EN), 32(EN), 33(EN), 39(EN) adverse effects of, 31(EN) Anti-thyroid peroxidase antibodies, 27t(EN), 28(EN), 29(EN), 30t(EN), 34t(EN) Anti-tumor necrosis factor-α, 37f(GA), 37t(GA), 38(GA) for Crohn disease, 37f(GA), 37t(GA), Q17(GA) for ulcerative colitis, 37f(GA), 37t(GA) Anti-U1-RNP antibodies in inflammatory myopathies, 61(RM) in mixed connective tissue disease, 7t(RM), 48(RM) in systemic lupus erythematosus, 7t(RM), 39t(RM), 48(RM) Anti-U3-RNP antibodies, in systemic sclerosis, 42t(RM) Antiviral agents. See also Antiretroviral therapy for herpes simplex virus infections, 28(DM), 29(DM) for herpes zoster, 29(DM), Q9(DM) for influenza, 95(ID), Q43(ID) Anxiety after critical illness, 93(PM) in Alzheimer disease, 43(NR), 44(NR), 45(NR) in anorexia nervosa, 114(GIM) coronary artery disease and, 13(CV) in critical care patients, 92(PM), 94(PM) in Parkinson disease, 49t(NR) pulmonary embolism and, 47(PM) Anxiety disorders, 110–112(GIM), Q146(GIM) Aorta, in Marfan syndrome, 74(RM) Aortic aneurysms abdominal, 96–97(CV), 97t(CV), Q81(CV) thoracic, 93–94(CV), 94t(CV), Q111(CV) Aortic arch, atheroma of, 37–38(NR), 40t(NR) Aortic atheromas, 96(CV), 96f(CV) Aortic coarctation, 86t(CV), 89–90(CV), 90f(CV), Q16(CV), Q69(CV), Q74(CV) Aortic dilatation, in Turner syndrome, Q16(CV) Aortic disease, 92–97(CV) acute, 95–96(CV), 95f(CV) genetic, 93(CV), 94t(CV) as pericarditis cause, 63t(CV) thoracic aortic imaging in, 92–93(CV) Aortic dissection, 64t(CV), 93–94(CV) acute, 95–96(CV), 95f(CV) chest pain in, 49(GIM), 50(GIM), 63t(CV), Q50(CV) echocardiography in, 64t(CV) type A, 95(CV), Q31(CV) type B, 95–96(CV), Q88(CV) vs. ST-elevation myocardial infarction, 22(CV) Aortic regurgitation, 72t(CV), 74t(CV), 76t(CV), 78(CV), Q77(CV) ventricular septal defects and, 86(CV) Aortic root dilation, 79(CV) Aortic root surgery, Q19(CV) Aortic stenosis, 70(CV), 72t(CV), 74t(CV), 76–78(CV), 76t(CV) aortic coarctation and, 90(CV) asymptomatic, 77(CV) evaluation of, 74t(CV) Heyde syndrome and, Q20(GA) with left ventricular dysfunction, Q35(CV) low-grade, 77(CV) management of, 76t(CV), 77(CV), 78(CV) mitral valve regurgitation and, 77(CV) natural history of, 77(CV) pathophysiology of, 77(CV) in Takayasu arteritis, 65–66(RM), 65t(RM) Aortic valve(s) bicuspid, 78–79(CV), 89(CV), Q16(CV), Q19(CV) lesions, 71(CV) mechanical, 82–83(CV) trileaflet, calcific degeneration of, 76–77(CV) Aortic valve replacement, 76t(CV), 78(CV), Q76(CV), Q90(CV) Aortoenteric fistulas, 75(GA) APACHE (Acute Physiologic and Chronic Health Evaluation) score, 24(GA), 95(PM) APACHE II (Acute Physiology and Chronic Health Evaluation II) score, 24(GA) Aphasia, in stroke, 40(NR)
Cumulative Index
Apheresis, therapeutic, 41–42(HO), 41t(HO) Aphthous ulcers in Crohn disease, 35–36(GA) in ulcerative colitis, 36(GA) Apical ballooning syndrome, 19(CV) Apixaban, for pulmonary embolism, 50t(PM) Aplasia, pure red cell, 3f(HO), 3(HO), 3t(HO) Aplastic anemia, 1–3(HO), 2f(HO), 2t(HO), 52(HO), Q2(HO), Q66(HO) Aplastic crisis, in sickle cell disease, 30t(HO), Q35(HO) Apley scratch test, 54(GIM), 54t(GIM) Apnea-hypopnea index (AHI), 65(PM), 66(PM) Apnea test, 81(NR), Q8(NR) Apolipoprotein A-1, 64(GIM) Apolipoprotein B, 64(GIM) Apolipoprotein E, in Alzheimer disease, 43(NR) Apoplexy, pituitary tumor, 18(EN), 19(EN), 22(EN), Q14(EN) Appendix, carcinoid tumors of, 83(HO), Q140(HO) Apprehension test, 54(GIM), 54t(GIM), 55f(GIM) Apraxia, Q50(NR) in Alzheimer disease, 43(NR) in Parkinson-like syndromes, 51(NR) ARBs. See Angiotensin receptor blockers Areflexia, in myelopathy, 64(NR) Arenaviridae, as viral hemorrhagic fever causal agent, 60t(ID) Arformoterol, for chronic obstructive pulmonary disease, 22t(PM) Argatroban effect on thrombin clotting time, 43(HO) for heparin-induced thrombocytopenia, 51(HO) for pulmonary embolism, 50t(PM) for venous thromboembolism, 56–57(HO) Arginine vasopressin, in pregnancy, 78(NP) Arginine vasopressin deficiency, in diabetes insipidus, 20(EN) Aristolochic acid, Q68(NP) Aromatase inhibitors adverse effects of, 69(HO), 72–73(HO), 111(HO) for breast cancer, 69(HO), 72–73(HO), 72(HO), 74(HO), Q142(HO) Arrhythmias, 48–61(CV) atrial fibrillation. See Atrial fibrillation atrial flutter, 50(CV), 55(CV), 55f(CV) atrioventricular block, 49–50(CV) bradycardia, 48–50(CV) diagnostic testing for, 11–12(CV), Q33(CV) in heart failure, 31(CV), 31t(CV) in hemochromatosis, 35(HO) in inflammatory myopathies, 60(RM) inherited syndromes of, 58–60(CV) post-myocardial infarction, 26(CV) in pregnancy, 106–107(CV), 106t(CV) as syncope cause, 46(GIM), Q156(GIM) tachycardia, 50–52(CV) in tumor lysis syndrome, 73(NP) ventricular, 57–58(CV) Arsenic trioxide, for acute myeloid leukemia, 11(HO) Arsine gas exposure, as hemolytic anemia cause, 35(HO) Arterial blood gas measurements, in chronic obstructive pulmonary disease, 19–20(PM), Q57(PM) Arterial insufficiency, in diabetic foot infections, 18(ID) Arterial oxygen saturation, pulse oximetry measurement of, 3(PM) Arterial ulcers, 73–74(DM) Arteriolopathy, calcific uremic, 88(NP) Arteriosclerosis. See Atherosclerosis Arteriovenous fistulas, 88(CV), Q83(CV) in Ehlers-Danlos syndrome, 73–74(RM) Arteriovenous malformations. See Angioectasia Arteritis giant cell, 2t(CV), 63t(RM), 64(RM), 65(RM), 92(CV), Q15(NP), Q24(RM), Q55(RM), Q92(NP) fever of unknown origin in, 53(ID) Takayasu, 63t(RM), 65–66(RM), 65t(RM), 93(CV), Q46(RM), Q79(CV) temporal, 99(GIM), Q95(GIM) Arthralgia in adult-onset Still disease, 72(RM), 73t(RM) in inflammatory myopathies, 59(RM) in mixed connective tissue disease, 47t(RM) in Sjögren syndrome, 47(RM) in systemic sclerosis, 43(RM) Arthritis, 2-3(RM). See also Osteoarthritis; Psoriatic arthritis; Reactive arthritis; Rheumatoid arthritis; Septic arthritis in adult-onset Still disease, 72(RM), 73t(RM) in Campylobacter infection, 67(ID) chronic obstructive pulmonary disease and, 19t(PM) crystalline. See Crystal-induced arthropathies in inflammatory myopathies, 59(RM) inflammatory vs. noninflammatory, Q65(RM) in Kawasaki disease, 66(RM) in Lyme disease, 25t(ID), 26(ID) in mixed connective tissue disease, 47(RM), 47t(RM), 48(RM) monoarticular, 2(RM), Q27(RM) oligoarthritis, 2(RM) polyarthritis, 2–3(RM) in shigellosis, 67(ID) Asbestos exposure, synergistic interaction with smoking, 58(PM) Asbestos-related lung disease, 40–42(PM), 40t(PM), 41f(PM) chest radiography in, 3(PM), Q60(PM) lung cancer, 84t(HO) mesothelioma, 40(PM), 40t(PM), 43t(PM), 62–63(PM), 62(PM) pleural effusion, 43t(PM) Ascending pinprick examination, 64(NR) Ascites, 70(GA), Q23(GA) in cancer of unknown primary site, 105(HO), Q141(HO) in cardiovascular disease, 63(GA), Q23(GA) in decompensated cirrhosis, Q8(GA) in hepatorenal syndrome, 73t(NP) new-onset, 62–63(GA), Q23(GA) in ovarian cancer, 76(HO), 77(HO), 105(HO), Q100(HO), Q141(HO) in spontaneous bacterial peritonitis, Q3(GA) Asherman syndrome, 579(EN), Q3(EN) Asian Americans cardiovascular disease in, 1(CV) epidermal growth factor receptor inhibitor therapy in, Q91(HO)
factor V Leiden in, 53(HO) melanoma in, 68(DM) prostate cancer in, 89(HO) Asians diverticula in, 43(GA) intracerebral hemorrhage in, 27(NR) intracranial atherosclerosis in, 27(NR) Stevens-Johnson syndrome in, 18(NR), 19(NR), 19t(NR), 20t(NR), Q85(NR) tuberculosis in, 32(ID) Aspartate aminotransferase in acute viral hepatitis, 53t(GA), Q5(GA) in alcohol-induced liver disease, 57(GA) in autoimmune hepatitis, 58(GA) in inflammatory myopathies, 60(RM), 61(RM) in liver disease, 53(GA), 53t(GA) in primary biliary cirrhosis, 60(GA) Aspergillomas, 40(ID) Aspergillosis, 40(ID) allergic bronchopulmonary, 10(PM), Q20(PM) differentiated from asthma, 8t(PM), 10(PM) differentiated from cystic fibrosis, 10(PM), Q20(PM) fever of unknown origin in, 53(ID) in immunocompromised patients, 39(GIM) pulmonary, in immunocompromised patients, Q108(ID) in transplant recipients, 75(ID), 76(ID), Q105(ID) Aspergillus fumigatus, 10(PM), Q20(PM) Aspiration, 3(GA) acute respiratory distress syndrome and, 71t(PM) of joints in prosthetic joint infections, 57(RM) in rheumatic disease, 8(RM), 9(RM) in septic arthritis, 54(RM), 55(RM) Aspirin for acute coronary syndromes, 20(CV), 22(CV) as adjunct to dyslipidemia management, 69(GIM), 69t(GIM) adverse effects of, 20(CV) for angina, 20(CV) for atrial fibrillation, 53t(CV), 54(CV) cardioprotective effects of, 6(EN), 17(CV), 86(NP) in chronic kidney disease, 86(NP) contraindication in hemophilia, 45(HO) for coronary artery disease, Q103(CV) for coronary stents, 19(CV) in diabetes mellitus, 6(EN) enteric-coated, 16(GA) for essential thrombocytopenia, 8(HO) gastrointestinal bleeding and, 16(GA), 69(GMI), 69t(GIM) for giant cell arteritis, 65(RM) hepatotoxicity of, 70(GA) for ischemic stroke prevention, 30(CV), Q62(CV) for metabolic syndrome, 68(GIM), 68t(GIM) as microscopic colitis cause, 39t(GA) for migraine, 7t(NR) for non-ST-elevation myocardial infarction, Q65(CV) overdose of, 90(PM) for pericarditis, 66(CV), 66t(CV), 67t(CV), Q26(CV) perioperative management of, 130(GIM), 132(GIM) for peripheral arterial disease, 99(CV) platelet function effects of, 52(HO), 53(HO) for polycythemia vera, 7(HO) for preeclampsia prevention, 80(NP), Q85(NP) in pregnancy, 108t(CV) for prosthetic valves, 82(CV), 83(CV) for ST-elevation myocardial infarction, 23(CV) for stroke, 31(NR), 38(NR), Q17(NR) for tension-type headache, 9(NR) toxicity of, Q57(NP) use in peptic ulcer disease, 12(GA) in women, 30(CV), Q62(CV) Aspirin sensitivity, asthma and, 10–11(PM), 14(PM) Assistive devices, use in osteoarthritis, 25(RM) AST. See Aspartate aminotransferase Asthma, 7–16(PM) aspirin-sensitive, 10–11(PM), 14(PM) bronchial challenge testing for, 1(PM), 8(PM), 9–10(PM) during pregnancy, 15–16(PM), Q29(PM) chest radiography in, 4(PM) clinical evaluation of, 7–8(PM) cough-variant, 9–10(PM), 37(GIM), 38f(GIM), 39(GIM), Q83(PM) differentiated from allergic bronchopulmonary aspergillosis, 8t(PM), 10(PM) cystic fibrosis, 8t(PM), Q20(PM), Q33(PM) heart failure, 8(PM), 8t(PM) diffusing capacity for carbon monoxide in, 3(PM) in eosinophilic esophagitis, 7(GA) epidemiology of, 7(PM) exacerbations of management of, 15(PM), 75–76(PM), 76t(PM), Q91(PM) respiratory failure in, 75(PM), 76(PM), Q51(PM) flow-volume loops in, 2f(PM) in gastroesophageal reflux disease, 9(GA) inadequately controlled/refractory, 12(PM), 15(PM), Q23(PM), Q38(PM) as indication for pneumococcal vaccination, 14(GIM), 16(GIM), Q159(GIM) management of, 11–15(PM) with allergen immunotherapy and allergen avoidance, 15(PM) with alternative and complementary therapies, 15(PM) in exacerbations, 15(PM), 75–76(PM), 76t(PM), Q91(PM) improper inhaler use in, 12(PM), Q23(PM) in mild persistent asthma, Q54(PM) with pharmacotherapy, 11–15(PM) during pregnancy, 16(PM), Q29(PM) in refractory asthma, 12(PM), Q23(PM), Q38(PM) severe asthma, Q73(PM) with step-down therapy, 11(PM), 13f(PM), Q9(PM) as mortality cause, 7(PM), 13(PM) natural history of, 7(PM) occupational, 8–9(PM), 39(PM) overview of, 7(PM) pathogenesis of, 7f(PM), 7(PM)
7
Cumulative Index
Asthma (continued) during pregnancy, 15–16(PM), Q29(PM) reactive airways dysfunction syndrome of, 9(PM), 84(PM) severity classification of, 11(PM), 12t(PM) syndromes of, 8–11(PM) triggers of, 7–8(PM) virus-induced, 9(PM) Asthma medications, 11–15(PM) Astrocytomas, 78(NR), 78t(NR), 107(HO) Ataxia adult-onset chronic, 52(NR) anticonvulsant-related, 19t(NR) evaluation of, 52(NR) subacute, 52(NR) tremor and, 53(NR) Atazanavir, 93(ID), 93t(ID) kidney stones and, Q24(NP) Atelectasis in acute respiratory distress syndrome, 70(PM) carcinoid tumors and, 62(PM) in chronic obstructive pulmonary disease, 17t(PM) in neuromuscular weakness, 73t(PM) pleural effusion in, 44t(PM) postoperative, 72(PM) rounded, 40t(PM), 41f(PM), 41(PM) Atenolol for arrhythmias, 51t(CV) in older patients, 39(NP) in pregnancy, 107–108(CV), 108t(CV) Atheroembolic disease, acute kidney injury in, 72–73(NP) Atheromas, aortic, 37–38(NR), 40t(NR), 96(CV), 96f(CV) Atherosclerosis, 33(NP), 68(GIM) in acute coronary syndromes, 19(CV) in acute limb ischemia, 101–102(CV), 102t(CV) aortic, 92(CV), 93(CV), 95–96(CV) ulceration in, 95(CV), 95f(CV) brain infarction and, 33(NP) intracranial, stroke and, 27(NR), 38(NR), Q10(NR) in nephrotic syndrome, 49t(NP) in peripheral arterial disease, 97(CV) renovascular, 41–42(NP), Q43(NP), Q62(NP) in systemic lupus erythematosus, 2(CV), 37(RM), Q5(RM) Atherosclerotic plaques, in acute kidney injury, 72–73(NP) Atherosclerotic vascular disease, in diabetes mellitus, 6(EN) Athletes concussions in, 11(NR), 11t(NR), Q11(NR) sickle cell trait screening in, 28–29(HO) Athlete’s heart, vs. hypertrophic cardiomyopathy, 41(CV) Atlantoaxial subluxation, in rheumatoid arthritis, 21(RM), Q33(RM) Atopic dermatitis, 5(DM), 8-10(DM). See also Eczema of hand, 6(DM), Q29(DM) Atorvastatin, 64–65(GIM) for dyslipidemia in HIV/AIDS, 89(ID), Q72(ID) Atovaquone, for babesiosis, 27(ID) Atovaquone/proguanil, as malaria prophylaxis, 62t(ID) ATRA. See All-trans-retinoic acid Atrial fibrillation, 52–55(CV) anticoagulation therapy for, 37(NR), 38(RN), Q40(NR) atrioventricular heart block and, 49–50(CV) as atrioventricular nodal blocker contraindication, 57(CV) central sleep apnea and, 67(PM) clinical presentation of, 52–53(CV) diastolic dysfunction and, 51(CV) electrocardiogram in, 52f(CV) heart failure and, Q30(CV) hypertrophic cardiomyopathy and, 44–45(CV) management of, 53–55(CV) nonpharmacological strategies for, 54–55(CV), Q10(CV) with pharmacotherapy, 53–54(CV), 53t(CV) rate versus rhythm control in, 54(CV) thromboprophylaxis in, 53–54(CV), 53t(CV), 55(CV), Q52(CV) mitral regurgitation and, 71(CV), Q67(CV) mitral stenosis and, 71(CV), 79(CV) in older adults, 50(CV) paroxysmal, Q37(CV) pericarditis and, 69(CV) in pregnancy, anticoagulants for, 108(CV), 110t(CV) repaired tetralogy of Fallot and, Q55(CV) right ventricular apical pacing and, 50(CV) stroke and, 26(NR), 27(NR), 32(NR), Q57(NR) stroke prevention in, 37(NR), 38(NR) in subclinical hyperthyroidism, 33(EN) Wolff-Parkinson-White syndrome and, 56(CV) Atrial flutter, 50(CV), 55(CV), 55f(CV) Atrial septal defects, 73t(CV), 84–85(CV), 84f(CV), Q14(CV) ostium primum defects, 84(CV), 85(CV), 86t(CV), Q41(CV) ostium secundum defects, 84(CV), 86t(CV), Q14(CV), Q101(CV) Atrial tachycardia, 57(CV) Atrioventricular block, 49–50(CV), Q98(CV) Atrioventricular nodal blockers, contraindications to, 57(CV) Atrioventricular nodal reentrant tachycardia, 56(CV), 56f(CV), Q59(CV) Atrioventricular node ablation, for atrial fibrillation, 54(CV) Atrioventricular reciprocating tachycardia, 56–57(CV) Atropine, contraindication to, 60(CV) Attention-deficit/hyperactivity disorder, 115(GIM), Q93(GIM) Attention deficits in dementia, 40t(NR) in Tourette syndrome, 55(NR) Attenuated familial adenomatous polyposis, 47(GA), 51t(GA) Auer rods, 10f(HO), 10(HO) Aura in epilepsy, 14(NR), 15(NR) in migraine, 5(NR), 6t(NR), 7(NR), 13t(NR), Q70(NR) in seizures, 13t(NR) Autism spectrum disorders, 115–116(GIM), Q128(GIM) Autoimmune diseases blistering (bullous) diseases in, 45–48(DM), 46t(DM), 65(DM), 65t(DM), Q46(DM) chronic tubulointerstitial disorders in, 45t(NP) in common variable immunodeficiency, 55(ID), Q1(ID)
8
erythroderma in, 65t(DM) hypocalcemia in, 65(EN) leukocytoclastic vasculitis in, 70(RM21(RM), Q33(RM) membranoproliferative glomerulonephritis in, 57(NP) periorofacial depigmentation in, 60(DM) silicosis and, 42(PM) as vasculitis cause, 64t(RM) Autoimmune hepatitis, 53t(GA), 58(GA) Autoimmune pancreatitis, 27–28(GA), 28f(GA), Q35(GA) Autoimmune pericarditis, 62t(CV), 65(CV) Autoimmune polyglandular syndrome, 64t(EN), Q33(EN) Autonomic dysfunction, in peripheral neuropathy, 69t(NR) Autonomic neuropathy, 71(NR), 71t(NR) Autosomal dominant polycystic kidney disease (ADPKD), 35(NP), 63–64(NP), 63t(NP), Q2(NP), Q88(NP) Autosomal recessive polycystic kidney disease (ARPKD), 63t(NP), 64(NP), Q88(NP) Azacitidine, for myelodysplastic syndromes, 6(HO), Q49(HO) Azathioprine adverse effects of, 93(NP), 93t(NP) for autoimmune hepatitis, 58(GA) for Behçet disease, 71(RM) corticosteroids and, 10(RM) for Crohn disease, 37f(GA), 37(GA), 37t(GA), Q17(GA) drug interactions of, Q68(RM) for inflammatory myopathies, 62(RM) in kidney transplant recipients, 93t(NP) in pregnancy, 11(RM), 41(RM) for rheumatic disease, 11(RM) for systemic lupus erythematosus, 41(RM) for systemic sclerosis-related lung disease, 44(RM) for ulcerative colitis, 37f(GA), 37(GA), 37t(GA) Azelaic acid for acne, 20t(DM) for rosacea, 22(DM) Azithromycin for babesiosis, 27(ID) for Campylobacter infections, Q9(ID) for cat-scratch disease, Q69(ID) for chancroid, 48t(ID) for community-acquired pneumonia, Q34(ID), Q50(ID) as infective endocarditis prophylaxis, 85t(ID) for Mycobacterium avium complex infections, 38(ID) for Neisseria gonorrhoeae infections, 45t(ID), 46(ID) for travelers’ diarrhea, 63t(ID) Azotemia, prerenal, 67(NP), 68(NP), Q67(NP) Babesia microti, as babesiosis causal agent, 27(ID), Q93(ID) Babesiosis, 25t(ID), 27(ID), Q93(ID) erythrocytapheresis for, 41(HO) as hemolytic anemia cause, 35(HO) transfusion-related transmission of, 40(HO) Bacille Calmette-Guérin for bladder cancer, 95(HO), Q127(HO) as tuberculosis prophylaxis, 31(ID), 33(ID), 36(ID) tuberculosis screening and, 33(ID), Q12(ID) Bacillus anthracis, as anthrax causal agent, 56t(ID), 57f(ID), 57(ID) Bacitracin, topical, allergy to, 33(DM) Back pain in ankylosing spondylitis, 29(RM), 31(RM), 32t(RM) in aortic syndromes, 96(CV) in compressive myelopathy, 65(NR) mediastinal masses and, 63(PM) in spinal cord disorders, 64(NR) in spondyloarthritis, 31–32(RM), Q69(RM) in thoracic aortic aneurysms, 93(CV), 94(CV) in vertebral osteomyelitis, 52(ID) Backwash ileitis, 36(GA) Baclofen for multiple sclerosis, 63(NR), 64(NR), Q63(NR) for restless legs syndrome, 56–57(NR) for spasticity, 63(NR), 63t(NR) Bacteremia in infective endocarditis, 81–82(CV), 84(ID), 85(ID) in salmonellosis, 68(ID) in septicemic plague, 58–59(ID) in spondylodiskitis, 51–52(ID) Bacterial infections. See also specific bacteria as arthritis cause, 54(RM), 55–58(RM), 57t(RM), Q17(RM) cutaneous, 22–26(DM) hypersensitivity pneumonitis and, 35(PM), 36t(PM) in transplant recipients, 75(ID) Bacterial overgrowth, in small intestine, 31t(GA), 32f(GA), 33(GA), 33t(GA), 34(GA), Q55(GA) Bacterial peritonitis, spontaneous, 63(GA), Q3(GA) Bacteriuria asymptomatic, 31(ID), 78(ID), Q85(ID) in pregnancy, 77(NP) screening for, 7t(GIM), 9(GIM) Bacteroides infections, of animal bites, 16(ID) Baker (popliteal) cyst, 61(GIM) Balanitis, circinate, 4t(RM), 31(RM) Ballism, 54(NR) Balloon dilatation, for achalasia, 3–4(GA) Balloon enteroscopy, in gastrointestinal bleeding, 80(GA), 81(GA) Balloon mitral valvuloplasty, for mitral stenosis, Q105(CV) Balloon valvotomy, for mitral stenosis, 79(CV) Balloon valvuloplasty for aortic stenosis, 77(CV) for bicuspid aortic valve disease, 79(CV) for pulmonary valve stenosis, Q43(CV) Balsalazide, for inflammatory bowel disease, 37t(GA) Band ligation, for variceal bleeding, 61–62(GA) Barcelona Classification for Liver Cancer, 65(GA), 66f(GA) Bariatric surgery, 21t(GA), 73–74(GIM), 73f(GIM), 73(GIM), 74t(GIM), Q15(GIM), Q150(GIM) complications of, 20–23(GA), 21t(GA), Q47(GA), Q67(GA) for diabetes mellitus, 4t(EN), 7(EN) malabsorptive procedures in, 20t(GA), 21–22(GA) restrictive procedures in, 20t(GA), 21(GA) Roux-en-Y procedure in, 20(GA), 20t(GA), 21–22(GA), 21f(GA) Barium enema, for colorectal cancer screening, 48(GA), 49t(GA)
Cumulative Index
Barium radiography (swallow) for achalasia, 3(GA), 6(GA) for diffuse esophageal spasm, 4–5(GA), Q14(GA) for multinodular goiter diagnosis, 37(EN) for peptic ulcer disease, 12(GA) Barrett esophagus, 7(GA), 10–11(GA), 10f(GA), 11f(GA), Q37(GA), Q73(GA) esophageal cancer and, 82(HO) Bartonella henselae infections, 17(ID), Q69(ID) Bartonella quintana infections, 32(DM) Bartonellosis fever of unknown origin in, 53(ID) as hemolytic anemia cause, 35(HO) in HIV/AIDS, 91–92(ID) Bartter-like syndrome, 19(NP), Q104(NP) Bartter syndrome, 31(NP) Basal cell carcinoma, 34–35(DM), 35f(DM), Q19(DM) Basal ganglia in movement disorders, 47(NR) in Wilson disease, 55(NR) Basic calcium phosphate deposition disease, 54(RM), Q4(RM) Bath Ankylosing Spondylitis Disease Activity Index, 9(RM) Bayes theorem, 4(GIM) Bazex syndrome, 59t(DM) BCR-ABL inhibitors for acute lymphoblastic leukemia, 12(HO) for chronic myeloid leukemia, 9(HO) Beau lines, 68(DM), 69f(DM), Q3(DM) Beclomethasone, for chronic obstructive pulmonary disease, 22t(PM) Bedbugs, 32(DM), 32f(DM), Q1(DM) Beer potomania, 12(NP) Bee stings, 31(DM), 44(DM) as hemolysis cause, 35(HO) Behavioral counseling, 16(GIM) Behavioral health. See Mental and behavioral health Behavioral therapy. See also Cognitive-behavioral therapy for obesity, 72(GIM) for urinary incontinence, 121–122(GIM) Behçet syndrome, 4t(RM), 70–71(RM), 70(DM), 71f(RM), Q83(RM) cardiovascular disease and, 2t(CV) Belimumab for rheumatic disease, 13t(RM) for systemic lupus erythematosus, 14(RM), 40(RM) Bell palsy, 70(NR) Bence-Jones protein, 46(NP) Benign pancreatic hyperenzymemia, 23(GA) Benign paroxysmal positional vertigo, 41(GIM), 42f(GIM), 43(GIM), Q14(GIM), Q20(GIM) Benign prostatic hyperplasia, 78(GIM), 78t(GIM), Q18(GIM), Q70(GIM) chronic tubulointerstitial disorders in, 47(NP) Benserazide, for Parkinson disease, 50(NR), 50t(NR) Benzodiazepines for alcohol poisoning, 89(PM) for Alzheimer disease, 45(NR) for cocaine-induced chest pain, Q88(PM) contraindication for cancer pain, 30(GIM) hepatotoxicity of, 70(GA) for insomnia, 44(GIM), 45(GIM), 45t(GIM), Q153(GIM) for neuroleptic malignant syndrome, Q67(PM) overdose/toxicity of, 73(PM), 91t(PM) for status epilepticus, 23(NR) Benzoyl peroxide, for acne, 20t(DM), 21(DM) Bereavement, 32(GIM), 109(GIM) Berlin diagnostic criteria, for acute respiratory distress syndrome, 70–71(PM) Best practice, in critical care, 94–95(PM) β-Blockers for acute coronary syndromes, 20(CV) adverse effects of, 29(CV), 49(CV) for angina, 16(CV)f, 17(CV), 20(CV), Q99(CV) for aortic intramural hematoma, Q9(CV) for aortic syndromes, 95(CV) for chronic stable angina, Q70(CV) contraindications to, 40t(NP) cocaine-related hypertensive crises, 90(PM) decompensated heart failure, 34(CV) for coronary artery disease, Q103(CV) coronary stents and, 19(CV) diabetes mellitus and, 29(CV) diltiazem as alternative to, Q57(CV) for heart failure, 32(CV), 33–34(CV), 33t(CV), 35–36(CV), Q17(CV), Q24(CV), Q36(CV) in decompensated heart failure, 38(CV) for hypertrophic cardiomyopathy, 43(CV), 45t(CV) indications for, 40t(NP) as lichen planus cause, 11(DM), 12(DM) for long QT syndrome, 58(CV) for migraine prevention, 7(NR) in pregnancy, 9(NR) for mitral regurgitation, 80(CV) for non-ST-elevation myocardial infarction, Q65(CV) in pheochromocytoma, 49(EN), 50(EN) perioperative use of, 126t(GIM), 127(GIM), 128(GIM), Q125(GIM) for peripartum cardiomyopathy, 107(CV) for peripheral arterial disease, 99(CV) post-revascularization use of, 19(CV) in pregnancy, 79t(NP), 107–108(CV), 108t(CV) for premature ventricular contractions, 57(CV) for restrictive cardiomyopathy, 47(CV) side effects of, 40t(NP) for ST-elevation myocardial infarction, 23(CV), 24f(CV), 25(CV) stroke prevention and, 39(NP) for supraventricular tachycardia, in pregnancy, 108(CV) toxicity of, 91t(PM) for variceal bleeding, 61–62(GA) β2-agonist bronchodilators excessive sensitivity to, 13(PM) for exercise-induced bronchospasm, 10(PM) long-acting adverse effects of, 13(PM), 14(PM) for asthma, 12–13(PM), 13f(PM), 14(PM)
for chronic obstructive pulmonary disease, 21(PM), 22t(PM), 23–24(PM), 23t(PM), 26(PM), 29(PM), Q13(PM) during pregnancy, 16(PM), Q29(PM) for refractory asthma, Q38(PM) for severe asthma, Q73(PM) for virus-induced asthma, 9(PM) short-acting for asthma, 12–13(PM), 13f(PM), 16(PM) for asthma exacerbations, 15(PM), 75(PM), Q51(PM) for chronic obstructive pulmonary disease, 21(PM), 22t(PM), 23(PM) for exercise-induced bronchospasm, Q44(PM) for mild persistent asthma, Q54(PM) during pregnancy, 16(PM) β-Lactam antibiotics, 98t(ID), 99(ID) allergy to, 17(ID) for cellulitis, Q77(ID) for community-acquired pneumonia, 21t(ID), 22(ID), 22t(ID), 23t(ID) β-Lactamase inhibitors, for human bites, 17(ID) β-Lactamase-producing organisms, extended-spectrum (ESBL), 83(ID) Bethesda assay, for clotting factor inhibitors, 43(HO) Bethesda Guidelines, for colorectal cancer screening, 46(GA), 47t(GA) Bevacizumab adverse effects of, 69(HO), 69t(HO), Q87(HO) for colorectal cancer, 80(HO) for gastrointestinal neuroendocrine tumors, 83(HO) for lung cancer, 86(HO) for ovarian cancer, 77(HO) for pancreatic cancer, 82(HO) for renal cell carcinoma, 96(HO) Bezold-Jarisch reflex, 26(CV) Bias, in study design, 1(GIM) lead-time, 7(GIM) length, 7(GIM) Biballism, 54(NR) Bicarbonate acid-buffering effect of, 24(NP) in metabolic acidosis, 22–23(NP), 23–24(NP) in pregnancy, 78(NP) Biceps tendinitis, 2t(RM) Bicuspid aortic valves, 78–79(CV), 89(CV), Q16(CV), Q19(CV) Bifidobacterium infantis, for irritable bowel syndrome, 42(GA) Bile acid deficiency, 31t(GA) Bile acid malabsorption, 31t(GA) Bile acid sequestrants, 65(GIM), 65t(GIM), Q75(GIM) for diabetes mellitus, 9t(EN) Bile duct obstruction, 53t(GA), 71(GA) Bile duct stones, 72(GA) Bilevel positive airway pressure (BPAP), Q102(PM) for obstructive sleep apnea, 66(PM) Biliary cancer, 73–74(GA) Biliary colic, 71–72(GA) Biliary cysts, 73(GA), 74(GA), Q70(GA) Biliary disease, liver chemistry studies in, 53(GA), 53t(GA) Bilirubin conjugated, in urine, 5(NP) in liver disease, 53(GA), 53t(GA) in primary sclerosing cholangitis, 60(GA) Binge-eating disorder, 89(PM), 114(GIM), Q154(GIM) Biofeedback for constipation, 41(GA) for migraine, 7(NR) Biologic agents immunization and, 12(RM), Q58(RM) for rheumatic disease, 12–14(RM), 13t(RM) for rheumatoid arthritis, 20(RM) for systemic lupus erythematosus, 40(RM) Biopsy in bladder cancer, 94–95(HO) bone, in osteomyelitis, 50(ID) bone marrow in amyloid light-chain amyloidosis, Q40(HO) in aplastic anemia, 3(HO) brain in brain tumors, 78(NR) in dementia, 43(NR) computed tomography-guided percutaneous needle, in vertebral osteomyelitis, 52(ID) cutaneous, in polyarteritis nodosa, 66(RM), 67(RM) endomyocardial, in heart failure, 32(CV) esophageal, 82(HO) fine-needle aspiration of goiters, 37(EN) of thyroid nodules, 35f(EN), 36(EN), 37(EN), 43(EN), Q20(EN), Q34(EN) intestinal in celiac disease, 32(GA) in chronic diarrhea, 30(GA) in inflammatory bowel disease, 38(GA) kidney in bladder cancer, 7(NP) contraindications to, 10(NP), Q61(NP) in glomerular diseases, 48(NP) in HIV/AIDS, 74(NP) indications for, 10(NP) in lupus nephritis, Q10(RM) in multiple myeloma, Q33(HO) in primary membranous glomerulopathy, Q54(NP) liver in autoimmune liver disease, 58(GA) in gastrointestinal bleeding, 74(GA) in hepatitis B, 54(GA) in hepatitis C, 55(GA) in hereditary hemochromatosis, Q66(GA) in primary biliary cirrhosis, 60(GA) lung in diffuse parenchymal lung disease, 32(PM) in lung cancer, 86(HO) in nonspecific interstitial pneumonia, 34(PM) pleural, 45(PM), Q71(PM) in sarcoidosis, 38(PM) transbronchoscopic, 5(PM)
9
Cumulative Index
Biopsy (continued) lymph node, in head and neck cancer, 88–89(HO) muscle in inflammatory myopathies, 61(RM), 62(RM) in mitochondrial myopathy, 76f(NR) in polymyositis, Q53(RM) ovarian, 76(HO) punch, in cervical cancer, 78(HO), 79(HO) sentinel lymph node in breast cancer, 71(HO) in melanoma, 106(HO) skin in alopecia, 65(DM) in autoimmune blistering disease, 46(DM) in basal cell carcinoma, 35(DM) in drug reactions, 14(DM) in erythroderma, 65(DM) in lentigo maligna, Q7(DM) in lichen planus, 12(DM) in melanoma, 37–38(DM) in nephrogenic systemic fibrosis, 54(DM) in pigmented purpura, 17(DM) in psoriasis, 10(DM), 11(DM) in rosacea, 21(DM), 22(DM) in small-fiber neuropathy, 70f(NR) in stasis dermatitis, 8(DM) in warts, 20 of skin. See Skin biopsy spinal, in tuberculous arthritis, 56(RM), Q36(RM) sural nerve, 69(NR) temporal artery, 2(NR) in giant cell arteritis, Q24(RM) transrectal, in prostate cancer, 90(HO) Bioterrorism agents of, 56–61(ID) anthrax, 56t(ID), 57–58(ID) botulism, 59(ID) class A agents, 56(ID), 56t(ID), 57(ID) class B agents, 56(ID), 57(ID) class C agents, 56(ID), 57(ID) plague, 58–59(ID) smallpox, 58f(ID), 58(ID) tularemia, 59–60(ID) viral hemorrhagic fever, 60–61(ID), 60t(ID) definition of, 56(ID), 57(ID) Bipolar disorder, 109(GIM), 112(GIM), Q140(GIM) epilepsy and, 16(NR) Bird droppings, hypersensitivity pneumonitis and, 35(PM), 36t(PM) Bisacodyl, for constipation, 41(GA) Bismuth, for microscopic colitis, 38(GA) Bismuth subsalicylate, for travelers’ diarrhea, 63(ID), 63t(ID) Bisoprolol, for heart failure, 33(CV), Q17(CV) Bisphosphonates acute tubular necrosis and, Q15(NP) adverse effects of, 15(HO), 69(HO), 70(EN) for breast cancer, 75(HO) contraindication in chronic kidney disease-mineral bone disorder, 88(NP), Q42(NP) with corticosteroids, 10(RM), 11(RM) drug holiday from, 70–71(EN) as esophagitis cause, 6(GA) for hypercalcemia, 63(EN), Q15(EN) intravenous, 70(EN) as jaw osteonecrosis cause, 15(HO) in lung cancer, 86(HO) for osteoporosis, 69(EN) Bite cells, 27f(HO), 27(HO) Bites bedbug, 32(DM), 32f(DM), Q1(DM) insect, 31(DM), 32(DM), 32f(DM), 44(DM) mosquito, 31(DM) spider, 32–33(DM), 33f(DM) Bite wounds animal, 16–17(ID) human, 17(ID) Bivalirudin for acute coronary syndromes, 21–22(CV) for heparin-induced thrombocytopenia, 51(HO) for pulmonary embolism, 50t(PM) for ST-elevation myocardial infarction, 26(CV) for venous thromboembolism, 56–57(HO) Biventricular pacing, 36(CV) “Black Death.” See Plague Blackheads, 18(DM) Bladder metastases to, 78(HO) overactive, in benign prostatic hypertrophy, 78(GIM) Bladder cancer, 10(GIM), 94–95(HO), Q111(HO), Q127(HO) risk factors for, 7(NP) screening for, 7(NP) Bladder outlet obstruction (BOO), 78(GIM) Blastocystis, 71(ID), Q48(ID) Blastomycosis, 41–42(ID), Q42(ID) Bleeding. See also Hemorrhage as anemia cause, 20(HO) bevacizumab-related, Q87(HO) diverticular, 77(GA), Q72(GA) in essential thrombocytopenia, 8(HO) gastrointestinal, in polycythemia vera, 7(HO) gastrointestinal. See Gastrointestinal bleeding in hemophilia, 98, 43(HO), 45(HO) hemorrhoidal, 77(GA) mucocutaneous, in platelet disorders, 47(HO) myelodysplasia-related, Q5(HO) postpartum in, von Willebrand disease, 45(HO), 46(HO) in thrombocytopenia, 47(HO) vaginal, in cervical cancer, 78(HO), 79(HO) variceal, 61–62(GA), 62t(GA), 63t(GA), 74–75(GA), Q75(GA) warfarin-related, 58(HO), 61(HO), Q74(HO)
10
Bleeding disorders, 42–47(HO) acquired, 42(HO), 46(HO) congenital, 42(HO), 43(HO), 44t–45t(HO), 45–46(HO) laboratory evaluation of, 43(HO) patient evaluation in, 42–43(HO) patient history of, 42(HO) physical examination in, 43(HO) Bleeding time tests, 52(HO) Bleomycin, as pneumonitis cause, 110(HO) Blepharitis, 95(GIM) Blepharospasm, 53(NR) Blistering diseases, autoimmune, 45–48(DM), 46t(DM), 65(DM), 65t(DM), Q46(DM) Blisters in burns, 34(DM) as emergent skin condition, 1(DM), 2(DM) in impetigo, 24f(DM) in lupus erythematosus, 49(DM) Blood. See also Bleeding; Hemorrhage in stool, 30(GA) Bloodborne pathogens, transfusion-related transmission of, 40(HO) Blood flow cerebral, 33(NP) renal, 33–34(NP) impaired autoregulation of, 68(NP) Blood glucose levels, 1(EN), 5(EN), 6(EN), 7(EN), 8–9t(EN), 10(EN), 11(EN), 14(EN) postprandial, in diabetes mellitus, Q35(EN) relationship with hemoglobin A1c, Q41(EN) Blood glucose monitors, with memory function, 6(EN) Blood glucose testing, in diabetes mellitus, 5(EN) Blood pressure. See also Hypertension; Hypotension normal, 38(NP) in pregnancy, 105(CV) target goal of, in diabetes mellitus, 6(EN) target level of, in pregnancy, 77(NP), 79(NP) Blood pressure measurement, 35–37(NP), 35t(NP), 36f(NP) ambulatory monitoring, 35–36(NP), 36f(NP), 37(NP), 42(NP), Q84(NP) in masked hypertension, 36(NP), 42(NP), Q46(NP) in resistant hypertension, Q12(NP) in white coat hypertension, 36(NP), 42(NP), Q23(NP) electronic, 36–37(NP) at home, 37(NP), Q33(NP) for hypertension classification, 37–38(NP), 37t(NP) Internet-based protocols for, 37(NP) in medical office, 35(NP), 35t(NP) variability in, Q84(NP) Bloodstream infections central line-associated, 80–82(ID), 81t(ID) in Staphylococcus aureus infections, Q10(ID) Blood substitutes, 38(HO) Blood transfusions acute respiratory distress syndrome and, 71t(PM) allogeneic, minimization of, 38(HO) hemoglobin A1c and, Q37(EN) for shock, 77(PM) for thalassemia, 28(HO) Blood urea nitrogen (BUN) in acute pancreatitis, Q54(GA) limitations as kidney function indicator, 1(NP), 2t(NP) Blood urea nitrogen-creatinine ratio, in prerenal azotemia, 67(NP) Blood viscosity, in hypertension, 35(NP) Blurred vision, in diabetes mellitus, 2(EN) BMD. See Bone mineral density BMI, Obstruction, Dyspnea, Exercise (BODE) Index, 19(PM), 20t(PM) BNP. See B-type natriuretic peptide Boceprevir, for hepatitis C, 55(GA) Body dysmorphic disorder, 113(GIM), Q85(GIM) Body mass index (BMI), 69(GIM), 70(GIM), 70t(GIM), Q150(GIM) in obesity hypoventilation syndrome, 68(PM) Bone, osteoporotic, 67(EN), 67f(EN) Bone density loss. See also Osteopenia; Osteoporosis in hypogonadotropic hypogonadism, 19(EN) in subclinical hyperthyroidism, 33(EN) treatment of, Q10(EN) Bone disease, metabolic, cirrhosis and, 69(GA) Bone marrow examination, in thrombocytopenia, 48(HO), 49(HO) Bone marrow failure syndromes, 1–4(HO) thrombocytopenia in, 52(HO) Bone mineral density (BMD) dual-energy x-ray absorptiometry measurement of, 62t(EN), 67(EN), 68f(EN) in osteoporosis, 66(EN), 67(EN), 71–72(EN) racial factors in, 67(EN) Bone mineral density testing, in cirrhosis, 69(GA), 70(GA) Bone remodeling, 67(EN), 72(EN) Bone scans in multiple myeloma, 13f(HO), 13(HO) in osteomyelitis, 50(ID) in Paget disease of bone, 73(EN), 73f(EN) Borrelia burgdorferi sensu stricto, as Lyme disease causal agent, 24(ID), 26(ID) neurologic manifestations of, Q19(ID) serologic testing for, 26(ID), Q23(ID), Q70(ID) Bortezomib, for multiple myeloma, 15(HO) Botulinum toxin for achalasia, 4(GA) for diffuse esophageal spasm, 5(GA) for focal dystonia, 53(NR) for spasmodic torticollis, Q94(NR) for spasticity, 63(NR) for tics, 55(NR) Botulism, 59(ID), Q51(ID) as bioterrorism agent, 56t(ID) bulbar signs of, 59(ID), Q51(ID) Bouchard nodes, 22f(RM), 22(RM) Boutonnière deformity, 17t(RM) Bovine spongiform encephalopathy, 12(ID) Bowen disease, 36(DM) Brachial plexopathy, 70(NR) Brachioradial pruritus, 43(DM), Q44(DM) Brachytherapy, for prostate cancer, 91(HO)
Cumulative Index
Bradycardia, 48–50(CV), Q98(CV) in anaphylaxis, 85(PM) Bradykinesia in atypical parkinsonism, 51(NR) in Parkinson disease, 48(NR), 49(NR), 50(NR) Brain, hypertension’s effects on, 33(NP) Brain abscess, 6–7(ID), 7t(ID), Q80(ID) Brain death, 80–81(NR), Q8(NR) Brain injury. See also Head injury ischemic, as frontotemporal dementia cause, 46(NR) Brain metastases increased intracranial pressure in, 108(HO), Q109(HO) in lung cancer, 86(HO), 88(HO) prophylactic cranial radiation for, 86(HO), 88(HO), Q85(HO) in melanoma, Q126(HO) Brainstem lesions, central sleep apnea and, 67(PM) Brain tumors, 67(HO), 77–80(NR), 78t(NR), 107(HO) epilepsy and, 15(NR) intracerebral hemorrhage and, 27(NR) management of, 79(NR) metastatic, 78t(NR) radiographic features of, 78t(NR) vs. multiple sclerosis, 60t(NR) BRCA1/BRCA2 gene mutations, 9(GIM) in breast cancer, 70(HO), 70t(HO), 75(HO), Q83(HO) carriers of, screening of, 71(HO) in ovarian cancer, 70(HO), 75(HO), Q138(HO) Breast candidiasis of, 27f(DM) cystic, 83(GIM) Paget disease of, 27f(DM) Breast cancer, 69–75(HO), 84(GIM) BRCA1/BRCA2 mutations in, 70(HO), 70t(HO), Q83(HO) as cancer of unknown primary site, 105(HO), Q89(HO) early-stage ductal carcinoma in situ, 71(HO), Q136(HO) invasive, 71(HO), Q112(HO) treatment of, 71–72(HO), Q142(HO) epidemiology of, 69–70(HO) estrogen-dependent, 72–73(HO) follow-up monitoring in, 74(HO), Q123(HO) genetic factors in, 67(HO), 70(HO), 70t(HO), 72(HO), Q83(HO) HER2/neu expression in, 68(HO), 72(HO), 73(HO), 74(HO) hormone therapy and, 88–89(GIM) inflammatory, 73–74(HO) lifetime risk of, 29–30(CV) locally advanced, 73–74(HO) in men, 72(HO) metastatic, 72(HO), 74–75(HO), 77(NR), 108(HO), Q109(HO) to the heart, 47(CV) as mortality cause, 57(PM), 58(PM) myasthenia gravis and, 74(NR) Peutz-Jeghers syndrome and, 47–48(GA) pleural effusion in, 109(HO) prognosis in, 72(HO) radiation therapy for, 102(CV) radiation therapy-related, 110–111(HO) recurrent, Q137(HO) risk factors for, 69–70(HO) risk reduction for, 70–71(HO) screening for, 7t(GIM), 9–10(GIM), 11(GIM), 69–70(HO), Q122(HO) sentinel lymph node biopsy in, 71(HO) survivorship in, 72(HO), 74(HO) treatment of, 71–75(HO) adjuvant chemotherapy in, 73(HO) adjuvant endocrine therapy in, 72–73(HO), Q142(HO) adjuvant systemic therapy in, 72–73(HO) adverse effects of, 110(HO), 111(HO), Q86(HO) breast-conserving, 71(HO), Q112(HO) for early-stage cancer, 71–72(HO), Q142(HO) patient evaluation for, 67(HO) for primary cancer, 71(HO) radiation therapy in, 71(HO) for recurrent cancer, Q137(HO) treatment of, pulmonary toxicity of, 37–38(PM) Breastfeeding anticonvulsant use in, 21(NR) cardiovascular drug therapy during, 108t(CV), 109t(CV) maternal HIV/AIDS as contraindication to, 94(ID) in multiple sclerosis, 61(NR) rheumatoid arthritis treatment and, 21(RM) Breast masses, palpable, evaluation of, 82–84(GIM), 83t(GIM), Q45(GIM), Q90(GIM) Breast pain, 84(GIM) Breast self-examination, 74(HO) Breath test for carbohydrate malabsorption, 32(GA) for chronic diarrhea, 30–31(GA) for Helicobacter pylori, 15(GA) for small intestinal bacterial overgrowth, 33(GA) Brief advice, 16(GIM) Brief interventions, 16(GIM) Brief Pain Inventory (BPI), 33(GIM) Bristol Stool Form Scale, 39f(GA), 39(GA) Bromocriptine, 9t(EN) for hyperprolactinemia, 24(EN) for macroprolactinomas, Q64(EN) for neuroleptic malignant syndrome, 56(NR) for prolactinomas, 24t(EN) for restless legs syndrome, 57(NR) use in pregnancy, 24(EN), 25(EN) Bronchial challenge testing, 1(PM), 3(PM) for asthma, 1(PM), 3(PM), 8(PM), 9–10(PM) cough-variant asthma, 9–10(PM), Q83(PM) during pregnancy, 15–16(PM), Q29(PM) Bronchial thermoplasty, for severe asthma, 15(PM) Bronchiectasis in allergic bronchopulmonary aspergillosis, 10(PM) brain abscess and, 7t(ID) in chronic obstructive pulmonary disease, 17t(PM)
differentiated from asthma, 8t(PM) in rheumatoid arthritis, 35(PM) Bronchioalveolar carcinoma, 85(HO) Bronchiolitis in chronic obstructive pulmonary disease, 16(PM) pathophysiology of, 16(PM) Bronchiolitis obliterans in inhalational injuries, 84(PM) post-lung transplantation, 28(PM) Bronchiolitis obliterans organizing pneumonia (BOOP), 32t(PM), Q96(PM) drug-induced, 37(PM), 37t(PM) idiopathic form of, 34(PM) Bronchioloalveolar carcinoma. See Adenocarcinoma, pulmonary, in situ Bronchitis chronic obstructive pulmonary disease and, Q85(PM) nonasthmatic eosinophilic, 37(GIM), 38f(GIM), 39(GIM), Q77(GIM) rheumatoid arthritis and, 35(PM) Bronchodilators. See also β2-agonist bronchodilators for silicosis, 42(PM) Bronchogenic carcinoma. See Lung cancer Bronchoscopy diagnostic, 5(PM), 6(PM) therapeutic, 5–6(PM) in tuberculosis, 34(ID) Bronchospasm bronchial challenge testing and, 1(PM) exercise-induced, 10(PM), 11(PM), Q44(PM) in inhalational injuries, 84(PM) Brown recluse spider bites, 32–33(DM), 33f(DM), 35(HO) Brucella, as brucellosis causal agent, 65(ID) Brucellosis as bioterrorism agent, 56(ID) fever of unknown origin in, 53(ID) in travelers, 65(ID) vertebral osteomyelitis in, 52(ID) Brugada syndrome, 59–60(CV), 59f(CV), 59t(CV) Bruxism, 90(PM) B-type natriuretic peptide, Q18(CV) in chronic kidney disease, 86(NP) in heart failure, 32(CV), 37(CV) in hypovolemic hyponatremia, 14(NP) in pericarditis, 69t(CV) pulmonary embolism and, 48(PM) in valvular heart disease, 73f(CV), 74–75(CV) Bubonic plague, 58(ID) Budd-Chiari syndrome, 70(GA), Q46(GA), Q48(HO) Budesonide for chronic obstructive pulmonary disease, 22t(PM) for microscopic colitis, 38(GA) Bulimia nervosa, 114(GIM), Q154(GIM) Bullosis diabeticorum, 60(DM) Bullous lupus erythematosus, 46t(DM), Q56(DM) Bundles for central line-associated bloodstream infection reduction, 81(ID), 82(ID) for hospital-acquired infection prevention, 77(ID) for ventilator-associated pneumonia prevention, 83(ID) Bunyaviridae, as viral hemorrhagic fever causal agents, 60t(ID) Bupropion, 17(GIM) Burkholderia cepacia infections, in transplant recipients, 75(ID) Burkitt lymphoma, 11(HO), 97(HO), 103(HO) Burning dysesthesia, in peripheral neuropathies, 68(NR), 69t(NR) Burning mouth syndrome, 106(GIM) Burns, 34(DM), 35t(DM) methicillin-resistant Staphylococcus aureus infections of, 14(ID) Burn victims inhalational injuries in, 84–85(PM) nutrition in, 93t(PM), Q48(PM) Bursitis ischial, 2t(RM) olecranon, 56(GIM), Q132(GIM) pes anserine, 2t(RM), 60(GIM), Q79(GIM) prepatellar, 60(GIM) trochanteric, 2t(RM), 58(GIM) Busulfan, adverse effects of, 7(HO) Butorphanol, for pruritus, 43(DM) Butterfly rash, 48(DM) in systemic lupus erythematosus, 4t(RM), 35f(RM), 35(RM), 35t(RM), 38t(RM) Butterfly sign, 42f(DM), 48(DM) Buttocks, overuse syndromes of, 2t(RM) Bypass surgery. See also Coronary artery bypass surgery for acute limb ischemia, 101–102(CV) Cabergoline for hyperprolactinemia, 24(EN), Q50(EN) for macroprolactinoma, Q64(EN) for prolactinomas, 24t(EN) use in pregnancy, 24t(EN) CAC. See Coronary artery calcium score Cachexia, lung cancer and, 59t(PM) CAD. See Coronary artery disease Caffeine hypertension and, 34t(NP), 35t(NP) for migraine, 7t(NR) as migraine cause, 6(NR), 7(NR) CAGE questionnaire, for alcohol abuse diagnosis, 17(GIM) Calcification imaging of, 4(PM) of pulmonary nodules, 56(PM), Q6(PM) vascular, in chronic kidney disease, 88(NP) Calcimimetic agents, 89(NP), Q42(NP) Calcineurin inhibitors for atopic dermatitis, 9(DM) for focal segmental glomerulosclerosis, 51(NP) for heart transplantation, 40(CV), Q20(CV) for kidney transplantation, 93t(NP) for lichen planus, 12(DM), 70(DM) nephrotoxicity of, 45t(NP), 47(NP) for psoriasis, 12f(DM) use in transplant recipients, 40(CV), 72(ID), 73(ID), 73t(ID), Q20(CV) Calciphylaxis, 53–54(DM), 88(NP), Q63(DM)
11
Cumulative Index
Calcitonin for hypercalcemia, 63(EN) for osteoporosis, 69(EN), 70t(EN), 71(EN), 72(EN) for Paget disease of bone, 73(EN) as thyroid tumor marker, 28(EN) Calcitriol, 87(NP) Calcium carbonate for enteric hyperoxaluria, Q81(NP) urinary crystals and, 6(NP) Calcium channel blockers for achalasia, 4(CA) action mechanism of, 38f(NP) for acute coronary syndromes, 20(CV) adverse effects of, 17(CV), 49(CV) for angina, 14(CV), 16–17(CV) for arrhythmias, 51t(CV) for chronic obstructive pulmonary disease, 25(PM) for chronic stable angina, Q70(CV) for cocaine cardiotoxicity, 90(PM), Q88(PM) combined with ACE inhibitors, 40(NP) contraindications to, 40t(NP) for diffuse esophageal spasm, 5(GA) drug interactions of, 40(CV), Q20(CV) for heart failure, 35(CV) as heart failure cause, 17(CV) in heart transplant recipients, 40(CV), Q20(CV) indications for, 40t(NP) for kidney stones, 76(NP), 77(NP), Q79(NP) for migraine, 7(NR) in pregnancy, 109t(CV) for premature ventricular contractions, 57(CV) for pulmonary arterial hypertension, 55t(PM) for reversible cerebral vasoconstriction syndrome, 3(NR), 4(NR) side effects of, 40t(NP) toxicity of, 91t(PM) Calcium chloride, for hyperkalemia, 21(NP) Calcium deficiency. See also Hypocalcemia after bariatric surgery, 22(GA), 22t(GA) with osteomalacia, 72(EN) Calcium disorders, 59-66. See also Hypercalcemia; Hypocalcemia Calcium gluconate, for hyperkalemia, 21(NP) Calcium homeostasis, 59–60(EN), 59f(EN) in chronic kidney disease, 87f(NP), 87(NP) Calcium kidney stones, 74–75(NP) Calcium malabsorption, low urine calcium excretion in, Q59(EN) Calcium oxalate kidney stones, 74(NP), 75(NP), 78t(NP), Q81(NP) Calcium oxalate urinary crystals, 6t(NP) Calcium phosphate kidney stones, 28(NP), 29–30(NP), 74(NP), 78t(NP) Calcium phosphate urinary crystals, 6t(NP), 73(NP) Calcium pyrophosphate crystals, 8(RM) Calcium pyrophosphate deposition disease, 52–54(RM), Q14(RM) radiographic findings in, 8t(RM) Calcium-sensing receptors, 59–60(EN) Calcium supplementation colorectal cancer risk and, 45–46(GA) with corticosteroids, 10(RM), 11(RM) for hypocalcemia, 66(EN) for osteomalacia, 72(EN) recommended daily intake of, 66t(EN), 69(EN) Calcium-to-creatinine clearance ratio, in benign familial hypocalciuric hypercalcemia, Q47(EN) Call-Fleming syndrome, 3(NR) Caloric restriction, for weight loss, 72(GIM), Q51(GIM) Calorimetry, indirect, 93(PM) Cameron lesions, 74(GA), 79(GA) Campylobacter infections, as reactive arthritis cause, 5(RM), 30–31(RM) Campylobacter infections, diarrhea in, 66(ID), 66t(ID), 67(ID) Canadian Task Force on Preventive Health Care, 8(GIM) Canadian Task Force on the Periodic Health Examination, 119(GIM) Canakinumab, for rheumatic disease, 13t(RM) Cancer, 66-111(HO). See also specific types of cancer acute kidney injury in, 73–74(NP), Q11(NP) cardiotoxic chemotherapy in, 63t(CV), 103–105(CV), 104t(CV), 105f(CV) chronic obstructive pulmonary disease and, 19t(PM) chronic tubulointerstitial disorders in, 45t(NP), 46(NP), 47(NP) clinical course of, 28f(GIM), 28(GIM) constipation in, 30(GIM) cure of, 68(HO) deep venous thrombosis in, 61(HO), Q53(HO) dermatomyositis in, 51(DM), Q40(DM) dyspnea in, 32(GIM) erythroderma in, 65t(DM) fatigue in, 30(GIM) fever of unknown origin in, 53(ID), 54(ID) headache in, 2(NR) in heart transplant recipients, 40(CV) Henoch-Schönlein purpura and, 70(RM) inflammatory myopathies and, 62(RM) in kidney transplant recipients, 4(NP), Q19(NP) Lambert-Eaton myasthenic syndrome and, 74(NR), 75(NR), Q16(NR) low back pain in, 51t(GIM) membranoproliferative glomerulonephritis in, 57(NP) membranous glomerulopathy in, 51(NP) paraneoplastic syndromes in, 46t(DM), 48(DM), 58(DM), 59t(DM) paraneoplastic syndromes of, 6t(RM), 79–80(NR), 80t(NR) as pericarditis cause, 62t(CV) pyoderma gangrenosum in, 56(DM) rheumatic disease and, 6t(RM) screening for, 1(DM), 1t(DM), 7t(GIM), 9–10(GIM), Q40(DM) secondary, cancer treatment-related, 110(HO) staging of, 66–67(HO) Sweet syndrome in, 58–60(DM) systemic lupus erythematosus and, 41(RM), Q11(RM) thromboembolism prevention in, 61(HO), 62(HO) treatment of, 67-69(HO). See also Chemotherapy; Radiation therapy adjuvant therapy in, 67(HO) adverse effects of, 68(HO), 109–111(HO) goal definition for, 67–68(HO) personalized, 68–69(HO), 69t(HO) quality of life issue in, 68(HO)
12
response rates in, 68(JO) with surgical resection, 67(HO) of unknown primary site, 104–106(HO), Q89(HO), Q98(HO), Q110(HO) urgencies/emergencies in, 107–109(HO) vasculitis cause and, 63t(RM), 64t(RM) as venous thromboembolism cause, 54(HO) Cancer pain, 29–30(GIM), 31t(GIM), Q19(GIM), Q65(GIM) Cancer survivors, cardiovascular disease in, 102–105(CV), Q6(CV), Q77(CV) Candesartan, for heart failure, 33t(CV) Candida. See Candidiasis Candidemia, 39(ID), 40(ID), Q3(IDS) Candidiasis as arthritis cause, 56(RM) central line bloodstream infections in, 81(ID), 82(ID) cutaneous, 17(DM), 27(DM), 27f(DM) esophageal, 6f(GA), 6(GA), 7(GA), Q52(ID) in HIV/AIDS, 90–91(ID), 92(ID) fever of unknown origin in, 53(ID) oral, 71(DM), 72(DM), 72f(DM), Q52(ID) in HIV/AIDS, 90(ID), 92(ID) systemic, 39(ID) in transplant recipients, 75(ID) prevention of, 76(ID) urinary tract infections in, 29(ID) vertebral osteomyelitis in, 52(ID) vulvovaginal, 92(GIM), 93(GIM), Q80(GIM) Canes, use in osteoarthritis, 25(RM) CA 19-9, as pancreatic cystic lesion marker, 29t(GA) Canker sores, 70(DM), 71f(DM) Cannabinoid hyperemesis syndrome, 17–18(GA), Q64(GA) CA-125, in ovarian cancer, 75(HO), 77(HO), 78(HO) CAP. See Pneumonia, community-acquired Capecitabine, for gastric cancer, 83(HO) Capgras syndrome, 43(NR), Q42(NR) Capillaries, glomerular, 48f(NP), 48(NP) Capillary leak syndrome, 23(GA) Capnocytophaga canimorsus infections, of animal bites, 16(ID) Capreomycin, for tuberculosis, 35t(ID) Capsaicin for diabetic neuropathy, 16(EN), Q67(EN) for neuropathic pain, 73(NR) Capsule endoscopy, in gastrointestinal bleeding, 80(GA), 81(GA) Capsulitis, adhesive, 55–56(GIM) Captopril for heart failure, 33t(CV) teratogenicity of, 108t(CV) urine ketone levels and, 4(NP) Carbamazepine, 18(NR), 19(NR), 20t(NR), Q85(NR) adverse effects of, 18(NR), 19(NR), 19t(NR), 20t(NR), Q85(NR) for epilepsy, 20t(NR) interaction with hormonal contraceptives, 21(NR) in pregnancy, 19(NR), Q12(NR) for restless legs syndrome, 56–57(NR) for trigeminal neuralgia, 5(NR) Carbapenem resistance, 83(ID), 84(ID) Carbapenems, for extended-spectrum β-lactamase–producing organisms, 83(ID) Carbidopa, for Parkinson disease, 50(NR), 50t(NR) Carbohydrate malabsorption, diarrhea in, 31t(GA), 32(GA) Carbohydrates, dietary intake of, in diabetes mellitus, 4(EN), 6–7(EN) insulin therapy dosage and, 10(EN) postexercise, Q76(EN), Q79(EN) Carbon dioxide output (VCO2), in critically ill patients, 72(PM) Carbon monoxide poisoning, 84–85(PM), 89(PM), 90(PM), Q86(PM) Carboxyhemoglobinemia, 84–85(PM), 89(PM), Q57(PM), Q86(PM) Carbuncles, staphylococcal, 22(DM), 23(DM), 23f(DM) Carcinoembryonic antigen (CEA) in colorectal cancer, 81(HO) as pancreatic cystic lesion marker, 29(GA), 29t(GA) Carcinoid syndrome, 59t(DM), 62(PM) Carcinoid tumors, 83(HO), Q95(HO), Q140(HO) gastric, 19(GA), Q28(GA) pulmonary, 62f(PM), 62(PM), Q6(PM), Q108(PM) false-negative PET scans in, 5(PM) Cardiac allograft vasculopathy, 40(CV), Q87(CV) Cardiac arrest. See also Sudden cardiac death cardiopulmonary resuscitation (CPR) for, 60–61(CV) Cardiac arrhythmias. See Arrhythmias Cardiac computed tomography angiography, in coronary artery disease, 14(CV) Cardiac devices. See also Prosthetic valves; Ventricular assist devices infection of, 61(CV), Q21(CV) Cardiac disease. See Cardiovascular disease Cardiac injury, as pericarditis cause, 62t(CV) Cardiac murmurs. See Heart murmurs Cardiac output in heart failure, 31t(CV) in pregnancy, 105(CV) Cardiac resynchronization therapy, 36(CV), 37(CV), Q54(CV) Cardiac risk assessment, perioperative, 125(GIM), 128t(GIM), Q149(GIM), Q168(GIM) Cardiac Risk Index (RCRI), Revised, 125(GIM), 128t(GIM), Q168(GIM) Cardiac stress testing. See Stress testing Cardiac tamponade, 68–69(CV) Cardiac transplant recipients, infective endocarditis prophylaxis in, 84(ID) Cardiac tumors, 47–48(CV) Cardiocentesis, subxiphoid, 109(HO) Cardiogenic shock. See Shock, cardiogenic Cardiology, diagnostic testing in, 3–12(CV) Cardiomyopathy, 40–41(CV) arrhythmogenic right ventricular, 59t(CV), 60(CV), Q119(CV) dilated, chemotherapy-related, 104t(CV), 105(CV), Q95(CV) hypertrophic, 31(CV), 41–46(CV) clinical course of, 43(CV) clinical presentation of, 41–42(CV) diagnosis of, 41–42(CV), Q51(CV) genetic testing for, 45–46(CV) hypotension in, Q106(CV) management of, 43–46(CV), Q94(CV), Q106(CV) obstructive, 73t(CV) risk stratification in, 43(CV) screening for, 45–46(CV)
Cumulative Index
infiltrative, 31–32(CV) amyloidosis and, 46(CV), Q7(CV) ischemic, 36(CV), 36t(CV) nonischemic, 36(CV), 36t(CV), Q54(CV) peripartum, 107(CV) premature ventricular contractions and, 57(CV) restrictive, 46–48(CV), Q93(CV) cancer treatment-related, Q40(CV) vs. constrictive pericarditis, 46(CV), 69t(CV) in systemic sclerosis, 45(RM) tachycardia-mediated, 41(CV) takotsubo (stress), 19(CV), 40(CV), Q64(CV) Cardiopulmonary resuscitation (CPR), 60–61(CV) Cardiorenal syndrome, 72(NP), 73(NP), Q38(NP) Cardiotoxicity, of cancer treatment, 110(HO), Q125(HO) Cardiovascular disease in acromegaly, 25(EN) acute kidney injury in, 72–73(NP) acute mesenteric ischemia in, 43(GA), 44(GA) ascites in, Q23(GA) atherosclerotic. See Atherosclerosis autosomal dominant polycystic kidney disease in, 63(NP) in cancer survivors, 102–105(CV) chest pain in, 48–50(GIM), 48t(GIM), Q101(GIM) chronic kidney disease and, 2(CV), 86(NP), Q96(NP), Q99(NP) vascular calcification in, 88(NP) chronic obstructive pulmonary disease and, 19t(PM) clinical course of, 28f(GIM) congenital. See Congenital heart disease in diabetes mellitus, 2t(EN), 3(EN), 5(EN), 6(EN) sudden cardiac death in, 16(EN) diabetic mellitus and, 28–29(CV) diagnostic testing in, 3–12(CV) in dialysis patients, 92(NP) dyslipidemia as risk factor for, 62–64(GIM), 63t(GIM) epidemiology of, 1–2(CV) in women, 29–30(CV) genetics of, 13(CV) in hemochromatosis, 35(HO) in HIV/AIDS, 90(ID) hypertension and, 33(NP), 34(NP), 36f(NP), 38(NP) in diabetes mellitus, 43(NP) J curve of, 44(NP) in inflammatory myopathies, 60(RM) in kidney transplant recipients, 93(NP), 94(NP) mortality from, 1(CV), Q22(CV) in pregnancy. See Pregnancy, cardiovascular disease in premature, 13(CV) psoriasis and, 10(DM) quality of care for, 3(CV) in rheumatoid arthritis, 19t(RM) risk assessment for, Q56(CV) risk factor reduction for in peripheral arterial disease, 99–100(CV) in women, 30(CV), Q32(CV), Q45(CV), Q62(CV) risk stratification for, Q66(GIM) in spondyloarthritis, 29t(RM) stroke and, 39(NR) structural. See Structural heart disease syncope in, 46(GIM), 47(GIM) systemic inflammatory conditions and, 2(CV), 2t(CV) in systemic lupus erythematosus, 37(RM), 38(RM), 41(RM) in systemic scleroderma, 44–45(RM) valvular. See Valvular heart disease in women, 29–30(CV), Q22(CV) hormone replacement therapy and, 30(CV) Cardiovascular magnetic resonance imaging, 5t(CV) in acute myocarditis, 11f(CV) in arrhythmias, 11(CV) in atrial septal defects, 85(CV) in heart failure, 32(CV) in hypertrophic cardiomyopathy, 42(CV) in pericarditis, 65(CV), 69t(CV) in sarcoidosis, Q108(CV) in structural heart disease, 9(CV), 10t(CV) Cardiovascular medications, perioperative management of, 126t(GIM) Cardiovascular perioperative medicine, 125(GIM), 127–128(GIM), 127f(GIM), 128t(GIM), Q125(GIM) Cardiovascular testing, preoperative, 125(GIM), Q125(GIM) Cardioversion. See also Implantable cardioverter-defibrillators for atrial fibrillation, 53(CV), Q10(CV) Care “bundles,” in intensive care units, 94(PM), 94t(PM) Carotid artery. See also Internal carotid artery dissection of, 36(NR), Q90(NR) stenosis of, Q62(NR) Carotid endarterectomy, 38(NR), Q55(NR) Carotid revascularization, 38(NR) Carpal tunnel syndrome, 2t(RM), 5(RM), 57(GIM), 70(NR), Q2(GIM), Q9(RM), Q81(RM) in diabetes mellitus, 16(EN) Carvedilol, 39(NP) for heart failure, 33(CV), 33t(CV) Case-control studies, 2(GIM), 2t(GIM) Case series, 2(GIM) Castleman disease, 48(DM), 63(PM) Casts, urinary, 4t(NP), 5–6(NP) in acute tubular necrosis, 68(NP), 71(NP) in glomerulonephritis, 6(NP), Q40(NP) in hematuria, 7(NP), Q40(NP) in postinfectious glomerulonephritis, 59(NP), 60(NP), Q60(NP) Cataracts, 97(GIM) chronic obstructive pulmonary disease and, 19t(PM) Cat bites, 16–17(ID) Catecholamine assays, in pheochromocytoma, 47(EN), 49(EN), 50(EN) Catecholamines, in pheochromocytoma, 49(EN), 50(EN) Catechol-O-methyltransferase inhibitors, for Parkinson disease, 50t(NR) Cathepsin, as inflammatory pain source, 1(RM) Catheter-associated urinary tract infections (CAUTI), 77–79(ID), 78t(ID) Catheterization cardiac
in aortic coarctation, 89–90(CV) in atrial septal defects, 85(CV) in patent ductus arteriosus, 88(CV) in pericarditis, 69t(CV) pulmonary artery, 9–10(CV) in acute respiratory distress syndrome, 71(PM) in shock, 76(PM) right-heart in pulmonary arterial hypertension, Q55(PM) in pulmonary embolism, 53(PM) urinary, care bundles for, 94t(PM) Catheters. See also Central lines antiseptic-coated, 78–79(ID), 81(ID) for hemodialysis, 81(ID) insertion techniques for, 81(ID) intravenous, in candidiasis, 39(ID), 40(ID) urinary tract infections associated with, 77–79(ID), 78t(ID), Q31(ID), Q32(ID) Cat-scratch disease, 17(ID), Q69(ID) Cauda equina syndrome, 50(GIM), 51t(GIM), 64(NR), Q40(NR) Cauliflower ear deformity, 71–72(RM) Cavernous malformations, 15f(NR), 15t(NR) Cavernous sinus, thrombosis of, 34(NR) Cayenne pepper lesions, 16(DM), 16f(DM), 17(DM) CD4 T-lymphocyte cell count in common variable immunodeficiency, Q1(ID) in HIV/AIDS, 87(ID), 88(ID), 88t(ID), 89(ID), Q33(ID) in cardiovascular disease, 90(ID) in chronic HIV, 86(ID) in cryptococcal meningitis, 91(ID) in cytomegalovirus infections, 91(ID), 92(ID) as indication for antiretroviral therapy, 92(ID) in Pneumocystis jirovecii pneumonia, 91(ID), 92(ID) in toxoplasmosis, 91(ID) Cefazolin, as infective endocarditis prophylaxis, 85t(ID) Cefotaxime, for pneumococcal meningitis, Q73(ID) Cefoxitin, interaction with serum creatinine, 1(NP) Ceftaroline, 98t(ID), 99(ID), Q84(ID) Ceftriaxone for bacterial meningitis, Q59(ID), Q73(ID) for cervicitis, Q11(ID) for gonococcal arthritis, 58(RM) as infective endocarditis prophylaxis, 85t(ID) for Lyme disease, 26t(ID), Q76(ID) for methicillin-resistant Staphylococcus aureus pneumonia, Q50(ID) for Neisseria gonorrhoeae infections, 45(ID), 45t(ID), 46(ID) for pelvic inflammatory disease, Q26(ID) for syphilis, 47t(ID) for variceal bleeding, 62t(GA) Cefuroxime, for Lyme disease, 26t(ID) Celecoxib, 11(RM), 35(GIM) renin synthesis-inhibiting effect of, Q44(NP) Celiac disease, 5(RM), 20(HO), 32–33(GA), 33t(GA), 34(GA), Q88(GA) dermatitis herpetiformis and, 48(DM), Q61(DM) diarrhea in, 30(GA), 31t(GA) hypothyroidism in, 33(EN) immunoglobulin A nephropathy in, 56(NP), 57(NP) irritable bowel syndrome and, 42(GA), Q10(GA) levothyroxine absorption in, 33(EN) osteomalacia in, 72(EN) osteoporosis in, Q59(EN) Celiac plexus blockade, for chronic pancreatitis, 26(GA) Cell membrane calcium-sensing receptors, 59–60(EN) Cellulitis, 12f(ID), 12(ID), 24f(DM), Q5(DM) in diabetic foot infections, 18(ID) in Lyme disease, 25(ID) in methicillin-resistant Staphylococcus aureus infections, 13(ID), Q102(ID) nonpurulent, Q77(ID) with systemic symptoms, Q102(ID) orbital, 99(GIM) purulent, Q62(ID), Q84(ID) staphylococcal, 22(DM), 24–25(DM) streptococcal, 24(DM), 25(DM) vs. stasis dermatitis, 8(DM), 8f(DM), 9t(DM) Centers for Disease Control and Prevention (CDC), 9(GIM) Advisory Committee on Immunization Practices, 12(GIM) cervicitis treatment recommendation from, 45(ID) chancroid diagnosis recommendation from, 48(ID) Escherichia coli O157:H7 strain diagnostic testing recommendation from, 68–69(ID) HIV testing recommendation from, 87(ID) human papillomavirus vaccination recommendation from, 48–49(ID) smallpox diagnostic tool of, 58(ID) syphilis treatment recommendation from, Q107(ID) tuberculosis diagnosis recommendation from, 34(ID) tuberculosis treatment recommendation from, 34(ID) Centers for Medicare and Medicaid Services (CMS), 77(ID) Centor criteria, for pharyngitis triage, 104(GIM), Q161(GIM) Central adiposity, 70(GIM) Central centrifugal cicatricial alopecia, 66–67(DM), 67f(DM) Central lines antiseptic-coated, 78–79(ID), 81(ID) care bundles for, 94t(PM) infections of bloodstream infections, 80–82(ID), 81t(ID) in transplant recipients, 74(ID) Central nervous system demyelination, 57(NR). See also Demyelinating diseases Central nervous system disorders, in systemic lupus erythematosus, 37t(RM) Central nervous system infections, 1–10(ID) encephalitis, 8–10(ID) focal infections, 6–8(ID) meningitis, 1–6(ID) prion diseases, 11–12(ID) Central retinal artery occlusion, 99f(GIM), 99(GIM), Q95(GIM) Central retinal vein occlusion, 99(GIM), Q61(GIM) Central sleep apnea syndromes, 67(PM), Q4(PM) high-altitude periodic breathing and, 69(PM), Q104(PM) Cephalexin for cellulitis, Q77(ID) as infective endocarditis prophylaxis, 85t(ID)
13
Cumulative Index
Cephalosporins for bacterial meningitis, Q59(ID) as neutropenia cause, 4(HO) for typhoid fever, 63(ID) Cerebellar degeneration, 80t(NR) Cerebellar-type atrophy, 52(NR) Cerebral angiography. See Computed tomography angiography Cerebral artery aneurysm of, 33(NR), 34f(NR) dissection of, stroke and, 26(NR) occlusion of, stroke and, 30(NR), 31f(NR) Cerebral edema, in stroke, 24(NR). See also Increased intracranial pressure, in stroke Cerebral infarction, 24(NR), 26(NR), 28(NR), Q79(NR). See Stroke, ischemic space-occupying, Q5(NR) Cerebral ischemia, in vascular dementia, 46(NR) Cerebral perfusion, management of, in stroke, 30–31(NR) Cerebral salt wasting, 14(NP) Cerebral vasospasm, Q36(NR) Cerebritis, in brain abscess, 7(ID) Cerebrospinal fluid analysis in anti-NMDA receptor encephalitis, 80(NR), Q47(NR) in bacterial meningitis, 1t(ID), 3(ID) in chronic inflammatory demyelinating polyradiculoneuropathy, 72(NR) in Creutzfeldt-Jakob disease, 11(ID) in cryptococcosis, 41(ID) in dementia, 42–43(NR) in Guillain-Barré syndrome, 72(NR), Q38(NR) in headache, 2(NR) in herpes simplex encephalitis, 9(ID), 10(ID) in herpes simplex virus infections, 95(ID) in idiopathic intracranial hypertension, 4(NR), 4t(NR), Q46(NR) in multiple sclerosis, 59(NR) in normal pressure hydrocephalus, 46(NR) in paraneoplastic syndromes, 80(NR) in peripheral neuropathy, 68(NR) in primary central nervous system lymphoma, 79(NR) in syphilis, 47(ID) in tuberculosis, 34(ID) in viral meningitis, 1(ID), 1t(ID) in West Nile virus, 10(ID) Cerebrospinal fluid shunts in idiopathic intracranial hypertension, 4(NR) in normal pressure hydrocephalus, 47(NR) Cerebrovascular accidents. See Stroke Certolizumab for rheumatic disease, 13t(RM) for rheumatoid arthritis, 20(RM) for spondyloarthritis, 34(RM) Certolizumab pegol, for inflammatory bowel disease, 37t(GA) Cerumen, impaction of, 103(GIM) Cervical cancer, 78–79(HO), Q82(HO), Q108(HO) Peutz-Jeghers syndrome and, 47–48(GA) screening for, 7t(GIM), 10(GIM), 10t(GIM), 11(GIM), Q34(GIM) Cervical lymphadenopathy, thyroid nodules and, 35(EN), 35t(EN), 36(EN) Cervical neurogenic pain, 53(GIM) Cervical spine, rheumatoid arthritis in, 16(RM) Cervical spine radiography, in rheumatoid arthritis, Q33(RM) Cervicitis, 43(ID) complications of, 44(ID) in genital herpes simplex infections, 46(ID) gonococcal, 45t(ID) treatment of, 45–46(ID), 45t(ID), Q11(ID) Cervicocephalic arterial dissection, stroke and, 36(NR), 40t(NR) Cetuximab, 69t(HO) for colorectal cancer, 80–81(HO) for lung cancer, 86(HO) for pancreatic cancer, 82(HO) Cevimeline, for Sjögren syndrome, 46(RM) CHADS2 score, for atrial fibrillation, 53–54(CV), 53t(CV), Q37(CV) Chagas disease, transfusion-related transmission of, 40(HO) Chancres, syphilitic, 47(ID), 48(ID), Q28(ID) Chancroid, 48(ID), 48t(ID) Channelopathies, 58–59(CV) Charcot changes, in diabetic foot infections, 18(ID) Charcot-Marie-Tooth disease, 71(NR) Charter on Medical Professionalism, 23(GIM), 23t(GIM) CH50 assay, for complement deficiencies, 6(RM) Checklists, for intensive care, 94(PM) Cheilitis, actinic, 71(DM), 71f(DM), 72f(DM), Q13(DM) Chelating agents, for Wilson disease, 56(NR) Chelation mobilization testing, for lead nephrotoxicity, 47(NP), Q31(NP) Chemical inhalational injuries, 84(PM) Chemical injuries, ocular, 99(GIM) Chemokines, as inflammatory pain source, 1(RM) Chemotherapy acute kidney injury in, 74(NP) adverse effects of, 67(HO), 73(HO), Q131(HO) cardiotoxicity, 63t(CV), 103–105(CV), 104t(CV), 105f(CV), 110(HO) neutropenia, 4(HO) pulmonary, 110(HO) skin changes, 15t(DM), 58(DM) tubular toxicity, 68t(NP) for aggressive lymphoma, 103(HO) for breast cancer, 73(HO) for cervical cancer, 78(HO) for chronic lymphocytic leukemia, 101–102(HO) for colorectal cancer, 80–81(HO), Q97(HO) for esophageal cancer, 82(HO) for gastric cancer, 83(HO) for gastroesophageal junction adenocarcinoma, Q90(HO) for gastrointestinal neuroendocrine tumors, 83(HO), 84(HO) for head and neck cancer, 89(HO), Q94(HO) for Hodgkin lymphoma, 103(HO), Q114(HO), Q129(HO) for lung cancer, 86(HO), 87(HO), 88(HO), Q96(HO), Q134(HO), Q139(HO) for lymphoma, 101(HO), Q119(HO) for ovarian cancer, 77(HO), 78(HO), Q121(HO) for pancreatic cancer, 82(HO) patient evaluation for, 67(HO)
14
personalized, 68–69(HO), 69t(HO) for poorly differentiated carcinoma, 105(HO) for prostate cancer, 90(HO), 92(HO) for rectal cancer, 80(HO), 81(HO) for testicular cancer, 94(HO) Cherry hemangiomas, 41(DM), 41f(DM), 75(DM) Chest, cardiotoxic radiation therapy to, 102–103(CV), 103t(CV), Q6(CV), Q40(CV), Q77(CV) Chest compressions, in cardiopulmonary resuscitation, 60–61(CV) Chest pain, 47-50(GIM). See also Angina pectoris acute, evaluation of, Q50(CV) in acute pulmonary embolism, 63t(CV) anginal. See Angina pectoris in anthrax, 57(ID), 58(ID) in aortic dissection, 63t(CV) in aortic syndromes, 95(CV), 96(CV) cardiovascular causes of, 48–50(GIM), 48t(GIM), Q101(GIM) cocaine and, Q88(PM) differential diagnosis of, 47–49(GIM), 63t(CV) in esophageal disorders, 9(GA) gastrointestinal causes of, 49(GIM) hospitalization for, 49–50(GIM) ischemic, 19–20(CV), 63t(CV) in lung cancer, 58(PM), 84(HO), 87(HO) mediastinal masses and, 63(PM) misdiagnosis of, 47(GIM) musculoskeletal causes of, 49(GIM), Q130(GIM) in myopericarditis, Q112(CV) nonanginal, 15t(CV) noncardiac, 9(GA), Q57(GA) in pericarditis, 61(CV), 63t(CV) pleuritic, 49(GIM), 50(GIM), Q104(GIM) pulmonary causes of, 49(GIM) in pulmonary embolism, 63t(CV), Q50(CV) in supraventricular tachycardia, 55(CV) typical, 15t(CV) in women, Q28(CV) Chest radiography in atrial septal defects, 86t(CV) in chronic obstructive pulmonary disease, 4(PM), 19–20(PM) in community-acquired pneumonia, 19(ID) in diffuse parenchymal lung disease, 3(PM) in emphysema, 19–20(PM) in idiopathic interstitial pneumonia, 34(PM) indications for, 3–4(PM), 4t(PM) in pericarditis, 69t(CV) in pulmonary embolism, 48–49(PM) in pulmonary nodules, 56(PM) in pulmonary valve stenosis, 86t(CV) in sarcoidosis, 3(PM), 4f(PM), 38(PM), 38t(PM), Q101(PM) in silicosis, 3(PM) in tuberculosis, 33(ID), 34(ID) Chest restriction, lung volume testing in, 3(PM) Chest tightness, in asthma, 8(PM) Cheyne-Stokes breathing, 67(PM), Q4(PM) Chickenpox. See Varicella Child abuse, 18(GIM) mandated reporting of, 26(GIM) Children absence seizures in, 14(NR) asthma development in, 7(PM) cat-scratch disease in, 17(ID) cellulitis in, 24(DM) corticosteroid absorption in, 3(DM) head lice in, 32(DM) hematogenous osteomyelitis in, 49(ID) hepatitis B in, 54(GA) impetigo in, 23–24(DM), 24f(DM) influenza in, 94(ID) juvenile polyposis syndrome in, 48(GA) Kawasaki disease in, 66–67(RM), Q96(RM) medical confidentiality for, 26(GIM) molluscum contagiosum in, 31(DM) osteogenesis imperfecta in, 73(RM) Parkinson disease in, 49(NR) primary immunodeficiencies in, 55(ID) refractory epilepsy in, 21–22(NR) tic disorders in, 55(NR) tuberculin skin testing in, 33(ID) viral gastroenteritis in, 71(ID) Chlamydia infections, 18(GIM) bacterial vaginosis as risk factor for, 92(GIM) fever of unknown origin in, 53(ID) as reactive arthritis cause, 30–31(RM), 32(RM), 34(RM), Q12(RM) screening for, 7t(GIM), 9(GIM), 11(GIM) Chlamydia trachomatis infections, 43(ID), 44(ID) treatment of, 45–45(ID), 45t(ID) Chlamydophila pneumoniae infections, 19(ID) as reactive arthritis cause, 31(RM) Chloracne, 18(DM) Chlorambucil adverse effects of, 7(HO) for cold agglutinin disease, 33(HO) for Waldenström macroglobulinemia, 17(HO) Chlorhexidine, 81(ID) Chloroquine, as malaria prophylaxis, 62(ID), 62t(ID) Plasmodium resistance to, 61t(ID), Q100(ID) Chlorpropamide, 7(EN), 8t(EN) Cholangiocarcinoma, 73(GA) primary sclerosing cholangitis and, 61(GA), 73(GA), Q60(GA) Cholangitis acute, Q85(GA) lymphocytic, 61f(GA) primary sclerosing, 60–61(GA), 61f(GA), Q60(GA) cholangiocarcinoma and, 61(GA), 73(GA), Q60(GA) liver chemistry studies in, 53t(GA) Cholecalciferol, 87(NP) in calcium homeostasis, 59(EN) for osteomalacia, 72(EN)
Cumulative Index
Cholecystectomy colorectal cancer and, 46(GA) for gallbladder cancer, 73(GA) laparoscopic, 72(GA) prophylactic, 71(GA) Cholecystitis acalculous, 72(GA), 72(ID), Q80(GA) acute, 71–72(GA) Choledocholithiasis, 72(GA) primary sclerosing cholangitis and, 60(GA) Cholestasis intrahepatic, of pregnancy, 68(GA), 69t(GA) lipoprotein X in, 10(NP) Cholestatic liver disease, 60–61(GA) Cholesterol, high levels of. See Dyslipidemia Cholesterol crystal embolization, Q80(NP) Cholesterol embolism syndrome, acute limb ischemia and, 101(CV), Q53(CV) Cholestyramine, for microscopic colitis, 38(GA) Cholinergic syndromes, 88t(PM) Cholinesterase inhibitors for Alzheimer disease, 44(NR), 44t(NR), 45(NR) for Lewy body dementia, 45–46(NR) Chondritis, in relapsing polychondritis, 71–72(RM), 72f(RM), 72t(RM) Chondrocalcinosis, 53f(RM), 53(RM), Q14(RM), Q89(RM) Chondroitin, for osteoarthritis, 25(RM) Chorea, 48t(NR), 53–54(NR) Chorea gravidarum, 54(NR), Q21(NR) Chronic diseases anemia in, 24(HO) screening for, 7t(GIM), 8–9(GIM) Chronic fatigue, 39–40(GIM) Chronic fatigue syndrome, 39–40(GIM), Q7(GIM), Q72(GIM) Chronic inflammatory demyelinating polyneuropathy, 71(NR), 72(NR) Chronic kidney disease, 81–94(NP) acute kidney injury and, 81(NP) anemia of, 89(NP), Q8(NP), Q105(NP) in autosomal dominant polycystic kidney disease, 63(NP) blood pressure target goal in, 39(NP) in cardiorenal syndrome, 73(NP) cardiovascular disease and, 2(CV), Q96(NP), Q99(NP) causes of, 81(NP), 82t(NP) chronic tubulointerstitial disorders and, 44(NP), 46(NP) classification of, 81(NP), 81t(NP) clinical manifestations of, 82–83(NP) complications of, 86–89(NP) contrast-induced nephropathy in, Q95(NP) definition of, 81(NP) in diabetes mellitus, 8t(EN), 54(NP), 54t(NP), 86(NP), Q73(NP) diabetic nephropathy in, 54(NP), 54t(NP) epidemiology of, 81(NP) in Fabry disease, 65(NP) in HIV/AIDS, 90(ID) hospitalization for, 90(NP) hyperparathyroidism in, 59(EN), Q42(EN) hypertension in, 83–84(NP), 84f(NP), 86(NP), Q82(NP) in African Americans, Q86(NP) management of, 39–40(NP), 41(NP), 83–84(NP), 84f(NP), 86(NP), Q39(NP), Q49(NP) over-the-counter medications and, Q82(NP) in pregnancy, 108(NP), Q14(NP), Q103(NP) imaging in, 90(NP), Q90(NP) low bone density in, 68t(EN), 69t(EN) management of, 83–90(NP), Q4(NP), Q49(NP) prevention of progression, 83–86(NP), Q22(NP), Q49(NP), Q73(NP) medical history of, 81(NP), 82t(NP) metabolic acidosis in, 26(NP), 84–85(NP), Q22(NP) pathophysiology of, 48(NP), 81(NP) in pregnancy, 78(NP), 79(NP), 80(NP), Q14(NP), Q103(NP) screening for, 81–82(NP), Q41(NP), Q73(NP) in secondary hyperparathyroidism, Q101(NP) special considerations in, 90(NP) vaccination in, 90(NP) venipuncture in, 90(NP), Q32(NP) volume overload in, Q58(CV) Chronic Kidney Disease Epidemiology Collaboration Study equation, 3t(NP), Q28(NP) Chronic kidney disease-mineral bone disorder, 87–89(NP), 87f(NP), Q42(NP) post-kidney transplant, 93(NP) Chronic mesenteric ischemia, 43(GA), 44(GA), 45(GA) Chronic obstructive pulmonary disease, 16–30(PM) air travel in, 69(PM), Q98(PM) chest radiography in, 4(PM), 19–20(PM) comorbid conditions of, 18–19(PM) diagnosis of, 19(PM), Q1(PM), Q81(PM) differentiated from asthma, 8t(PM) disease progression, assessment and monitoring of, 19–21(PM) end-stage, dyspnea management in, Q58(PM) epidemiology of, 16(PM) exacerbations of, 20–21(PM), Q85(PM) criteria and classification of, 29t(PM) home management of, 29(PM) management of, 28–30(PM), Q32(PM), Q107(PM) noninvasive positive pressure ventilation for, 78(PM), Q61(PM) preoperative, Q107(PM) respiratory failure in, 75(PM), 76(PM), Q42(PM) extrapulmonary effects of, 18–19(PM) flow-volume loops in, 2f(PM) genetic factors in, 18(PM) immunizations in, 25(PM), 26(PM), Q41(PM) management of, 21–30(PM) with anticholinergics, 13(PM) in exacerbations, 28–30(PM), Q32(PM), Q107(PM) hospital discharge and follow-up in, 29–30(PM) inappropriate inhaler technique in, Q63(PM) with lung transplantation, 21(PM), 28(PM), 28t(PM), Q75(PM) with lung volume reduction surgery, 21(PM), 27–28(PM), 28t(PM), Q95(PM) in moderate COPD, Q13(PM) with noninvasive positive pressure ventilation, 78–79(PM) nonpharmacologic therapy, 26–28(PM), Q5(PM), Q68(PM), Q75(PM), Q95(PM)
pharmacologic therapy, 21–26(PM) preoperative, 27(PM) in severe COPD, Q85(PM) step therapy for, 24f(PM) as mortality cause, 16(PM) pathophysiology of, 16(PM), 17f(PM) as perioperative pulmonary complications cause, 128(GIM), 128t(GIM) pneumothorax and, 46(PM) preoperative care in, 128(GIM), Q47(GIM) pulmonary complications of, 17t(PM) risk factors for, 17–18(PM), 18t(PM) sleep-related hypoventilation syndromes and, 68(PM), 68t(PM) ventilator weaning in, 78–79(PM) ventilatory dead space in, 72(PM) Chronic pain in elderly patients, Q144(GIM) noncancer, 33–36(GIM), 34t(GIM), Q117(GIM) pelvic in men, 80–81(GIM) in women, 91–92(GIM), 91t(GIM), Q135(GIM) Chronic Prostatitis Symptom Index, 80(GIM) Churg-Strauss syndrome, 4(RM), 44(PM), 61(NP), 63t(RM), 67(RM), 68(RM), 69(RM), Q70(RM) Chvostek sign, 64(EN) Cicatricial pemphigoid, 46t(DM) Ciclesonide, for chronic obstructive pulmonary disease, 22t(PM) Cidofovir for acyclovir-resistant herpesvirus infections, Q91(ID) for smallpox, 58(ID) Cigarette smoking. See Smoking Cilostazol, for peripheral arterial disease, 99–100(CV) Cimetidine, serum creatinine level and, 1(NP) Cinacalcet, 89(NP) Ciprofloxacin for gonococcal arthritis, 58(RM) for infected kidney cysts, Q2(NP) for inflammatory bowel disease, 37t(GA) for pyelonephritis, 31(ID), Q71(ID) for shigellosis, Q9(ID) for travelers’ diarrhea, 63t(ID) Circadian rhythm, disruptions in, 64–65(PM) Circinate balanitis, 4t(RM), 31(RM) Circulatory support, mechanical, 39–40(CV), Q75(CV) Cirrhosis alcohol-induced, 57(GA) with ascites, pleural effusion and, 43t(PM) autoimmune hepatitis and, 58(GA) decompensated, liver transplantation for, Q8(GA) drug toxicity in, 70(GA) health care maintenance in, 69–70(GA) hepatocellular carcinoma and, 65(GA), Q24(GA) hepatopulmonary syndrome and, 64(GA), Q27(GA) in hepatorenal syndrome, 73(NP), 73t(NP) hereditary hemochromatosis and, 59(GA) hypogonadism and, 69(GA) metabolic bone disease and, 69(GA) nutrition in, 70(GA) perioperative management of, 133–134(GIM), Q62(GIM) portal vein thrombosis and, 71(GA) primary biliary, 53t(GA), 60(GA), Q93(GA) variceal bleeding and, 74–75(GA) Cisapride, for gastroparesis, 18t(GA) Cisplatin cardiotoxicity of, 104t(CV) as contraindication to hyperbaric oxygen therapy, 102(ID) for gastric cancer, 83(HO) for head and neck cancer, 89(HO) for lung cancer, 86(HO), 87(HO) CKD. See Chronic kidney disease Cladribine, for hairy cell leukemia, 102(HO), Q113(HO) Clarithromycin as infective endocarditis prophylaxis, 85t(ID) for Mycobacterium avium complex treatment, 38(ID) Claudication in aortic coarctation, Q69(CV) in peripheral arterial disease, 98(CV), Q91(CV) Clenched-fist injuries, antibiotic treatment for, Q13(ID) Clindamycin for babesiosis, 27(ID) for clenched fist injuries, Q13(ID) for nonpurulent cellulitis, Q102(ID) for purulent cellulitis, Q62(ID) for toxic shock syndrome, 16(ID) Clindamycin resistance, in methicillin-resistant Staphylococcus aureus pneumonia, 13–14(ID) Clinical COPD Questionnaire, 21(PM) Clinical decision support, 22(GIM) Clinical practice guidelines, 4(GIM), 7(GIM) Clobetasol propionate, 2(DM), 2t(DM) Clonazepam, for restless legs syndrome, 56–57(NR) Clonidine for restless legs syndrome, 56–57(NR) for tics, 55(NR) Clopidogrel for acute coronary syndromes, 20–21(CV) adverse effects of, 12(GA) for coronary artery disease, 18(CV), 18t(CV) coronary revascularization and, 20–21(CV) coronary stents and, 18(CV), 18t(CV), 19(CV), 20(CV) drug interactions of, 8(GA) for non-ST-elevation myocardial infarction, Q65(CV), Q68(CV) perioperative management of, 130(GIM), 132(GIM) for peripheral arterial disease, 99(CV) in pregnancy, 108t(CV) for ST-elevation myocardial infarction, 23(CV), 26(CV) for stroke, 38(NR), Q34(NR) for unstable angina, Q68(CV) Clostridial sepsis as hemolytic anemia cause, 35(HO) Clostridium botulinum, as botulism causal agent, 56t(ID), 59(ID)
15
Cumulative Index
Clostridium difficile infections, Q10(NP) acute diarrhea and, Q4(GA) diarrhea in, 69–71(ID), 70t(ID) inflammatory bowel disease and, 36(GA), Q29(GA) protein malabsorption and, 32(GA) proton pump inhibitors and, 8(GA) in transplant recipients, 74(ID), 75(ID) treatment of, 70–71(ID), 70t(ID), Q4(ID) ulcerative colitis and, 36(GA), Q29(GA) Clostridium infections necrotizing fasciitis in, 14(ID) as reactive arthritis cause, 5(RM), 31(RM) Clostridium perfringens infections, necrotizing fasciitis in, 14(ID) Clubbing, digital in cystic fibrosis, 8(PM) in diffuse parenchymal lung disease, 31(PM), Q49(PM) in lung cancer, 59t(PM), 85f(HO), 85(HO) Clue cells, 92f(GIM), 92(GIM) “Clunk” sign, 54t(GIM) Cluster headaches, 10(NR), Q19(NR) Cluster-randomized trials, 1(GIM), 2t(GIM) Coagulation, mechanisms of, 42(HO) Coagulation factors, 42f(HO), 42(HO) factor III, 42(HO) factor V Leiden, 53(HO), 54(HO) screening for, 56(HO) factor VIIa, recombinant, activated, for hemophilia, Q22(HO) factor VIII, in pregnancy, 65(HO) factor VIII concentrates, for hemophilia, 45(HO) factor IX concentrates, for hemophilia, 45(HO) factor IX deficiency, 58(HO), Q11(HO) factor X deficiency, 16(HO) Coagulopathies in fulminant hepatic failure, 66(GA) of liver disease, 46(HO) in nephrotic syndrome, 48(NP) preoperative evaluation of, 131(GIM) therapeutic apheresis-related, 42(HO) as vasculitis cause, 63t(RM) Coal dust exposure, lung disease and, 39(PM), Q50(PM) Coal tar, topical, for psoriasis, 12(DM), 12f(DM) Coal tar derivatives, as acne cause, 18(DM) Coarctation, of the aorta, 86t(CV), 89–90(CV), 90f(CV), Q16(CV), Q69(CV), Q74(CV) Cobalamin. See Vitamin B12 Cocaine as coronary spasm cause, 19(CV) hypertension and, 34t(NP) as intracranial hemorrhage cause, Q81(NR) toxicity of, 90(PM), Q88(PM) Coccidioides. See Coccidioidomycosis Coccidioidomycosis, 42(ID), 65(ID), 65t(ID) acute, Q35(ID) in transplant recipients, 75–76(ID) Cochrane collection, 4(GIM) Cockcroft-Gault equation, 2(NP), 3t(NP), Q28(NP) Codeine, 31t(GIM) Coenzyme Q10, for Parkinson disease, 50(NR) Cognitive-behavioral therapy for anxiety disorders, 111(GIM) for chronic fatigue, 40(GIM) for chronic pain, 34–35(GIM) for depression, 109(GIM) for eating disorders, 114(GIM) for insomnia, 44(GIM) for obsessive-compulsive disorder, 112(GIM), Q3(GIM) for social anxiety disorder, 111(GIM) Cognitive impairment after critical illness, 93(PM) aging-related, 41(NR) in Alzheimer disease, 43(NR), 44(NR), 45(NR) in amyotrophic lateral sclerosis, 73(NR) in dementia, 40(NR), 42(NR) differential diagnosis of, 42(NR) driving in, 47(NR), Q13(NR) in epilepsy, 16(NR) in Lewy body dementia, 45(NR) in multiple sclerosis, 63t(NR), 64(NR) in normal pressure hydrocephalus, 46(NR) in Parkinson disease, 49t(NR) Cohort studies, 2(GIM), 2t(GIM) Coin-shaped lesions, 7(DM) Colchicine for basic calcium phosphate deposition disease, 54(RM) for Behçet disease, 71(RM) for gout, 14(RM), 51–52(RM), Q63(RM) for pericarditis, 66(CV), 66t(CV), 67t(CV), Q26(CV) for pseudogout, 53(RM), 54(RM), Q92(RM) for rheumatic disease, 10(RM) Cold agglutinin disease, 32–33(HO), 32t(HO), 33f(HO) Colectomy, for ulcerative colitis, 38(GA) Colesevelam, 9t(EN) Colic, biliary, 71–72(GA), 74(GA) Colistin, 100(ID), 100t(ID), Q45(ID) Colistin base activity (CBA), 100(ID) Colitis hemorrhagic, 68(ID), Q8(ID) ischemic, 44–45(GA), 44t(GA) microscopic, 30(GA), 33(GA), 38–39(GA), 39t(GA), Q89(GA) chronic diarrhea in, 31t(GA) NSAID-induced, 36(GA), Q89(GA) ulcerative. See Ulcerative colitis Collagen, diseases of, 73–75(RM), 74t(RM), 75t(RM) Colon cancer, 107(GIM). See also Colorectal cancer in acromegaly, 25(EN) screening for, 7t(GIM), 11(GIM), Q48(GIM) Colonic diverticula, 79(GA) Colonic ischemia, 44–45(GA), 44t(GA) Colonic pseudo-obstruction, hypokalemia in, Q52(NP)
16
Colonoscopy, 107(GIM), Q48(GIM) after colorectal cancer treatment, 81(HO) in colorectal cancer screening, 48(GA), 49(GA), 49t(GA), 50–51(GA), 50t(GA), 51t(GA), 52(GA), Q9(GA), Q31(GA) postoperative surveillance, 52(GA), Q77(GA) in constipation, 40(GA), 41(GA), Q41(GA) contraindication to, 43(GA) in gastrointestinal bleeding, 78(GA), 79(GA) gastrointestinal bleeding after, 77(GA) in obscure gastrointestinal bleeding, 79(GA), 80(GA), Q36(GA) preoperative, 79(HO) risks of, 50–51(GA) screening, 79(HO) in ulcerative colitis, Q9(GA), Q38(GA) without adequate bowel preparation, Q95(GA) Colony-forming units (CFUs), of bacteria in urine, 29(ID), Q32(ID) Colorectal cancer, 45–53(GA), 79–81(HO) chemoprevention of, 52(GA), Q6(GA) clinical presentation of, 52(GA) diagnosis of, 42(GA), 52(GA) epidemiology of, 45(GA) follow-up of, 81(HO), Q143(HO) genetics of, 45(GA), 46(GA), Q40(GA) hereditary syndromes of, 46–48(GA), 47t(GA), Q40(GA) inflammatory bowel disease and, 38(GA) metastatic, 52(GA), 80–81(HO), Q135(HO) metastatic to the lung, Q84(PM) as mortality cause, 57(PM), 58(PM) nonpolyposis, 20(GA) pathophysiology of, 45(GA) Peutz-Jeghers syndrome and, 47–48(GA) postoperative surveillance of, 81(HO) risk factors for, 45–48(GA), Q6(GA) screening for, 79(HO) screening/surveillance for, 48–52(GA), 49t(GA), 51t(GA), Q1(GA), Q31(GA), Q45(GA), Q95(GA) guidelines for, 48(GA), 49t(GA), Q40(GA) in high-risk patients, 51(GA), Q9(GA) postoperative/posttreatment, 52(GA), Q77(GA) tests in, 48–51(GA), 50t(GA), 51t(GA), Q31(GA) staging of, 52(GA), 79(HO), 79t(HO), 80(HO) survival rate in, 52(GA) treatment of, 80–81(HO), 80(HO), Q97(HO), Q115(HO) Colorectal neoplasms. See Colorectal cancer Colostomy, permanent, for colorectal cancer, 80(HO), 81(HO) Colposcopy, in cervical cancer, 78(HO), 79(HO) Coma in encephalitis, 8(ID) myxedema, 39–40(EN), Q49(EN) Comedones, 18(DM), 18f(DM), 19f(DM) Common bile duct stones, 72(GA) Common symptoms, 32–50(GIM) chest pain, 47–50(GIM) chronic fatigue, 39–40(GIM) chronic noncancer pain, 33–36(GIM) cough, 36–39(GIM) dizziness, 40–43(GIM) edema, 50(GIM) insomnia, 43–45(GIM) syncope, 45–47(GIM) Common variable immunodeficiency (CVID), 55(ID), Q1(ID) Comparative effectiveness research (CER), 3(GIM) Compartment syndrome abdominal, 72(NP), Q77(NP) vs. peripheral arterial disease, 98t(CV) Complementary therapies, for asthma, 15(PM) Complement deficiencies, 55–56(ID) in cutaneous purpura mononeuritis multiplex, 69(RM) in rheumatic disease, 6(RM) in systemic lupus erythematosus, 35(RM) Complete blood count (CBC) in anemia, 18(HO) in thrombocytopenia, 47–48(HO), 49(HO) Compression devices, for deep venous thrombosis prevention, 39(NR) Compression stockings, 50(GIM), Q22(GIM) Compression therapy, for stasis ulcers, 8(DM), 73(DM), 74(DM), Q2(DM), Q38(DM) Computed tomography, 4(PM), 5f(PM) in acute pancreatitis, 24f(GA) of adrenal incidentalomas, 47(EN), 47f(EN), 48–49(EN) in Alzheimer disease, 44(NR), 45(NR) in asbestosis, Q60(PM) in autoimmune pancreatitis, 28f(GA) in carcinoid tumor, Q108(PM) cardiac, 5t(CV) chest, in structural heart disease, 10t(CV) in chronic pancreatitis, 26f(GA) comparison with positron emission tomography, 5(PM) in concussion, 11(NR) coronary, 5t(CV) in dementia, 42(NR) in dural sinus venous thrombosis, 34(NR) in epilepsy, 16(NR) in headache, 2(NR) in hematuria, 7(NP), 9t(NP) in hepatitis B, Q24(GA) high-resolution in diffuse parenchymal lung disease, 31–32(PM), 33t(PM), 35(PM) in hypersensitivity pneumonitis, 36(PM) in idiopathic pulmonary fibrosis, Q64(PM) in lymphangioleiomyomatosis, 39(PM) in idiopathic pulmonary fibrosis, Q49(PM), Q64(PM) in insulinoma, 30f(GA) in kidney transplant candidates, Q19(NP) low-dose spiral, for lung cancer screening, 58(PM) in lung cancer, 55(PM) in lung cancer screening, 84(HO) in myasthenia gravis, 74(NR), Q44(NR) noncontrast helical, 9(NP) in nephrolithiasis, 76(NP), Q21(NP), Q75(NP)
Cumulative Index
of osteomyelitis, 50(ID), Q39(ID) of osteoporotic fractures, 36(RM), Q95(RM) in Parkinson disease, 49(NR) in pulmonary embolism, 49(PM) in pulmonary nodules, 56f(PM), 56(PM), Q27(PM) radiation exposure in, 4(PM), Q34(PM) in rheumatic disease, 8(RM) in stroke, 24f(NR), 24(NR), 26f(NR), 29(NR), 30(NR), 31f(NR), Q7(NR) in structural heart disease, 9(CV) in subarachnoid hemorrhage, 26f(NR), 27(NR), Q36(NR), Q68(NR) in subdural hematoma, 10(NR), 33(NR), Q68(NR) in traumatic brain injury, 10(NR), 11(NR) in upper lobe mass, 6f(PM) in urologic bleeding, 9(NP) Computed tomography angiography, 4(PM), Q89(PM) in giant cell arteritis, Q55(RM) in internal carotid artery dissection, 36(NR) in peripheral arterial disease, 99(CV) in subarachnoid hemorrhage, Q36(NR) Computed tomography colonography, in colorectal cancer, 48(GA), 49–50(GA), 49t(GA) Computed tomography enterography, in inflammatory bowel disease, 36(GA) Computed tomography myelography, in spinal cord disorders, 65(NR) Computerized physician order entry (CPOE), 22(GIM) Concierge medicine, 6t(GIM) Concussion. See also Head injury in athletes, 11(NR), 11t(NR), Q11(NR) postconcussion syndrome of, 11–12(NR), 12t(NR), Q56(NR) Condoms, 85t(GIM), 86(GIM) Condylomata acuminata, 30(DM), 30f(DM), 48–49(ID) C1 inhibitor deficiency, 55(ID), 75(PM), 85(PM) Confidence interval (CI), 1(GIM) Confidentiality, 25–26(GIM) Conflicts of interest, 26(GIM), 27t(GIM) Confounding, 1(GIM) Confusion, in Alzheimer disease, 43(NR), Q18(NR) Confusion Assessment Method for the ICU, 92(PM) Congenital heart disease, in adults, 83–92(CV) aortic coarctation, 86t(CV), 89–90(CV), 90f(CV) atrial septal defects, 73t(CV), 84–85(CV), 84f(CV) cyanotic, 91–92(CV) Eisenmenger syndrome, 85(CV), 86t(CV), 87(CV), 88(CV), 92(CV) patent ductus arteriosus, 88(CV), Q100(CV) patent foramen ovale, 83–84(CV), 83f(CV), 86t(CV), Q110(CV) in pregnancy, 106–107(CV), 106t(CV) pulmonary stenosis, 76(CV), 88–89(CV) tetralogy of Fallot, 86t(CV), 90–91(CV), 91f(CV) Congestive heart failure. See Heart failure Conivaptan, for hyponatremia, 38(CV) Conjunctivitis, 93–94(GIM), 95(GIM) bacterial, 94f(GIM), 94(GIM) in Kawasaki disease, 66(RM) in reactive arthritis, 29t(RM), 30(RM), 31(RM), Q12(RM) viral, 93(GIM), 94f(GIM), Q11(GIM) Connective tissue disease diffuse parenchymal lung disease and, 35(PM), Q72(PM) mixed, 47–48(RM), 47t(RM), Q26(RM) undifferentiated, 39(RM) Constipation, 39–41(GA), 39f(GA), 39t(GA), 40f(GA), Q90(GA) with alarm features, 40–41(GA), Q41(GA) in colorectal cancer, 52(GA) in irritable bowel syndrome, 41t(GA), 42(GA) slow-transit, vs. irritable bowel syndrome, 41(GA) in typhoid fever, Q75(ID) Constipation, in cancer patients, 30(GIM) Contact dermatitis, 5(DM) allergic, 5–6(DM), 5f(DM), 6f(DM), 34f(DM), Q4(DM), Q41(DM), Q49(DM) of hand, 5(DM) Continuous ambulatory electrocardiographic monitoring, of arrhythmias, 11–12(CV), 51(CV), Q33(CV), Q117(CV) Continuous positive airway pressure for central sleep apnea, 67(PM) central sleep apnea-exacerbating effect of, 67(PM) for hypoxemic respiratory failure, 79(PM), Q40(PM) for obstructive sleep apnea, 66(PM), 78(PM), Q21(PM) perioperative, 72(PM) Contraception. See also Condoms; Oral contraceptives for breast cancer survivors, 74(HO) emergency, 85t(GIM), 86(GIM) for men, 85t(GIM), 86(GIM) for women, 84–86(GIM), Q69(GIM), Q164(GIM) for women smokers, 84(GIM), 86(GIM), Q164(GIM) Contractures, Dupuytren, in diabetes mellitus, 5(RM), 6t(RM) Contrast media contraindication in multinodular goiters, 36(EN) as contraindication to metformin, 11(EN) nephrotoxicity of, 68–70(NP), 69t(NP), 70t(NP), 71(NP), 85(NP), 86(NP), 90(NP), Q19(NP), Q95(NP) thyrotoxicosis-inducing effect of, 31(EN) Control groups, Q92(GIM) Conversion disorder, 112–113(GIM) Cooley anemia, 28(HO) Coombs test, direct, 26(HO), 32(HO), 33(HO), Q73(HO) COPD. See Chronic obstructive pulmonary disease COPD Assessment Test (CAT), 21(PM) Copper accumulation, in Wilson disease, 55–56(NR) Copper deficiency vs. multiple sclerosis, 60t(NR) as noncompressive myelopathy cause, Q96(NR) Copper deposition, in Wilson disease, 59(GA) Core measure sets, 20(GIM) Cornea abrasions to, 94–95(GIM) edema of, 97(GIM) ulcers of, 95(GIM) Coronary angiography, 5t(CV), 8(CV), 8f(CV) in acute coronary syndromes, 22(CV) in coronary artery disease, 14(CV), 17–18(CV) in new-onset heart failure, Q82(CV) radiation dose of, 8(CV)
risk stratification and, 28(CV) timing of, 22(CV) Coronary artery bypass grafting, 125(GIM), 130(GIM) clopidogrel and, 18t(CV) in diabetic patients, 29(CV) pleural effusion and, 43t(PM) for radiation-induced pericardial constriction, 102(CV), 103(CV) Coronary artery calcium score, 5t(CV), 8(CV), 9(CV), 13–14(CV), Q46(NP) Coronary artery disease, 12–30(CV) angina in, 14–19(CV), Q99(CV) anxiety and, 13(CV) asymptomatic, 29(CV) chest pain in, 48(GIM), 48t(GIM) chronic kidney disease and, 86(NP) depression and, 13(CV) diabetes mellitus and, 12(CV), 12t(CV), 13(CV), 17(CV), 28–29(CV), Q12(CV) diagnosis of, 15f(CV) diagnostic testing for, 3–9(CV) pretest probability of, 3(CV), 15t(CV) risks of, 8–9(CV) stress testing, 3–8(CV), 4t–5t(CV), 6f(CV), 7f(CV), 7t(CV), 14(CV), 15f(CV), 28–30(CV), Q1(CV), Q115(CV) diastolic blood pressure levels in, 44(NP) erectile dysfunction management in, Q166(GIM) premature, in cancer survivors, Q6(CV) with previous myocardial infarction, Q103(CV) radiation-induced, 102–103(CV), 105(CV), Q40(CV) in rheumatoid arthritis, 18(RM), 19(RM), 19t(RM) risk factors for, 12–14(CV) emerging, 13–14(CV), Q18(CV) management of, Q5(CV), Q13(CV), Q32(CV) modifiable, 12–13(CV), Q5(CV), Q13(CV) risk stratification in, 28(CV) screening for, 8–9(GIM) in spondyloarthritis, 29t(RM) in women, 30(CV) Coronary heart disease dyslipidemia management in, 63(GIM), 63t(GIM) hormone therapy and, 88(GIM) Coronary microvascular dysfunction, 30(CV) Coronary revascularization. See Revascularization Coronary sinus defects, 84(CV) Coronary spasms, 19(CV) Cor pulmonale, chronic obstructive pulmonary disease and, 17t(PM) Cortical development abnormalities, as epilepsy cause, 15(NR), 16f(NR) Corticobasal ganglionic degeneration, 51(NR) Corticosteroids, 30(GIM), 32(GIM) as acne cause, 19t(DM) for acute interstitial pneumonia, 34–35(PM) for acute respiratory distress syndrome, 71–72(PM), 71t(PM) adrenal secretion of, 40–41(EN), 40f(EN) adverse effects of, 10(RM), 30(RM), 42(RM), 52–53(NR), 61–62(NR), Q56(RM) in kidney transplant recipients, 93(NP) for alcohol-induced liver disease, 58(GA) for allergic bronchopulmonary aspergillosis, 40(ID) for allergic contact dermatitis, 6–7(DM), Q4(DM) with antifungals, 3–4(DM) for autoimmune hepatitis, 58(GA) for autoimmune pancreatitis, 28(GA), Q35(GA) for basic calcium phosphate deposition disease, 54(RM) for Behçet disease, 71(RM) with bisphosphonates, 10(RM), 11(RM) for brain tumors, 79(NR) for Churg-Strauss syndrome, 68(RM) in combination with herpes zoster antiviral therapy, 97(ID) contraindication in alopecia areata, 66(DM) pregnancy, 21(RM) sepsis, 83(PM), 84(PM) for dermatomyositis, 62(RM), Q40(RM) for drug-induced systemic reactions, 16(DM) for eosinophilic esophagitis, 7(GA) for fibrillary glomerulopathy, 53(NP) for focal segmental glomerulosclerosis, 51(NP), 53(NP) for giant cell arteritis, 65(RM) for gout, 51(RM), 52(RM) for Henoch-Schönlein purpura, 69(RM) for hypersensitivity pneumonitis, 36(PM) hypertension and, 34t(NP) for immune (idiopathic) thrombocytopenic purpura, 49(HO) for immunotactoid glomerulopathy, 53(NP) for increased intracranial pressure, 108(HO), Q109(HO) for inflammatory bowel disease, 37f(GA), 37t(GA), 38(GA) for inflammatory bowel disease-associated arthritis, 30(RM) inhaled adverse effects of, 15(PM) for asthma, 11(PM), 14(PM), 15(PM), Q38(PM), Q54(PM) for chronic obstructive pulmonary disease, 22t(PM), 24–25(PM), 26(PM), Q93(PM) intra-articular injections of, 10(RM) for osteoarthritis, 25(RM) for reactive arthritis, 34(RM) for spondyloarthritis, 33(RM) intravenous, for chronic obstructive pulmonary disease, 25(PM) for Kawasaki disease, 67(RM) low bone mass and, 68t(EN) for microscopic colitis, 38–39(GA) for microscopic polyangiitis, 68(RM) for minimal change glomerulopathy, 52–53(NP) for mixed connective tissue disease, 48(RM) for multiple sclerosis, 61–62(NR) for nummular dermatitis, 7(DM) oral for asthma, 13f(PM), 15(PM), Q9(PM) for chronic obstructive pulmonary disease, 25(PM), 29(PM), Q95(PM) for pericarditis, 66(CV), 66t(CV), 67(CV), 67t(CV) perioperative management of, 126t(GIM), 132–133(GIM) for polyarteritis nodosa, 66(RM), 67(RM), Q22(RM) for polymyalgia rheumatica, 65(RM) for polymyositis, 62(RM)
17
Cumulative Index
Corticosteroids (continued) in pregnancy, 4(DM) for pseudogout, Q92(RM) radiation-induced pneumonitis and, 110(HO) resistance to, in transverse myelitis, 66(NR), Q9(NR) for reversible cerebral vasoconstriction syndrome, 3(NR) for rheumatic disease, 10(RM) for rheumatoid arthritis, 20(RM) for sarcoidosis, 75(RM) as scleroderma renal crisis cause, 44(RM) for septic shock, 77(PM) as skin atrophy and thinning cause, 3(DM), 3f(DM) skin eruptions due to, 15t(DM) for Sweet syndrome, 60(DM) for systemic sclerosis, 42(RM) for systemic sclerosis-related lung disease, 44(RM) topical, 2–4(DM) for atopic dermatitis, 9(DM) for bedbug bites, Q1(DM) contraindication in herpes simplex virus infections, 96(ID) for lichen planus, 12(DM), 70(DM) for pityriasis rosea, 14(DM) potency of, 2–4(DM), 2t(DM) preparations of, 2–3(DM) for psoriasis, 12f(DM) side effects of, 2–4(DM), 3f(DM) use in pregnancy, 4(DM), 4t(DM) for xerotic eczema, 7(DM) as tremor cause, 52–53(NR) for tuberculous pericarditis, Q37(ID) use in transplant recipients, 72(ID), 73t(ID) for warm autoimmune hemolytic anemia, 32(HO) for Wegener granulomatosis, 68(RM) Corticotropin-releasing hormone, 17(EN), 20(EN), 41(EN) adrenal secretion of, 40(EN), 40f(EN) suppression of, 20(EN) Cortisol. See also Hypercortisolism; Hypercortisolemia; Hypocortisolism adrenal secretion of, 40–41(EN), 40f(EN) in critical illness, Q48(EN) in Cushing syndrome, 43(EN), 44(EN) in hypoglycemia, 13–14(EN), 16(EN) Cortisol deficiency. See also Hypocortisolism adrenal insufficiency in, 41t(EN), 42(EN) Cortisol-secreting adrenal tumors, 41t(EN), 42(EN), 46(EN), 47(EN) Corynebacterium minutissimum, 25(DM), Q48(DM) Costochondritis, Q130(GIM) “Cotton wool” spots, 15(EN) Cough, 36–39(GIM) ACE inhibitors and, Q1(PM), Q81(GIM) acute, 37(GIM) in anthrax, 57(ID), 58(ID) in aspergillomas, 40(ID) in aspergillosis, 75(ID), Q105(ID) in asthma, 8(PM), 9–10(PM), Q1(PM) chronic, 37–39(GIM), 38f(GIM), Q38(GIM) in chronic obstructive pulmonary disease, Q1(PM) in community-acquired pneumonia, 19(ID), 20(ID) in diffuse parenchymal lung disease, 30(PM) in gastroesophageal reflux disease, 9(GA), 37(GIM), 38f(GIM), 39(GIM), Q38(GIM) in histoplasmosis, Q6(ID) in immunocompromised patients, 39(GIM) in influenza, 94(ID) in lung cancer, 84(HO), 87(HO) mediastinal masses and, 63(PM) methotrexate and, 37(PM) in Mycobacterium avium complex infections, 38(ID) nitrofurantoin and, 37(PM) in nonasthmatic eosinophilic bronchitis, 37(GIM), Q77(GIM) in Pneumocystis jirovecii infections, Q64(ID) in pneumonic plague, 59(ID) in pulmonary embolism, 47(PM) smoking and, 35(PM) subacute, 37–39(GIM) in typhoid fever, 63(ID) Coxiella burnetii, as bioterrorism agent, 53(ID), 56(ID) COX-1 inhibitors, for rheumatic disease, 9(RM) COX-2 inhibitors, 11(RM), 35(GIM) as gastroprotectants, 16(GA) for gout, 51(RM) for osteoarthritis, 25(RM) for rheumatic disease, 9(RM) CPAP. See Continuous positive airway pressure C-peptide in diabetes mellitus, 1–2(EN), 17(EN), 17t(EN) as insulin resistance indicator, 1–2(EN) in obesity, 2(EN) suppressed, Q70(EN) Crackles in diffuse parenchymal lung disease, 30–31(PM) in heart failure, 8(PM) in high-altitude pulmonary edema, 69(PM) in idiopathic pulmonary fibrosis, 30–31(PM), Q101(PM) in pulmonary embolism, 47(PM) Cradle cap, 14(DM) Cranial nerve palsy, in Lyme disease, 25(ID), 25t(ID) Craniopharyngiomas, 18(EN), 18t(EN), 23t(EN) diabetes insipidus and, 20(EN), 22(EN) incidentalomas and, 26(EN) Craniotomy, for subdural empyema, 8(ID) C-reactive protein, 64(GIM), Q66(GIM) in cardiovascular disease, 13(CV), Q18(CV), Q56(CV) in giant cell arteritis, 64(RM) in gout, 51(RM) in headache, 2f(NR), 2(NR) in mycobacterial arthritis, 56(RM) in necrotizing fasciitis, 14(ID) in osteomyelitis, 50(ID) in polymyalgia rheumatica, 65(RM) in rheumatic disease, 6(RM), 9(RM)
18
in rheumatoid arthritis, 16(RM), 18(RM) in spondyloarthritis, 32(RM) in Takayasu arteritis, 65(RM), Q46(RM) in vertebral osteomyelitis, 52(ID) Creams, corticosteroid, 2–3(DM) Creatine kinase, 65(GIM), 67(GIM) in chronic kidney disease, 86(NP) in myopathies, 75(NR), 75t(NR), Q2(NR) in rhabdomyolysis, 70(NP) Creatine kinase-MB in cardiovascular disease, 19–20(CV), 19f(CV) in inflammatory myopathies, 60(RM) Creatinine in acute kidney injury, 66(NP), 66t(NP) in antihypertensive therapy, Q91(NP) in chronic kidney disease, 41(NP), 81–82(NP), 83(NP), Q41(NP) in contrast-induced nephropathy, 68–69(NP), 71(NP) dronedarone and, 52(CV), Q23(CV) in hematuria, Q40(NP) as kidney function indicator, 1f(NP), 1(NP), 2t(NP), Q91(NP) in pregnancy, 78(NP), 79(NP) renin-angiotensin system blockers and, Q43(NP) in women, Q14(NP) Creatinine clearance equation, 3t(NP) CREST syndrome, 4(RM), 41f(RM), 41(RM) Creutzfeldt-Jakob disease, 11–12(ID), 11t(ID), 54(NR), Q78(NR) sporadic, 11t(ID), Q49(ID) transfusion-related transmission of, 40(HO) variant, 11t(ID), 12(ID) Critical care, 70–94(PM) best practice in, 94(PM) critical early interventions in, 70(PM) emergent disorders in, 84–94(PM) acute abdominal surgical emergencies, 90(PM), 92(PM), 92t(PM) acute inhalational injuries, 84–85(PM) anaphylaxis, 85(PM) hypertensive emergencies, 85–86(PM), 86t(PM) hyperthermic emergencies, 86–87(PM) hypothermic emergencies, 87–88(PM), 87f(PM) toxicology, 88–90(PM), 88t(PM), 89t(PM) identification of critically ill patients for, 70(PM) invasive mechanical ventilation in, 80–82(PM) neuropsychiatric disorders after, 93(PM), 94(PM), Q3(PM) noninvasive positive pressure ventilation in, 78–79(PM) nutrition in, 93(PM), 93t(PM), Q90(PM) for respiratory failure, 70–76(PM) for sepsis, 82–84(PM) for shock, 76–78(PM) supportive care in, 92–94(PM) Critical care patients, acute kidney injury in, 72(NP) Critical illness adrenal function in, 43(EN), Q48(EN), Q55(EN) diabetes mellitus in, 11(EN) hypothyroidism in, Q61(EN) Critical illness myopathy, 76–77(NR), Q2(NR) Critical illness polyneuropathy, 72–73(NR), Q2(NR) Critically ill patients, status epilepticus in, 22–23(NR) Crohn disease, 56(DM) clinical manifestations of, 35–36(GA) colorectal cancer surveillance in, 50t(GA) diarrhea in, 30(GA) extraintestinal manifestations of, 36(GA) fistulizing, 38(GA), Q53(GA) gastrointestinal bleeding in, 74(GA) risk factors for, 34(GA), 35(GA) short-bowel syndrome in, 33(GA) treatment of, 37–38(GA), 37f(GA), Q17(GA), Q53(GA) vs. ulcerative colitis, 36(GA) Cromolyn, for asthma, 13f(PM) Cross-arm test, 54t(GIM) Crossed straight-leg raise test, 51(GIM) Cross-sectional studies, 2(GIM) Cryoglobulinemia, 16f(DM), 57(DM), 58(DM) essential mixed, 57(RM) in hepatitis C, 69(RM) in membranoproliferative glomerulonephritis, 57(NP) in vasculitis, 61(NP) Cryoglobulinemic vasculitis, 63t(RM), 69(RM), 70(RM), Q48(RM) Cryoglobulins, in rheumatic disease, 7t(RM) Cryoprecipitate transfusions, 37t(HO), 39(HO) Cryopyrin-associated syndromes, 3(RM) Cryptococcosis, 41(ID) disseminated, in HIV/AIDS, 91(ID), 92(ID) Cryptorchidism, as testicular cancer risk factor, 93(HO) Cryptosporidiosis, 72(ID) Crystal-induced arthropathies, 48–54(RM) basic calcium phosphate deposition disease, 54(RM) calcium pyrophosphate deposition disease, 8t(RM), 52–54(RM), Q14(RM) gout, 48-52(RM). See also Gout Crystals, urinary, 4t(NP), 6(NP), 6t(NP) CT. See Computed tomography Cubital tunnel syndrome, 56(GIM), Q132(GIM) CURB-65 score, for community-acquired pneumonia, 20–21(ID), Q103(ID) Cushing disease, 26(EN) lung cancer in, 85(HO) pituitary adenomas and, 24t(EN) Cushing syndrome, 43–46(EN), 60(DM) adrenocorticotropic hormone-dependent, 44f(EN), 44t(EN), 45f(EN), 46(EN), Q84(EN) adrenocorticotropic hormone-independent, 44t(EN), 45f(EN), 46(EN) definition of, 43(EN) dexamethasone suppression testing in, 43(EN), 44(EN), 45(EN), 45f(EN), Q25(EN) diabetes mellitus and, 1t(EN), 5(EN), 43(EN), Q6(EN) diagnosis of, 43–46(EN), 45f(EN), 48–49(EN), Q7(EN) evaluation of, Q71(EN) low bone mass in, 68t(EN) lung cancer and, 59t(PM) pituitary adenomas and, 44f(EN), 46(EN) sellar masses and, 21(EN), Q46(EN) treatment of, 46(EN)
Cumulative Index
Cutaneous leukocytoclastic vasculitis, 63t(RM), 69–70(RM), 70f(RM) Cutaneous lupus erythematosus, 48–50(DM), 49f(DM), Q67(DM) acute, 48(DM) chronic, 49(DM), 50(DM) discoid, 49(DM), 49f(DM), 67(DM), 67f(DM), Q62(DM) drug-related, 58(DM), Q67(DM) rare variants of, 49(DM) subacute, 49(DM), 49f(DM), Q67(DM) vs. psoriasis, 10–11(DM) Cutaneous purpura mononeuritis multiplex, 69(RM) Cuts, 33–34(DM), 34f(DM) Cyanide toxicity, 89–90(PM) Cyanotic heart disease, in adults, 91–92(CV), Q113(CV) Eisenmenger syndrome, 85(CV), 86t(CV), 87(CV), 88(CV), 92(CV), Q47(CV) iron-deficiency anemia in, Q113(CV) in pregnancy, 106–107(CV) Cyclobenzaprine for fibromyalgia, 27(RM) for multiple sclerosis, 63(NR), 64(NR), Q63(NR) Cyclooxygenase inhibitors-1. See COX-1 inhibitors Cyclooxygenase inhibitors-2. See COX-2 inhibitors Cyclophosphamide adverse effects of, 12(RM), 40(RM) for Behçet disease, 71(RM) cardiotoxicity of, 104t(CV) for Churg-Strauss syndrome, 68(RM) for cold agglutinin disease, 33(HO) as contraindication to pregnancy, 80(NP) for polyarteritis nodosa, 66(RM), 67(RM) in pregnancy, 12(RM) for rheumatic disease, 12(RM) for systemic lupus erythematosus, 40(RM) for systemic sclerosis-related lung disease, 44(RM) for Takayasu arteritis, 66(RM) for transverse myelitis, 66(NR), Q9(NR) for Waldenström macroglobulinemia, 17(HO) for Wegener granulomatosis, 68(RM) Cycloserine, for tuberculosis, 35t(ID) Cyclosporine adverse effects of, 12(RM) for Behçet disease, 71(RM) drug interactions of, 73(ID), Q18(ID) for inflammatory bowel disease, 37f(GA), 37t(GA) for kidney transplant recipients, 93t(NP) nephrotoxicity of, 47(NP) for psoriasis, 11(DM) for rheumatic disease, 12(RM) for spondyloarthritis, 34(RM) for Sweet syndrome, 60(DM) as thrombotic thrombocytopenic purpura cause, 51(HO) Cystadenomas, 67(GA) mucinous, 29t(GA) serous, 29t(GA) Cystatin C, as glomerular filtration rate indicator, 1(NP), 3t(NP) Cystectomy, radical, for bladder cancer, 95(HO) Cystic fibrosis chest radiography in, 3(PM) diabetes mellitus in, 5(EN) differentiated from allergic bronchopulmonary aspergillosis, 10(PM), Q20(PM) asthma, 8t(PM), Q33(PM) low bone mass in, 69t(EN) Cystic neoplasms, pancreatic, 28–29(GA), 28f(GA) Cystine kidney stones, 75(NP), 78t(NP) Cystine urinary crystals, 6t(NP) Cystitis diagnosis of, 30(ID) interstitial, 91(GIM), 91t(GIM), Q135(GIM) radiation-related, 110(HO) in women, 30(ID), Q36(ID) Cysts amebic, 68(GA) Baker (popliteal), 61(GIM) biliary, 73(GA), 74(GA), Q70(GA) branchial, 35t(EN) breast, 83(GIM) dermoid, 35t(EN) epidermal inclusion, 41–42(DM) epididymal, 79(GIM) ganglion, 57(GIM) hepatic, 67(GA), Q49(GA) of lymphangioleiomyomatosis, 39(PM), Q45(PM) pancreatic, 28(GA), 29(GA) protein inclusion, 57(DM) Rathke cleft, 18(EN), 18t(EN), 22(EN), 26(EN) sebaceous, 41–42(DM) thyroglossal duct, 35t(EN) thyroid nodule, 36t(EN) Cysts/cystic disorders, of the kidney, 63–64(NP), 63t(NP) acquired renal cystic disease, 92(NP) in tuberous sclerosis complex, 63t(NP), 64(NP) Cytarabine, as hand-foot syndrome cause, 58(DM) Cytochrome P-450 3A4 isoenzyme inhibitors, 64–65(GIM) Cytogenetic analysis, in aplastic anemia, 2(HO) Cytokines in asthma, 7(PM) as hematopoiesis regulators, 1f(HO) as inflammatory pain source, 1(RM) Cytomegalovirus infections chronic tubulointerstitial disorders and, 46(NP) esophagitis and, 6(GA), Q33(GA) fever of unknown origin in, 53(ID) in HIV/AIDS, 91(ID), 92(ID) inflammatory bowel disease and, 36(GA) in kidney transplant recipients, 92(NP), Q10(NP) neutropenia in, 4(HO) in transplant donors, screening for, 73(ID) in transplant recipients, 73(ID), 74(ID), 75(ID), Q58(ID) prevention of, 76(ID)
in travelers, 61t(ID) Cytotoxins A and B, in Clostridium difficile infections, 71(ID) Dabigatran for atrial fibrillation, 54(CV) for pulmonary embolism, 50t(PM), 51(PM) for stroke, 38(NR) for thromboprophylaxis, 58(HO) Dactylitis in ankylosing spondylitis, 29(RM) in psoriatic arthritis, 31(RM), Q62(RM) in reactive arthritis, 28f(RM) in spondyloarthritis, 28f(RM), 32(RM) Dalfampridine, for multiple sclerosis, 64(NR) Danazol contraindication during pregnancy and lactation, 4t(DM) for primary myelofibrosis, 9(HO) Dandruff, 14(DM) Daptomycin, 97–98(ID), 98t(ID), Q10(ID) Darbepoetin, 89(NP) Darbepoetin alfa, for myelodysplastic syndromes, 5–6(HO) Darunavir, 93(ID), 93t(ID) Dasatinib, for chronic myeloid leukemia, 9(HO) Daunorubicin, cardiotoxicity of, 104t(CV) Dawn phenomenon, Q31(EN) D-dimer assays in bleeding disorders, 43(HO) in pulmonary embolism, 48(PM), 52(PM), Q37(PM), Q79(PM) in thrombocytopenia, 48(HO) in venous thromboembolism, 56(HO) Decarboxylase inhibitors, for Parkinson disease, 50(NR), 50t(NR) Decisional capacity, 24–25(GIM), 26(GIM), Q109(GIM) Decitabine, for myelodysplastic syndromes, 6(HO) Deep brain stimulation for epilepsy, 21(NR) for essential tremor, 53(NR) for Parkinson disease, 51(NR), 51t(NR), Q39(NR) Deep venous thrombosis. See Thrombosis/thromboembolism, venous Defecation, dyssynergic, 40(GA), 41(GA) Deferasirox, for secondary iron overload, 36(HO), Q58(HO) Defibrillation. See Implantable cardioverter-defibrillators Dehydroepiandrosterone (DHEA) adrenal function of, 40(EN), 41(EN) in adrenal incidentalomas, 47(EN) adrenal secretion of, 40(EN), 40f(EN), 41t(EN), Q62(EN) deficiency of, in adrenal insufficiency, 42(EN) in hyperandrogenism, Q62(EN) Dehydroepiandrosterone sulfate (DHEAS), 18(DM) adrenal function of, 40(EN), 41(EN) in adrenal incidentalomas, 47(EN) adrenal secretion of, 40(EN), 40f(EN), 41t(EN) deficiency of, in adrenal insufficiency, 42(EN) Déjà vu, 17(NR) Delayed gastric emptying, in gastroparesis, 17(GA), 18(GA) Delirium assessment of, 92(PM) care bundles for, 94t(PM) in critical care patients, 92–93(PM), 94(PM), Q53(PM) definition of, 41t(NR) in neuroleptic malignant syndrome, 56(NR) in terminally ill patients, 32(GIM) Delirium tremens, 89(PM), Q17(PM) Delta anion gap, 23–24(NP) Delusions, in dementia, 43(NR), Q42(NR) Dementia, 40-47(NR), 118(GIM). See also Alzheimer disease Capgras syndrome in, 43(NR), Q42(NR) clinical course of, 28f(GIM) cortical vs. subcortical, 42(NR) in corticobasal ganglionic degeneration, 51(NR) in Creutzfeldt-Jakob disease, 11(ID), Q49(ID) definition of, 40–41(NR), 41t(NR) delusions in, 43(NR), Q42(NR) diagnosis of, 41–42(NR), 42–43(NR) differential diagnosis of, 42(NR) driving with, 47(NR), Q13(NR) evaluation of, 41–42(NR), 41(NR), 41t(NR) frontotemporal, 42(NR), 46f(NR), 46(NR), 73(NR) Lewy body, 45–46(NR), 45f(NR), Q33(NR) mild cognitive impairment and, 41(NR) mortality rate in, 41(NR) neurodegenerative, 42(NR) in Parkinson disease, 42(NR), 49(NR) in Pick disease, 46(NR) rapidly progressive, Q78(NR) reversible, 42(NR), 42t(NR) treatment of, 45t(NR) tremor and, 53(NR) vascular, 42(NR), 46(NR) Demyelinating diseases, 57-64(NR), Q27(NR). See also Multiple sclerosis Dengue fever/virus, 60(ID), 61t(ID), 64(ID), Q55(ID) Denosumab, for osteoporosis, 70t(EN), 71(EN), Q10(EN) Dental disease/infection, 105(GIM), 106(GIM) Dental procedures, antibiotic prophylaxis for, 82(CV), 85(ID), 85t(ID), Q78(ID) Dental sepsis, brain abscess in, 7t(ID) Dentinogenesis imperfecta, 73(RM) Depression, 108–110(GIM) after critical illness, 93(PM) in Alzheimer disease, 44(NR), 45(NR) in anorexia nervosa, 114(GIM) in bipolar disorder, 109(GIM), 112(GIM), Q140(GIM) in chronic fatigue, 40(GIM) coronary artery disease and, 13(CV) vs. dementia, 42(NR) as dementia cause, 42t(NR) in elderly patients, 119(GIM), Q99(GIM) in fibromyalgia, Q85(RM) in Lewy body dementia, 45(NR) in low back pain, 50(GIM) management of, 109(GIM), 110t(GIM), Q56(GIM) in multiple sclerosis, 63t(NR), 64(NR)
19
Cumulative Index
Depression (continued) in pain, 35(GIM) in Parkinson disease, 42(NR), 49t(NR), 50(NR) postpartum, 109(GIM) poststroke, 39(NR), 40(NR) screening for, 7t(GIM), 8(GIM), Q145(GIM) in terminally ill patients, 32(GIM) Depressive disorders, diagnosis of, 108–109(GIM) De Quervain tenosynovitis, 2t(RM), 57(GIM), Q96(GIM) Dermatitis. See also Atopic dermatitis; Contact dermatitis; Stasis dermatitis drug-related, 19t(DM) granulomatous, 53(DM) of hand, 5(DM), 6–7(DM), 6f(DM), 7t(DM), 10(DM), Q29(DM) nummular, 7(DM), 8f(DM) periorificial, 5f(DM), 19t(DM) vs. rosacea, 21–22(DM) as pruritus cause, 42(DM), 44(DM) seborrheic, 11t(DM), 14(DM), 14f(DM) Dermatitis herpetiformis, 46t(DM), 47f(DM), Q61(DM) Dermatofibromas, 41(DM), 41f(DM), Q51(DM) Dermatographism, 43(DM), 44(DM) Dermatologic disorders approach to patient in, 1–2(DM) in cutaneous leukocytoclastic vasculitis, 69–70(RM), 70f(RM) in dermatomyositis, 4t(RM), 59(RM) eczematous, 5–10(DM) emergent, 1–2(DM), 61–65(DM) examination in, 1(DM) in inflammatory bowel disease, 36(GA) ocular involvement in. See Eye papulosquamous, 10–14(DM) in pregnancy, 4(DM), 4t(DM), 21(DM), 34(DM), 55(DM) in rheumatic disease, 3(RM), 4t(RM) in rheumatoid arthritis, 19t(RM) in Sjögren syndrome, 46t(RM) in spondyloarthritis, 28f(RM), 29t(RM) in systemic disease, 48–61(DM) in systemic lupus erythematosus, 35(RM), 35t(RM) in systemic sclerosis, 42–43(RM) treatment of, 2–4(DM) in pregnancy, 4(DM), 4t(DM) topical agents in, 2–4(DM), 2t(DM), 3f(DM). See also specific topical agents in ulcerative colitis, 36(GA), Q76(GA) Dermatomyositis, 50–51(DM), 50f(DM), 58(RM), 59(RM), Q24(DM) amyopathic, 4t(RM), 50(DM), 59(RM) biopsy in, 61(RM) in cancer, 51(DM), 58(DM), 59t(DM), Q40(DM) cancer and, 62(RM) clinical features of, 59–60(RM), Q73(RM) dermatologic disorders in, 4t(RM), 59(RM) diagnosis of, Q73(RM) differential diagnosis of, 61(RM), 61t(RM) epidemiology of, 58(RM) hypomyopathic, 50(DM) lung cancer and, 59t(PM) prognosis of, 62(RM) vs. psoriasis, 10–11(DM) vs. rosacea, 22(DM) treatment of, 62(RM), Q40(RM) Dermatophyte infections, 26-27(DM). See also Tinea Dermatosis papulosa nigra, 77(DM), 77f(DM) Desipramine, for diabetic neuropathy, Q67(EN) Desmopressin for diabetes insipidus, 21(EN) for hemophilia, 45(HO) for hypopituitarism, 19t(EN) for uremia-related platelet dysfunction, 53(HO) Desmopressin response, in diabetes insipidus, 16(NP), Q26(NP) Desmopressin stimulation test, for Cushing syndrome, 45–46(EN) Devic disease, 57(NR) DEXA. See Dual-energy x-ray absorptiometry Dexamethasone, 32(GIM) for adrenal insufficiency, 42t(EN), 43(EN) adverse effects of, Q13(HO) for amyloid light-chain amyloidosis, 17(HO) for bacterial meningitis, 3–4(ID), Q59(ID) for high-altitude illness prevention, 69(PM), Q52(PM) for increased intracranial pressure, 108(HO) Dexamethasone suppression test, for Cushing syndrome, 43(EN), 44(EN), 45(EN), Q25(EN), Q46(EN) Dextrose for hyponatremia, 16(NP), Q37(NP) for salicylate toxicity, 26(NP) DHEA. See Dehydroepiandrosterone DHEAS. See Dehydroepiandrosterone sulfate Diabetes insipidus, 15(NP), 16(NP), 16t(NP), 20–21(EN) central, 15(NP), 16(NP), 16t(NP), 20–21(EN) differentiated from nephrogenic diabetes insipidus, Q26(NP) hypothalamic lesions in, 18(EN) nephrogenic, 15(NP), 16t(NP), Q26(NP) nonpituitary lesions in, 22(EN) sellar masses in, 18(EN) Diabetes mellitus, 1–16(EN) acute coronary syndromes and, 26(CV) acute tubular necrosis in, 69t(NP) blood pressure target goal in, 39(NP) cardiovascular disease risk factors in, 29(CV), Q2(CV) chronic kidney disease in, 86(NP), Q73(NP) chronic obstructive pulmonary disease and, 19t(PM) chronic pancreatitis and, 26(GA) cirrhosis and, 70(GA) colorectal cancer and, 46(GA), 48(GA) complications of acute, 11–14(EN), 12f(EN), 13t(EN) chronic, 15–16(EN), 15t(EN) contrast-induced nephropathy in, 69t(NP) coronary artery disease and, 12(CV), 12t(CV), 13(CV), 17(CV), 28–29(CV), Q12(CV) corticosteroids and, 10t(RM) Cushing syndrome and, 1t(EN), 5(EN), 43(EN), Q6(EN)
20
diagnostic criteria for, 2(EN) drug-induced, 1(EN), 1t(EN) dyslipidemia management in, 63(GIM) end-stage liver disease and, 66–67(GA) foot infections in, 17–18(ID), 51(ID) foot ulcers in, 74(DM) gastroparesis and, 18(GA) gestational, 4–5(EN), Q73(EN) glycemic monitoring in, 5–6(EN), 5t(EN) in heart transplant recipients, 40(CV) hyperglycemia in, 2(EN), 3(EN) inpatient treatment of, 11(EN) microvascular and macrovascular effects of, 5(EN) patient self-monitoring of, 5(EN) postexercise, Q76(EN) severe, 12(EN) hypertension in, 35(NP), 39(NP) hypertension management in, 39(NP), 43(NP), 44(NP), Q29(NP) hypoglycemia in, 13–14(EN) asymptomatic, 14(EN) documented symptomatic, 14(EN) exercise-induced, 14(EN), Q79(EN) hyperadrenergic symptoms of, 5(EN), 14(EN) nocturnal, 5(EN), Q31(EN) patient self-monitoring of, 5(EN) plasma glucose level in, 13–14(EN) postexercise, Q79(EN) insulin therapy for, 7–11(EN) basal, 7(EN), 10(EN), 11(EN), Q63(EN) dosage of, 10(EN) in hospitalized patients, 11(EN), Q63(EN) hypoglycemia and, 14(EN) missed doses in, 11–12(EN) pancreatic beta-cell function after, 2–3(EN) patient self-monitoring of, 5(EN) preprandial, 10(EN), 11(EN) underdosing in, 11–12(EN) metabolic syndrome and, 67(GIM) nephropathy in, 1(EN), 15–16(EN), 53–54(NP), 54t(NP), Q71(NP), Q89(NP) post-kidney transplant, 93(NP) neuropathies and, 68(NR), 70–71(NR), 71t(NR), 73(NR) neuropathy in, 1(EN), 16(EN), Q67(EN) obesity and, 70(GIM), Q51(GIM), Q57(GIM) osteomyelitis in, 51(ID), Q53(ID) as pancreatic cancer risk factor, 81(HO) perioperative management of, 132(GIM), Q160(GIM) peripheral arterial disease and, 99(CV), 100(CV) in pregnancy, 80(NP) prevention of, 72(GIM) primary membranous glomerulopathy in, Q54(NP) proteinuria in, 85(NP) proteinuria screening in, 7(NP) retinopathy in, 1(EN), 15(EN), 15t(EN), Q1(EN) rheumatic manifestations of, 5(RM), 6t(RM) screening for, 2(EN), 2t(EN), 7t(GIM), 8(GIM), 70(GIM) in pregnancy, 4(EN) skin disorders in, 40(DM), 60(DM), 74(DM) skin tags, 40(DM) stroke and, 26(NR), 29–30(NR), 39(NR), 40t(NR) type 1, 1(EN), 1t(EN), Q73(EN) in children and young adults, 2(EN), Q73(EN) delayed hypoglycemia in, Q79(EN) diagnostic criteria for, 2–3(EN), 3t(EN) differentiated from type 2, 2(EN), Q11(EN) inpatient management of, 11(EN) insulin therapy for, 2–3(EN), 9t(EN), 10(EN), Q35(EN) new-onset, 11–12(EN) nocturnal hypoglycemia in, Q31(EN) in obese patients, 2(EN) type 2, 1(EN), 1t(EN) in acromegaly, 25(EN) diagnostic criteria for, 3(EN), 3t(EN) differentiated from type 1, 2(EN), Q11(EN) gestational diabetes and, 4–5(EN) inpatient management of, 11(EN) insulin therapy for, 2–3(EN), 7(EN), 9t(EN), 10(EN), 10f(EN), 11(EN) natural history of, 7(EN) nonpharmacologic management of, 6–7(EN) in obese patients, 2(EN) in older patients, Q53(EN) pharmacologic management of, 7(EN), 8–9t(EN), Q45(EN) prediction of, 3(EN) prevention or delay of, 3(EN), 4t(EN) statins for, Q45(EN) sulfonylurea contraindication in, Q53(EN) type 1A, Q73(EN) type 1B, Q73(EN) urinary tract infections in, 29(ID) Diabetes Recognition Program (DRP), 6t(GIM) Diabetic amyotrophy, 16(EN), 71(NR), 71t(NR), Q87(NR) Diabetic dermatopathy, 60(DM) Diabetic lumbosacral radiculoneuropathy. See Diabetic amyotrophy Diagnostic errors, 20(GIM), 21t(GIM), Q12(GIM) Diagnostic tests interpretation of, 3–4(GIM), 5t(GIM) preoperative, 124(GIM), Q8(GIM) properties of, 4(GIM), 5t(GIM) Diagnostic tests, pulmonary, 1–7(PM) imaging and bronchoscopy, 3–6(PM) bronchoscopy, 5–6(PM) chest radiography, 3–4(PM), 4f(PM), 4t(PM) computed tomography, 4(PM) positron emission tomography, 4–5(PM) pulmonary function testing, 1–3(PM) bronchial challenge testing, 1(PM), 3(PM) diffusing capacity for carbon monoxide, 3(PM) lung volume, 3(PM) 6-minute walk test, 3(PM) spirometry, 1(PM), 1t(PM), 2f(PM)
Cumulative Index
Dialysis. See also Hemodialysis; Peritoneal dialysis in chronic kidney disease, 90(NP) complications of, 92(NP) in end-stage kidney disease, 91–92(NP) withdrawal from, 92(NP) for platelet dysfunction, 53(HO) in rhabdomyolysis, Q25(NP) in tumor lysis syndrome, 74(NP) vein patency maintenance for, 90(NP), Q32(NP) Dialysis patients cardiovascular disease mortality in, 2(CV) pregnancy in, 80(NP) Diaphragmatic hernia, 10f(GA) Diarrhea, 30–31(GA), 66(ID) acute, 30(GA), 30t(GA), 31(GA), Q4(GA) bloody, 64(ID) in celiac disease, 32–33(GA), 34(GA) chronic, 30(GA), 31t(GA) clinical definition of, 30(GA) in cytomegalovirus infections, Q10(NP) evaluation of, 30–31(GA), 30t(GA), 32f(GA), Q81(GA) factitious, 31t(GA) in hemolytic uremic syndrome, 51(HO) in HIV/AIDS, 87t(ID) iatrogenic, 31t(GA) infectious (bacterial or viral), 65–72(ID) in Campylobacter infections, 66(ID), 66t(ID), 67(ID) clinical features of, 66(ID), 66t(ID) in Clostridium difficile infections, 69–71(ID) epidemiology of, 66t(ID) in Escherichia coli infections, 66(ID), 66t(ID) in giardiasis, 66t(ID), 71(ID), Q98(ID) in malaria, 61(ID), 62(ID) in salmonellosis, 66(ID), 66t(ID) in shigellosis, 66, 66t, 67, Q9 transmission of, 66(ID) in Vibrio infections, 66t(ID) in viral gastroenteritis, 71(ID) in yersiniosis, 66t(ID) inflammatory, 30(GA), 31(GA) in intestinal obstruction, 92(PM) in irritable bowel syndrome, 41t(GA), 42(GA), Q81(GA) malabsorptive, 30(GA), 31–33(GA), 31(GA) management of, 30–31(GA) in microscopic colitis, 38(GA), 39(GA) noninfectious causes of, 65(ID) normal anion gap metabolic acidosis in, Q45(NP) osmotic, 30(GA), 31(GA), 34(GA) in parasitic infections, 66(ID), 71–72(ID) in reactive arthritis, 31(RM) in rheumatic disease, 5(RM) secretory, 30(GA), 31(GA) in small intestinal bacterial overgrowth, 33(GA), Q55(GA) in systemic lupus erythematosus, 37–38(RM) travelers’, 61t(ID), 63–64(ID), 63t(ID), Q82(ID), Q97(ID) Diastolic dysfunction, radiation therapy-related, Q40(CV) Dicloxacillin, for cellulitis, Q77(ID) Diet “acid-ash” content of, 2–3(NP) in colorectal cancer, 45–46(GA), 48(GA) coronary artery disease and, 12t(CV) for diabetes mellitus control, 6–7(EN) for dyslipidemia management, 64(GIM) for epilepsy control, 21–22(NR) fiber in for constipation, 40–41(GA) for irritable bowel syndrome, 42(GA) gluten-free, 33, 34(GA), 48(DM) high-purine, as gout cause, 48(RM), 49–50(RM) for osteoarthritis, 24(RM) pancreatic cancer and, 81(HO) prostate cancer and, 89(HO) for weight loss, 72(GIM), Q51(GIM) Dietary behavioral counseling, 16(GIM) Dieulafoy lesions, 79(GA) Difficult patient encounters, 116(GIM) Diffuse alveolar hemorrhage syndromes, 32t(PM) Diffuse cutaneous systemic sclerosis, 41(RM), 42(RM), Q7(RM), Q93(RM) Diffuse esophageal spasm, 4–5(GA), Q14(GA) Diffuse idiopathic skeletal hyperostosis, 8t(RM), 23–24(RM), 23f(RM), Q57(RM) Diffuse parenchymal lung disease, 30–39(PM) with acute onset, 30(PM), 32t(PM) chest radiography in, 3(PM) classification of, 30(PM), 32t(PM) diagnostic approach and evaluation in, 30–32(PM) drug-induced, 36–37(PM), 37t(PM) epidemiology of, 30(PM) idiopathic, 30(PM) of known cause, 30(PM), 31t(PM), 35–38(PM) miscellaneous, 38–39(PM) overview of, 30(PM) radiation-induced, 36(PM), 37(PM) of unknown cause, 30(PM), 31t(PM) Diffusing capacity for carbon monoxide (DLCO), 3(PM) in asthma, 3(PM) in chronic obstructive pulmonary disease, 19(PM) in lung cancer, 60–61(PM) DiGeorge syndrome, 64t(EN), 65(EN) Digoxin for arrhythmias, 51t(CV), 52(CV) for heart failure, 34(CV) for hypertrophic cardiomyopathy, 43(CV) for peripartum cardiomyopathy, 107(CV) in pregnancy, 109t(CV) for supraventricular tachycardia, in pregnancy, 108(CV) toxicity of, Q98(CV) Digoxin, toxicity of, 91t(PM) Dihydroergotamine, for migraine, 6(NR), 7t(NR), 9(NR) 1,25-Dihydroxyvitamin D
in calcium homeostasis, 59(EN), 59f(EN), 60(EN) for chronic hypoparathyroidism, 66(EN) Diltiazem for arrhythmias, 51t(CV) in pregnancy, 109t(CV) for restrictive cardiomyopathy, 47(CV) for unstable angina, Q57(CV) Dimple sign, of dermatofibrosis, 41(DM) Dipeptidyl peptidase-4 inhibitors, 7(EN), 9t(EN) Diphenhydramine for insomnia, 44(GIM), 45(GIM) for pruritus, 43(DM) Diphenoxylate, for traveler’s diarrhea, 64(ID) Diphtheria vaccine, 12t(GIM), 13(GIM) Diplopia, pituitary tumors and, 21(EN) Dipstick urinalysis, 2–5(NP), 4t(NP) Dipyridamole in pregnancy, 108t(CV) in stress testing, 5t(CV) for stroke prevention, 38(NR) Direct thrombin inhibitors for atrial fibrillation, 54(CV) for pulmonary embolism, 50t(PM), 51(PM) DIRE score, 35–36(GIM) Disability, in stroke, 40(NR) Discharge, from hospital, 21(GIM), Q94(GIM) of chronic obstructive pulmonary disease patients, 29–30(PM) Discharge summaries, 21(GIM), 22t(GIM) Discoid lupus erythematosus, 35(RM), 36f(RM), 49(DM), 49f(DM), 67(DM), 67f(DM), Q62(DM) Discoid rash, in systemic lupus erythematosus, 38t(RM) Disease Activity Score (DAS), 9(RM), 19(RM) Disease-modifying antirheumatic drugs, 11–14(RM) biologic immunization and, 12(RM), Q58(RM) for rheumatoid arthritis, 20(RM) for systemic lupus erythematosus, 40(RM) nonbiologic, 11–12(RM), 12–14(RM), 13t(RM) for rheumatoid arthritis, 20(RM) for spondyloarthritis, 33(RM), 34(RM) for rheumatoid arthritis, 20(RM), Q67(RM) Disease-modifying therapies for multiple sclerosis, 62–63(NR), 62t(NR), 64(NR) for optic neuritis, Q29(NR) Disopyramide for arrhythmias, 51t(CV) for hypertrophic cardiomyopathy, 43(CV) in pregnancy, 109t(CV) Disseminated gonococcal infection, 43–44(ID), 45t(ID), 55f(RM), 55(RM), Q29(ID), Q38(RM) Disseminated intravascular coagulation, 10(HO), 11(HO), 39(HO), 46(HO), 47t(HO), Q3(PM) in septicemic plague, 58–59(ID) Diuretics adverse effects of, 34(CV) for ascites, 63(GA) for cardiorenal syndrome, 72(NP), Q38(NP) for edema, 50(GIM), Q22(GIM) for heart failure, 34(CV) for hypertension, 43(NP) in chronic kidney disease, 83(NP) for hyperuricemia, 50(RM) hypokalemia and, 17(NP), 18f(NP), 19(NP) hyponatremia and, 13–14(NP) loop for heart failure, 34(CV), 38(CV), 39(CV), Q58(CV) for hyperkalemia, 21(NP), Q74(NP) for hypertension, Q39(NP), Q74(NP) for pericarditis, 70(CV) metabolic alkalosis and, 31(NP) for peripartum cardiomyopathy, 107(CV) potassium-sparing, for hypokalemia, 19(NP) in pregnancy, 109t(CV) thiazide, 40t(NP) diabetes mellitus and, 29(CV) for hypercalciuria, Q30(NP) for hypertension, 43(NP), Q29(NP), Q39(NP) hyponatremia and, 14(NP), 43(NP) as lichen planus cause, 11(DM), 12(DM) in pregnancy, 79t(NP) Diuretics abuse, hypokalemic metabolic acidosis in, Q45(NP) Divalproex sodium, for migraine, 8(NR), 9(NR), Q83(NR) Diverticula colonic, 79(GA) Meckel, 79(GA) Diverticular disease, 42–43(GA) Diverticulitis, 43(GA), 43t(GA), Q13(GA), Q26(GA) Diverticulosis, 42–43(GA) bleeding in, 77(GA), Q72(GA) Dix-Hallpike maneuver, 41(GIM), 41t(GIM), Q14(GIM), Q50(GIM) Dizziness, 40–43(GIM), Q55(GIM) nonspecific, 43(GIM) D-lactic acidosis, 24–25(NP), 24t(NP) DNA testing, fecal, 48(GA), 49(GA), 49t(GA) Dobutamine, for cardiogenic shock, 39t(CV) Dobutamine stress testing, 5t(CV), 77(CV), Q107(CV) Dofetilide, for arrhythmias, 51t(CV) Dog bites, 16–17(ID) Domestic violence, 18–19(GIM), Q117(GIM), Q126(GIM) Domperidone, for gastroparesis, 18(GA), 18t(GA) Donepezil, for Alzheimer disease, 44(NR), 44t(NR), 45(NR) Dopamine for cardiogenic shock, 39t(CV) clinical use and physiologic effects of, 77t(PM) Dopamine agonists adverse effects of, 24(EN), 50–51(NR), Q84(NR) for diabetes mellitus, 9t(EN) for hyperprolactinemia, 23(EN), 24(EN), 24t(EN) for macroprolactinomas, Q64(EN) as movement disorder cause, 54t(NR) for Parkinson disease, 50(NR), 50t(NR), Q84(NR) for prolactinomas, 22(EN)
21
Cumulative Index
Dopamine agonists (continued) for restless legs syndrome, 56(NR) use in pregnancy, 24–25(EN) Dopamine deficiency, in Parkinson disease, 47(NR) Dopamine precursors, for Parkinson disease, 50t(NR) Dopamine receptor-blocking agents as neuroleptic malignant syndrome cause, Q64(NR) as tardive dyskinesia cause, 54(NR), Q82(NR) for tics, 55(NR) Dopamine-responsive dystonia, 53(NR) Doripenem, 98t(ID), 99(ID) Double-balloon enteroscopy, in gastrointestinal bleeding, 80(GA) Down syndrome acute myeloid leukemia and, 10(HO) congenital heart disease in, 84(CV), 86–87(CV) Doxepin, for pruritus, 43(DM) Doxorubicin cardiotoxicity of, 103(CV), 104t(CV), Q95(CV) as contraindication to hyperbaric oxygen therapy, 102(ID) Doxycycline for acne, 20t(DM) for erythema migrans, Q23(ID) for human bites, 17(ID) for human granulocytic anaplasmosis, 28(ID) for human monocytic ehrlichiosis, 28(ID) for Lyme disease, 25t(ID), 26(ID), 26t(ID) as malaria prophylaxis, 62t(ID) for methicillin-resistant Staphylococcus aureus pneumonia, Q50(ID) for pelvic inflammatory disease, Q26(ID) for rickettsial infections, 65(ID), Q87(ID) for Southern tick-associated rash illness, 27(ID) for syphilis, 47t(ID) for Vibrio infections, 69(ID) DRESS (drug reaction with eosinophilia and systemic symptoms), 16(DM), Q35(DM) Dressings for burns, 34(DM) for stasis ulcers, 73(DM) for wounds, 33(DM), 34(DM), Q69(DM) Drinking water, purification of, 63(ID) Drivers, older, 120(GIM), Q118(GIM) Driving with dementia, 47(NR), Q13(NR) with epilepsy, 14(NR) with Parkinson disease, Q13(NR) with seizures, 14(NR) Dronedarone, for arrhythmias, 51t(CV), 52(CV) Drooling. See Sialorrhea Drop-arm test, 54t(GIM) Drug abuse, 18(GIM). See also Injection drug use chancroid and, 48(ID) of opioids, 36(GIM) in physicians, 27(GIM), 27t(GIM) Drug Abuse Screening Test (DAST-10), 18(GIM) Drug hypersensitivity syndrome, 15t(DM), 16(DM) Drug-induced lupus, 13(RM), 39(RM), Q1(RM), Q35(RM) Drug-induced neutropenia, 4(HO) Drug reactions, 14-16(DM), 14f(DM). See also names of specific drugs as acne cause, 18(DM), 19t(DM) as allergic, 6(DM), 33(DM) autoimmune blistering disease, 46(DM), 46t(DM) chemotherapy-related, 15t(DM), 58(DM) as cutaneous small vessel purpura cause, 52–53(DM) as erythema cause, 64(DM), 64f(DM), 65t(DM) lichenoid, 11(DM), 11t(DM), 12(DM) as lupus erythematosus cause, 49(DM) morbilliform, 14(DM), 15t(DM) in persons of color, 66(DM), 68(DM), 76–78(DM) severity of, 14(DM) as Stevens-Johnson syndrome cause, 62–63(DM), 64(DM) teratogenicity, 4(DM), 4t(DM), 20t(DM), 21(DM) to topical agents, 2–3(DM), 3f(DM) as toxic epidermal necrolysis cause, 62–63(DM), 64(DM) urticarial, 15t(DM), 44–45(DM) Drug reaction with eosinophilia and systemic symptoms (DRESS), 16(DM), Q35(DM) Drugs of abuse, toxicity of, 90(PM) Drug therapy averse or allergic reactions to. See Drug reactions cardiovascular-protective, 17(CV) hepatotoxic, 57–58(GA), 70(GA) as microscopic colitis cause, 39t(GA) as myopathy cause, 77(NR), 77t(NR) as neutropenia cause, 4(HO) as pancreatitis cause, 23t(GA) as pericarditis cause, 63t(CV) in pregnancy, 4(DM), 4t(DM), 21(DM), 55(DM) QT interval-prolonging, 58–59(CV), Q73(CV) teratogenicity of, 107–108(CV), 107t(CV), 108t(CV) as tremor cause, 52–53(NR) as vasculitis cause, 63t(RM), 64t(RM) Dry eye, 97–98(GIM), Q44(GIM) in Sjögren syndrome, 3(RM), 46(RM) Dry mouth, in Sjögren syndrome, 46(RM) Dry powder inhalers (DPIs) for asthma, 12(PM) for chronic obstructive pulmonary disease, 21(PM) Dry skin in the elderly, 42(DM), 74(DM), 76(DM) in HIV/AIDS, 61(DM) in hypothyroidism, 61(DM) as pruritus cause, 42(DM), 44(DM), 74(DM), 76(DM) topical corticosteroid-related, 2–3(DM) xerotic eczema-related, 7(DM) Dual-energy x-ray absorptiometry (DEXA) for osteoporosis treatment monitoring, 71–72(EN) T-scores on, 62f(EN), 67(EN), 68f(EN), 69(EN) Z-scores on, 67(EN), 68f(EN), 69(EN) Duchenne muscular dystrophy, 76(NR) Ductal carcinoma, of the breast invasive, Q112(HO)
22
in situ, 71(HO), Q136(HO) Ductal hyperplasia, 70(HO) Ductus arteriosus, patent, 88(CV), Q100(CV) Duloxetine for fibromyalgia, 27(RM), Q85(RM) for neuropathic pain, 73(NR) Dumping syndrome, 22(GA) Duodenal ulcers. See Peptic ulcer disease Duodenum, adenomas of, 47(GA) Duplex ultrasound, Q83(CV) Dupuytren contractures, in diabetes mellitus, 5(RM), 6t(RM) Durable power of attorney for healthcare, 24(GIM) Dural arteriovenous fistulas, vs. multiple sclerosis, 60t(NR) Dust masks, 65(ID) Dysrhythmias. See Arrhythmias Dysarthria-clumsy hand syndrome, 29t(NR) Dysentery. See also Diarrhea in shigellosis, 67(ID) Dysequilibrium, 43(GIM) Dysesthesias, 56(NR) in small-fiber neuropathy, 68(NR) Dysfibrinogenemia, 55(HO) Dyshidrotic eczema, of hand, 6(DM), 6f(DM), 7(DM) Dyskinesias, drug-induced, 50–51(NR) in Parkinson disease, 54(NR), Q39(NR) Dyslipidemia as adverse effect of testosterone replacement therapy, 55(EN) in chronic kidney disease, 86(NP), Q96(NP) coronary artery disease and, 12–13(CV), 12t(CV) in type 2 diabetes mellitus, Q45(EN) in elderly patients, 68–69(GIM) evaluation of, 62–64(GIM), 63t(GIM), Q141(GIM) in heart transplant recipients, 40(CV) in HIV/AIDS, 89(ID), Q72(ID) hypertension and, 35(NP) management of, 64–67(GIM), 65t(GIM), 66t(GIM), 68t(GIM), Q66(GIM) in membranous glomerulopathy, 51(NP) as metabolic syndrome component, 3(EN), 4(EN) myocardial infarction and, Q48(CV) in nephrotic syndrome, 48(NP), 49(NP) in nonalcoholic steatohepatitis, 58–59(GA), Q2(GA) in pregnancy, Q75(GIM) pseudohyponatremia and, 10(NP) screening for, 62(GIM) stroke risk factor, 36(NR), Q62(NR) in subclinical hypothyroidism, 34(EN) tocilizumab and, Q34(RM) treatment for, 17(CV) in diabetes mellitus, 29(CV), Q2(CV) in type 2 diabetes mellitus, Q45(EN) Dysmenorrhea, 90–91(GIM), Q131(GIM) Dyspareunia, 82(GIM), 88(GIM), 89(GIM), Q5(GIM) Dyspepsia, 13(GA), 14f(GA), Q15(GA) in Helicobacter pylori infection, 14–15(GA), Q63(GA) Dysphagia candidal, 6(GA), 7(GA) esophageal, 1(GA), 1t(GA), 2f(GA), 2(GA), 4(GA), 5(GA), 11(GA), Q59(GA) in esophageal candidiasis, 90–91(ID), 92(ID) in esophageal carcinoma, 11(GA) in esophageal motility disorders, 4(GA), 5(GA) oropharyngeal, 1–2(GA), 1t(GA), 2(GA), 3(GA), Q79(GA) in Parkinson disease, 50(NR) in stroke, 39(NR) in thoracic aortic aneurysms, 93(CV) Dysplasia cortical, 16f(NR) esophageal, 10–11(GA), Q37(GA), Q73(GA) fibromuscular, 42(NP), Q58(NP) intestinal, in inflammatory bowel disease, Q38(GA) Dysplastic nevi, 39–40(DM), 39f(DM) Dyspnea acute, Q42(PM) in anthrax, 57(ID), 58(ID) in aortic regurgitation, 78(CV) in aortic stenosis, 77(CV) in asthma, 8(PM) in cardiac allograft vasculopathy, 40(CV) in cardiac tamponade, 68(CV) in chronic obstructive pulmonary disease, 19(PM), 20t(PM), 25(PM), Q5(PM), Q42(PM), Q58(PM) in constrictive pericarditis, Q29(CV) at end of life, 32(GIM), Q6(GIM) in heart failure, 30–31(CV), 32(CV) in idiopathic pulmonary fibrosis, Q64(PM) in lung cancer, 84(HO), 87(HO) methotrexate and, 37(PM) in mixed connective tissue disease, 47(RM), 48(RM) paroxysmal nocturnal, 67(PM) in Pneumocystis jirovecii pneumonia, Q64(ID) of pregnancy, 15(PM) in pulmonary embolism, 47(PM), Q42(PM) in pulmonary hypertension, 53(PM) in supraventricular tachycardia, 55(CV) in valvular regurgitation, 71(CV), 75(CV) Dystonia, 48t(NR), 53(NR) in neuroleptic malignant syndrome, 56(NR) in Parkinson disease, 49t(NR) tardive, 53(NR), Q82(NR) Dysuria in catheter-associated urinary tract infections, 78(ID) in cervicitis, 43(ID) in cystitis, 30(ID) Ear, in relapsing polychondritis, 71–72(RM), 72f(RM), 72t(RM) Ear, nose, mouth and throat disorders, 100–107(GIM) cerumen impaction, 103(GIM) epistaxis, 105(GIM) hearing loss, 100–101(GIM), 101t(GIM) oral health, 105–106(GIM) otitis externa, 102–103(GIM)
Cumulative Index
otitis media, 102(GIM) temporomandibular disorders, 106–107(GIM) tinnitus, 101–102(GIM) upper respiratory tract infections, 103–105(GIM) Eastern equine encephalitis virus, 9t(ID) Eating, fear of, 44(GA) Eating disorder not otherwise specified (EDNOS), 114(GIM) Eating disorders, 113–114(GIM), Q143(GIM), Q154(GIM) domestic violence and, 19(GIM) in men, 77(GIM) Ebstein anomaly, 80–81(CV), Q47(CV) Ecchymoses, corticosteroid-related, 3f(DM) Echinocandins, for candidiasis, 39(ID), 40(ID), Q3(ID) Echocardiography in aortic dissection, 64t(CV) in arrhythmias, 11(CV) dobutamine, 5t(CV) Doppler in hypertrophic cardiomyopathy, 42(CV), 43f(CV) in structural heart disease, 9(CV) hand-held, in structural heart disease, 9(CV) in heart failure, 31(CV), 32(CV), 37(CV) in hypertrophic cardiomyopathy, 41–42(CV), 42f(CV) in infective endocarditis, 81(CV) in myocardial ischemia, 64t(CV) in pericarditis, 64t(CV), 65(CV), 69t(CV) in pulmonary embolism, 49(PM), 64t(CV) stress, 4t(CV) in coronary artery disease, 15f(CV) in hypertrophic cardiomyopathy, 41(CV) in women, 30(CV) of thoracic aorta, 93t(CV) three-dimensional, in structural heart disease, 9(CV), 10t(CV) transesophageal in atrial fibrillation, 53(CV) in endocarditis, Q109(CV) in heart murmurs, Q3(CV) of mitral valve, 11f(CV) in structural heart disease, 9(CV), 10t(CV) in valvular heart disease, 73t(CV) transthoracic in aortic coarctation, 89(CV) in asymptomatic heart murmurs, Q34(CV) in atrial fibrillation, 11f(CV) in atrial septal defects, 84–85(CV) in heart murmurs, Q3(CV) in intracardiac shunts, Q114(CV) in pulmonary valve stenosis, 88–89(CV) in restrictive cardiomyopathy, Q93(CV) in structural heart disease, 9(CV), 10t(CV) in valvular heart disease, 71(CV), 73f(CV), 75(CV) in ventricular septal defects, 87(CV) in valvular heart disease, 74t(CV) Eclampsia, 63(HO), 80(NP), Q14(NP) Eculizumab, for paroxysmal nocturnal hemoglobinuria, 34(HO), 35(HO) Ecologic fallacy, 2–3(GIM) “Ecstasy” hypertension and, 34t(NP) toxicity of, 90(PM) Ectasia, gastric antral vascular, 74(GA) Ecthyma, staphylococcal, 22(DM) Ectopia lentis, 74(RM) Eczema definition of, 5(DM) dyshidrotic, of hand, 6(DM), 6f(DM), 7t(DM) nummular, 14(DM) xerotic (asteatotic), 7(DM), 7f(DM) Eczema craquelé, 8f(DM) Eczema herpeticum, 10(DM) Eczematous dermatologic disease, 5–10(DM) Edema, 50(GIM) cerebral in hypernatremia treatment, 16(NP), 17(NP) in respiratory acidosis, 31(NP) in respiratory alkalosis, 32(NP) cerebral high-altitude, 69(PM) corneal, 97(GIM) in heart failure, 30–31(CV) of the knee, 58–59(GIM) laryngeal, 85(PM) in necrotizing fasciitis, 14(ID), 15(ID) in nephrotic syndrome, 48(NP), 49(NP), 49t(NP) in osteomyelitis, 49(ID) in postinfectious glomerulonephritis, 59(NP), 60(NP), Q60(NP) pulmonary cardiogenic, 72(PM), 78(PM) high-altitude, 69(PM), 70(PM) in inhalational injuries, 84(PM) in systemic sclerosis, 42–43(RM) tumor-associated vasogenic, 79(NR) venous stasis–related, 50(GIM), Q22(GIM) Edmonton Symptom Assessment Scale, 29(GIM) Efavirenz, teratogenicity of, 93(ID), 94(ID) Effect size, 4(GIM) Ehlers-Danlos syndrome, 51(DM), 73–74(RM) vascular form of, 94t(CV) Ehrlichiosis, human monocytic, 25t(ID), 28(ID) Eicosapentaenoic acid, 66–67(GIM) Eikenella corrodens infections, of human bites, 17(ID) Eisenmenger syndrome, 85(CV), 86t(CV), 87(CV), 88(CV), 92(CV), Q47(CV) Ejection click, in pulmonary valve stenosis, Q78(CV) Ejection fraction in heart failure, 35–36(CV), 35f(CV), 37(CV), Q15(CV) left ventricular in acute coronary syndromes, Q12(CV) in hypertrophic cardiomyopathy, 43(CV) in nonischemic cardiomyopathy, Q54(CV) post-myocardial infarction, 28(CV)
Elastin, in Marfan syndrome, 74(RM) Elbow golfer’s, 56(GIM), Q132(GIM) overuse syndromes of, 2t(RM) psoriatic arthritis of, 28(RM) rheumatoid arthritis of, 16(RM) Elbow pain, 56(GIM) Elder abuse, 18(GIM) Elderly patients blood pressure goal in, 39(NP) community-acquired pneumonia in, 18(ID) compressive cervical myelopathy in, Q25(NR) epilepsy treatment in, Q67(NR) fever of unknown origin in, 53(ID) HIV testing in, 87(ID) hypertension management in, 43(NP), 44(NP), Q98(NP) ischemic stroke in, 26(NR) kidney function measurement in, 1(NP) lacerations in, Q69(DM) nontuberculous mycobacterial infections in, 36–37(ID) skin changes in, 74–76(DM), 74f(DM), 75f(DM), 75t(DM) trigeminal neuralgia in, 4–5(NR) urinary tract infections in, 29(ID) Electrocardiography (ECG) in aortic dissection, 64t(CV) in atrial flutter, 55f(CV) in atrial septal defects, 86t(CV) in chest pain, Q92(CV) continuous monitoring, in arrhythmias, 11–12(CV), 51(CV), Q33(CV), Q117(CV) in Eisenmenger syndrome, Q47(CV) in heart failure, 31–32(CV) in hyperkalemia, 19(NP), 21(NP) in hypertension, 35(NP), Q33(NP) in hypertrophic cardiomyopathy, 41(CV), 42f(CV) in myocardial ischemia, 64t(CV) in non-ST-elevation myocardial infarction, 4f(CV) in palpitations, 51(CV) in pericarditis, 61(CV), 64f(CV), 64t(CV), 65(CV), 69t(CV) in previous myocardial infarction, 3(CV) in propofol-related infusion syndrome, Q65(NP) in pulmonary embolism, 48–49(PM), 64t(CV) in pulmonary valve stenosis, 86t(CV) in stress testing in arrhythmias, 11(CV) in coronary artery disease, 3–8(CV), 4t–5t(CV), 6f(CV), 6t(CV) for syncope evaluation, 46(GIM), 47(GIM) in valvular heart disease, 74(CV) in ventricular tachycardia, 58f(CV) in wide-complex tachycardia, Q104(CV) Electrocautery, pacemaker-inhibiting effect of, 50(CV), 61(CV) Electroencephalography. See also Video electroencephalography monitoring in convulsive syncope, Q20(NR) in epilepsy, 17f(NR), 17(NR), 18f(NR) in seizures, 14(NR) in status epilepticus, 22(NR), 23(NR) Electromyography in carpal tunnel syndrome, Q81(RM) in inflammatory myopathies, 61(RM), 62(RM) in peripheral neuropathy, 68–69(NR) Electronic Health Record (EHR) Incentive program, 6t(GIM) Electronic health records (EHRs), 22(GIM) Electronic pacemakers. See Pacemakers, electronic Electronic prescribing, 6t(GIM) Electrophysiologic studies, in multiple sclerosis, 59(NR) Eletriptan, for migraine, 7t(NR) Embolectomy, 51(PM) Embolism pulmonary, 64t(CV) chest pain in, 63t(CV) echocardiography in, 64t(CV) stroke and, 39(NR) Embolism. See also Thromboembolism in patent foramen ovale, 86t(CV) pulmonary, 64t(CV) acute, 46–52(PM) chest pain in, 49(GIM), 63t(CV), Q50(CV) chest radiography in, 4(PM) chronic thromboembolic hypertension and, 54(PM) computed tomography angiography in, 4(PM), Q89(PM) D-dimer assay of, 48(PM), 52(PM), Q37(PM), Q79(PM) deep venous thrombosis and, 46–47(PM), 49(PM), 51–52(PM), Q94(PM) diagnosis of, 47–49(PM), 48t(PM), 56(HO) echocardiography in, 64t(CV) in hemodynamically stable patients, 49–51(PM) in hemodynamically unstable patients, 51(PM) in kidney disease, Q97(PM) lenalidomide-associated, Q13(HO) obstructive lung disease and, 75(PM) pathophysiology and epidemiology of, 46–47(PM) pleural effusion and, 43t(PM) in pregnancy, Q18(HO) recurrent, prevention of, 51–52(PM), Q37(PM) risk factors for, 47f(PM), 47(PM) stroke and, 39(NR) treatment of, 49–51(PM), 61–62(HO), 61t(HO), Q46(PM), Q97(PM) Embolization, in acute limb ischemia, 102(CV) Emergencies in cancer, 107–109(HO) dermatologic, 1–2(DM), 61–65(DM) Emergent disorders, in critical care. See Critical care, emergent disorders in Emery-Dreifuss muscular dystrophy, 76(NR) Emollients for pruritus, 43(DM), 44(DM) for psoriasis, 12f(DM) Emphysema diffusing capacity for carbon monoxide (DLCO) in, 3(PM) pathophysiology of, 16(PM) Empty delta sign, of dural sinus venous thrombosis, 34(NR)
23
Cumulative Index
Empyema brain abscess and, 7t(ID) in community-acquired pneumonia, 23(ID) cranial subdural, 6(ID), 7–8(ID) definition of, 44(PM) management of, 45(PM) Emtricitabine, 90(ID), 93(ID), 93t(ID) Enalapril for heart failure, 33t(CV) teratogenicity of, 108t(CV) Enalaprilat, for hypertensive crises, 86t(PM) Encephalitis, 8–10(ID) anti-NMDA receptor, Q47(NR) definition of, 8(ID) herpes simplex, 9–10(ID), 9t(ID), 10f(ID), 95(ID), 96(ID) in HIV/AIDS-associated toxoplasmosis, 91(ID), 92(ID) in influenza, 94(ID) limbic, 80(NR), 80t(NR) in varicella (chickenpox), 96(ID) viral, 13(NR) in West Nile virus infections, 10(ID) Encephalomyelitis, acute disseminated, 57(NR), Q27(NR) Encephalopathy bovine spongiform, 12(ID) hepatic, 63–64(GA), 64t(GA), Q17(PM) as fulminant hepatic failure, 65–66(GA), 67t(GA) refractory, Q91(GA) hypoglycemia and, Q36(PM) Endarterectomy, for peripheral arterial disease, 100(CV), 101(CV) End-expiratory positive airway pressure (EPAP), 78(PM) Endocardial cushion defects, 84(CV) Endocarditis infective, 62t(CV), 81–82(CV), 81t(CV), 83(CV), Q76(CV), Q109(CV) brain abscess and, 7t(ID) in brucellosis, 65(ID) fever of unknown origin in, 53(ID), 54(ID) prevention of, 84–85(ID), 85t(ID), Q78(ID) lung cancer and, 59t(PM) Endocrine disorders perioperative management of, 132–133(GIM) skin changes in, 57–58(DM), 57f(DM) Endocrine Society hypogonadism diagnosis guideline from, 53(EN), Q51(EN) testosterone replacement therapy monitoring guideline from, 55(EN), 55t(EN) vitamin D supplementation guideline from, 69(EN) Endocrine therapy, for breast cancer, 72–73(HO) End-of-life care, 25(GIM), 28-29(GIM), 28f(GIM). See also Palliative care Endoleaks, 94(CV) Endolymphatic hydrops, 41(GIM) Endometrial cancer, colorectal cancer and, 46(GA) Endometriosis, 91(GIM), 91t(GIM), 92(GIM) in von Willebrand disease, 45(HO), 46(HO) Endomyocardial biopsy, in heart failure, 32(CV) Endomyocardial disorders, restrictive cardiomyopathy in, 47t(CV) Endophthalmitis, 97(GIM), 99(GIM) End-organ damage, in hypertension, 33(NP) Endoscopic pneumatic balloon dilatation, for achalasia, 3–4(GA) Endoscopic retrograde cholangiopancreatography in acute cholangitis, Q85(GA) in acute pancreatitis, 24(GA), 25(GA) in cholangiocarcinoma, Q60(GA) in choledocholithiasis, 72(GA) in chronic pancreatitis, 25(GA) gastrointestinal bleeding and, 74(GA) Endoscopic ultrasound in chronic pancreatitis, 25(GA), 26(GA) in insulinomas, 30(GA), Q48(GA) in pancreatic cancer, Q74(GA) Endoscopic variceal ligation, for variceal bleeding, 62t(GA), 63t(GA), Q75(GA) Endoscopic variceal sclerotherapy, for variceal bleeding, 62t(GA) Endoscopy in ampullary carcinoma, Q21(GA) in Barrett esophagus, Q73(GA) capsule, in gastrointestinal bleeding, 80(GA), 81(GA) in diverticulitis, Q13(GA) in esophageal disorders, 2(GA), 3(GA), 10(GA), 11f(GA), 11t(GA) in gastric cancer screening, 20(GA) in gastric carcinoid tumors, 19(GA), Q28(GA) in gastroesophageal reflux disease, 7(GA), 9(GA), Q25(GA) in gastrointestinal bleeding, 75(GA), 76f(GA), 76(GA), 79(GA), 80(GA), Q12(GA), Q16(GA) intraoperative, 80(GA) in peptic ulcer disease, 13(GA), Q19(GA) Endothelin-1 receptor antagonists, for pulmonary arterial hypertension, 55t(PM) Endotracheal intubation with mechanical ventilation, 80(PM) in asthma, Q51(PM) in chronic obstructive pulmonary disease, 27(PM), 27t(PM) in sepsis, 83(PM) in upper airway obstruction, 75(PM), 76(PM) Endovascular aneurysm repair, 97(CV) End-stage liver disease, skin changes in, 57–58(DM), 57f(DM) Entamoeba histolytica, as amebiasis causal agent, 72(ID) Entecavir, for hepatitis B, 55(GA), 55t(GA) Enteral feeding, 93(PM), 93t(PM) in burn victims, 93t(PM), Q48(PM) Enteritis, eosinophilic, chronic diarrhea in, 31t(GA) Enterobacteriaceae, carbapenem-resistant, 83–84(ID), 99(ID), 100(ID) Enterobacter infections, of urinary tract, 29(ID) Enterococcus, antibiotic therapy for, 98t(ID), 99(ID) in vancomycin resistance, 97–98(ID), 100(ID), Q101(ID) Enterococcus faecalis, antibiotic therapy for, 98t(ID), 99(ID) Enteroscopy balloon, in gastrointestinal bleeding, 80(GA), 81(GA) push, in gastrointestinal bleeding, 80(GA) spiral, in gastrointestinal bleeding, 80(GA) Entry inhibitors, for HIV/AIDS, 93t(ID) Enzyme immunoassay (EIA), in HIV/AIDS, 87(ID), 88(ID) Enzyme-linked immunosorbent assay (ELISA) in fever of unknown origin, 53(ID)
24
in Lyme disease, 25t(ID), 26(ID) Enzymes, muscle-related, in inflammatory myopathies, 60(RM), 61(RM) Eosinophilia in acute interstitial nephritis, 70–71(NP) in allergic bronchopulmonary aspergillosis, 10(PM) in Churg-Strauss syndrome, 68(RM), 69(RM), Q70(RM) in diffuse parenchymal lung disease, 5(PM) Eosinophilic enteritis, chronic diarrhea in, 31t(GA) Eosinophilic esophagitis, 6–7(GA), Q59(GA), Q83(GA) Eosinophilic fasciitis, 45(RM), Q77(RM) Eosinophils, in pleural effusion, 44(PM), Q14(PM) in asbestosis, 41(PM) in tuberculosis, Q14(PM) Eosinophils, in urine, 5(NP) Ependymomas, 78(NR), 78t(NR) Epicondylitis, 56(GIM), Q132(GIM) lateral, 2t(RM), Q59(RM) Epidemiologic studies, 2–3(GIM) Epidermal growth factor, skin eruptions due to, 15t(DM) Epidermal growth factor receptor inhibitors, 69(HO) adverse effects of, 81(HO) for colorectal cancer, 80–81(HO) for lung cancer, 68(HO), 87(HO), Q91(HO) for pancreatic cancer, 82(HO) Epidermolysis bullosa acquisita, 46t(DM) Epididymis-orchitis, 44(ID), 45(ID) Epididymitis, 44–45(ID), 78(GIM), 79(GIM), Q42(GIM) Epidural hematoma, 12(NR), 65(NR), Q40(NR) Epidural spinal cord metastases, Q77(NR) Epilepsy, 12–23(NR) clinical features of, 12–13(NR), 13t(NR) comorbidities of, 16(NR) complications of, 16(NR) diagnosis of, 13(NR), 16–18(NR) electroencephalography in, 17f(NR), 17(NR), 18f(NR) epidemiology of, 12–13(NR) generalized, 15(NR) idiopathic generalized, 15(NR), 17f(NR) imaging studies in, 16(NR) juvenile myoclonic, 15(NR), 16(NR), Q61(NR) vs. myoclonus, 55t(NR) partial (focal), 15(NR) refractory, 21–22(NR), Q26(NR) temporal lobe, 15f(NR), 15(NR), 18f(NR) refractory, Q26(NR) treatment of, 18–22(NR) discontinuation of, 21(NR) nonpharmacologic, 21–22(NR) pharmacologic, 18–21(NR), 20t(NR) Epilepsy monitoring units, 17–18(NR) Epilepsy surgery, 21(NR), 22(NR), Q26(NR) Epilepsy syndromes, 15–16(NR) Epinephrine for anaphylaxis, 85(PM), Q19(PM) clinical use and physiologic effects of, 77t(PM) in hypoglycemia, 13–14(EN) racemic, for inhalation injury, 84(PM), 85(PM) Epiphora, 98(GIM) Epirubicin, cardiotoxicity of, 104t(CV) Episcleritis, 95f(GIM), 95(GIM) in rheumatic disease, 5t(RM) Epistaxis, 105(GIM), Q4(GIM) in mucormycosis, 40(ID) Eplerenone for heart failure, 33t(CV), 34(CV), Q17(CV) for primary hyperaldosteronism, 51(EN), 52(EN) Epley maneuver, 41(GIM), 42f(GIM) Epoetin, 89(NP) for myelodysplastic syndromes, 5–6(HO) Epstein-Barr virus-associated posttransplant lymphoproliferative disease, 73(ID), 74(ID), 75(ID) Epstein-Barr virus infection, 71(DM) chronic tubulointerstitial disorders and, 46(NP) as cold agglutinin disease cause, 32(HO) fever of unknown origin in, 53(ID) as head and neck cancer cause, 88(HO) as lymphoma cause, 97(HO), 98(HO) multiple sclerosis and, 57(NR) neutropenia in, 4(HO) in transplant recipients, 74(ID) in travelers, 61t(ID) Epworth Sleepiness Scale, 64(PM) Erectile dysfunction, 74–76(GIM), 75t(GIM), 76t(GIM), Q112(GIM) in cardiovascular disease patients, 75(GIM), 76t(GIM), Q166(GIM) in chronic obstructive pulmonary disease, 19t(PM) in diabetes, 16(EN) in hyperprolactinemia, 23(EN) in hypogonadism, 53(EN) management of, 75(GIM), 76t(GIM), Q112(GIM), Q166(GIM) post-prostatectomy, 91(HO) Erlotinib, for pancreatic cancer, 82(HO) Errors, medical. See Medical errors Erysipelas, 12(ID), 22(DM), 25(DM) Erythema bacitracin-related, 34f(DM) in cellulitis, 12f(ID), 12(ID) as emergent skin condition, 1(DM) joint, 1(RM) malar, 48(DM) in patients of color, 78(DM) Erythema chronicum migrans, 4t(RM), 5f(RM) Erythema marginatum, 4t(RM) Erythema migrans, 13(DM) in Lyme disease, 24–25(ID), 26f(ID) vs. pityriasis rosea, 13(DM) Erythema multiforme, 16(DM), 61–62(DM), 62f(DM), Q33(DM) chemotherapy-related, 58(DM) in herpes simplex infection, Q16(DM) overlap with Stevens-Johnson syndrome, 61(DM), 62t(DM) vs. urticaria, 44(DM), 44f(DM), 45(DM)
Cumulative Index
Erythema nodosum, 5f(RM), 29t(RM), 55–56(DM), 55t(DM), 56f(DM), 75(RM), Q11(DM) in coccidioidomycosis, Q35(ID) in ulcerative colitis, 36(GA), Q76(GA) Erythematous lesions, in necrotizing fasciitis, 14(ID), 15(ID) Erythrasma, 25(DM), 25f(DM), Q48(DM) Erythrocytapheresis, 41(HO) Erythrocyte abnormalities, in anemia, 18(HO), 18t(HO) Erythrocyte casts in hematuria, 7(NP), Q40(NP) in postinfectious glomerulonephritis, 59(NP), 60(NP), Q60(NP) Erythrocyte count, in thalassemia, Q31(HO) Erythrocytes, in urine, 4t(NP), 5(NP) in hematuria, Q18(NP) Erythrocyte sedimentation rate in giant cell arteritis, 64(RM) in gout, 51(RM) in mycobacterial arthritis, 56(RM) in polymyalgia rheumatica, 65(RM) in rheumatic disease, 6(RM), 9(RM) in rheumatoid arthritis, 16(RM), 18(RM) in spondyloarthritis, 32(RM) in Takayasu arteritis, 65(RM) in vertebral osteomyelitis, 52(ID) Erythrocyte-stimulating agents, for myelodysplastic syndromes, 5–6(HO) Erythrocyte transfusions, 36–38(HO), 37t(HO), Q7(HO) for myelodysplastic syndromes, 5(HO) for sickle cell disease, 31(HO), Q67(HO) in pregnancy, 63(HO) Erythrocytosis in polycythemia vera, 7(HO) secondary, Q25(HO) Erythroderma, 64–65(DM), 64f(DM), 65t(DM), Q11(DM) Erythrodermic psoriasis, 10(DM) Erythromelalgia, Q89(ID) Erythromelalgia, in essential thrombocytopenia, 8(HO) Erythromycin for acne, 20t(DM) for gastroparesis, 18(GA), 18t(GA) Erythroplakia, 71(DM) Erythropoiesis-stimulating agents, 12(HO), 89(NP), Q8(NP), Q105(NP) for anemia of kidney disease, 24–25(HO) Erythropoietin in anemia of kidney disease, 24(HO), Q36(HO) recombinant human, 38(HO), 39(HO) Eschars in anthrax, 57f(ID), 57(ID), 58(ID) in rickettsial infections, 64(ID) Escherichia coli diarrheagenic, 68–69(ID), 68t(ID) enterotoxigenic, 68t(ID), Q82(ID), Q97(ID) Escherichia coli infections diarrhea in, 68–69(ID), 68t(ID) travelers’ diarrhea, 63–64(ID), Q82(ID) hepatic, 68(GA) meningitis in, 2(ID), 2t(ID), 5t(ID) O157:H7 strain, 62(NP), 66(ID) diagnostic testing for, 68–69(ID) Shiga toxin-producing, 68–69(ID), 68t(ID) in transplant recipients, 75(ID) urinary, 4–5(NP) of urinary tract, 29(ID) Esmolol, in pregnancy, 108t(CV) Esophageal cancer/carcinoma, 11–12(GA), 63(PM), 82–83(HO), Q50(GA) adenocarcinoma, 10(GA), 11–12(GA), Q50(GA) chemotherapy for, 67(HO) Peutz-Jeghers syndrome and, 47–48(GA) radiation therapy-related, 110–111(HO) squamous cell carcinoma, 11(GA) Esophageal disorders, 1–12(GA) metaplastic and neoplastic, 10–12(GA) motility, 3–6(GA) nonmalignant, 3–10(GA) Esophageal dysfunction in mixed connective tissue disease, 47(RM), 47t(RM) in systemic sclerosis, 43(RM) Esophageal dysphagia, 1(GA), 1t(GA), 2f(GA), 2(GA), 4(GA), 5(GA), 11(GA), Q59(GA) Esophageal lesions, 63(PM) Esophageal manometry in achalasia, 3(GA), 5f(GA) normal, 4f(GA) Esophageal motility disorders, 3–6(GA) hypertonic (spastic), 3–5(GA) hypotonic, 3(GA), 5–6(GA) Esophageal pH monitoring, 6(GA), 7(GA), 83(GA) Esophageal spasm, diffuse, 4–5(GA), Q14(GA) Esophageal sphincters in achalasia, 3(GA), 5f(GA), Q87(GA) effect of nicotine on, 7(GA) in esophageal hypomotility, 5–6(GA) in gastroesophageal reflux disease, 7(GA) in swallowing, 3(GA) Esophageal strictures, in scleroderma, 5–6(GA) Esophagitis bisphosphonates-induced, 70(EN) cytomegalovirus infections and, 6(GA), Q33(GA) eosinophilic, 6–7(GA), Q59(GA), Q83(GA) in gastroesophageal reflux disease, 7(GA) gastrointestinal bleeding in, 74(GA), 75(GA) infectious, 6(GA), Q33(GA) pill-induced, 6(GA), 7(GA) in scleroderma, 5–6(GA) Esophagus Barrett, 7(GA), 10–11(GA), 10f(GA), 11f(GA), Q37(GA), Q73(GA) bird’s beak appearance of, 3(GA), 4f(GA) corkscrew, 4–5(GA), Q14(GA) multinodular goiter impingement in, Q66(EN) nutcracker, 5(GA) rupture of, Q50(CV) scleroderma, 6(GA)
Essential cryoglobulinemic vasculitis, 63t(RM) Essential thrombocytopenia, 8(HO), Q48(HO) Estrogen deficiency, in hyperprolactinemia, 23–24(EN) Estrogen-progesterone, for diabetes mellitus prevention, 4t(EN) Estrogens for colorectal cancer, 52(GA), Q6(GA) prolactin secretion and, 22(EN) Estrogen therapy contraindication during pregnancy and lactation, 4t(DM) for hypoactive sexual desire disorder, 82(GIM), Q147(GIM) for menopause symptoms, 88–89(GIM), 89t(GIM), Q25(GIM) for osteoporosis, 69(EN), 70t(EN), 71(EN), Q10(EN) perioperative, 126t(GIM) Etanercept for rheumatic disease, 12(RM), 13t(RM) for rheumatoid arthritis, 20(RM) Ethambutol for Mycobacterium avium complex infections, 38(ID) for Mycobacterium kansasii infections, 38(ID) for tuberculosis, 35(ID), 35t(ID), 36(ID) Ethanol, hypertension and, 34t(NP) Ethanol poisoning, 89(PM) Ethics, 22–27(GIM), 23t(GIM) Ethionamide, for tuberculosis, 35t(ID) Ethnicity. See Race/ethnicity Ethylene glycol toxicity, 89(PM), 89t(PM), Q7(PM) anion gap metabolic acidosis in, 25–26(NP), 25(NP), 27(NP), Q7(NP) Etoposide, for lung cancer, 87(HO) European Respiratory Society, idiopathic diffuse parenchymal lung disease classification statement from, 30(PM) European Society of Intensive Care Medicine, acute respiratory distress syndrome classification recommendation from, 70(PM) Euthanasia, 25(GIM) Euthyroid sick syndrome, 38(EN) Event recording of arrhythmias, 11–12(CV), Q89(CV), Q117(CV) of palpitations, 51(CV) Everolimus for gastrointestinal neuroendocrine tumors, 83(HO) for renal cell carcinoma, 96(HO) Evidence, sources of, 4(GIM) Evidence-based medicine, 4(GIM) Excessive daytime sleepiness, 64(PM), 64t(PM), 65–66(PM), 67(PM), Q12(PM), Q30(PM) Exenatide, for type 2 diabetes mellitus, 7(EN), 8t(EN) Exercise bronchospasm and, 10(PM), 11(PM), Q44(PM) coronary artery disease and, 12t(CV) for diabetes mellitus management, 4t(EN), 6–7(EN) in gestational diabetes, 4(EN) hyperglycemia and, Q76(EN) hypoglycemia and, 14(EN), Q79(EN) in fibromyalgia, 27(RM) in osteoarthritis, 24(RM) for polycystic ovary syndrome management, 58(EN) for weight control, 72(GIM), Q51(GIM) Exercise stress testing. See also Stress testing cardiopulmonary, 32(CV) in coronary artery disease, 3(CV), 4t(CV), 6(CV), 15f(CV), Q1(CV), Q115(CV) with diabetes mellitus, 28–29(CV) in heart failure, 32(CV) in hypertrophic cardiomyopathy, 41(CV) in post-revascularization angina, 19(CV) in valvular heart disease, 75(CV) vs. pharmacologic stress testing, 3–4(CV), 6(CV) in women, 30(CV), Q28(CV) Exercise therapy, for peripheral arterial disease, 100(CV), 101(CV), Q91(CV) Experimental studies, 1(GIM), 2t(GIM) Expiratory reserve volume (ERV), 3(PM) Extended spectrum β-lactamase-producing organisms (ESBL), 83(ID) External validity, 1(GIM) Extra-articular manifestations, of rheumatic disease, 3–5(RM), 4t(RM), 5f(RM), 5t(RM), 6t(RM) Extracorporeal membrane oxygenation, for acute respiratory distress syndrome, 71t(PM), 72(PM) Extracorporeal shock wave lithotripsy, for kidney stones, 76(NP), 77(NP) Extragonadal germ cell cancer syndrome, 105(HO), Q98(HO) Extrapyramidal symptoms, 54(NR) Extubation, 81(PM), 82(PM) noninvasive positive pressure ventilation following, 78–79(PM) Eye disorders, 93–100(GIM) in ankylosing spondylitis, 29t(RM) in Behçet disease, 70(RM), 71(RM), Q83(RM) blepharitis, 95(GIM) cataracts, 97(GIM) in cicatricial pemphigoid, 46t(DM) conjunctivitis, 93–94(GIM), 94f(GIM), 95(GIM), Q11(GIM) corneal conditions, 94–95(GIM), 97(GIM) dry eye, 97–98(GIM), Q44(GIM) episcleritis, 95f(GIM), 95(GIM) excessive tearing, 98(GIM) eye emergencies, 99–100(GIM), 99t(GIM) glaucoma, 96–97(GIM), 97t(GIM), 119(GIM), Q95(GIM), Q165(GIM) in herpes zoster infections, 29(DM), Q9(DM) macular degeneration, 96f(GIM), 96(GIM), 119(GIM), Q148(GIM) in multiple sclerosis, 58(NR) in myopathy, 76(NR) in progressive supranuclear palsy, 51(NR), Q76(NR) in reactive arthritis, 29t(RM), 30(RM) in relapsing polychondritis, 72(RM), 72t(RM) retinal detachment, 98f(GIM), 98(GIM), Q29(GIM) retinal vascular occlusion, 99f(GIM), 99(GIM) in rheumatic disease, 3(RM), 5t(RM) in rheumatoid arthritis, 19t(RM) in rosacea, 21–22(DM) scleritis, 95(GIM) in Sjögren syndrome, 3(RM), 46(RM) in spondyloarthritis, 28f(RM), 29t(RM) in Stevens-Johnson syndrome, 22(DM), 62t(DM) in stroke, 29t(NR) subconjunctival hematoma, 94f(GIM), 94(GIM) in toxic epidermal necrolysis, 62t(DM)
25
Cumulative Index
Eye disorders (continued) uveitis, 95(GIM) in Wegener granulomatosis, 67(RM) Eye examinations, in elderly patients, 119(GIM) Eye protection, in Bell palsy, 70(NR) Ezetimibe, 65(GIM), 65t(GIM), 66(GIM) for hyperlipidemia, 17(CV) FABER test, 58f(GIM), 58(GIM) Fabry disease, 65(NP), Q88(NP) vs. hypertrophic cardiomyopathy, 41–42(CV) Facial masking, in Parkinson disease, 48(NR) Facial nerve palsy, 70(NR) Facial pain, in trigeminal neuralgia, 4(NR) Factor III, 42(HO) Factor V Leiden, 53(HO), 54(HO) screening for, 56(HO) Factor VII in pregnancy, 65(HO) recombinant, activated, for hemophilia, Q22(HO) Factor VIII concentrates, for hemophilia, 45(HO) Factor IX concentrates for hemophilia, 45(HO) Factor IX deficiency, 58(HO), Q11(HO) Factor X deficiency, 16(HO) Factor Xa inhibitors, for pulmonary embolism, 50t(PM), 51(PM) Falls causes of, 68t(EN) chronic hyponatremia as risk factor for, 14(NP) in elderly patients management of, Q87(GIM) patient assessment after, 117–118(GIM), Q78(GIM) prevention of, 117–118(GIM), 119(GIM), Q67(GIM) as fracture cause, 69(EN) gait evaluation in, 51(NR) in Parkinson disease, 49(NR) in parkinsonism, 51(NR), 52(NR) risk prediction of, 52(NR), Q60(NR) Famciclovir for herpes simplex virus infections, 96(ID), Q5(ID) for herpes zoster infection, 96(ID) Familial adenomatous polyposis, 20(GA), 46–47(GA) ampullary adenocarcinoma and, 73(GA), Q21(GA) attenuated, 47(GA), 51t(GA) colorectal cancer screening in, 51t(GA) Familial aortic artery aneurysms, 93–94(CV), 94t(CV) Familial autoinflammatory diseases, 73(RM), 74t(RM) Familial cold autoinflammatory syndrome, 74t(RM) Familial colorectal cancer type X, 46(GA) colorectal cancer surveillance in, 50t(GA) Familial Mediterranean fever, 3(RM), 10(RM), 54(ID), 73(RM), 74t(RM), Q78(RM), Q89(ID) Family history, 11(GIM) Fanconi anemia, 2(HO), 10(HO), 52(HO) Fanconi syndrome, 44t(NP), 46(NP) Fasciitis eosinophilic, 45(RM), Q77(RM) necrotizing, 14–15(ID), 14f(ID), 15f(ID) hyperbaric oxygen therapy for, 101–102(ID) in Streptococcus group A β-hemolytic infections, Q67(ID) Vibrio vulnificus-associated, Q16(ID) Fatal familial insomnia, 11t(ID) Fatigue chronic, 39–40(GIM), Q7(GIM), Q72(GIM) distinguished from sleepiness, 64(PM) end-stage illness–related, 30(GIM) in fibromyalgia, 26(RM) joint inflammation and, 1(RM) in multiple sclerosis, 58(NR), 63–64(NR), 63t(NR), Q49(NR) in pulmonary hypertension, 53(PM) in rheumatoid arthritis, 19(RM), 19t(RM) Fat malabsorption, 32(GA) diarrhea in, 32(GA) in primary biliary cirrhosis, 60(GA) Fatty liver disease, nonalcoholic, in diabetes mellitus, Q45(EN) Febrile nonhemolytic transfusion reaction, 40(HO), 41(HO) Febuxostat for gout, 15(RM), 52(RM) interaction with azathioprine, Q68(RM) Fecal immunochemical test, for colorectal cancer screening, 49(GA), 49t(GA) Fecal occult blood test, for colorectal cancer screening, 48–49(GA), 49t(GA), Q31(GA) Feeding tubes, 32(GIM), 93(PM), 93t(PM), Q48(PM) Felbamate adverse effects of, 19t(NR) interaction with hormonal contraceptives, 21(NR) Felodipine, for heart failure, 35(CV) Felty syndrome, 4(HO), 18(RM), 19(RM) Fenofibrate, 66(GIM), Q41(GIM) Fenoldopam, for hypertensive crises, 86t(PM) Fenoterol, for chronic obstructive pulmonary disease, 22t(PM), 23t(PM) Fentanyl transdermal patches, 30(GIM), 31t(GIM), Q19(GIM) Ferritin in adult-onset Still disease, 73(RM), Q87(RM) in inflammatory anemia, 24(HO), Q26(HO) in pregnancy-related iron deficiency, 62(HO) Ferrous sulfate, for iron deficiency anemia, 21(HO) Fetal growth retardation, maternal hyperthyroidism and, Q78(EN) FEV1. See Forced expiratory volume exhaled in one second (FEV1) Fever in adult-onset Still disease, 72(RM), 73t(RM), Q87(RM) in aspergillosis, 75(ID), Q105(ID) in brucellosis, 65(ID) in Campylobacter infections, 67(ID) cancer treatment-related, 109–110(HO) in Clostridium difficile-related diarrhea, 71(ID) in dengue fever, 64(ID) in erysipelas, 12(ID) familial Mediterranean, 3(RM), 10(RM), 54(ID), 73(RM), 74t(RM), Q78(RM), Q89(ID) in HIV/AIDS, 87t(ID) in influenza, 94(ID) in malaria, 62(ID)
26
in mixed connective tissue disease, 48(RM) in pneumonic plague, 59(ID) in rheumatic disease, 3(RM) in rickettsial infections, 64(ID) Rocky Mountain spotted, 25t(ID), 28f(ID), 28(ID), Q87(ID) in salmonellosis, 67(ID) transfusion-related, 40(HO), 41(HO) in typhoid fever, 61t(ID), 63(ID), Q75(ID) of unknown origin, 52–54(ID) health care-associated, 52(ID) viral hemorrhagic fever, 56t(ID), 60–61(ID), 60t(ID) Fiber, dietary for constipation, 40–41(GA) for irritable bowel syndrome, 42(GA) Fibrates, 64–65(GIM), 65t(GIM), 66(GIM), 67(GIM), 68(GIM), Q41(GIM), Q66(GIM) Fibrinogen, 42(HO) in disseminated intravascular coagulation, 46(HO) Fibrinolytics. See also Thrombolytics for stroke, 29–30(NR) Fibroadenomas, 83(GIM) Fibroelastomas, papillary, 47(CV) Fibroma, esophageal, 63(PM) Fibromyalgia, 26–27(RM), 26f(RM), 27t(RM), Q85(RM) tender points in, 26–27(RM), 26f(RM), 27t(RM) vs. systemic lupus erythematosus, 1(RM) Fibrosis hepatic in autosomal recessive polycystic kidney disease, 63t46(NP), 6446(NP) in hepatitis, 55–56(GA) in nonalcoholic steatohepatitis, 58(GA) nephrogenic systemic, 45(RM), 54(DM), Q47(DM) pulmonary amiodarone and, 37t(PM) chest radiography in, 3(PM) diffusing capacity for carbon monoxide (DLCO) in, 3(PM) idiopathic, 32–34(PM) acute exacerbations of, 74–75(PM), Q39(PM), Q64(PM) imaging of, 4(PM), 5f(PM), Q49(PM), Q60(PM) parenchymal, in inhalational injuries, 84(PM) pleural, asbestos exposure and, 40t(PM), 41(PM), Q60(PM) silicosis and, 42t(PM) renal interstitial, nephrotoxins and, 63t46(NP), 64(NP) nephrogenic systemic, 70(NP), 90(NP), Q19(NP) Fidaxomicin, for Clostridium difficile infections, 70(ID) Field cancerization effect, 88(HO), Q76(HO) Figure 3 sign, of aortic coarctation, 89(CV), 90f(CV) Filoviridae, as viral hemorrhagic fever causal agent, 60t(ID) Finasteride for alopecia, 66(DM) contraindication during pregnancy and lactation, 4t(DM) Fingernails. See Nails Fingers in Marfan syndrome, 74(RM) in reactive arthritis, 31f(RM) in systemic sclerosis, 41–42(RM), 42f(RM) Fingers, clubbing of, in lung cancer, 85f(HO), 85(HO) Fingolimod, for multiple sclerosis, 62t(NR), 63(NR) Fish oil cardioprotective effects of, 66–67(GIM) for hypertension management, 39(NP) Fistulas aortoenteric, 75(GA) in Crohn disease, 38(GA), Q53(GA) dural arteriovenous, vs. multiple sclerosis, 60t(NR) duropleural, 44t(PM) 5α-Reductase inhibitors for benign prostatic hyperplasia, 78(GIM), 78t(GIM), Q70(GIM) for prostate cancer prevention, 89–90(HO) Fixed drug reactions, 14(DM), 16(DM) Flank pain in pyelonephritis, 31(ID) in urinary tract infections, 29(ID), 30(ID) Flaviviridae as dengue fever causal agents, 64(ID) as viral hemorrhagic fever causal agents, 60t(ID) Flecainide for arrhythmias, 51t(CV) in pregnancy, 109t(CV) for supraventricular tachycardia, in pregnancy, 108(CV) Fleischner Society for Thoracic Imaging and Diagnosis, 56(PM), 56t(PM), Q27(PM) “Flesh-eating bacteria.” See Streptococcus pyogenes infections Flow-volume loops in airway obstruction, 1(PM), 2f(PM), Q22(PM) in asthma, 2f(PM) in chronic obstructive pulmonary disease, 2f(PM) in tracheal obstruction, 2f(PM) in vocal cord dysfunction, 10(PM), 11f(PM), Q22(PM) Fluconazole for candidiasis, 39(ID), 40(ID), Q52(ID) for coccidioidomycosis, 42(ID) for cryptococcosis, 41(ID) Flucytosine for cryptococcosis, 41(ID), Q25(ID) interaction with serum creatinine, 1(NP) Fludarabine, for chronic lymphocytic leukemia, 101(HO) Fludrocortisone, for adrenal insufficiency, 43(EN) Fluid gain, hypertonic, in hypernatremia, 16t(NP) Fluid loss, hypotonic, in hypernatremia, 15(NP), 16t(NP) Fluid restriction, in hyponatremia, 14–15(NP), 15t(NP), Q13(NP) Fluid resuscitation for acute pancreatitis, 24(GA), Q86(GA) for shock, 77(PM), 78(PM), Q10(PM) Flumazenil, for respiratory depression, 73(PM) Fluoroquinolone resistance, 63(ID), 67(ID) Fluoroquinolones for community-acquired pneumonia, 21t(ID) for human bites, 17(ID) for pyelonephritis, 31(ID), Q71(ID)
Cumulative Index
for shigellosis, 67(ID), Q9(ID) for typhoid fever, 63(ID) for urinary tract infections, 30(ID) for Vibrio infections, 69(ID) 5-Fluorouracil for anal cancer, 81(HO), Q116(HO) cardiotoxicity of, 104t(CV) for colorectal cancer, 80(HO), Q115(HO) contraindication during pregnancy and lactation, 4t(DM) for gastric cancer, 83(HO) for pancreatic cancer, 82(HO) for rectal cancer, 80(HO) Flushing, in rosacea, 21(DM) Flutamide, contraindication during pregnancy and lactation, 4t(DM) Fluticasone, for chronic obstructive pulmonary disease, 22t(PM) Fluvastatin, 65(GIM) Foams, corticosteroid, 2(DM) Focal nodular hyperplasia, 67(GA) Folate/folic acid bariatric surgery-related deficiency in, 22t(GA) colorectal cancer and, 46(GA) deficiency of, 23(HO) anemia in, 4(HO) pancytopenia in, 4(HO) in pregnancy, 62(HO) thrombocytopenia in, 52(HO) vs. vitamin B12 deficiency, 23(HO) supplemental, 87(GIM) for folate deficiency, 23(HO) for hemolytic anemia, 26(HO) for hereditary spherocytosis, Q27(HO) for methanol poisoning, 26(NP) in pregnancy, 21(NR), 62(HO) for vitamin B12 deficiency, 23(HO) FOLFOX adjuvant chemotherapy, for colorectal cancer, 80(HO), Q115(HO) Follicle-stimulating hormone, 87–88(GIM) hypothalamic production of, 17(EN) in males, in hypogonadism, 53(EN), 53f(EN), Q38(EN) in menstrual cycle, 56(EN), 56f(EN) in primary ovarian insufficiency, Q77(EN) Follicle-stimulating hormone deficiency, in hypopituitarism, 19t(EN) Follicular Lymphoma International Prognostic Index, 98(HO), 100(HO), 100t(HO) Folliculitis, 22–23(DM) acne keloidalis nuchae, 77(DM), 77f(DM) bacterial, 19t(DM), Q54(DM) eosinophilic, in HIV/AIDS, 61(DM) fungal, 22–23(DM), 26(DM) Gram-negative, 19t(DM) herpetic, 22–23(DM) staphylococcal, 22–23(DM), 23f(DM) steroid, 19t(DM) vs. herpes zoster, 29(DM) Folstein Mini-Mental State Examination, 41(NR), 43(NR), 47(NR) Fomepizole for ethylene glycol poisoning, 89t(PM), Q7(PM) for methanol poisoning, 25–26(NP), 27(NP), Q7(NP) for propylene glycol toxicity, 26(NP), Q7(NP) Fondaparinux for pulmonary embolism, 50(PM), 50t(PM), Q97(PM) reversal of, 59t(HO) for venous thromboembolism, 57–58(HO), 61(HO) Food allergies, 44(DM) Food-borne illness Escherichia coli infections, 68–69(ID) salmonellosis, 67–68(ID) shigellosis, 67(ID) Vibrio infections, 69(ID) Food poisoning, differentiated from infectious diarrhea, 66(ID) Foot overuse syndromes of, 2t(RM) psoriasis of, 10f(DM) rheumatoid arthritis of, 16(RM) Foot infections, diabetic, 17–18(ID), 51(ID) Foot pain forefoot, 62(GIM) hindfoot, 61–62(GIM) midfoot, 62(GIM) Foot ulcers, diabetic, 16(EN) Foramen ovale, patent, 83–84(CV), 83f(CV), 86t(CV), Q110(CV) Forced expiratory volume exhaled in one second (FEV1) in bronchial challenge testing, 1(PM) in chronic obstructive pulmonary disease, Q5(PM), Q13(PM), Q81(PM) definition of, 1(PM) in lung cancer, 60–61(PM) in severe asthma exacerbations, Q91(PM) Forced expiratory volume exhaled in one second /forced vital capacity ratio (FEV1/FVC), 1(PM) in chronic obstructive pulmonary disease, 19(PM), 19t(PM), Q1(PM), Q81(PM) Forced vital capacity (FVC), definition of, 1(PM) Forefoot pain, 62(GIM) Formoterol for asthma, 12–13(PM) for chronic obstructive pulmonary disease, 22t(PM) Fosfomycin, 100(ID), 100t(ID), 101(ID) for cystitis, 30(ID), 30t(ID) Fosinopril, for heart failure, 33t(CV) Fosphenytoin, for status epilepticus, 22(NR), Q43(NR) 4 T score, for heparin-induced thrombocytopenia, 50(HO), 50t(HO), 51(HO) Fractional excretion of phosphate (FEPO4), in hypophosphatemia, 22(NP), Q50(NP) Fractional excretion of sodium (FENa) in acute kidney injury, 66(NP), 67t(NP) in acute tubular necrosis, 67(NP), 71(NP) Fracture Risk Assessment Tool (FRAX), 69(EN), Q10(EN) Fractures in ankylosing spondylitis, Q51(RM) compression, as low back pain cause, 51t(GIM) epilepsy and, 16(NR) fragility/osteoporotic, 66(EN), 67(EN), 69(GA), 70(EN), Q59(EN) aromatase inhibitor-related, 111(HO) breast cancer therapy-related, 72(HO)
in hyperparathyroidism, Q54(EN) prediction of, 69(EN) prevention of, 69–72(EN) in rheumatoid arthritis, 18(RM) risk factors for, 68t(EN) in systemic lupus erythematosus, 36(RM), Q95(RM) vertebral, 66(EN), 67(EN), 70(EN) in osteogenesis imperfecta, 73(RM) post-hip arthroplasty, 26(RM) in spondyloarthritis, 29t(RM), Q51(RM) stroke and, 39(NR) of wrist and hand, 57(GIM) Fragile X mutation, 57(EN) Fragile X tremor ataxia syndrome, 53(NR) Frail elderly. See also Geriatric medicine clinical course in, 28f(GIM) outcome measures for, 5(GIM) urinary incontinence screening in, 121(GIM) FRAMES model, of brief interventions, 16(GIM) Framingham risk score, for cardiovascular events, 12(CV), 14(CV) in women, 30(CV), Q45(CV) Francisella tularensis, as tularemia causal agent, 56t(ID), 59–60(ID) FRAX. See Fracture Risk Assessment Tool Free cortisol excretion test, for Cushing syndrome, 43(EN), 44–45(EN) Free testosterone assays, 52–53(EN), Q33(EN), Q51(EN) Fresh frozen plasma, 37t(HO) Fresh frozen plasma, 37t(HO) ABO compatibility of, 36t(HO) for coagulopathy of liver disease, 46(HO) for warfarin-related bleeding, 58(HO) Friction rub, pericardial, 61(CV) Frovatriptan, for migraine, 7t(NR) FSH. See Follicle-stimulating hormone Fulminant hepatic failure, 65–66(GA), 67t(GA), Q71(GA), Q82(GA) in Wilson disease, 59(GA), Q82(GA) Functional assessment, of elderly patients, 116–120(GIM) Functional capacity, 6-minute walk test of, 3(PM), 33(PM) Fundoplication, for gastroesophageal reflux disease, 3(GA), Q52(GA) Funduscopy, in dural sinus venous thromboembolism, 33–34(NR) Fungal infections, 39–43(ID) as arthritis cause, 3(RM), 54(RM), 56(RM), 58(RM), Q84(RM) aspergillosis and aspergillomas, 40(ID) blastomycosis, 41–42(ID) candidiasis, 39–40(ID) coccidioidomycosis, 42(ID) cryptococcosis, 41(ID) false-positive PET scans in, 5(PM) histoplasmosis, 42(ID) hypersensitivity pneumonitis and, 35(PM), 36t(PM) mucormycosis, 40–41(ID) of nails, 68–69(DM), 69f(DM), 70t(DM) of skin, in organ transplant recipients, 26–27(DM) sporotrichosis, 42–43(D) in transplant recipients, 74(ID), 75–76(ID), Q105(ID) travel-associated, 65(ID), 65t(ID) tumor necrosis factor-α inhibitors and, 12(RM) Fungus balls, 40(ID) Furosemide for hyperkalemia, Q74(NP) for hypertension, Q39(NP), Q74(NP) for hyponatremia, Q69(NP) as lichen planus cause, 11(DM), 12(DM) Furuncles staphylococcal, 22(DM), 23(DM), 23f(DM) vs. epidermal inclusion cysts, 42(DM) FVC. See Forced vital capacity Gabapentin, 35(GIM), Q65(GIM) adverse effects of, 19(NR), 19t(NR), 20t(NR) for epilepsy, 20t(NR) for fibromyalgia, 27(RM) for neuropathic pain, 63t(NR) Gait, 51–52(NR) antalgic, 52(NR) ataxic, 51(NR), 52(NR) choreic, 52(NR) evaluation of, 51–52(NR) in multiple sclerosis, 64(NR) in normal pressure hydrocephalus, 46–47(NR) in Parkinson disease, 48–49(NR), 50(NR) in parkinsonism, 46–47(NR), 52(NR) psychogenic, 52(NR), Q66(NR) in spinal cord disorders, 65(NR) Gait analysis, in elderly patients, 117(GIM) Galactorrhea, in hyperprolactinemia, 23(EN), 24(EN) Galantamine, for Alzheimer disease, 44(NR), 44t(NR), 45(NR) Gallbladder disorders of, 71–72(GA), Q78(GA) porcelain, 71(GA), 73(GA) Gallbladder cancer, 73(GA) Gallstone pancreatitis, 23(GA), 23t(GA), 25(GA) Gallstones asymptomatic, 71(GA), 72(GA), Q42(GA) pancreatitis and, 23(GA), 23t(GA), 25(GA) Gallstones, in hereditary spherocytosis, 26(HO), Q41(HO) Gangrene, hyperbaric oxygen therapy for, 101–102(ID) Gastric adenocarcinoma, 20(GA) Gastric antral vascular ectasias, 74(GA) Gastric antral venous ectasia, Q88(RM) Gastric bypass. See Bariatric surgery Gastric cancer, 67(HO), 83(HO) Helicobacter pylori infection and, 14(GA) Peutz-Jeghers syndrome and, 47–48(GA) Gastric carcinoid tumors, 19(GA), Q28(GA) Gastric emptying, delayed, in gastroparesis, 17(GA), 18(GA) Gastric motility drugs, hyperprolactinemia and, 22(EN) Gastric outlet obstruction, in peptic ulcer disease, 13(GA) Gastric polyps, 19(GA), Q84(GA) Gastric subepithelial masses, 19(GA) Gastric surgery, complications of, 20–23(GA)
27
Cumulative Index
Gastric ulcers. See Peptic ulcer disease Gastrinomas, 29(GA), 29t(GA) Gastritis, Helicobacter pylori infection and, 14(GA) Gastroduodenal manometry, in gastroparesis, 18(GA) Gastroenteritis. See also Diarrhea in Escherichia coli infections, 68–69(ID) infectious, irritable bowel syndrome and, 41(GA) in salmonellosis, 67–68(ID), 67(ID), 68(ID) self-limited, Q4(GA), Q51(GA) in Vibrio infections, 69(ID) viral, 71(ID) in yersiniosis, 69(ID) Gastroesophageal junction adenocarcinoma, 83(HO), Q90(HO) Gastroesophageal reflux disease (GERD), 2–3(GA), 3t(GA), 7–9(GA) in asthma, 10(PM) chest pain in, 3(GA), 49(GIM) in chronic obstructive pulmonary disease, 19t(PM) classification of, 9f(GA) cough in, 9(GA), 10(PM), 37(GIM), 38f(GIM), 39(GIM), Q1(PM), Q38(GIM) diagnosis of, 3(GA), 7(GA) vs. eosinophilic esophagitis, 6(GA), 7(GA), Q83(GA) esophageal hypomotility in, 5–6(GA) extraesophageal manifestations of, 9(GA) globus sensation in, 3(GA) heartburn in, 2(GA), 9(GA), Q15(GA) in idiopathic interstitial pneumonia, 33(PM) treatment of, 7–9(GA), 8f(GA), Q15(GA), Q25(GA), Q52(GA), Q69(GA) vocal cord dysfunction in, 10(PM) Gastroesophageal varices. See Varices, gastroesophageal Gastrointestinal bleeding, 74–81(GA) in bariatric surgery, 21(GA) in ischemic bowel disease, 43(GA), 45(GA) lower, 77–79(GA) lower vs. upper, 77–78(GA) obscure, 78(GA), 79–81(GA), 79t(GA), Q20(GA), Q36(GA), Q65(GA) in peptic ulcer disease, 12(GA), 13(GA), 74(GA), 75–76(GA), 76f(GA), 77f(GA) in polycythemia vera, 7(HO) postpolypectomy, 77(GA) in systemic sclerosis, 43(RM), Q88(RM) in ulcerative colitis, 39(GA) upper, 74–77(GA), Q16(GA), Q58(GA) Gastrointestinal cancer, 79–84(HO) as cancer of unknown primary site, Q110(HO) gastrointestinal bleeding in, 74(GA) upper, 74(GA) Gastrointestinal disorders in inflammatory myopathies, 60(RM) in mixed connective tissue disease, 47t(RM), 48(RM) pleural effusion and, 43t(PM) in Sjögren syndrome, 46t(RM) skin disorders in, 56–57(DM), 56f(DM) in spondyloarthritis, 28(RM), 29t(RM) in systemic lupus erythematosus, 37–38(RM) Gastrointestinal medications, perioperative management of, 126t(GIM) Gastrointestinal neuroendocrine tumors, 83–84(HO) Gastrointestinal reflux disease, as esophageal cancer risk factor, 82(HO) Gastrointestinal stromal tumors, 19(GA), 74(GA) Gastrointestinal surgery patients, hyperkalemia in, Q56(NP) Gastrointestinal syndromes, infectious, 65–72(ID) Gastrointestinal tract, potassium loss in, 18(NP) Gastroparesis, 7(GA), 17–19(GA), 17t(GA), 18t(GA) in diabetes, 16(EN) vs. irritable bowel syndrome, 41(GA) Gastropathy, portal hypertensive, 74(GA) Gatifloxacin, for tuberculosis, 35t(ID) GAVE lesions, 74(GA) Gefitinib, 69t(HO) Gemcitabine for pancreatic cancer, 82(HO) as thrombotic thrombocytopenic purpura cause, 51(HO) Gene array analysis, of breast cancer, 72(HO) Gene expression profiling analysis, for cancer of unknown primary site, 105(HO) General anesthesia, atelectasis and, 72(PM) Generalizability, of study results, Q127(GIM) Generalized anxiety disorder (GAD), 110–111(GIM), Q146(GIM) Genetic counseling for autosomal recessive polycystic kidney disease, 64(NP) referral for, 11–12(GIM), Q1(GIM), Q16(GIM) Genetic disorders, and kidney disease, 63–65(NP) kidney cystic disorders, 63–64(NP), 63t(NP) kidney noncystic disorders, 64–65(NP) Genetic testing, 11(GIM), Q1(GIM), Q16(GIM) Genital herpes, 46–47(ID), 46t(ID), Q27(ID) differentiated from chancroid, 48(ID) in HIV/AIDS, Q91(ID) meningitis and, 1(ID) Genital herpes, bacterial vaginosis as risk factor for, 92(GIM) Genitals herpes virus infections of, 27(DM), 28f(DM) herpetic ulcers of, 28(DM), 28f(DM) lichen planus of, 11–12(DM), 13f(DM) skin cancer of, 1(DM) warts of, 30(DM), 30f(DM) Genital warts, 48–49(ID) Genitourinary cancer, 89–96(HO) bladder, 94–95(HO) prostate, 89–93(HO) renal cell, 95–96(HO) testicular, 93–94(HO) Genitourinary disorders chemotherapy-related, 110(HO) radiation therapy-related, 110(HO) in spondyloarthritis, 28(RM), 29t(RM) Genitourinary tract cancer, hematuria in, 7(NP) Gentamicin Bartter-like syndrome and, Q104(NP) for pneumonic plague, 59(ID) for tularemia, 60(ID) Geographic tongue, 106(GIM)
28
GERD. See Gastroesophageal reflux disease Geriatric medicine, 116–124(GIM) acetaminophen use, 35(GIM), Q144(GIM) chronic pain management, Q144(GIM) depression, 119(GIM), Q99(GIM) dizziness, 40(GIM), Q55(GIM) driving, 120(GIM), Q118(GIM) dyslipidemia management, 68–69(GIM) falls, 117–118(GIM), 119(GIM), Q67(GIM), Q78(GIM), Q87(GIM) frail elderly, 5(GIM), 28f(GIM), 121(GIM) functional assessment, 116–120(GIM) levels of care in, 120(GIM) polypharmacy, 120–121(GIM), Q46(GIM) pressure ulcers, 123–124(GIM), 124t(GIM), Q17(GIM), Q24(GIM) syncope management, Q156(GIM) urinary incontinence, 121–123(GIM), 122f(GIM) Germ cell tumors, 93(HO), 105(HO), Q98(HO) Germinomas diabetes insipidus and, 20(EN) hypopituitarism and, 18(EN) Gerstmann-Sträussler-Scheinker syndrome, 11t(ID) Gestational anemia, 62(HO), Q10(HO) Gestational thrombocytopenia, 63–65(HO), Q56(HO) Ghon complex, 32(ID) Giant cell arteritis, 2t(CV), 5t(RM), 63t(RM), 64(RM), 65(RM), 92(CV), Q15(NP), Q24(RM), Q55(RM), Q92(NP) Giant cell myocarditis, 41(CV) Giardia lamblia. See Giardiasis Giardiasis, 55(ID), 66(ID) diagnosis of, 66t(ID), 71(ID), Q98(ID) stool assay for, 71(ID), Q98(ID) Gitelman syndrome, 31(NP), Q17(NP) Glasgow Coma Scale (GCS), 10(NR), 10t(NR), 11(NR), 94(PM) in bacterial meningitis, 3(ID) Glatiramer acetate for multiple sclerosis, 62(NR), 62t(NR), Q29(NR) for optic neuritis, Q29(NR) Glaucoma, 119(GIM) acute angle closure, 97(GIM), Q95(GIM) adverse effects of treatment for, 96(GIM), 97t(GIM), Q165(GIM) chronic obstructive pulmonary disease and, 19t(PM) primary open angle, 96–97(GIM), 97t(GIM) Gleason score, in prostate cancer, 90(HO) Gliclazide, 8t(EN) Glimepiride, 8t(EN) Glioblastoma multiforme, 78(NR), 78t(NR), 79f(NR), Q4(NR) Gliomas, 78t(NR) Glipizide, 8t(EN), Q53(EN) Global Initiative for Chronic Obstructive Lung Disease (GOLD), 19(PM), 20t(PM), Q1(PM) Globe, traumatic injury to, 99(GIM) Globus sensation, 3(GA) Glomerular diseases, 48–62(NP) nephritic syndrome-associated, 48–49(NP), 56–62(NP) nephrotic syndrome-associated, 1(NP), 49–56(NP) pathophysiology of, 48(NP) urine protein-creatinine ratio in, 6–7(NP) Glomerular filtration rate (GFR), 1–2(NP), 1f(NP) bisphosphonate use and, Q42(NP) in chronic kidney disease, 81(NP), 81t(NP), 82(NP), 83(NP), 85(NP), 86(NP), Q90(NP) hypertension treatment and, Q39(NP) in chronic tubulointerstitial disease, 44t(NP) contrast media nephrotoxicity and, 9(NP) in diabetic nephropathy, 54(NP), 54t(NP) in end-stage kidney disease, 90(NP), 91(NP) in glomerular injury, 48(NP) in hyperkalemia, 21(NP) in hypertension, 35(NP) in immunoglobulin A nephropathy, 57(NP) methods for estimating, 2(NP), 3t(NP), 9–10(NP), Q28(NP) in pregnancy, 77(NP) relationship to serum creatinine level, 1(NP), 1f(NP) Glomerulonephritis differentiated from kidney injury, 67(NP) in Henoch-Schönlein purpura, 69(RM) immune complex, Q20(NP) membranoproliferative, 50t(NP), 56t(NP), 57(NP) hepatitis B and, 58(NP) hepatitis C and, 57(NP), Q20(NP) pauci-immune, 67–68(RM) pauci-immune crescentic, 56t(NP), 61(NP) postinfectious, 56t(NP), 58–59(NP), 60(NP), Q5(NP), Q16(NP), Q51(NP) rapidly progressive, 48(NP), 49(NP), Q83(NP) in anti-glomerular basement membrane antibody disease, 60(NP) in pauci-immune crescentic glomerulonephritis, 61(NP) in postinfectious glomerulonephritis, Q53(NP), Q60(NP) urinary casts in, 6(NP), Q40(NP) Glomerulopathy fibrillary, 50t(NP), 53(NP) immunotactoid, 50t(NP), 53(NP) membranous, 50t(NP), 51(NP), 52f(NP), Q35(NP) in hepatitis B, 56(NP) low-risk primary, Q64(NP) minimal change, 50t(NP), 52–53(NP), Q78(NP) Glomerulosclerosis, focal segmental, 49(NP), 50t(NP), 51(NP), Q16(NP) nephrotic syndrome of, 49(NP), 50t(NP), 51(NP), Q16(NP) in transplanted kidneys, 93(NP) Glomerulus, injury to, 48–49(NP) Glossitis, atrophic, 106(GIM) Gloves, protective, for health care workers, 95(ID) Glucagon, in hypoglycemia, 13–14(EN) Glucagon-like peptide-1 mimetics, 8t(EN) Glucagonomas, 29(GA), 29t(GA) diabetes mellitus and, 1t(EN), 5(EN) Glucagonoma syndrome, 59t(DM) Glucocorticoids for adrenal insufficiency, 42–43(EN), 42t(EN), Q39(EN) for Cushing syndrome, 46(EN) exogenous adrenal insufficiency and, 41(EN), 43(EN)
Cumulative Index
Cushing syndrome and, 43(EN) for hypopituitarism, Q80(EN) for myxedema coma, Q49(EN) for pituitary tumor apoplexy, 18(EN), 19(EN), Q14(EN) for Sheehan syndrome, Q69(EN) Gluconeogenesis, hepatic, 16(EN) Glucosamine, for osteoarthritis, 25(RM) Glucose in pleural effusions, 44–45(PM) for salicylate toxicity, 26(NP) Glucose control, in ST-elevation myocardial infarction, 26(CV) Glucose infusion, for hypoglycemia, Q65(EN) Glucose intolerance, polyneuropathy in, 71(NR) Glucose-6-phosphate dehydrogenase deficiency, 11–12(HO), 26–27(HO), Q59(HO) α-Glucosidase inhibitors, 7(EN), 8t Glutamate dehydrogenase, as Clostridium difficile infection marker, 70(ID) Glutathione, for Parkinson disease, 50(NR) Gluten-free diet, 33(GA), 34(GA), 48(DM) Glyburide, for diabetes mellitus, 8t(EN) contraindication in older diabetic patients, Q53(EN) use in pregnancy, 4(EN) Glycemic control in type 1 diabetes mellitus, 1(EN), 3(EN), Q19(EN) in diabetic nephropathy, 15–16(EN) in diabetic retinopathy, 15(EN) inadequate, 1(EN) in the intensive care unit, 83–84(PM) neuropsychiatric disorders and, 93(PM), Q3(PM) Glycemic monitoring, in diabetes mellitus, 5–6(EN), 5t(EN) Glycolipopeptides, 97–99(ID), 98t(ID) Glycoprotein IIb/IIIa, 42(HO) Glycoprotein IIb/IIIa inhibitors for acute coronary syndrome, 21(CV) for non-ST-elevation myocardial infarction, Q25(CV) for ST-elevation myocardial infarction, 26(CV) Glycosuria, 4(NP) test for, 4t(NP) Glycyclines, 98t(ID), 99(ID) Goblet cell hyperplasia, asthma and, 7(PM) Goiter in Graves disease, 31(EN) multinodular, 29f(EN), 35f(EN), 37(EN), Q66(EN) as contraindication to contrast dye, 36(EN) toxic, 31–32(EN) simple, 37(EN) Gold salts, as neutropenia cause, 4(HO) Golfer’s elbow, 56(GIM), Q132(GIM) Golimumab for rheumatic disease, 13t(RM) for rheumatoid arthritis, 20(RM) Gonadotropin deficiency, 19–20(EN) Gonadotropin-releasing hormone hypothalamic production of, 17(EN) in males, 53(EN), 53f(EN) in menstrual cycle, 56(EN), 56f(EN) in opiate-induced hypogonadism, Q38(EN) Gonadotropin-releasing hormone antagonists, for prostate cancer, 92(HO) Gonadotropin-releasing hormone test, in hypogonadotropic hypogonadism, Q21(EN) Gonadotropin-secreting pituitary adenomas, 21(EN), 26(EN) Gonococcal infections, as arthritis cause, 55(RM), 55f(RM), 57(RM), 58(RM) disseminated, 55(RM), 55f(RM), Q38(RM) Gonorrhea bacterial vaginosis and, 92(GIM) screening for, 7t(GIM), 9(GIM), 11(GIM) Goodpasture syndrome, 60(NP), 62(NP) Gottron papules, 4t(RM), 50(DM), 51(DM), 59(RM), 59f(RM), Q24(DM), Q73(RM) Gout acute, 50–51(RM) chronic, 50(RM) classification of, 51t(RM) clinical features of, 50(RM) diagnosis of, 50–51(RM) differential diagnosis of, 51t(RM) epidemiology of, 48(RM) intercritical, 50(RM), Q79(RM) in medullary cystic kidney disease, 63t(NP), 64(NP) pathophysiology of, 48–50(RM), 48f(RM), 49f(RM), 49t(RM) septic arthritis and, 54(RM), Q17(RM) tophaceous, 50(RM), 50f(RM) treatment of, 10(RM), 14–15(RM), 51–52(RM), Q63(RM), Q79(RM) Graft-versus-host disease, 73(ID), 74–75(ID) hematopoietic stem cell transplantation and, 12(HO), 13(HO) transfusion-related, 2(HO), 40(HO) Gram-negative infections aminoglycoside therapy for, 100(ID), 101(ID) as arthritis cause, 55–56(RM), 57t(RM) Gram-positive infections, as arthritis cause, 57t(RM), Q27(RM) Granulocyte colony-stimulating factor contraindication in aplastic anemia, 2(HO) for myelodysplastic syndromes, 5(HO) for neutropenia, 4(HO), 109–110(HO), 111(HO) Granulocyte-macrophage colony-stimulating factor, for neutropenia, 109–110(HO), 111(HO) Granuloma annulare, 60(DM) Granulomas Majocchi, 26(DM) pyogenic, 41(DM), 42f(DM) sarcoidal, 54(DM) Granulomatosis with polyangiitis. See Wegener granulomatosis Granulomatous diseases, hypercalcemia in, 61t(EN), 62–63(EN), Q5(EN) Graves disease, 30–31(EN), 61(DM) radioactive iodine uptake scans in, 28–29(EN) thyroid antibodies in, 28(EN) Graves ophthalmopathy, 30(EN), 31(EN), Q8(EN) as contraindication to radioactive iodine treatment, 31(EN) Grief, 32(GIM), 109(GIM), Q137(GIM) Groin pain, 58(GIM) Ground-glass opacity pulmonary nodules, 57(PM), 57f(PM), Q64(PM), Q99(PM) Group A streptococcal pharyngitis, 104(GIM) Grover disease, 17(DM), 17f(DM), Q59(DM)
Growth factors, as inflammatory pain source, 1(RM) Growth hormone in acromegaly, 25–26(EN), Q74(EN), Q83(EN) in hypoglycemia, 13–14(EN), 16(EN) for pituitary apoplexy, 18(EN) Growth hormone deficiency, 19(EN) adult-onset, 19(EN) diagnosis of, Q21(EN) in hypopituitarism, 18(EN), 19t(EN) low bone mass in, 68t(EN) Growth hormone deficiency stimulation test, Q46(EN) Growth hormone-releasing hormone, hypothalamic production of, 17(EN) Growth hormone-secreting pituitary adenomas, 25(EN) Guaiac fecal occult blood test, for colorectal cancer screening, 48–49(GA), 49t(GA), Q31(GA) Guillain-Barré syndrome, 71–72(NR), 73(NR), Q38(NR) in Campylobacter infections, 67(ID) in influenza, 94(ID) in varicella, 96(ID) ventilatory failure in, 74(PM), Q15(PM) Gullo syndrome, 23(GA) Gummas, 47(ID) Guttate psoriasis, 10(DM) Gynecomastia, 56(EN), Q18(EN) HACEK organisms, 53(ID) Haemophilus infections, of human bite wounds, 17(ID) Haemophilus influenzae immunization, in transplant recipients, 77t(ID) Haemophilus influenzae infections, 25(PM) community-acquired pneumonia in, 19(ID), 23t(ID) meningitis in, 2(ID), 2t(ID), 5t(ID) pneumonia in, 94(ID) primary immunodeficiency syndromes in, 55(ID) Hair disorders of, 65–67(DM) in African Americans, 66(DM) loss of. See Alopecia Hairy cell leukemia, 102(HO), 102f(HO), Q113(HO) HAIs. See Hospital-acquired infections Halitosis, 106(GIM) Hallucinations in encephalitis, 8(ID) in Lewy body dementia, 45(NR), 46(NR), Q33(NR) in Parkinson disease, 49t(NR) Hallux valgus, 62(GIM) Haloperidol for delirium, 93(PM), Q17(PM) for delirium tremens, Q17(PM) for tic disorders, 55(NR) Hamartomas, in tuberous sclerosis complex, 63t(NP), 64(NP) Hamate bone, fractures of, 57(GIM) Hampton hump, 49(PM) Hand. See also Fingers in CREST syndrome, 41f(RM) dermatitis of, 5(DM), 6–7(DM), 6f(DM), 7t(DM), 10(DM), Q29(DM) in dermatomyositis, 59(RM), 59f(RM) dermatomyositis of, 50(DM) dyshidrotic eczema of, 6(DM), 6f(DM), 7t(DM) in gout, 50f(RM) innervation of, 56f(GIM) mechanic’s, 4t(RM), 59(RM) osteoarthritis of, 22(RM), 22f(RM), 23(RM), 24(RM), Q47(RM) overuse syndromes of, 2t(RM) psoriasis of, 6(DM), 6f(DM), 7t(DM) rheumatoid arthritis of, 8t(RM), 16(RM), 18f(RM) in sarcoidosis, 75(RM) in systemic lupus erythematosus, 35–36(RM) in systemic sclerosis, 41–42(RM), 41f(RM), 42f(RM) Hand-foot syndrome, 58(DM) Hand-grip maneuver, Q51(CV) Hand hygiene, 77(ID), 81(ID), Q38(ID) Hand pain, 57(GIM) Hansel stain, 5(NP) Hantavirus, 56(ID) HAP. See Hospital-acquired pneumonia Harris-Benedict equation, 93(PM) Hawkins test, 54(GIM), 54t(GIM), 55f(GIM) Hazard ratio, 3(GIM) Headache, 1–10(NR) algorithmic approach to, 2f(NR) in anthrax, 57(ID), 58(ID) in brain abscess, 7(ID) in brucellosis, 65(ID) cervicogenic, 12t(NT) cluster, 10(NR), Q19(NR) in dengue fever, 64(ID), Q55(ID) in disseminated cryptococcal infections, 91(ID), 92(ID) in dural sinus venous thromboembolism, 33(NR) first or worst, 1(NR), 33(NR) in human granulocytic anaplasmosis, 28(ID) in human monocytic ehrlichiosis, 28(ID) in hyperprolactinemia, 22–23(EN), 24(EN) in idiopathic intracranial hypertension, 4(NR) imaging studies in, 2(NR) in influenza, 94(ID) in internal carotid artery dissection, 36(NR) in Lyme disease, 25(ID), 25t(ID) in malaria, 61(ID), 62(ID) medication overuse, 6(NR) in meningitis, 1(ID), 3(ID) in mucormycosis, 40(ID) pain patterns in, 1(NR) in paroxysmal hemicrania, 10(NR) pheochromocytomas and, 49(EN), 49t(EN) pituitary tumors and, 21–23(EN) in postconcussion syndrome, 12t(NR) primary, 1(NR), 1t(NR), 3t(NR), 5–10(NR) in rickettsial infections, 64(ID) secondary, 1–5(NR), 1t(NR), Q37(NR) in Southern tick-associated rash illness, 27(ID) in subarachnoid hemorrhage, 2t(NR), 27(NR), 33(NR)
29
Cumulative Index
Headache (continued) in subdural empyema, 8(ID) in SUNCT syndrome, 2f(NR), 10(NR) tension-type, 9–10(NR), Q28(NR) in postconcussion syndrome, 12t(NR) thunderclap, 1(NR), 3(NR), 3t(NR) in reversible cerebral vasoconstriction syndrome, 3(NR), 3t(NR), Q22(NR) in trigeminal neuralgia, 4–5(NR) in typhoid fever, 63(ID) Head and neck cancer, 88–89(HO), Q94(HO), Q103(HO) cervical lymphadenopathy in, 104(HO), 105(HO) field cancerization effect in, 88(HO) Head injury, 10–11(NR) concussion in, 11(NR), 11t(NR) in military personnel, 12(NR) traumatic brain injury, 10–11(NR), 12(NR) Head lice, 32(DM) Health assessment instruments, 9(RM) Health care-associated infections, treatment of, 99(ID) Health care Effectiveness Data and Information Set (HEDIS), 6(GIM), 6t(GIM) Health care industry, conflicts of interest with, 26(GIM), 27t(GIM) Health care providers herpetic whitlows in, 95(ID) smallpox immunization in, Q17(ID) Health care services, unsafe and low-value, 23(GIM), 24(GIM) Health care workers, vaccinations for, 15(GIM), 16(GIM) Health examinations, periodic, 8(GIM) Health information technology (HIT), 22(GIM) Hearing loss cerumen impaction and, 103(GIM) common causes of, 100(GIM), 101t(GIM) evaluation of, 100(GIM) in older adults, 119(GIM) otitis media and, 102(GIM) screening for, 119(GIM) sensorineural, in Alport syndrome, 64(NP) sudden sensorineural, 100(GIM), Q20(GIM), Q108(GIM) unilateral sensorineural, 100(GIM), Q20(GIM) Heart athlete’s, vs. hypertrophic cardiomyopathy, 41(CV) hypertension’s effects on, 33(NP) tumors of, 47–48(CV) Heart block atrioventricular, 49–50(CV), 49f(CV), Q98(CV) complete, 49–50(CV), 50(CV), 50f(CV), 50t(CV) atrial septal defects and, 85(CV) myocardial infarction and, 26(CV) in Lyme disease, 25(ID) pacemakers for, 50t(CV) in restrictive cardiomyopathy, 47(CV) Heartburn, 2(GA), 9(GA), 13(GA), Q15(GA) Heart disease. See Cardiovascular disease Heart enlargement. See also Cardiomyopathy, hypertrophic; Ventricular hypertrophy in heart failure, 31t(CV) in repaired tetralogy of Fallot, Q55(CV) Heart failure, 30–41(CV) advanced refractory, 39–40(CV) in amyloidosis, Q35(NP) aortic stenosis and, 77(CV), 78(CV) atrial fibrillation in, 52–53(CV), Q30(CV) calcium channel blockers and, 17(CV) central sleep apnea in, 67(PM), Q4(PM) chemotherapy-related, 103(CV), 104(CV), 104t(CV), 105(CV) chest radiography in, 3(PM), 4(PM) chronic, 37(CV) clinical evaluation of, 30–31(CV), 31t(CV) decompensated, 34(CV) acute, 37–38(CV), Q58(CV) as contraindication to dronedarone, 52(CV) diagnosis of, 9(CV), 30–32(CV) differential diagnosis of, 35f(CV) differentiated from asthma, 8(PM), 8t(PM) dyspnea in, Q42(PM) endocarditis and, Q76(CV) epidemiology of, 1(CV) in hemochromatosis, 35(HO) hospital discharge for, 39(CV), 39t(CV), Q80(CV) hospital readmission rates for, 39(CV) left-sided, distinguished from acute respiratory distress syndrome, 72(PM) management of device therapy in, 36–37(CV), 36t(CV), 39–40(CV), Q75(CV) drug therapy in, 32–36(CV) follow-up in, 37(CV) inpatient, 37–39(CV) with preserved ejection fraction (HFPEF), 35–36(CV), 35f(CV) serial assessment in, 37(CV) myopericarditis and, Q96(CV) new-onset, Q82(CV) in obese patients, Q11(CV) in obstructive lung disease, 75(PM) patent ductus arteriosus and, Q100(CV) pleural effusion in, 43(PM), 43t(PM), 44t(PM), Q74(PM) post-myocardial infarction, 26(CV) in pregnancy, 107(CV) preoperative, 127(GIM) with preserved ejection fraction, 35–36(CV), 35f(CV), Q15(CV) prognosis in, 31(CV), 37(CV) quality of care core measures for, 3(CV) systolic drug therapy for, 32–35(CV), Q17(CV), Q24(CV), Q36(CV), Q102(CV) prognosis for, 31(CV), 37(CV) resistant hypertension in, Q120(CV) Heart injury, as pericarditis cause, 62t(CV) Heart-lung transplantation, for pulmonary arterial hypertension, 55(PM) Heart murmurs asymptomatic, Q34(CV) in atrial septal defects, 84(CV), 85(CV), Q14(CV), Q41(CV) benign, 9(CV), 10(CV) diagnosis of, 9(CV), Q3(CV)
30
in hypertrophic cardiomyopathy, 41(CV), 42(CV), Q51(CV) in infective endocarditis, 81(CV) innocent flow, 73t(CV) low-intensity, Q3(CV) in patent ductus arteriosus, Q100(CV) in pulmonary valve stenosis, 88(CV) in valvular dysfunction, 71(CV) in ventricular septal defect, 87(CV) Heart rate, in pregnancy, 105(CV) Heart transplantation, 40(CV), 41(CV), 43(CV), 45t(CV), Q20(CV), Q75(CV), Q87(CV) Heart transplant recipients, infective endocarditis prophylaxis in, 84(ID) Heart valves, mechanical, microangiopathic hemolytic anemia and, Q65(HO) Heat rash (miliaria), 17(DM), 17f(DM), 17t(DM), Q32(DM) Heat stroke, 86–87(PM) Heavy metals, tubular toxicity of, 68t(NP) Heberden nodes, 22(RM), 22f(RM) Heinz bodies, 27(HO) Helicobacter pylori infections, 13–15(GA) clinical features of, 13–14(GA) diagnosis of, 14–15(GA) dyspepsia and, 13(GA), Q63(GA) eradication of, 74(GA), 76–77(GA), Q62(GA) failure of, Q96(GA) eradication testing for, 15(GA) gastric adenocarcinoma and, 20(GA) as gastric cancer cause, 83(HO), Q80(HO) as lymphoma cause, 101(HO) NSAID use and, 16(GA), 17(GA) Heliotrope rash, 21(DM), 50(DM), 50f(DM), 51(DM), Q24(DM) Heliotrope rash, in dermatomyositis, 4t(RM), 59f(RM), 59(RM), Q73(RM) HELLP syndrome, 34(HO), 63(HO), 64(HO), 64t(HO), 65(HO), 68(GA), 69t(GA), 80(NP), Q37(HO), Q85(NP) Helminthic infections, in transplant recipients, 76(ID) Hemangiomas, cherry, 41(DM), 41f(DM), 75(DM) Hematemesis, 74(GA), 75(GA) Hematochezia, 74(GA), 77(GA), 78(GA), 78f(GA), 107(GIM), Q16(GA), Q48(GIM), Q72(GA) Hematologic disorders. See also Bleeding disorders in pregnancy, 62–66(HO) in rheumatoid arthritis, 19t(RM) in Sjögren syndrome, 46t(RM) in systemic lupus erythematosus, 37(RM), 38t(RM) Hematologic perioperative medicine, 129–132(GIM) Hematoma acute intramural, 95(CV), 95f(CV) epidural, 12(NR), 65(NR), Q40(NR) iliopsoas, 70(NR), Q92(NR) subconjunctival, 94(GIM), 94f(GIM) subdural, 12(NR), Q68(NR) Hematopoiesis, 1(HO), 1f(HO) Hematopoietic disorders, 1–13(HO) cancer treatment-related, 109–110(HO) Hematopoietic growth factors, 12(HO) in ovarian cancer, 78(HO) Hematopoietic stem cells, characteristics of, 1(HO) Hematopoietic stem cell transplantation, 12–13(HO) for acute lymphoblastic leukemia, 12(HO) for acute myeloid leukemia, Q39(HO) for aggressive lymphoma, 103–104(HO) for aplastic anemia, 2(HO), 3(HO), Q2(HO) for chronic lymphocytic leukemia, 102(HO), Q118(HO) complications of, 12–13(HO) graft-versus-host disease and, 12(HO), 13(HO), 40(HO) for Hodgkin lymphoma, 103–104(HO) immunizations and, 76(ID) immunosuppression prior to, 73(ID) for lymphoma, 101(HO) for mantle cell lymphoma, 103(HO) for multiple myeloma, 15(HO) for myelodysplastic syndromes, 6(HO) opportunistic infections and, 74–76(ID), 74f(ID), Q92(ID), Q105(ID) for primary myelofibrosis, 9–10(HO) for thalassemia, 28(HO) Hematuria in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) in bladder cancer, 94(HO), Q111(HO) clinical evaluation of, 5(NP), 7–9(NP), 8f(NP), Q18(NP) glomerular, Q18(NP), Q40(NP) gross, 7(NP) in Henoch-Schönlein purpura, 69(RM), 70(RM) imaging evaluation of, 7(NP), 9t(NP) in immunoglobulin A nephropathy, 57(NP), Q51(NP) isomorphic, 7(NP) kidney stones and, 76(NP) microscopic, 5(NP), Q40(NP) in Alport syndrome, 64(NP) in nephritic syndrome, 49(NP) nonglomerular, Q18(NP), Q40(NP) in rapidly progressive glomerulonephritis, Q83(NP) Hemiballism, 54(NR) Hemicrania, chronic paroxysmal, 10(NR), Q35(NR) Hemicraniectomy, 38(NR), Q5(NR) Hemiparesis, in stroke, 29t(NR), 31f(NR), 39(NR), 40(NR) Hemobilia, 74(GA) Hemochromatosis, 35–36(HO) cardiomyopathy and, 46(CV) hereditary, 59(GA), Q66(GA) hypopituitarism in, 18(EN) as osteoarthritis cause, Q19(RM) Hemodialysis catheter insertion sites in, 81(ID) for end-stage kidney disease, 91(NP) for ethylene glycol or methanol poisoning, 25–26(NP), Q7(NP) for hyperkalemia, 21(NP) for salicylate toxicity, Q66(NP) Hemoglobin in inflammatory anemia, 24(HO) urine levels of, 4(NP) dipstick tests for, 4(NP), 4t(NP) in pigment nephropathy, 70(NP)
Cumulative Index
Hemoglobin A1c blood transfusions and, Q37(EN) insulin therapy dosage and, 10(EN) interpretation of, Q41(EN) in iron deficiency anemia, Q41(EN) monitoring of, 5(EN), 6(EN) in older patients, Q53(EN) relationship with plasma glucose levels, 5–6(EN), 5t(EN), Q41(EN) for type 2 diabetes mellitus diagnosis, Q24(EN) Hemoglobin C, heterozygous, 31(HO) Hemoglobin D, 31(HO) Hemoglobin E, 31(HO) Hemoglobin S, 28(HO), 29t(HO), 63(HO) Hemoglobin transfusion threshold, 39(HO) Hemoglobinuria, paroxysmal nocturnal, 34–35(HO), Q60(HO) Hemoglobulin electrophoresis, in thalassemia, 28(HO), Q47(HO) Hemolysis, in pigment nephropathy, 70(NP) Hemolytic anemia acquired, 25–26(HO), 25t(HO), 32–35(HO) autoimmune, 32(HO) drug-induced, 33(HO) warm, 32(HO), 32t(HO), Q73(HO) cold agglutinin disease, 32–33(HO), 32t(HO), 33f(HO) congenital, 25–26(HO), 25t(HO), 26–32(HO) in hemolytic uremic syndrome, 62(NP), Q47(NP) in hereditary spherocytosis, 25(HO) microangiopathic, 33–34(HO), 34t(HO), 61(NP), 62(NP) mechanical heart valves and, Q65(HO) in thrombotic thrombocytopenic purpura, 34(HO), 51(HO), 52(HO), Q55(HO) in paroxysmal nocturnal hemoglobinuria, 34–35(HO) in thrombotic thrombocytopenic purpura, 25(HO), 34(HO), 51(HO), 52(HO), Q55(HO) treatment of, 23(HO) urobilinogen levels in, 5(NP) Hemolytic transfusion reactions, 39–40(HO) delayed, Q50(HO), Q67(HO) Hemolytic uremic syndrome, 34t(HO), 62(NP), 71(NP), Q47(NP) overlap with thrombotic thrombocytopenic purpura, 51–52(HO) in pregnancy, 64(HO), 64t(HO) Hemophilia, 6t(RM), 43(HO), Q11(HO) acquired, 46–47(HO), Q8(HO), Q22(HO) Hemoptysis, 39(GIM) in aspergillosis, Q105(ID) in pneumonic plague, 59(ID) Hemorrhage abnormal uterine, 90(GIM), Q53(GIM) adrenal, adrenal insufficiency in, 41t(EN), Q60(EN) alveolar amiodarone and, 37t(PM) diffuse, Q64(PM) in systemic lupus erythematosus, 37(RM) cerebral, 33(NP) intracerebral, 12(NR), Q8(NR), Q48(NR) in cocaine abuse, Q81(NR) stroke and, 26f(NR), 27(NR), 32–33(NR) intracranial complications of, 39(NR) vs. hemorrhagic stroke, 24(NR) recombinant tissue plasminogen activator-related, 30(NR), 32(NR) statin-related, 36(NR) intracranial, thrombocytopenia and, Q5(HO) in nephrotic syndrome, 49t(NP) rectal, 107(GIM), Q48(GIM) risk factors for, 40t(NR) subarachnoid, 12(NR), 33(NR), Q7(NR), Q24(NR) complications of, 39(NR), Q36(NR) headache and, 2(NR), 2f(NR) internal carotid artery aneurysm and, 34f(NR) normal pressure hydrocephalus and, 46(NR) stroke and, 26f(NR), 27(NR) thunderclap headache and, 3(NR), 3t(NR) subarachnoid, hypopituitarism in, 18(EN) Hemorrhoids, 107(GIM), Q48(GIM) bleeding from, 77(GA) Hemosiderin, 8(DM), 8f(DM) Hemostasis regulation of, 42(HO), 42f(HO) secondary, 42f(HO) Hemostatic disorders. See Bleeding disorders Hemosuccus pancreaticus, 75(GA) Hemothorax, pleural effusion in, 44(PM) Henoch-Schönlein purpura, 53(DM), 63t(RM), 69(RM), Q42(DM), Q80(RM) Heparin for acute coronary syndromes, 21–22(CV) for acute limb ischemia, 101(CV) for atrial fibrillation, 53(CV) for dural sinus venous thrombosis, 35(NR) effect on thrombin clotting time, 43(HO) low-molecular-weight for pulmonary embolism, 50(PM), 50t(PM), Q97(PM) vs. unfractionated heparin, 62(HO) for non-ST-elevation myocardial infarction, Q65(CV) perioperative, 129–130(GIM) in pregnancy, 108–109(CV), 110t(CV), Q49(CV) for prosthetic valves, 82–83(CV) reversal of, 59t(HO) for ST-elevation myocardial infarction, 25–26(CV) for stroke, 31–32(NR), 39(NR) as thrombocytopenia cause, 50–51(HO), 50t(HO), Q68(HO) unfractionated, for pulmonary embolism, 50(PM), 50t(PM), Q46(PM) for venous thromboembolism, 56(HO), 57(HO), 57t(HO), 59(HO), Q24(HO), Q48(NR) in cancer patients, 61(HO), Q53(HO) postoperative, Q46(HO) in pregnancy, 66(HO) Hepatic adenomas, 67–68(GA) Hepatic cysts, 67(GA), Q49(GA) Hepatic encephalopathy, 63–64(GA), 64t(GA) as fulminant hepatic failure, 65–66(GA), 67t(GA) refractory, Q91(GA) Hepatic venous outflow tract obstruction, 70(GA), Q46(GA)
Hepatitis acute, 53t(GA) alcoholic, 53t(GA), 57–58(GA), Q18(GA) autoimmune, 53t(GA), 58(GA) chronic, 53t(GA) herpes simplex, 95(ID) herpesvirus-induced, 65(GA) ischemic (shock liver), 53t(GA) liver chemistry studies in, 53t(GA) perioperative management of, 133(GIM) viral, 53t(GA) Hepatitis A, 54(GA), 57(GA) cirrhosis and, 69(GA) coinfection with HIV/AIDS, 90(ID) immunization for, 54(GA), 69(GA) in travelers, 64(ID) Hepatitis A immunization, 12t(GIM), 15(GIM) in HIV/AIDS patients, 88(ID), 89(ID) in transplant recipients, 77t(ID) in travelers, 64(ID) Hepatitis B, 18(GIM), 57(GA) arthritis and, 57(RM), 58(RM) cirrhosis and, 69(GA) coinfection with HIV/AIDS, 90(ID) diagnosis of, 54(GA), 54t(GA) extrahepatic manifestations of, 55(GA) fulminant, 65(GA) hepatocellular carcinoma and, 55(GA) immune-tolerant, Q56(GA) immunization for, 55(GA), 69(GA), Q30(GA) kidney disease in, 56(NP), 58(NP) membranous glomerulopathy, 51(NP) polyarteritis nodosa, 58(NP), Q92(NP) as lymphoma risk factor, 97(HO), 98(HO) management of, 54–55(GA), 55t(GA) polyarteritis nodosa and, 66(RM), 67(RM), Q22(RM) polyarthritis and, 2(RM) screening for, 7t(GIM), 9(GIM), 11(GIM) serologic studies in, 54(GA), 54t(GA) transfusion-related transmission of, 40(HO) transmission via human bite wounds, 17(ID) in transplant donors, screening for, 73(ID), 74(ID) in transplant recipients, 75(ID) tumor necrosis factor-α inhibitors and, 12–13(RM) Hepatitis B immunization, 12t(GIM), 15(GIM), 15t(GIM), 16(GIM), Q162(GIM) in HIV/AIDS patients, 88(ID), 89(ID) in transplant recipients, 77t(ID) Hepatitis B surface antigen, 54(GA) Hepatitis C, 18(GIM), 55–56(GA) arthritis and, 57(RM), 58(RM) coinfection with HIV/AIDS, 90(ID), 92(ID) coinfection with HIV infection, 56(GA) cryoglobulinemia in, 69(RM) diagnosis of, 55(GA) kidney disease in, Q24(NP) cryoglobulinemic vasculitis, 61(NP), 62(NP) membranoproliferative glomerulonephritis, 57(NP), Q20(NP) membranous glomerulopathy, 51(NP) lichen planus and, 11(DM) mixed cryoglobulinemia and, 57(DM), 58(DM), Q30(DM) porphyria cutanea tarda and, 57(DM), 58(DM) prevention of, 56(GA) screening for, 7t(GIM), 9(GIM), 11(GIM) transfusion-related transmission of, 40(HO) transmission via human bite wounds, 17(ID) in transplant donors, screening for, 73(ID), 74(ID) in transplant recipients, 75(ID) treatment for, 55–56(GA), Q32(GA) adverse effects of, 55–56(GA), 56t(GA), 57(GA) tumor necrosis factor-α inhibitors and, 12–13(RM) Hepatitis D, 56(GA) Hepatitis E, 56(GA) Hepatocellular carcinoma, 65(GA) cirrhosis and, Q24(GA) hepatitis B and, 55(GA), Q24(GA) Hepatopulmonary syndrome, 64(GA), Q27(GA) Hepatorenal syndrome, 64(GA), 73(NP), 73t(NP), Q61(GA) Hepatosplenomegaly, in typhoid fever, 63(ID) Hepatotoxicity, statin-related, 65(GIM), Q158(GIM) Hepcidin, 35(HO) Hepcidin deficiency, in iron deficiency, 20(HO), 21(HO) Herald patch, 11t(DM), 13–14(DM), 13f(DM) Herbal supplements hepatotoxicity of, 57(GA) hypertension and, 34(NP), 34t(NP) for menopausal symptoms, 89(GIM) nephrotoxicity of, 68t(NP), 85(NP), 85t(NP), 86(NP) for pain, 35(GIM) preoperative discontinuation of, 126t(GIM) Hereditary hemochromatosis, 59(GA), Q66(GA) Hereditary hemorrhagic telangiectasia, 48(GA), 74(GA) Hereditary neuropathies, 71(NR) Hereditary nonpolyposis colorectal cancer, 46(GA), 47t(GA), 48(GA), 75(HO), Q1(GA) Hereditary pancreatitis, 26(GA) Hereditary periodic fever syndromes, 54(ID) Hereditary polyposis syndromes, 73(GA), 74(GA) Hereditary spastic paraplegia, 67(NR) Hereditary spherocytosis, 26(HO), Q41(HO) anemia in, 25(HO), 25t(HO), Q27(HO) HER1/HER2 inhibitors, for breast cancer, 74–75(HO) HER2/neu, in breast cancer, 68(HO), 72(HO), 73(HO), 74(HO) Hernia diaphragmatic, 10f(GA) inguinal, 81(GIM) Heroin use, focal segmental glomerulosclerosis and, 49(NP), 50t(NP), 51(NP) Herpes labialis, reactivation of, Q13(DM) Herpes simplex virus infections, 18(GIM), 27–29(DM), 27f(DM), 28f(DM), 95–96(ID) cervicitis in, 43(ID) encephalitis in, 1–2(ID), 8(ID)
31
Cumulative Index
Herpes simplex virus infections (continued) erythema multiforme in, 63(DM), 64(DM), Q16(DM) as esophagitis cause, 6(GA) folliculitis in, 22–23(DM) genital, 1(ID), 46–47(ID), 46t(ID), 48(ID), Q27(ID), Q91(ID) pneumonia in, 95(ID) Stevens-Johnson syndrome in, 63(DM) transmission via human bite wounds, 17(ID) vs. aphthous ulcers, 70(DM) Herpes simplex virus-1 infections encephalitis in, 9–10(ID), 9t(ID), 10f(ID) genital ulcers in, 46(ID) Herpes simplex virus-2 infections encephalitis in, 9(ID) genital ulcers in, 46(ID) meningitis in, Q22(ID) Herpesvirus infections, as hepatitis cause, 65(GA) Herpes zoster, 29–30(DM), 29f(DM), 75(DM), Q9(DM) chest pain and, 47(GIM) Herpes zoster immunization, 12t(GIM), 14(GIM), 30(DM) Herpes zoster ophthalmicus, 99–100(GIM) Herpetiformis dermatitis, 46t(DM), 47f(DM) Heterotopia, periventricular nodular, 16f(NR) Heterozygous hemoglobin C, 31(HO) Heuristics, 21t(GIM), Q12(GIM) Heyde syndrome, Q20(GA) Hidradenitis suppurativa, 22(DM), 22f(DM), Q31(DM) High-altitude cerebral edema, 69(PM), 70(PM) High-altitude periodic breathing (HAPB), 69(PM), 70(PM), Q52(PM), Q104(PM) High-altitude-related illnesses, 67(PM), 69–70(PM) High-density lipoprotein (HDL) cholesterol, 62(GIM), 63t(GIM), 64(GIM), 65t(GIM), 66(GIM) low-carbohydrate diet and, 72(GIM) smoking cessation and, 67(GIM) Highly-active antiretroviral therapy (HAART), 61(DM), 89(ID) Hindfoot pain, 61–62(GIM) Hip arthroplasty of for osteoarthritis, 26(RM) for spondyloarthritis, 34(RM) bone mineral density of, 68f(EN) osteoarthritis of, 22(RM), 24(RM), 25(RM) osteonecrosis of, 58(GIM), Q116(GIM) osteoporotic fractures of, 66(EN), 67(EN), 70(EN) overuse syndromes of, 2t(RM) rheumatoid arthritis of, 16(RM) Hip pain, 58(GIM), 58f(GIM) Hip replacement, venous thromboembolism prevention in, 60(HO), 61(HO) Hirsutism definition of, 58(EN) in hyperandrogenism, Q62(EN) in hyperprolactinemia, 23(EN) in polycystic ovary syndrome, 58(EN), Q82(EN) Hirudin, for pulmonary embolism, 50t(PM) Hispanics cardiovascular disease in, 1(CV) cervical cancer in, 78(HO) lupus nephritis in, 60(NP) tuberculosis in, 32(ID) Histamine in anaphylaxis, 85(PM) in asthma, 7(PM) Histamine challenge testing, 1(PM) Histamine-2-receptor blockers, in NSAID use, 16(GA) Histoplasmosis, 42(ID) fever of unknown origin in, 53(ID) pulmonary, Q6(ID) in transplant recipients, 75–76(ID) travel-associated, 65(ID), 65t(ID) HIV/AIDS, 86–94(ID) acute kidney injury in, 74(NP), Q24(NP) acute retroviral syndrome of, 86(ID), 86t(ID), Q99(ID) AIDS diagnosis in, 86(ID) antiretroviral therapy for for acute retroviral syndrome, 86(ID) adverse effects of, 89–90(ID) drug interactions of, 93(ID) dyslipidemia in, 89(ID), Q72(ID) failure of, 93(ID), 94(ID), Q68(ID) in genital herpes infections, Q91(ID) highly active (HAART), 89(ID) initiation of, 88–89(ID), 92–93(ID), Q33(ID) in pregnancy, 94(ID) regimens of, 93(ID), 93t(ID) resistance testing for, 93(ID), 94(ID), Q68(ID) in tuberculosis, 36(ID) bacterial vaginosis as risk factor for, 92(GIM) brain tumors in, 78t(NR) candidiasis in, 72(DM) chronic HIV infection, 86(ID), 87t(ID) coinfection with hepatitis A, B, or C, 90(ID), 92(ID) coinfection with hepatitis C, 56(GA) complications of, 89–90(ID) cryoglobulinemic vasculitis in, 61(NP), 62(NP) diagnosis of, 87–88(ID) fever of unknown origin in, 53(ID) focal segmental glomerulosclerosis in, 49(NP), 50t(NP), 51(NP), Q24(NP) hemolytic uremic syndrome in, 62(NP) herpes zoster in, 29(DM) immunoglobulin A nephropathy in, 56(NP), 57(NP) Kawasaki disease in, 66–67(RM), Q96(RM) lymphoma and, 97(HO) as lymphoma risk factor, 97(HO), 98(HO) natural history of, 86(ID) nephropathy in, 55(NP) neutropenia in, 4(HO) opportunistic infections in, 86(ID), 90–92(ID), 91f(ID), 92f(ID) cryptococcal meningitis, Q21(ID), Q25(ID) cryptosporidiosis, 72(ID) immunizations and prophylaxis for, 88–89(ID), 89t(ID)
32
Pneumocystis jirovecii pneumonia, 89t(ID), 91(ID), 92(ID), Q64(ID) tuberculosis, 35(ID), 36(ID), 89(ID), 91(ID), 92(ID), Q2(ID) urinary tract infections, 29(ID) oral hairy leukoplakia in, 71(DM) pathophysiology of, 86–87(ID) polyarthritis in, 2(RM) psoriatic arthritis in, 32(RM), 33(RM) reactive arthritis in, 32(RM), 33(RM) screening for, 7t(GIM), 9(GIM), 11(GIM), 87(ID), 88(ID), Q123(GIM) seborrheic dermatitis in, 14(DM) sexual transmission of, 18(GIM) signs and symptoms of, 86–87(ID), 86t(ID), 87t(ID) skin diseases in, 61(DM), Q27(DM) spondyloarthritis in, 28(RM) thrombotic thrombocytopenic purpura in, 51(HO), 52(HO) transfusion-related transmission of, 40(HO) transmission via human bite wounds, 17(ID) in transplant donors, screening for, 73(ID) transverse myelitis-like syndrome of, 66(NR) tuberculosis prophylaxis in, 89(ID), Q2(ID) tumor necrosis factor-α inhibitors and, 12–13(RM) Hives. See Urticaria HIV protease inhibitors, diabetes mellitus and, 1(EN) HIV testing, 46(ID) during acute retroviral syndrome stage, 86(ID) at-home, 87(ID) indications for, 88t(ID) in pregnancy, 94(ID) recommendations for, 87(ID) HLA alloimmunization, 37(HO), 38(HO) HLA antigens (human leukocyte antigens), 38–39(HO) in Behçet disease, 71(RM) in inflammatory myopathies, 58(RM) in Sjögren syndrome, 46(RM) in spondyloarthritis, 28(RM), 32(RM), Q69(RM) Hoarseness, in anaphylaxis, 85(PM) Hodgkin lymphoma, 97(HO), 103–104(HO), 110–111(HO), Q78(NP), Q114(HO), Q129(HO) Holster sign, of dermatomyositis, 50(DM) Holt-Oram syndrome, 84(CV) Home safety, for elderly patients, 118(GIM) Homocysteine in coronary artery disease, 14(CV) in vitamin B12 deficiency, 22(HO) Hormone replacement therapy cardiovascular disease and, 30(CV) for hypopituitarism, 18(EN), 19t(EN) for menopause symptoms, 88–89(GIM), 89t(GIM), Q25(GIM), Q60(GIM) in systemic lupus erythematosus, 40(RM) Hormones, in rheumatoid arthritis, 16(RM) Horner syndrome, Q90(NR) Hospice care, 28–29(GIM) for end-stage kidney disease patients, 92(NP) Hospital-acquired infections (HAIs), 76–82(ID) central line-associated bloodstream infections, 80–82(ID), 81t(ID) definition of, 77(ID) multidrug-resistant organism-related, 83–84(ID) prevention of, 77(ID), 87(ID), Q38(ID) reimbursement for, 77(ID) surgical site infections, 79–80(ID), 80t(ID) Hospital-acquired pneumonia (HAP), 82–83(ID), 82t(ID) Hospital discharge, of chronic obstructive pulmonary disease patients, 29–30(PM) Hospitalization for asthma exacerbations, 15(PM) of chronic kidney disease patients, 90(NP) for chronic obstructive pulmonary disease, 29(PM), 29t(PM) for community-acquired pneumonia, 18(ID), 20–21(ID), 21t(ID), 22(ID), 23–24(ID), Q46(ID), Q79(ID) for high-risk peptic ulcer disease, 76(GA), Q19(GA) Hospitalized patients, diabetes mellitus management in, 11(EN) Hot flushes, 88(GIM) “Hot tub lung,” 38(ID) “Housemaid’s knee,” 60(GIM) Human chorionic gonadotropin, thyroid hormone production and, 38(EN), 39(EN) β-Human chorionic gonadotropin, in testicular cancer, 93(HO) Human granulocytic anaplasmosis, 25t(ID), 28(ID), Q87(ID), Q93(ID) Human herpes virus-6 infections, encephalitis in, 9t(ID) Human immunodeficiency virus (HIV) infection. See HIV/AIDS Human immunodeficiency virus (HIV) protease inhibitors, diabetes mellitus and, 1(EN) Human immunodeficiency virus–positive patients, vaccination of, 13(GIM), Q129(GIM) Human leukocyte antigens (HLA), 38–39(HO) Human monocytic ehrlichiosis, 25t(ID), 28(ID), Q87(ID) Human papillomavirus, 10(GIM), 18(GIM) as cervical cancer cause, 78(HO), 79(HO) genital warts and, 48–49(ID) as head and neck cancer cause, 88(HO) in kidney transplant recipients, 54(DM) squamous cell carcinoma cause, 36(DM) as wart cause, 30(DM), 30f(DM), Q28(DM) Human papillomavirus immunization, 12t(GIM), 14–15(GIM), 40(RM), 48–49(ID) in HIV/AIDS patients, 88(ID), 89(ID) in transplant recipients, 77t(ID) Human T-cell lymphotropic virus type-1, as lymphoma cause, 97(HO), 98(HO) Humeral hypercalcemia of malignancy, 61t(EN), 63(EN), Q15(EN), Q17(EN) Hungry bone syndrome, 65(EN), Q42(EN) Huntington disease, 54(NR) Hutchinson sign, 68f(DM), 99–100(GIM) Hyaluronic acid, for osteoarthritis, 25(RM) Hydroxyzine, 4(DM) Hydralazine for heart failure, 33t(CV), 34–35(CV) for hypertensive crises, 86t(PM) as lupus erythematosus cause, 39(RM) for peripartum cardiomyopathy, 107(CV) in pregnancy, 79t(NP), 109t(CV) for refractory hypertension, 84(NP) Hydralazine-isosorbide dinitrate, for heart failure, 32(CV), 33t(CV), Q102(CV) Hydration therapy for enteric hyperoxaluria, Q81(NP) for prerenal azotemia, 67(NP)
Cumulative Index
Hydrocele, 79(GIM) Hydrocephalus, Q7(NR) normal pressure, 46–47(NR), Q52(NR) obstructing, 108(HO) posttraumatic vascular, 49(NR) Hydrochlorothiazide, gout and, Q79(RM) Hydrocodone, 31t(GIM) Hydrocortisone for adrenal insufficiency, 42–43(EN), 42t(EN), Q25(EN), Q27(EN), Q39(EN) for myxedema coma, Q49(EN) stress doses of, in critical illness, Q55(EN) Hydrogen breath test for carbohydrate malabsorption, 32(GA) for small intestinal bacterial overgrowth, 33(GA) Hydromorphone, 30(GIM), 31t(GIM), Q19(GIM) Hydrops fetalis, 28(HO) Hydrothorax, hepatic, pleural effusion and, 44t(PM) β-Hydroxybutyrate, 4(NP) Hydroxychloroquine adverse effects of, 12(RM), Q32(RM) for lupus, 11(RM) as malaria prophylaxis, 62t(ID) in pregnancy, 11(RM), 21(RM), 41(RM), Q66(RM) for rheumatoid arthritis, 11(RM), 20(RM) for systemic lupus erythematosus, 40(RM), 41(RM) Hydroxyurea for essential thrombocytopenia, 8(HO) as macrocytic anemia cause, Q72(HO) for primary myelofibrosis, 9(HO) for sickle cell disease, 29(HO), 30(HO), 31(HO) skin eruptions due to, 15t(DM) teratogenicity of, 63(HO) 25-Hydroxyvitamin D, in hypocalcemia, Q22(EN) Hyperaldosteronism diagnosis of, Q16(EN) primary, 50–52(EN), Q33(NP), Q36(NP), Q62(NP) adrenal adenomas and, 51(EN), 52(EN) idiopathic, 50–51(EN) in renovascular hypertension, 42(NP) screening for, Q71(EN) Hyperamylasemia, in diabetic ketoacidosis, Q58(EN) Hyperandrogenism adrenal incidentalomas and, 47(EN) in ovarian cancer, Q62(EN) in polycystic ovary syndrome, 58(EN), Q82(EN) Hyperbaric oxygen therapy, 101–102(ID) for carbon monoxide poisoning, 89(PM), 90(PM), Q86(PM) Hyperbicarbonatemia, in respiratory acidosis, 31(NP), 33(NP) Hypercalcemia, 60–63(EN) acute, treatment of, 63(EN), Q15(EN) benign familial hypocalciuric, Q47(EN), Q81(EN) in cancer, 109(HO) in multiple myeloma, 13(HO), Q33(HO) cancer-associated, 61t(EN), 63(EN) causes of, 60–63(EN) clinical manifestations of, 60(EN) diagnosis of, 60–63(EN), 61t(EN) differential diagnosis of, 61t(EN) factitious, 60(EN) in familial hyperparathyroidism, Q81(EN) in granulomatous diseases, 61t(EN), 62–63(EN), Q5(EN) humeral, of malignancy, 61t(EN), 63(EN), Q15(EN), Q17(EN) 25-hydroxyvitamin D in, Q22(EN) local osteolytic, 63(EN) long-term management of, 63(EN) malignancy-associated, 61f(EN), 61t(EN), 63(EN), Q15(EN), Q17(EN) in multiple myeloma, 74(NP), Q11(NP) non-parathyroid hormone–mediated, 61f(EN), 61t(EN), 62–63(EN) parathyroid hormone–mediated, 60–62(EN), 61f(EN), 61t(EN), 62t(EN), Q17(EN), Q54(EN) in primary hyperparathyroidism, 60–62(EN), 61t(EN), 62t(EN), Q54(EN) in sarcoidosis, 61t(EN), 62–63(EN), Q5(EN), Q17(EN) in tuberculosis, 61t(EN), 62–63(EN), Q5(EN) Hypercalciuria hypoparathyroidism treatment and, 66(EN) kidney stones and, 75(NP), Q30(NP) Hypercapnia. See also Respiratory failure, ventilatory (hypercapnic) in acute respiratory distress syndrome, 72–73(PM) permissive, 80(PM) in sleep-related hypoventilation syndromes, 68(PM), Q69(PM) Hypercholesterolemia, in chronic obstructive pulmonary disease, 19t(PM) Hypercoagulability, pulmonary embolism and, 47f(PM) Hypercoagulable disorders, dural sinus venous thrombosis and, 34(NR), 35(NR) Hypercortisolism in adrenal adenomas, Q84(EN) in adrenocortical cancer, 52(EN) in Cushing syndrome, 43(EN), 44(EN), Q84(EN) dexamethasone suppression testing in, 43(EN), 44(EN), 45(EN) evaluation of, 43–44(EN) Hyperemesis gravidarum, 68(GA), 69t(GA) Hyperglycemia in diabetes mellitus, 2(EN), 3(EN) inpatient treatment of, 11(EN) microvascular and macrovascular effects of, 5(EN) patient self-monitoring of, 5(EN) postexercise, Q76(EN) postprandial, Q41(EN) severe, 12(EN) in diabetic nephropathy, 53(NP) in hypertension, 35(NP) hypertonic hyponatremia and, 11(NP), 15(NP) in metabolic syndrome, 13(CV) in neuropsychiatric disorders, 93(PM), Q3(PM) in sepsis, 83–84(PM) in ST-elevation myocardial infarction, 26(CV) Hyperglycemic crisis, 13t(EN) Hyperglycemic hyperosmolar syndrome, 11(EN), 12–13(EN) Hyper-immunoglobulin D syndrome, 54(ID) Hyperimmunoglobulinemia D with periodic fever syndrome, 74t(RM)
Hyperinflation, in chronic obstructive pulmonary disease, 16(PM) Hyperkalemia, 19–21(NP) ACE inhibitor-related, 34(CV), Q102(CV) in chronic kidney disease, Q22(NP), Q74(NP) in chronic tubulointerstitial disease, 44t(NP) definition of, 19(NP) evaluation of, 19(NP), 20f(NP) in gastrointestinal surgery patients, Q56(NP) in hemorrhage-induced adrenal insufficiency, Q60(EN) hypertension and, Q74(NP) nephrotoxins and, 85t(NP), Q44(NP) in primary adrenal insufficiency, 20(EN) treatment of, 21(NP), Q22(NP), Q56(NP), Q74(NP) in tumor lysis syndrome, 73(NP) Hyperkinetic disorders, 47(NR), 48t(NR). See also Parkinson disease Hyperlipidemia. See Dyslipidemia Hypermagnesemia, nephrotoxins and, 85t(NP) Hypernatremia, 15–17(NP) causes of, 15–16(NP), 16t(NP) definition of, 15(NP) in polyuria, 15–16(NP) treatment of, 16–17(NP), Q108(NP) Hyperoxaluria, calcium oxalate kidney stones and, 75(NP), Q81(NP) Hyperparathyroidism familial forms of, 62(EN), Q81(EN) familial hypocalciuric, 62(EN) low bone mass in, 68t(EN) post-kidney transplant, 93(NP) primary hypercalcemia in, 60–62(EN), 61f(EN), 61t(EN), Q17(EN) parathyroidectomy for, 62(EN), 62t(EN), Q42(EN), Q54(EN) rheumatic manifestations of, 6t(RM) secondary, bone loss in, 68(EN) secondary, in chronic kidney disease, 87(NP), 88(NP), 89(NP), Q49(NP), Q101(NP) Hyperphosphatemia, 22(NP) in chronic kidney disease-mineral bone disorder, 87(NP), 87f(NP), 88–89(NP) nephrotoxins and, 85t(NP) in tumor lysis syndrome, 73(NP) Hyperpigmentation flagellate, 58(DM) postinflammatory, 76(DM), 76f(DM) serpentine supravenous, 58(DM) Hyperplasia angiofollicular lymph node, 48(DM) benign prostatic, 78(GIM), 78t(GIM), Q18(GIM), Q70(GIM) focal nodular, 67(GA) gingival, 105(GIM) sebaceous, 40(DM), 40f(DM) Hyperplastic polyposis, 48(GA) colorectal cancer screening in, 51t(GA) Hyperprolactinemia, 22–25(EN) amenorrhea/oligomenorrhea in, 4(EN), 22(EN), 23(EN), 57(EN), Q7(EN) drug-induced, 23–24(EN), 23t(EN) hypogonadotropic hypogonadism in, 19–20(EN), Q50(EN) osteoporosis in, 23(EN) in pregnancy, Q7(EN), Q40(EN) sellar masses and, 22–23(EN), 23t(EN), Q50(EN) Hyperreflexia, in myelopathy, 64(NR) Hypersensitivity reactions, in acute interstitial nephritis, 70–71(NP), Q67(NP) Hypertension, 33-44(NP). See also Antihypertensive agents in acromegaly, 25(EN) in Alport syndrome, 64(NP) in aortic disease, 93(CV), Q69(CV) in aortic intramural hematoma, Q9(CV) in atrial fibrillation, 52–53(CV) in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) in autosomal recessive polycystic kidney disease, 63t(NP), 64(NP) in chronic kidney disease, 2(CV), 83–84(NP), 84f(NP), 86(NP), Q82(NP) in African Americans, Q86(NP) management of, 39–40(NP), 41(NP), 83–84(NP), 84f(NP), 86(NP), Q39(NP), Q49(NP) over-the-counter medications and, Q82(NP) in pregnancy, Q14(NP) chronic obstructive pulmonary disease and, 19t(PM) classification of, 37–43(NP) complications of, 33–34(NP) in coronary artery disease, 12(CV), 12t(CV), 13(CV), Q13(CV) corticosteroid-related, 10t(RM) in Cushing syndrome, 43(EN), Q6(EN) in diabetes mellitus, 6(EN), 29(CV), 43(NP), 44(NP), Q29(NP) in diabetic nephropathy, 54(NP), 54t(NP) in elderly patients, Q98(NP) essential, 38–41(NP) management of, 39–41(NP), 40t(NP) pathogenesis of, 38–39(NP) evaluation of, 34–35(NP), Q33(NP) gestational, 79(NP), 80(NP), Q103(NP) in heart failure, Q120(CV) in heart transplant recipients, 40(CV) in HIV-associated nephropathy, 55(NP) hyperkalemia and, Q74(NP) intra-abdominal, 72(NP) intracranial idiopathic, 4(NR), 4t(NR), Q46(NR) lifestyle modification-based management of, 39(NP), 40(NP), Q1(NP) management of, in stroke, 30–31(NR), 33(NR) masked, 42(NP), Q46(NP) in metabolic alkalosis, 31(NP) as metabolic syndrome component, 3(EN) in nephritic syndrome, 49(NP) in nonalcoholic steatohepatitis, Q2(GA) in peripheral arterial disease, 99(CV), 100(CV) in pheochromocytoma, 49(EN) portal, 61–62(GA), 70(GA), 74(GA) portopulmonary, 64–65(GA) in postinfectious glomerulonephritis, 59(NP), 60(NP) in pregnancy, 63(HO), 78–80(NP), Q70(NP), Q85(NP), Q97(NP) in primary hyperaldosteronism, 51(EN) proteinuria screening in, 7(NP)
33
Cumulative Index
Hypertension (continued) pulmonary, 52–55(PM) air travel and, 69(PM) in atrial septal defects, 84(CV), 85(CV) as chest pain cause, 49(GIM) in chronic obstructive pulmonary disease, 17t(PM) chronic thromboembolic (CTEPH), 52t(PM), 54(PM), Q105(PM) classification of, 52–53(PM), 52t(PM) in diffuse parenchymal lung disease, 30–31(PM) in mitral regurgitation, 76t(CV), Q86(CV) in mitral stenosis, 76t(CV), 79(CV) neuromuscular weakness and, 73t(PM) pathophysiology and epidemiology of, 52–53(PM) in pregnancy, 107(CV) pulmonary artery pressure in, 52(PM), 52t(PM), 53(PM), 54(PM), 55(PM) in sickle cell disease, 31(HO) treatment of, 53–54(PM) in ventricular septal defects, 87(CV) pulmonary arterial, 52t(PM), 54–55(PM), Q55(PM) in mixed connective tissue disease, 47(RM), 47t(RM), 48(RM), Q26(RM) pathophysiology of, 52–53(PM) in systemic sclerosis, 44(RM) treatment of, 55(PM), 55t(PM) renovascular, 41–42(NP), Q43(NP), Q58(NP), Q62(NP) as contraindication to kidney biopsy, Q61(NP) in primary hyperaldosteronism, Q62(NP) resistant, 41(NP), 43(NP), Q12(NP), Q39(NP) screening for, 7t(GIM), 8(GIM), Q102(GIM) secondary, 41–42(NP), Q33(NP) in special populations, 43–44(NP) stage 2, Q1(NP) stroke and, 36(NR), 40t(NR), Q10(NR), Q41(NR) in Takayasu arteritis, 65(RM) tyrosine kinase inhibitor-related, 69(HO) vs. hypertrophic cardiomyopathy, 41–42(CV) white coat, 42(NP), Q23(NP), Q84(NP) Hypertensive emergencies, 85–86(PM), 90(PM), Q43(PM) Hyperthermia malignant, 87(PM), Q67(PM) in neuroleptic malignant syndrome, 56(NR), Q64(NR) Hyperthermic emergencies, 86–87(PM) Hyperthyroidism, 61(DM) amenorrhea in, 57(EN) atrial fibrillation in, 52–53(CV) in Graves disease, 30–31(EN) iodine-induced, 32–33(EN) in multinodular goiter, 31(EN) in older patients, 29(EN) preeclampsia and, Q78(EN) in pregnancy, 34(EN), Q78(EN) rheumatic manifestations of, 6t(RM) subclinical, 33(EN) bone loss in, 68(EN) untreated in pregnancy, Q78(EN) thyroid storm and, Q72(EN) Hypertriglyceridemia, 63–64(GIM) management of, 65t(GIM), 66–67(GIM), Q41(GIM) Hypertrophic cardiomyopathy. See Cardiomyopathy, hypertrophic Hypertrophic scars, 41(DM) Hyperuricemia, 48-50. See also Gout asymptomatic, Q52(RM) in chronic kidney disease, 47(NP) in medullary cystic kidney disease, 63t(NP), 64(NP) in tumor lysis syndrome, 73(NP) Hyperviscosity syndrome, of Waldenström macroglobulinemia, 13(HO), 17(HO), Q63(HO) Hypervolemia hyponatremia and, 14–15(NP) in metabolic acidosis, Q9(NP) Hypoactive sexual desire disorder, 81–82(GIM), Q5(GIM), Q147(GIM) Hypoalbuminemia hypocalcemia and, 63–64(EN), 66(EN) in nephrotic syndrome, 48(NP), 49(NP), 49t(NP) pleural effusion and, 44t(PM) Hypoaldosteronism hyporeninemic, Q44(NP) in renal tubular acidosis, 28–29(NP) Hypobicarbonatemia, in respiratory alkalosis, 32(NP), 33(NP) Hypocalcemia, 63–66(EN) causes of, 64–65(EN), 66(EN) in chronic kidney disease-mineral bone disorder, 87(NP), 87f(NP), 88–89(NP) diagnosis of, 63–64(EN), 64–65t(EN), 66(EN) in hungry bone syndrome, Q42(EN) hypoalbuminuria and, 63–64(EN), 66(EN) hypomagnesemia and, 64t(EN), 65(EN), Q75(EN) hypoparathyroidism and, 61f(EN), 64t(EN), 65(EN), Q36(EN) plasma exchange-associated, Q9(HO) treatment of, 66(EN) Hypocapnia in high-altitude periodic breathing, 69(PM) in pregnancy, 78(NP) Hypochondriasis, 113(GIM) Hypocitraturia, 75(NP) Hypocortisolism in adrenocorticotropic hormone deficiency, 20(EN) in critical illness, Q48(EN) megestrol acetate and, 20(EN) in primary adrenal insufficiency, Q39(EN) Hypofibrinogenemia, 39(HO), 46(HO) Hypoglycemia in diabetes mellitus, 13–14(EN) asymptomatic, 14(EN) documented symptomatic, 14(EN) exercise-induced, 14(EN), Q79(EN) hyperadrenergic symptoms of, 5(EN), 14(EN) nocturnal, 5(EN), Q31(EN) patient self-monitoring of, 5(EN) plasma glucose level in, 13–14(EN) postexercise, Q79(EN)
34
diagnosis of, in nondiabetic patients, 2(EN) in encephalopathy, Q36(PM) fasting, 17(EN), 17t(EN) in nondiabetic patients, Q70(EN) neurologic findings in, Q65(EN) nocturnal, 5(EN), Q31(EN) in nondiabetic patients, 2(EN), 16–17(EN), 17t(EN) postprandial, in non-diabetic patients, 17(EN) relative, 14(EN) severe, 14(EN) sulfonylurea-induced, Q53(EN) in older patients, 14(EN), Q65(EN) Hypoglycemic agents, perioperative management of, 126t(GIM) Hypoglycemic unawareness, 14(EN), Q19(EN) Hypogonadism cirrhosis and, 69(GA) hypogonadotropic, 19–20(EN), Q21(EN) acquired, in females, 19(EN) with anosmia, 53(EN) low bone mass in, 68t(EN), 69(EN) in males central, Q26(EN), Q38(EN) diagnosis and evaluation of, 53–54(EN), 54f(EN), Q51(EN) drug-induced, Q38(EN) in obesity, Q33(EN) osteoporosis and, 69(EN) primary, 53(EN), 54(EN) secondary, 53(EN), 54(EN), Q26(EN), Q38(EN) treatment of, 54–55(EN), 69(EN) Hypoinsulinemia, hyperglycemia and, Q76(EN) Hypokalemia, 17–19(NP) clinical manifestations of, 17t(NP) in colonic pseudo-obstruction, Q52(NP) in Cushing syndrome, Q6(EN) definition of, 17(NP) in diabetic ketoacidosis, 25(NP) diuretics and, 43(NP) evaluation of, 17–19(NP), 17t(NP), 18f(NP) in metabolic alkalosis, 30–31(NP), Q45(NP), Q94(NP), Q104(NP) in renal tubular acidosis, 27–28(NP), 30(NP), Q17(NP) treatment of, 19(NP), 19(PM) Hypokalemic periodic paralysis, 17(NP) Hypokinetic disorders, 48t(NR) Hypomagnesemia, hypocalcemia and, 64t(EN), 65(EN), Q75(EN) Hyponatremia, 10–15(NP) acute, 14(NP) asymptomatic, 14–15(NP), Q13(NP) causes of, 10–12(NP) chronic, 14(NP) clinical presentation of, 14(NP) definition of, 10(NP) evaluation of, 12–14(NP) in heart failure, 38(CV) in hemorrhage-induced adrenal insufficiency, Q60(EN) hypertonic, 11(NP) hypervolemic, 13–15(NP), 13t(NP), 15t(NP) hypotonic, 11(NP), 12f(NP), Q27(NP) with high urine osmolality, 12–13(NP) with low urine osmolality, 12(NP) overcorrection of, 14(NP), Q37(NP) treatment of, 15t(NP) isosmotic, 11–12(NP) plasma osmolality in, 10(NP), 11(NP), 11f(NP) symptomatic, 14(NP), 15(NP), Q69(NP) in syndrome of inappropriate antidiuretic hormone secretion, 14–15(NP), 15t(NP), Q13(NP), Q69(NP) thiazide diuretics and, 14(NP), 43(NP) treatment of, 14–15(NP) Hypoparathyroidism after thyroidectomy, Q36(EN) chronic, treatment of, 66(EN) hypocalcemia and, 61f(EN), 64t(EN), 65(EN), Q36(EN) Hypopharyngeal cancer, 89(HO) Hypophosphatemia, 22(NP), 22t(NP), Q50(NP) Hypopigmentation postinflammatory, 76(DM), 76f(DM) in pruritus, 5(DM) Hypopituitarism, 18–21(EN), 18t(EN), Q40(EN), Q41(EN) hormonal replacement therapy for, 18(EN), 19t(EN), Q80(EN) radiation-induced, Q57(EN) in Sheehan syndrome, Q69(EN) treatment of, 18(EN), 19t(EN), Q80(EN) Hypotension in anaphylaxis, 85(PM) in aortic stenosis, Q90(CV) in heart failure, 37(CV), 38(CV) in hemorrhage-induced adrenal insufficiency, Q60(EN) in hypertrophic cardiomyopathy, Q106(CV) orthostatic, 46(GIM), 47(GIM), Q86(GIM) therapeutic apheresis-related, 42(HO) in toxic shock syndrome, 15(ID), 16t(ID) Hypothalamic disease, 17–18(EN) Hypothalamic masses, hyperprolactinemia in, 22–23(EN) Hypothalamic-pituitary-adrenal axis in hypopituitarism, 18(EN) megestrol-induced suppression of, Q25(EN) Hypothalamic-pituitary-adrenal function, regulation of, 40–41(EN), 40f(EN) Hypothalamic-pituitary axis, 27(EN) Hypothalamic-pituitary-ovarian axis, 56(EN), 56f(EN) Hypothermia in myxedema coma, 39–40(EN) therapeutic, 88(PM) Hypothermic emergencies, 87–88(PM), 87f(PM) Hypothyroidism, 33–34(EN), 61(DM) amenorrhea in, 57(EN) amiodarone-induced, 33(EN), Q61(EN) in carpal tunnel syndrome, 5(RM) central, Q69(EN) radiation-induced, Q57(EN)
Cumulative Index
in thyroid-stimulating hormone deficiency, 20(EN) treatment of, Q80(EN) congenital, 33(EN) drug-induced, 33(EN), Q61(EN) in pregnancy, 38(EN), 39(EN), Q4(EN), Q13(EN) rheumatic manifestations of, 6t(RM) subclinical, 34(EN), Q4(EN) thyroid hormone levels in, 28(EN), Q61(EN) ventilatory failure in, 73(PM) Hypoventilation in neuromuscular weakness, Q102(PM) sleep-related syndromes of, 68(PM), 68t(PM) Hypovolemia in hyponatremia, 13–15(NP), 13t(NP), 15t(NP) prerenal azotemia and, 67(NP) Hypoxemia in asthma exacerbations, 75(PM) in chronic obstructive pulmonary disease exacerbations, 75(PM) in fibrotic lung disease, 74(PM) in respiratory failure, 70–72(PM), Q40(PM) in immunocompromised patients, 78(PM) Hypoxia hypobaric, 69(PM) in respiratory acidosis, 31(NP), 32(NP), 33(NP) Hypoxia altitude simulation test (HAST), Q98(PM) Hypoxia induction factors, 18(HO) Hydroxyurea, in polycythemia vera, 7(HO) Ibandronate, for osteoporosis, 69(EN), 70(EN), 70t(EN) Ibritumomab, for lymphoma, 98(HO) Ibuprofen for migraine, 7t(NR) for tension-type headache, 9(NR), Q28(NR) ICD. See Implantable cardioverter-defibrillators Idiopathic inflammatory myopathies. See Inflammatory myopathies Idiopathic ventricular tachycardia, 57–58(CV), 58f(CV) Id reaction, 6(DM) IDSA/ATS criteria, for community-acquired pneumonia, 21(ID), 21t(ID), 22(ID) Ileitis, backwash, 36(GA) Iliac artery stenosis, stenting treatment for, 101f(CV) Iliotibial band syndrome, 60(GIM) Imaging studies renal, 9–10(NP), 9t(NP) in rheumatic disease, 7–8(RM), 8t(RM) of urinary tract, for hematuria evaluation, 7(NP), 9t(NP) Imatinib, 69t(HO) for systemic sclerosis, 42(RM) Imidazole, for tinea versicolor, Q45(DM) Imipramine, for diffuse esophageal spasm, 5(GA) Imiquimod, for warts, 30(DM) Immediate postconcussion assessment and cognitive testing (ImPACT) test, 11(NR) Immune globulin therapy anaphylactic reactions to, 55(ID), Q86(ID) for common variable immunodeficiency, 55(ID) for necrotizing fasciitis, 15(ID) for varicella-zoster, 97(ID), Q14(ID) Immune (idiopathic) thrombocytopenic purpura, 49–50(HO), 63–64(HO), Q23(HO), Q45(HO) Immune reconstitution inflammatory syndrome, 90(ID), Q21(ID) Immunization for adults, 12–16(GIM), 12t(GIM) biologic disease-modifying antirheumatic drugs and, 12(RM), Q58(RM) in chronic kidney disease patients, 90(NP) in chronic obstructive pulmonary disease patients, 25(PM), 26(PM), Q41(PM) in cirrhosis, 69(GA) in complement deficiencies, 56(ID) for hepatitis A, 54(GA), 69(GA) for hepatitis B, 55(GA), 69(GA), Q30(GA) for influenza, 69(GA) in kidney transplant recipients, 93(NP) live-vaccine, contraindication in immunosuppressed patients, Q30(GA) multiple-dose, 15(GIM), Q162(GIM) in multiple sclerosis, 61(NR), 64(NR) preconception administration of, 87(GIM) in rheumatoid arthritis, 21(RM) in sickle cell disease, 31(HO) in transplant recipients, 76(ID), 77t(ID) for varicella, Q30(GA) Immunocompromised patients. See also HIV/AIDS cellulitis treatment in, 24–25(DM) cough in, 39(GIM) dementia in, 43(NR) diverticulitis-related complications in, 43(GA) fever of unknown origin in, 53(ID) fungal arthritis in, 56(RM), Q84(RM) headache in, 2(NR) herpes simplex infections in, 95(ID) herpes zoster infections in, 29(DM) infectious esophagitis in, 6(GA) inflammatory bowel disease in, Q30(GA) live vaccine contraindication in, Q30(GA) molluscum contagiosum in, 31(DM) noninvasive positive pressure ventilation in, 78(PM) pneumococcal immunization in, 14(GIM), 14t(GIM) seizures in, 13–14(NR) squamous cell carcinoma in, 36(DM) tuberculosis prophylaxis in, Q2(ID) varicella prophylaxis in, Q14(ID) Immunodeficiencies, primary, 55–56(ID) Immunoglobulin(s), monoclonal, urinary content of, 7(NP) Immunoglobulin A in linear bullous dermatosis, 47f(DM), 48(DM) in pemphigus, 46t(DM), 48(DM) Immunoglobulin A deficiency anaphylactic transfusion reactions in, 40(HO), 41(HO) selective, 32(GA), 55(ID), Q86(ID) Immunoglobulin A deposition, in Henoch-Schönlein purpura, 69(RM) Immunoglobulin A nephropathy. See Nephropathy, immunoglobulin A Immunoglobulin E in allergic bronchopulmonary aspergillosis, 10(PM), Q20(PM) in asthma, 8(PM), Q73(PM)
Immunoglobulin G in autoimmune pancreatitis, 27–28(GA) in multiple sclerosis, 59(NR) nephrotoxicity of, 71(NP) Immunoglobulin G2 subclass deficiency, 55(ID) Immunologic disorders, in systemic lupus erythematosus, 38t(RM) Immunomodulators hepatotoxicity of, 57(GA) perioperative management of, 126t(GIM) Immunosuppression as cervical cancer risk factor, 78(HO) in heart transplant recipients, 40(CV), Q20(CV) immunization in, 12(RM) in inflammatory bowel disease, 38(GA) therapeutic adverse effects of, 111(HO) for aplastic anemia, 2(HO) for atopic dermatitis, 9(DM) biologic agent-related, 12–14(RM) for dermatomyositis, 62(RM) for hand dermatitis, 7(DM) for inflammatory bowel disease, 37–38(GA), 37f(GA), 37t(GA), 38(GA) for mixed connective tissue disease, 48(RM) for polymyositis, 62(RM) for reactive arthritis, 34(RM) for systemic sclerosis-related lung disease, 44(RM) Immunosuppressive agents diabetes mellitus and, 1(EN) drug interactions of, 73(ID) for focal segmental glomerulopathy, 51(NP), 53(NP) as infection risk factor, 72–73(ID) for kidney transplant recipients, 92(NP), 93t(NP) for pauci-immune crescentic glomerulonephritis, 61(NP) Immunotherapy for asthma, 15(PM) for connective tissue disease, 35(PM) for prostate cancer, 92(HO) for renal cell carcinoma, 96(HO) IMPACT (immediate postconcussion assessment and cognitive testing) test, 11(NR) Impetigo, 22(DM), 23–24(DM), 24f(DM), Q6(DM) Implantable cardioverter-defibrillators for arrhythmogenic right ventricular cardiomyopathy, Q119(CV) for Brugada syndrome, 60(CV) for hypertrophic cardiomyopathy, 43–44(CV), 45(CV), 46(CV), Q94(CV) for idiopathic ventricular fibrillation, 60(CV) infection of, 61(CV) for long QT syndrome, 58(CV) for short QT syndrome, 59(CV) for sudden cardiac death prevention, 36(CV), 36t(CV), Q94(CV) surgery and, Q71(CV) for ventricular arrhythmias, 61(CV) Implantable loop recorders, 12(CV), Q89(CV), Q117(CV) Implants, infections of, 79(ID), 80(ID) Incidentalomas adrenal, 26(EN), 47–49(EN), Q2(EN) asymptomatic, Q71(EN) pituitary, Q46(EN) Incisional surgical site infections, 79(ID) Inclusion body myositis, 60(RM), Q71(RM) Incontinence, 121–123(GIM), 122f(GIM), Q33(GIM), Q88(GIM) in Alzheimer disease, 43(NR), 45(NR) in normal pressure hydrocephalus, Q52(NR) in spinal cord disorders, 65(NR) Increased intracranial pressure, in stroke, 33(NR) Indacaterol, for chronic obstructive pulmonary disease, 22t(PM) Indinavir, urinary crystals and, 6(NP) Indomethacin for chronic progressive hemicrania, 10(NR), Q35(NR) for gout, 51(RM) for thunderclap headaches, 3(NR) Infarcts, subcortical (lacunar), 27(NR), 29t(NR) Infections in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) of cardiac devices, 61(CV), Q21(CV) in chronic tubulointerstitial disorders, 45t(NP) dementia and, 42t(NR) fever of unknown origin in, 53(ID) in kidney transplant recipients, 93(NP), 94(NP) low back pain and, 51t(GIM) multiple sclerosis and, 64(NR) in nephrotic syndrome, 49t(NP) as pericarditis cause, 62t(CV) of prosthetic joints, 57(RM), 58(RM), Q86(RM) in sickle cell disease, 31(HO) stroke and, 39(NR) transfusion-related, 40(HO) as vasculitis cause, 63t(RM), 64t(RM) Infectious arthritis. See Septic arthritis Infectious diseases chronic tubulointerstitial disorders in, 45t(NP), 46(NP) reporting of, 26(GIM) screening for, 7t(GIM), 9(GIM) Infectious Disease Society of America soft tissue infection management guidelines from, 13(ID) travelers’ diarrhea prophylaxis and treatment guidelines from, 63(ID), 63t(ID) Infectious gastrointestinal syndromes, 65–72(ID) Infective endocarditis, 81–82(CV), 81t(CV), 83(CV), Q76(CV), Q109(CV) Inferior vena cava filters, 129(GIM) for pulmonary embolism, 52(PM) Infertility in hyperprolactinemia, 23(EN), 24(EN) in men, 24(EN), 55–56(EN), Q12(EN) in women, 23(EN), 24(EN), 59(EN) Inflammation acute gouty, 50(RM) in chronic obstructive pulmonary disease, 16(PM) clinical features of, 1(RM), 1t(RM), Q65(RM) measurement of, 6–7(RM)
35
Cumulative Index
Inflammation (continued) in osteoarthritis, 22(RM) in rheumatoid arthritis, 17t(RM) Inflammatory bowel disease, 34–39(GA) arthritis in, 3t(RM), 27–28(RM), 29t(RM), 30(RM), Q30(RM) chronic diarrhea in, 31t(GA), 32f(GA) clinical manifestations of, 35–39(GA) colorectal cancer and, 46(GA), 48(GA) colorectal cancer surveillance in, 50t(GA) diagnosis of, 36(GA) erythema nodosum in, 56(DM) extraintestinal manifestations of, 36(GA) eye disorders in, 5t(RM) flares of, 36(GA), Q29(GA) health maintenance in, 28(GA) in immunocompromised patients, Q30(GA) polyarthritis in, 5(RM) psoriasis in, 10(DM) pyoderma gangrenosum in, 56–57(DM), 56f(DM), Q10(DM) risk factors for, 34–35(GA) travelers’ diarrhea prophylaxis in, 63(ID), Q97(ID) treatment of, 37–38(GA), 37f(GA), 37t(GA) Inflammatory chronic polyarthritis, 3t(RM) Inflammatory disorders, fever of unknown origin in, 53(ID), 54(ID) Inflammatory mediators, in asthma, 7(PM) Inflammatory myopathies, 58–62(RM), 76(NR). See also Dermatomyositis; Inclusion body myositis; Polymyositis cancer and, 62(RM) clinical features of, 59–60(RM), 59f(RM), Q49(RM) diagnosis of, 60–62(RM), 60t(RM) differential diagnosis of, 61(RM), 61t(RM) epidemiology of, 58–59(RM) imaging studies in, 61(RM), 62(RM) pathophysiology of, 58(RM) prognosis of, 62(RM) treatment of, 62t(RM) Inflammatory polyradiculoneuropathies, 71–72(NR) Inflammatory rheumatic disease, vs. noninflammatory rheumatic disease, 1(RM), 1t(RM), Q65(RM) Infliximab for Behçet disease, 71(RM) for inflammatory bowel disease, 37t(GA) for rheumatic disease, 13t(RM) for rheumatoid arthritis, 20(RM) for spondyloarthritis, 34(RM) Influenza community-acquired pneumonia and, 19(ID) in hospitalized patients, 95(ID) management of, 95(ID), Q43(ID) Influenza A virus, 94(ID), 95(ID) Influenza B virus, 94(ID), 95(ID) Influenza C virus, 94(ID) Influenza immunization, 12t(GIM), 13(GIM), 15(GIM), 69(GA), 87(GIM), 95(ID), Q71(GIM) in chronic obstructive pulmonary disease patients, 25(PM), 26(PM), Q41(PM) in community-acquired pneumonia patients, 24(ID) in HIV/AIDS patients, 88(ID), 89(ID) in pregnancy, Q88(ID) in transplant recipients, 77t(ID) Influenza virus, asthma and, 9(PM), 11(PM) Informed consent, 24(GIM), Q133(GIM) Inhalational injuries, acute, 39(PM), 84–85(PM) Inherited arrhythmia syndromes, 58–60(CV) Inherited thrombophilic conditions, 53–54(HO) In situ hybridization test, for chronic myeloid leukemia, 101(HO), Q32(HO) Injection drug users gram-negative joint infections in, 55–56(RM) osteomyelitis in, 49(ID) tuberculosis skin testing in, Q57(ID) INR (international normalized ratio), 75(GA), Q12(GA) Insect bites and stings, 31(DM), 32(DM), 32f(DM), 44(DM) Insomnia, 43–45(GIM) anxiety disorders and, 110(GIM) evaluation of, 44(GIM), Q115(GIM) fatal familial, 11t(ID) management of, 44–45(GIM), 45t(GIM), Q115(GIM), Q153(GIM) Inspiratory capacity (IC), 3(PM) Inspiratory positive airway pressure (IPAP), 78(PM) Institute for Clinical Systems Improvement, 33(GIM) Institute for Healthcare Improvement, 81(ID), 94(PM) Institute of Medicine (IOM) calcium and vitamin D daily intake recommendation from, 66t(EN), 69(EN) To Err is Human: Building a Safer Health System, 19(GIM) fall prevention recommendations of, 117(GIM) obesity definition of, 69(GIM) vitamin D supplementation recommendation of, 118(GIM) Instructive directives, 24(GIM) Instrumental activities of daily living (IADLs), 116–117(GIM), 117t(GIM) Insulin exogenous injections of, 17(EN), 17t(EN), Q70(EN) neutral protamine Hagedorn, Q35(EN), Q45(EN) Insulin aspart, perioperative administration of, Q63(EN) Insulin detemir, 7(EN), 9t(EN), 10(EN) Insulin glargine, 7(EN), 9t(EN), 10(EN perioperative administration of, Q63(EN) Insulin-like growth factor 1 in acromegaly, 25(EN), 26(EN), Q74(EN), Q83(EN) in growth hormone deficiency, 19(EN), Q21(EN) in pituitary macroadenoma, Q46(EN) Insulin lispro, Q35(EN) Insulin, neutral protamine hagedorn (NPH), Q35(EN) Insulinomas, 29(GA), 29t(GA), 30f(GA), Q48(GA) detection of, Q70(EN) Insulin resistance, 1–2(EN), 60(DM), 68(GIM) in type 2 diabetes mellitus, 3(EN) in HIV/AIDS, 89(ID) in metabolic syndrome, 13(CV) in polycystic ovary syndrome, 58(EN) type A, 5(EN) Insulin secretagogues, for diabetes mellitus prevention, 4t(EN) Insulin therapy, 8t(EN)
36
basal for type 2 diabetes mellitus, 7(EN) dosage of, 10(EN), 11(EN) cost of, 10(EN) for diabetes mellitus dosage of, 10(EN) in hospitalized patients, 11(EN) hypoglycemia and, 14(EN) missed doses in, 11–12(EN) pancreatic beta-cell function after, 2–3(EN) patient self-monitoring of, 5(EN) preprandial, 10(EN), 11(EN) underdosing in, 11–12(EN) for type 1 diabetes mellitus, 10(EN), Q35(EN) for type 2 diabetes mellitus, 7(EN), 9t(EN), 10(EN), 11(EN) plasma insulin profiles of, 10f(EN) premixed insulin, 7(EN), 9t(EN), 10(EN), 11(EN) for diabetic ketoacidosis, 13t(EN), 25(NP) for gestational diabetes, 4(EN) for hyperglycemic hyperosmolar syndrome, 13t(EN) for hyperkalemia, 21(NP) perioperative, 132(GIM), Q160(GIM) for sepsis, 83–84(PM) surreptitious, 17(EN), 17t(EN), Q70(EN) Integrase inhibitors, for HIV/AIDS, 93(ID), 93t(ID) Intensive care unit care. See also Critical care for chronic obstructive pulmonary disease, 29(PM), 29t(PM) Intensive care units best practice in, 94–95(PM), 94t(PM) prognosis in, 94–95(PM) Interferon-α, cardiotoxicity of, 104t(CV) Interferon alfa for polycythemia vera, 7(HO) in pregnancy, 7(HO) Interferon beta for multiple sclerosis, 62(NR), 62t(NR), Q29(NR), Q93(NR) for optic neuritis, Q29(NR) Interferon-γ release assays, 32(ID), 33(ID), 34(ID), Q12(ID) in HIV/AIDS patients, 89(ID) Interleukin-1β inhibitors, 14(RM) Interleukin-2, cardiotoxicity of, 104t(CV) Intermittent explosive disorder, 112(GIM) Internal carotid artery aneurysm of, 34f(NR) dissection of, in stroke, 36(NR), 37f(NR) stenosis of, Q55(NR) asymptomatic, 40(NR) revascularization procedures for, 38(NR) in stroke, 27(NR), 28f(NR) Internal disease, skin manifestations of, 48–61(DM) Internal validity, in study design, 1(GIM) International AIDS Society U.S.A. Panel, 92(ID) International Index of Erectile Dysfunction-5 (IIEF-5), 75(GIM) International normalized ratio (INR), 75(GA), Q12(GA) in coagulopathy of liver disease, 46(HO) in thromboembolism, Q24(HO), Q29(HO) in vitamin K deficiency, 47(HO) for warfarin, 58(HO), 61(HO), Q24(HO), Q29(HO) in warfarin therapy, 51(PM) International Prognostic Index, for lymphoma, 98(HO), 100(HO), 100t(HO) International Prognostic Scoring System, for myelodysplastic syndromes, 6t(HO) International Society on Hypertension in Blacks, 40(NP), 43(NP), Q86(NP) Intertrigo, candidal, 17(DM) Intestinal disorders, 30–34(GA) Intestinal obstruction, 92(PM) Intestinal pseudo-obstruction, 41(GA) Intestinal resection, acid suppression therapy after, 33–34(GA), Q39(GA) Intimate partner violence, 18–19(GIM), Q117(GIM), Q126(GIM) Intra-abdominal infections, treatment of, 98t(ID), 99(ID) Intra-abdominal pressure, increased, 72(NP), Q77(NP) Intra-aortic balloon pumps, for cardiogenic shock, 38–39(CV) Intracorporeal lithotripsy, for distal ureteral stones, 77(NP) Intracranial pressure, increased in brain metastases, 108(HO), Q109(HO) in disseminated cryptococcal infections, 91(ID), 92(ID) Intracranial tumors. See Brain tumors Intraductal papillary mucinous neoplasms, 28–29(GA), 28f(GA) Intrahepatic cholestasis of pregnancy, 68(GA), 69t(GA), Q11(GA) Intraocular pressure (IOP), 96–97(GIM) Intravenous immune globulin for Guillain-Barré syndrome, 72(NR) for immune (idiopathic) thrombocytopenic purpura, 49(HO) for inflammatory myopathies, 62(RM) for Kawasaki disease, 67(RM) for myasthenia gravis, 74(NR) for pure red cell aplasia, 3(HO) Intravenous pyelography in hematuria, 7(NP), 9t(NP) in kidney stones, Q21(NP), Q75(NP) in malignancy, Q19(NP) Invasive mechanical ventilation. See Mechanical ventilation Inverse psoriasis, 10(DM) Iodine dietary intake of, 33(EN) for thyroid storm, 39(EN) Iodine deficiency, 27(EN) goiters and, 37(EN) Iodine exposure, thyrotoxicosis and, 31(EN), 32–33(EN) Iodoquinol, for amebiasis, 72(ID) iPLEDGE program, 4(DM), 21(DM) Ipratropium for asthma, 13(PM), 15(PM), Q38(PM) for chronic obstructive pulmonary disease, 23(PM), 23t(PM) Irinotecan for lung cancer, 87(HO) for pancreatic cancer, 82(HO) Iris lesions, of erythema multiforme, 62(DM), 62f(DM) Iron absorption of, 20(HO), 20f(HO), 35(HO)
Cumulative Index
supplemental in dialysis patients, 25(HO) in pregnancy, 62(HO) Iron chelation therapy for myelodysplastic syndromes, 5(HO) for secondary iron overload, 36(HO), Q58(HO) for thalassemia, 28(HO) Iron deficiency after bariatric surgery, 22(GA), 22t(GA) in systemic sclerosis, Q88(RM) Iron-deficiency anemia, 20–21(HO), 20f(HO), 24(HO) in anisopoikilocytosis, 21(HO), Q19(HO) in celiac disease, 33t(GA), Q88(GA) in chronic kidney disease, 89(NP), Q8(NP), Q105(NP) in cyanotic heart disease, Q113(CV) hemoglobin A1c in, Q41(EN) menstrual blood loss-related, 35(HO), Q61(HO) in microangiopathic hemolytic anemia, 34(HO) in pregnancy, 62(HO) Iron dextran, in pregnancy, 62(HO) Iron overload in hereditary hemochromatosis, 59(GA) in myelodysplastic syndromes, 5(HO) secondary, 36(HO) in thalassemia, 27(HO), Q58(HO) Iron overload syndromes, 35–36(HO) hypocalcemia in, 65(EN) Iron sulfate, esophagitis and, 6(GA) Irritable bowel syndrome, 41–42(GA), 91(GIM), 92(GIM) celiac disease screening in, 42(GA), Q10(GA) chronic diarrhea in, 31t(GA) constipation-predominant, 41t(GA), Q44(GA) evaluation of, 41–42(GA), 41t(GA) Irritant allergic contact dermatitis, 5(DM) of hand, 7t(DM) Ischemia in acute tubular necrosis, 68(NP) digital, in systemic sclerosis, 43(RM), Q61(RM) intestinal, 43–45(GA), 44t(GA) chronic diarrhea in, 31t(GA) colonic, 44–45(GA), 44t(GA) mesenteric, 43–44(GA), 43(GA), 44(GA), 45(GA), Q7(GA), Q94(GA) short-bowel syndrome in, 33(GA) limb acute, 101–102(CV), 102t(CV), Q85(CV) critical, 97(CV), 100(CV), 102(CV) myocardial chest pain in, 63t(CV) echocardiography in, 64t(CV) electrocardiography in, 64t(CV) evaluation of, 32(CV) in heart failure, 32(CV) silent, Q82(CV) stress testing-provoked, 3(CV) in vasculitis, 62(RM) Ischemic cardiomyopathy, 36(CV) Ischemic colitis, 44–45(GA), 44t(GA) Ischemic hepatitis (shock liver), 53t(GA) Ischemic penumbra, 29(NR) Ischemic stroke. See Stroke Ischial bursitis, 2t(RM) Islet cell tumors, 29–30(GA), 29t(GA), 30f(GA), 83–84(HO) Isoniazid for Mycobacterium kansasii infections, 38(ID) for tuberculosis, 34(ID), 35(ID), 35t(ID) use in transplant recipients, 76(ID) Isopropyl alcohol poisoning, 4(NP), 89(PM), 89t(PM) Isosorbide dinitrate, for heart failure, 33t(CV), 34–35(CV) Isotretinoin for acne, 20t(DM) contraindication during pregnancy and lactation, 4t(DM) teratogenicity of, 20t(DM), 21(DM) Itching. See Pruritus “Itch that rashes,” 42(DM), 42f(DM) Itraconazole for allergic bronchopulmonary aspergillosis, 40(ID) for blastomycosis, 42(ID), Q42(ID) for coccidioidomycosis, 42(ID) for histoplasmosis, 42(ID), Q30(ID) for sporotrichosis, 43(ID) Ivermectin for lice, 32(DM) for scabies, 31(DM) Ixodes scapularis, as Lyme disease vector, 24(ID) Jaccoud arthropathy, 36(RM) Jacksonian seizures, 14(NR) JAK2 mutation, 7(HO), 8(HO), 9(HO), Q6(HO) Jaundice, 57(DM) in acute viral hepatitis, Q5(GA) in autoimmune pancreatitis, 28(GA) in choledocholithiasis, 72(GA) in hepatitis A, 54(GA) in hereditary spherocytosis, 25(HO), 26(HO) obstructive, bilirubin levels in, 5(NP) in pancreatic adenocarcinoma, 27(GA) in primary sclerosing cholangitis, 60(GA) Jaw, bisphosphonate-related osteonecrosis of, 15(HO), 70(EN) JC virus infection, 38(GA) encephalitis and, 9t(ID) Jet lag, 64(PM), 64t(PM) Jod-Basedow phenomenon, 31(EN) Joint Commission (formerly JCAHO), 20(GIM), 22(GIM) Joint infections. See Septic arthritis Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 8(GIM), 37(NP), 37t(NP), 38(NP), 39–40(NP), 83(NP), 131(NP), Q33(NP), Q102(GIM) Joint replacement surgery for osteoarthritis, 25–27(RM) for spondyloarthritis, 34(RM)
Jugular venous distention in atrial septal defects, 84(CV) in cardiac tamponade, 68(CV) in constrictive pericarditis, 69(CV), Q29(CV) in pulmonary valve stenosis, Q78(CV) Juvenile myoclonic epilepsy, 15(NR), 16(NR), Q61(NR) Juvenile polyposis syndrome, 20(GA), 48(GA) colorectal cancer screening in, 51t(GA) Kallmann syndrome, 53(EN) Kanamycin, for tuberculosis, 35t(ID) Kaposi sarcoma, 61(DM), 91–92(ID), 92f(ID) Kawasaki disease, 63t(RM), 66–67(RM), Q96(RM) cardiovascular disease and, 2t(CV) Kayser-Fleischer rings, 56(NR) Kegel exercises, 121(GIM), Q33(GIM), Q88(GIM) Keloids, 41(DM), 42f(DM), 76–77(DM), 78(DM), Q50(DM) Keratitis, in herpes simplex virus-1 infections, 95(ID) Keratoacanthoma, 37(DM), 37f(DM) Keratoconjunctivitis sicca, 3(RM), 97–98(GIM), Q44(GIM) Keratoderma blenorrhagicum, 4t(RM), 31(RM) Keratolysis, 25–26(DM), 25f(DM) Keratoses actinic, 35–36(DM), 35f(DM), 75(DM), 75f(DM), 76(DM), Q71(DM) seborrheic, 39(DM), 39f(DM), 75(DM), 75f(DM), Q8(DM), Q58(DM) Kerley B lines, 37(PM) Ketoacidosis alcoholic, 4(NP), 25(NP) diabetic, 4(NP) causes of, 11–12(EN) in type 1 diabetes mellitus, 2(EN), 3(EN) increased anion gap metabolic acidosis in, 25(NP), Q93(NP) management of, 13(EN), Q58(EN) metabolic decompensation in, 12(EN), 12f(EN), 13(EN) mucormycosis in, Q65(ID) Ketoconazole for coccidioidomycosis, 42(ID) for tinea versicolor, Q45(DM) Ketones conditions associated with, 4(NP) tests for, 4t(NP) Kidney hypertensive, 33–34(NP), 35(NP) in pregnancy, 77–81(NP) Kidney cystic disorders. See Cysts/cystic disorders, of the kidney Kidney disease. See also Chronic kidney disease; Kidney injury, acute anemia in, 24–25(HO), Q36(HO) deep venous thrombosis and, Q46(HO) in diffuse cutaneous systemic sclerosis, 41(RM) end-stage, 34(NP) in Alport syndrome, 64–65(NP), Q59(NP) delay of progression to, 83(NP) hematuria in, 7(NP) kidney cystic disorders and, 63(NP) kidney transplantation for, 90–91(NP), 91t(NP), 92–94(NP), 93t(NP), Q4(NP), Q19(NP) pathophysiology of, 48(NP) in pregnancy, 80–81(NP) skin changes in, 43(DM), 53–54(DM) treatment of, 90–94(NP) in gout, 48(RM) hemolysis-induced, 70(NP) in hemolytic uremic syndrome, 52(HO) hereditary interstitial, 47(NP) hypertension in, 41(NP) intrinsic, 67–71(NP) in mixed connective tissue disease, 47–48(RM), 47t(RM) perioperative management of, 133(GIM) in Sjögren syndrome, 46t(RM) in systemic lupus erythematosus, 38(RM), 38t(RM) in thrombotic thrombocytopenic purpura, 51(HO) Kidney Disease Improving Global Outcomes, 87(NP), 89(NP) Kidney disorders, cancer treatment-related, 110(HO) Kidney failure in acute tubular necrosis, 68(NP) central sleep apnea in, 67(PM) in diabetes mellitus, 15(EN) in hyperthermic emergencies, 86(PM), 87(PM) myeloma-related, 15(HO) nutrition in, 93t(PM) oliguric, 68(NP) pulmonary embolism treatment in, Q97(PM) Kidney function clinical evaluation of, 1–10(NP) glomerular filtration rate (GFR), 1–2(NP) imaging studies, 10(NP) interpretation of the urinalysis, 2–9(NP) kidney biopsy, 10(NP) methods for estimating, 2(NP), 3t(NP) in pregnancy, Q14(NP) Kidney injury, acute, 65–74(NP) in cancer, 73–74(NP), Q11(NP) in cardiovascular disease, 72–73(NP) causes of, 67–72(NP) chronic kidney disease and, 81(NP), Q41(NP) classification of, 65(NP), 66t(NP) clinical manifestations and diagnosis of, 65–67(NP), 66f(NP) in critical care patients, 72(NP) definition of, 65(NP) in hemolytic uremic syndrome, 61(NP), 72(NP), Q47(NP) HIV/AIDS in, 74(NP), Q24(NP) hyperkalemia and, Q56(NP) immunoglobulin A nephropathy in, Q51(NP) iodinated contrast-related, 90(NP) in liver disease, 73(NP) metabolic acidosis in, 26(NP) normotensive ischemic, Q80(NP) obstructive, 67(NP), 72(NP), Q106(NP) oliguric, 67t(NP) in postinfectious glomerulonephritis, Q60(NP) in specific clinical settings, 72–74(NP)
37
Cumulative Index
Kidney-liver transplantation, for autosomal recessive polycystic kidney disease, 64(NP) Kidney mass, evaluation of, Q104(HO) Kidney stones, 74–77(NP) in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) clinical manifestations of, 75(NP) diagnosis of, 76(NP), Q75(NP) in distal ureter, 77(NP), Q79(NP) epidemiology of, 74(NP) hematuria in, 7(NP) hypercalciuria and, 66(EN) imaging of, 76(NP), Q21(NP), Q75(NP) management of, 78t(NP) acute, 76–77(NP), 76f(NP), Q79(NP) subsequent, 77(NP), 78t(NP) prevention of, 77(NP), 78t(NP) pyuria and, 5(NP) risk factor evaluation of, 77(NP) types of, 74–75(NP) Kidney transplantation for end-stage kidney disease, 90–91(NP), 92–94(NP), Q4(NP) for Alport syndrome, 65(NP), Q59(NP) cardiovascular disease risk after, 93(NP) disease recurrence after, 93(NP) evaluation for, Q19(NP) graft rejection and loss after, 5(NP), 93(NP), 94(NP) graft survival in, 91t(NP) immunosuppressive therapy for, 92(NP), 93t(NP) preemptive, 91(NP) risks of, 92–93(NP) for myeloma cast nephropathy, 74(NP) pregnancy after, 80–81(NP) vaccination prior to, 90(NP) Kidney transplant donors, kidney disease screening in, 63(NP) Kidney transplant recipients cancer in, 4(NP), Q19(NP) chronic tubulointerstitial disorders in, 46(NP) cytomegalovirus infections in, Q58(ID) infections in, Q10(NP) polyoma BK virus in, 92(NP), Q72(NP) skin cancer in, 54(DM), Q23(DM) tacrolimus nephrotoxicity in, Q18(ID) urinary tract infections in, 29(ID) Klatskin tumors, 73(GA) Klebsiella infections, 75(NP) meningitis in, 2(ID), 2t(ID) in transplant recipients, 75(ID) urinary tract infections in, 29(ID) Klebsiella pneumoniae infections, 4–5(NP) community-acquired pneumonia in, 19(ID) Klinefelter syndrome, 53(EN), 93(HO), Q26(EN), Q33(EN) Knee arthroplasty for, 26(RM) chondrocalcinosis of, 53f(RM) effusion in, 1(RM) ligamentous injuries to, 59(GIM) osteoarthritis of, 22(RM), 23f(RM), 24(RM), 25(RM), 58(GIM), 59(GIM), Q3(RM), Q8(RM), Q13(RM), Q37(RM) in Lyme disease, 26(ID) overuse syndromes of, 2t(RM) psoriatic arthritis of, 28(RM) rheumatoid arthritis of, 16(RM) sarcoidosis of, 75(RM) in systemic lupus erythematosus, 35–36(RM) Knee pain, 58–61(GIM) diagnosis and evaluation of, 58–59(GIM), 59f(GIM), 60f(GIM) Knee replacement, venous thromboembolism prevention in, 61(HO) Koebner phenomenon, 10(DM), 11(DM) KOH test. See Potassium hydroxide (KOH) test Kuru, 11t(ID) Kussmaul sign, 69(CV) Kyphoscoliosis, respiratory complications of, 74(PM) sleep-related hypoventilation syndromes, 68(PM), 68t(PM) Kytococcus sedentarius, 25(DM), Q26(DM) Labetalol for hypertension in cocaine abuse, Q81(NR) in stroke, 32(NR), 33(NR) for hypertensive crises, 86t(PM) in pregnancy, 78–79(NP), 79t(NP), 108t(CV), Q70(NP) Lacerations, 33–34(DM), 34f(DM) in the elderly, Q69(DM) Lachman test, 59(GIM), 59f(GIM) Lacosamide adverse effects of, 19t(NR), 20t(NR) for epilepsy, 20t(NR) Lacrimal gland dysfunction, in Sjögren syndrome, 46(RM) Lacrimation, 98(GIM) Lactate dehydrogenase in hemolytic anemia, 26(HO) in testicular cancer, 93(HO) Lactic acidosis, 24–25(NP), 24t(NP), Q76(NP) D-, 24–25(NP), 24t(NP) in liver disease, 32(NP) type B, Q93(NP) Lactose intolerance, after giardiasis treatment, 71(ID) Lactose malabsorption, 34(GA), 42(GA), Q51(GA) Lactulose, for hepatic encephalopathy, 64(GA), Q91(GA) Lacunae, 27(NR) Lacunar syndromes, 27(NR), 29t(NR) Lady Windemere syndrome, 38(ID) Lambert-Eaton myasthenic syndrome, 59t(PM), 74–75(NR), 85(HO), Q92(PM), Q101(HO) Lamivudine, 90(ID) for hepatitis B, 55(GA), 55t(GA) use in pregnancy, 94(ID), Q54(ID) Lamotrigine adverse effects of, 18–19(NR), 19t(NR), 20t(NR), 21(NR), Q85(NR) in the elderly, Q67(NR) for epilepsy, 20t(NR) interaction with hormonal contraceptives, 21(NR), Q32(NR)
38
Langerhans cell histiocytosis chest radiography in, 3(PM) diabetes insipidus and, 20(EN) hypopituitarism and, 18(EN) Lanreotide, for acromegaly, 24t(EN), 25(EN) Lansoprazole, colitis and, Q89(GA) Lapatinib, for breast cancer, 74–75(HO) Large cell carcinoma, 57(PM) pulmonary, 85(HO) Large granular lymphocytosis, 3(HO), Q69(HO) Large intestine, disorders of, 30–45(GA) Laryngeal cancer, 88(HO), 89(HO), Q76(HO) Laryngitis, in gastroesophageal reflux disease, 9(GA) Laser photocoagulation, for diabetic retinopathy, 15(EN), Q1(EN) Lateral epicondylitis, 2t(RM), Q59(RM) Lateral femoral cutaneous nerve, entrapment syndrome of, 58(GIM), Q155(GIM) Lavage bronchoscopic, 5(PM) mini-bronchoalveolar, 81(PM) Laxative abuse, normal anion gap metabolic acidosis in, Q17(NP), Q45(NP) Laxatives, 30(GIM) contraindication in chronic kidney disease, 85t(NP), Q76(NP) for irritable bowel syndrome, 42(GA) stimulant, 41(GA) Lead, nephrotoxicity of, 45t(NP), 47(NP), 68t(NP), Q31(NP) Leflunomide adverse effects of, 11(RM) for rheumatoid arthritis, 11(RM), 20(RM) for spondyloarthritis, 34(RM) teratogenicity of, 11(RM), 12(RM), 21(RM) Left bundle branch block, 22–23(CV), 57(CV), 58f(CV), Q92(CV) Left coronary artery, percutaneous coronary intervention in, 18(CV) Left ventricular dysfunction chemotherapy-related, 104t(CV) mildly symptomatic, Q97(CV) in mitral regurgitation, 80(CV) systolic in aortic regurgitation, 78(CV) in aortic stenosis, 77(CV), Q35(CV) in heart failure, 31(CV), Q82(CV) Left ventricular ejection fraction in acute coronary syndromes, Q12(CV) in hypertrophic cardiomyopathy, 43–44(CV) in nonischemic cardiomyopathy, Q54(CV) post-myocardial infarction, 28(CV) Left ventricular free wall rupture, post-myocardial infarction, 27(CV), 27t(CV) Left ventricular hypertrophy, 33(NP), Q33(NP) in aortic stenosis, 77(CV) concentric, 70(CV) eccentric, 70(CV) in heart failure, Q15(CV) Left ventricular infarction, post-myocardial infarction, 27t(CV) Left ventricular outflow tract obstruction, 41(CV), 43(CV), 45(CV), Q51(CV), Q106(CV) Left ventricular remodeling, 70(CV) Left ventricular systolic dysfunction, cardiogenic pulmonary edema in, 72(PM) Legionella pneumonia, 18(ID), 19(ID), 23t(ID), Q79(ID) fever of unknown origin in, 53(ID) in transplant recipients, 74(ID) Legionella urine antigen test, 19(ID) Leg ulcers, 72–74(DM) arterial, 73–74(DM), 73f(DM) diabetic, 60(DM) neuropathic, 72(DM), 74(DM), 74f(DM), Q60(DM) in pyoderma gangrenosum, 56(DM), 56f(DM) venous stasis, 8(DM), 8f(DM), 72-73(DM), 72f(DM). See also Stasis dermatitis Leiomyomas, esophageal, 63(PM) Leishmaniasis, Q75(ID) Lemierre syndrome, 104(GIM), Q157(GIM) Lenalidomide for multiple myeloma, 15(HO), Q13(HO) for myelodysplastic syndromes, 6(HO) Lentigines, 75(DM) Lentigo maligna, 37(DM), 38f(DM), 61(DM), Q7(DM), Q43(DM) Lepirudin effect on thrombin clotting time, 43(HO) for heparin-induced thrombocytopenia, 51(HO) for venous thromboembolism, 56–57(HO) Leriche syndrome, Q4(CV) Leser-Trélat sign, 59t(DM) Leucovorin for colorectal cancer, 80(HO), Q115(HO) for gastric cancer, 83(HO) for pancreatic cancer, 82(HO) Leukemia acute lymphoblastic, 11–12(HO) induction therapy for, 12(HO), Q51(HO) acute myeloid, 10–11(HO), 10f(HO), 10t(HO), 58(DM), 59–60(DM), Q10(DM), Q39(HO) essential thrombocytopenia and, 8(HO) acute promyelocytic, 10(HO), 11(HO) cancer treatment-related, 110(HO) chronic lymphocytic, 101–102(HO), 102t(HO), Q118(HO), Q132(HO) chronic myeloid, 8–9(HO) chronic myelomonocytic, 6(HO) hairy cell, 102(HO), 102f(HO), Q113(HO) promyelocytic, 10(HO) pulmonary aspergillosis in, Q108(ID) rheumatic disease in, 6t(RM) varicella-zoster immune globulin use in, Q14(ID) Leukemia cutis, 10(HO) Leukocyte count in gout, 51(RM), 54(RM) in inflammatory arthritis, Q65(RM) in Lyme arthritis, 56(RM) in rheumatoid arthritis, 54(RM) in septic arthritis, 54–55(RM) Leukocyte esterase, urine levels of, 4–5(NP), 4t(NP) Leukocytes in pleural effusion, 44(PM) in synovial fluid, 8(RM), 9(RM)
Cumulative Index
in urine, 4t(NP), 5(NP) Leukocytosis in chronic myelomonocytic leukemia, 6(HO) in diabetic ketoacidosis, Q58(EN) in hyperkalemia, 19–20(NP) in polycythemia vera, 7(HO) thrombocytopenia and, 48(HO) Leukopenia in systemic lupus erythematosus, 37(RM) thrombocytopenia in, 48(HO) Leukoplakia, 71(DM), 71f(DM) Leukotriene-modifying drugs, for asthma, 11(PM), 13f(PM), 14(PM) Leukotriene receptor antagonists, for asthma, 14(PM), Q23(PM) during pregnancy, 16(PM) Leukotrienes, in asthma, 7(PM) Levalbuterol, for chronic obstructive pulmonary disease, 22t(PM), 23(PM) Levetiracetam adverse effects of, 19t(NR), 20t(NR) teratogenicity of, 21(NR) Levodopa adverse effects of, 50–51(NR) nonresponse to, in atypical parkinsonism, Q3(NR) for Parkinson disease, 50(NR), 50t(NR) urine ketone levels and, 4(NP) Levofloxacin for travelers’ diarrhea, 63t(ID) for tuberculosis, 35t(ID) Levothyroxine adrenal insufficiency and, 39(EN) contraindication in older patients, Q56(EN) for destructive thyroiditis, 32(EN) for hypothyroidism, 33–34(EN) in pregnancy, 39(EN), Q4(EN), Q13(EN) for myxedema coma, 40(EN), Q49(EN) for subclinical hypothyroidism, 34(EN) for thyroid cancer, 38(EN) thyrotoxicity of, Q66(EN) Lewy bodies in Alzheimer disease, 45(NR) in essential tremor, 53(NR) in Parkinson disease, 47–48(NR), 49(NR) Lewy body dementia, 45–46(NR), 45f(NR), Q33(NR) Leydig cells, 52(EN) LH. See Luteinizing hormone Lhermitte sign, in multiple sclerosis, 58(NR) Libido, decreased in men, 77(GIM) in women, 81–82(GIM), Q5(GIM), Q147(GIM) Lice, 32(DM), 32f(DM) Lichenification in atopic dermatitis, 9(DM) in contact dermatitis, 5(DM) in HIV/AIDS, 61(DM) in pruritus, 5(DM) Lichenoid drug reactions, 11(DM), 11t(DM), 12(DM) Lichen planopilaris, 67(DM), 67f(DM) Lichen planus, 11–12(DM), 11t(DM), 42(DM), 70(DM) of nails, 68(DM), 68f(DM) oral, 11–12(DM), 11t(DM), 13f(DM), 42(DM), 70(DM), 70f(DM), Q52(DM) Lichen simplex chronicus, 57(DM), 61(DM) Licorice, hypertension and, 34t(NP) Liddle syndrome, Q36(NP) Lidocaine for arrhythmias, 51t(CV) in pregnancy, 109t(CV) Lidocaine patches, for osteoarthritis, 25(RM) Lifestyle modifications for hypertension management, 39(NP), 40(NP), Q1(NP) for osteoarthritis, 24(RM) Lifestyle risk factors, interventions for, 16–19(GIM) Life-sustaining treatment, withholding or withdrawing of, 25(GIM), Q43(GIM) Likelihood ratio (LR), 4(GIM), 5t(GIM) Limb ischemia acute, 101–102(CV), 102t(CV), Q85(CV) critical, 97(CV), 100(CV), 102(CV) Linear IgA bullous dermatosis, 47f(DM), 48(DM) Linezolid, 98t(ID), 99(ID) for multidrug-resistant organisms, 83(ID), Q101(ID) for purulent cellulitis, Q62(ID) side effects of, 98t(ID), 99(ID) Linezolid, toxicity of, Q93(NP) Liothyronine, for hypothyroidism, 34(EN) Lipase inhibitors, for diabetes mellitus, 4t(EN), 8t(EN) Lip cancer, 88(HO) Lipemia, in pseudohyponatremia, 10(NP) Lipid-lowering therapy. See also Statins for acute coronary syndromes, 22(CV) hepatotoxicity of, 57(GA), 58(GA) for peripheral arterial disease, 99(CV), 100(CV) for stroke patients, 36(NR) Lipoatrophy, in HIV/AIDS, 89–90(ID) Lipodystrophy, in HIV/AIDS, 89–90(ID) Lipohyalinosis, arterial, 27(NR) Lipomas, 42(DM) cardiac, 47(CV) esophageal, 63(PM) thyroid, 35t(EN) Lipopeptides, 97–99(ID), 98t(ID) Lipoprotein(a), coronary artery disease and, 14(CV) Lipoprotein X, cholestasis-associated, 10(NP) Liraglutide, for type 2 diabetes mellitus, 7(EN), 8t(EN) Lisinopril for heart failure, 33t(CV) in stroke, Q10(NR) teratogenicity of, 108t(CV), Q70(NP) Listeria monocytogenes. See Listeriosis Listeriosis meningitis in, 2(ID), 2t(ID), 5(ID), 5t(ID) in transplant recipients, 74(ID), 75(ID)
Lithium hypothyroidism and, 33(EN) nephrotoxicity of, 45t(NP), 47(NP), Q55(NP), Q78(NP) for thyroid storm, 39(EN) toxicity of, 91t(PM) Livedoid vasculopathy, 73(DM) Livedo reticularis, 51(DM), 51f(DM), 52t(DM), 53(DM), 66(RM), Q53(CV) Liver abscess of, 68(GA) acute fatty, of pregnancy, 64t(HO) adenomas of, 67–68(GA) cysts of, 67(GA), Q49(GA) fatty. See also Cirrhosis acute, of pregnancy, 68–69(GA), 69t(GA) alcoholic, 57(GA) nonalcoholic, 58–59(GA) fibrosis of, 55–56(GA), 58(GA) inflammation of, 53t(GA) vascular disorders of, 70–71(GA) Liver biopsy. See Biopsy, liver Liver chemistry tests abnormal, 53(GA), 53t(GA) in statin use, 65(GIM), Q158(GIM) Liver disease, 53-71(GA). See also Cirrhosis; Hepatitis alcohol-induced, 57–58(GA) bilirubin levels in, 5(NP) cholestatic, 60–61(GA) coagulopathy of, 46(HO) complications of, 61–65(GA) drug-induced, 57–58(GA) end-stage, 57–58(DM), 57f(DM) in HIV/AIDS, 90(ID) infiltrative, 53t(GA) liver chemistry studies in, 53t(GA) metabolic, 58–59(GA) perioperative management of, 133–134(GIM) pregnancy-related, 68–69(GA), 69t(GA), Q11(GA) pruritus in, 43(DM) toxin-induced, 57–58(GA) Vibrio vulnificus infections in, Q16(ID) Liver failure fulminant, 65–66(GA), 67t(GA), Q71(GA), Q82(GA) in Wilson disease, 59(GA), Q82(GA) in hepatitis A, 54(GA) in hepatitis B, 54(GA) Liver spots, 41(DM) Liver transplantation, 66–67(GA) for α1-antitrypsin deficiency, 59(GA) for autoimmune liver disease, 58(GA) for Budd-Chiari syndrome, 70(GA) contraindications to, 66(GA), 67t(GA) for decompensated cirrhosis, Q8(GA) for fulminant hepatic failure, 66(GA), Q71(GA) for hepatocellular carcinoma, 65(GA) for hepatorenal syndrome, 73(NP) for portopulmonary hypertension, 64–56(GA) for primary biliary cirrhosis, 60(GA) for primary sclerosing cholangitis, 61(GA) for Wilson disease, 56(NR) Living wills, 24(GIM) Lobectomy for lung cancer, 61(PM) thyroid, Q43(EN) Lobular carcinoma in situ, of the breast, 70(HO) Loeys-Dietz syndrome, 94t(CV) Löfgren syndrome, 38(PM), 55(DM), 75(RM), Q6(RM), Q77(PM) Long QT syndrome, 58–59(CV), 59t(CV) Long-term care, 120(GIM) Loop event recorders, implantable, 12(CV), Q89(CV), Q117(CV) Loperamide for irritable bowel syndrome, 42(GA) for traveler’s diarrhea, 64(ID) Lopinavir, use in pregnancy, 94(ID), Q54(ID) Lorazepam for alcohol withdrawal, Q17(PM) for status epilepticus, 22(NR), Q43(NR) Lorcaserin, 73(GIM) Lotions for atopic dermatitis, 9(DM) corticosteroid, 3(DM) Lovastatin, 64–65(GIM) interaction with protease inhibitors, 93(ID) Low back pain, acute, 50–52(GIM), 51t(GIM), Q91(GIM) Low-density lipoprotein (LDL) cholesterol evaluation of, 62–63(GIM) goal level of, 62(GIM), 63(GIM), 63t(GIM) management of, 63t(GIM), 64–66(GIM), 65t(GIM), 67(GIM), 68t(GIM), 69(GIM), Q52(GIM), Q75(GIM) metabolic syndrome and, 68(GIM), 68t(GIM) pregnancy and, 65t(GIM), Q75(GIM) stroke and, 69(GIM) target level, 22(CV) in diabetes mellitus, 29(CV) in peripheral arterial disease, 99(CV) Lower respiratory tract infections, as cough cause, 37(GIM) Lower urinary tract symptoms (LUTS), in men, 78(GIM) Lp(a) lipoprotein, 64(GIM) LTBI. See Tuberculosis, latent Lubiprostone for constipation, 41(GA) for irritable bowel syndrome, 42(GA), Q44(GA) Lumbar disk disease, 58(GIM) Lumbar puncture in bacterial meningitis, 3(ID), 5(ID), Q104(ID) contraindication to, 108(HO) in idiopathic intracranial hypertension, 4(NR), Q46(NR) in seizure patients, 13–14(NR) in subarachnoid hemorrhage, Q24(NR)
39
Cumulative Index
Lumbar spinal stenosis, 65(NR) vs. peripheral arterial disease, 98t(CV) Lumbar spine, ankylosing spondylitis of, 33f(RM) Lumbosacral plexopathy, 70(NR), Q92(NR) Lumpectomy, for breast cancer, 71(HO) Lung, trapped, pleural effusion in, 44t(PM) Lung cancer, 57–63(PM), 84–88(HO) adenocarcinoma, 68(HO), 85(HO), 87(HO) asbestos exposure and, 41–42(PM) brain tumors and, 77(NR) chemotherapy for, 67(HO) chronic obstructive pulmonary disease and, 17t(PM) clinical presentation of, 84–85(HO), 87(HO) diagnosis and evaluation of, 58–60(PM), 59t(PM) diagnosis of, 84–85(HO), 87(HO) epidemiology of, 84(HO) false-negative PET scans in, 5(PM) genetic factors in, 84(HO) imaging of, 5(PM) Lambert-Eaton myasthenic syndrome in, 85(HO), Q101(HO) metastatic, 58–59(PM), 86(HO), 108(HO), Q91(HO) imaging of, 6f(PM) of metastatic origin, 56(PM), 63(PM), 63f(PM), Q84(PM) metastatic to the heart, 47(CV) as mortality cause, 57(PM), 58(PM) non-small cell, 57(PM), 84(HO), 85–87(HO), Q91(HO), Q96(HO), Q106(HO), Q134 (HO) clinical findings in, 59t(PM), Q71(PM) staging of, 59–60(PM), 60t(PM) subtypes of, 57–58(PM) treatment of, 60–61(PM) paraneoplastic syndromes of, 58(PM), 59t(PM), 85(HO) Peutz-Jeghers syndrome and, 47–48(GA) pleural effusion in, 84(HO), 108(HO), 109(HO), Q106(HO) primary prevention of, 58(PM), Q87(PM) prognosis and follow-up in, 61–62(PM) radiation therapy-related, 84(HO), 110–111(HO) risk factors for, 58(PM), Q81(HO) screening for, 58(PM), 84(HO) small-cell, 57(PM), 84(HO), 87–88(HO), Q85(HO), Q92(PM), Q139(HO) Lambert-Eaton myasthenic syndrome and, 74(NR), 75(NR) myasthenia gravis and, 74(NR) treatment of, 61(PM) staging of, 59–60(PM), 60t(PM), 61–62(PM), 85–86(HO), Q62(PM) superior vena cava syndrome in, 107(HO) surgical treatment of, 61(PM), Q65(PM), Q84(PM) treatment of, 86–88(HO) Lung disease interstitial in diffuse cutaneous systemic sclerosis, 41(RM), Q93(RM) in inflammatory myopathies, 60(RM), Q49(RM) in mixed connective tissue disease, 47(RM), 47t(RM) in rheumatoid arthritis, 19(RM) in systemic lupus erythematosus, 37(RM) in systemic sclerosis, 4(RM), 44(RM) in vasculitis, Q39(RM) nontuberculous mycobacterial, 36–37(ID), 37t(ID) obstructive. See Obstructive lung disease occupational. See Occupational lung disease parenchymal. See Parenchymal lung disease pleural. See Pleural lung disease in relapsing polychondritis, 72(RM), Q45(RM) restrictive. See Restrictive lung disease in rheumatic disease, 4(RM) in rheumatoid arthritis, 19t(RM) in Sjögren syndrome, 46t(RM) in spondyloarthritis, 29t(RM) in systemic lupus erythematosus, 37(RM) in Wegener granulomatosis, 67–68(RM) Lung injury acute, rheumatoid arthritis and, 35(PM) acute respiratory distress syndrome in, 71(PM), 71t(PM) transfusion-related, 40(HO), 41(HO) Lung transplantation for chronic obstructive pulmonary disease, 21(PM), 28(PM), 28t(PM), Q75(PM) contraindications to, 28(PM) eligibility criteria for, 28t(PM) for pulmonary arterial hypertension, 55(PM) for silicosis, 42(PM) Lung transplant recipients, aspergillosis in, Q105(ID) Lung tumors, 55-57(PM). See also Nodules, pulmonary malignancy risk evaluation of, 55–56(PM), 56t(PM) management of, 56–57(PM) Lung volume expansion, perioperative, 128(GIM), 129(GIM), Q47(GIM) Lung volume measurements, 3(PM) in chronic obstructive pulmonary disease, 19–20(PM) Lung volume reduction surgery, for chronic obstructive pulmonary disease, 21(PM), 27–28(PM), 28t(PM), Q95(PM) Lupus band test, 35(RM) Lupus erythematosus cutaneous. See Cutaneous lupus erythematosus vs. dermatomyositis, 50(DM) discoid, 35(RM), 35t(RM), 36f(RM) drug-induced, 13(RM), 39(RM), Q1(RM), Q35(RM) neonatal, 40(RM) subacute cutaneous, Q16(RM) systemic. See Systemic lupus erythematosus Lupus nephritis, 38(RM), 40(RM), 56t(NP), 59–60(NP), Q10(RM), Q16(NP), Q78(NP) proliferative, 59t(NP), 60(NP), Q5(NP) Lupus pernio, 54(DM) Luteinizing hormone in male hypogonadism, 53(EN), 53f(EN), Q38(EN) in menstrual cycle, 56(EN), 56f(EN) Luteinizing hormone deficiency, in hypopituitarism, 19t(EN) Luteinizing hormone-secreting pituitary adenomas, 21(EN), 26(EN) Lyme disease, 2(RM), 3(RM), 4t(RM), 24–27(ID), 56(RM), 57(RM) “chronic,” 26(ID) geographic distribution of, 24(ID), 24f(ID) myocarditis in, 25(ID), 25t(ID), Q76(ID)
40
serologic tests for, 26(ID), Q23(ID), Q70(ID) “target” lesion of, 24(ID), 26f(ID) Lymphadenitis, in bubonic plague, 58(ID) Lymphadenopathy axillary, in breast cancer, 105(HO), Q89(HO) in cat-scratch disease, 17(ID) cervical benign, Q130(HO) in head and neck cancer, 88(HO), 89(HO), 104(HO), 105(HO) in HIV/AIDS, 87t(ID) inguinal, 105(HO) in lymphogranuloma venereum, 48(ID) in syphilis, 47(ID) isolated regional, 105(HO) in Kawasaki disease, 66(RM) in Lyme disease, 25(ID) lymphoma and, 97(HO) mediastinal, 105(HO) retroperitoneal, 105(HO) in sarcoidosis, 75(RM) in Sjögren syndrome, 46(RM) in systemic lupus erythematosus, Q11(RM) in thrombocytopenia, 47(HO) Lymphangioleiomyomatosis, 38–39(PM), Q45(PM), Q96(PM) Lymphangitis, in streptococcal infections, 13(ID) Lymph node(s), in cervical cancer, 78(HO) Lymph node biopsy, sentinel in breast cancer, 71(HO) in melanoma, 106(HO) Lymph node dissection, retroperitoneal, in testicular cancer, 94(HO) Lymphocyte-depleting agents, 73(ID), 73t(ID) Lymphocytic hypophysitis, 23t(EN), Q40(EN) hypopituitarism and, 18(EN), 18t(EN) Lymphocytosis, 5(PM) large granular, 3(HO), Q69(HO) Lymphogranuloma venereum, 48(ID), 48t(ID), Q27(ID) Lymphoma, 97–104(HO) aggressive, 102–104(HO) B-cell, 98(HO) diffuse large cell, 103(HO), Q119(HO) Burkitt, 11(HO), 97(HO), 103(HO) chronic tubulointerstitial disorders and, 45t(NP), 46(NP) classification of, 98(HO), 99t(HO) cutaneous T-cell, 10–11(DM), 65(DM), Q57(DM) diagnosis of, 98(HO) diffuse large cell, 102–103(HO) B-cell, 103(HO), Q119(HO) epidemiology of, 97(HO) fever of unknown origin in, 53(ID) follicular, 100–101(HO), 100t(HO), Q75(HO), Q77(HO) gastric, Helicobacter pylori-related, Q80(HO) Hodgkin, 97(HO), 103–104(HO), 110–111(HO), Q114(HO), Q129(HO) breast cancer and, 110–111(HO) myasthenia gravis and, 74(NR) radiation therapy for, 102(CV), Q40(CV) indolent, 98(HO), 100–102(HO), 100t(HO) large cell, 102(HO) mantle cell, 103(HO), 104(HO), Q88(HO) mediastinal, 63(PM) mucosa-associated lymphoid tissue (MALT), 14–15(GA), 46(RM), 47(RM), 101(HO) paraneoplastic pemphigus and, 48(DM) pleural effusion in, 109(HO) primary central nervous system, 78t(NR), 79(NR) prognosis of, 98(HO), 100t(HO) rheumatic disease in, 6t(RM) risk factors for, 97(HO) in Sjögren syndrome, 46(RM), 47(RM), Q74(RM) T-cell, 98(HO), 104(HO) thyroid, 35t(EN), 37(EN) diagnosis of, Q68(EN) treatment of, 101(HO), 103–104(HO) tumor necrosis factor-α inhibitors and, 13(RM) Lymphopenia, in systemic lupus erythematosus, 37(RM) Lynch syndrome, 46(GA) colorectal cancer surveillance in, 50t(GA), Q1(GA) Lytic bone disease, in multiple myeloma, 13f(HO), 13(HO), 15(HO) Macroadenomas, pituitary in acromegaly, 25(EN) nonfunctioning, Q46(EN) with suprasellar extension, 21(EN) treatment of, 22(EN) Macroalbuminuria, albumin-creatinine ratio in, 16(EN) Macroamylasemia, 23(GA) Macrocytosis, hydroxyurea-related, Q72(HO) Macroglossia, in amyloid light-chain amyloidosis, 16(HO), 17f(HO) Macrolide antibiotics for community-acquired pneumonia, 21t(ID), 22(ID), Q34(ID) drug interactions of, 73(ID), Q18(ID) for Mycobacterium avium complex infections, 38(ID) Macroprolactinomas, Q64(EN) Macrovascular disease, in diabetes mellitus, 1(EN) Macular degeneration, 96f(GIM), 96(GIM), 119(GIM), Q148(GIM) Maddrey discriminant function score, in alcoholic hepatitis, 57(GA), Q18(GA) Magnesium ammonium phosphate (struvite) urinary crystals, 6t(NP) Magnesium sulfate, for preeclampsia, 80(NP) Magnetic resonance angiography in giant cell arteritis, Q55(RM) in internal carotid artery dissection, 36(NR), 37f(NR) in peripheral arterial disease, 99(CV) Magnetic resonance cholangiopancreatography in chronic pancreatitis, 25(GA) in intraductal papillary mucinous neoplasms, 28f(GA) in primary sclerosing cholangitis, 60(GA), 61f(GA) Magnetic resonance imaging, 9t(NP) of adrenal incidentalomas, 48(EN) in Alzheimer disease, 44(NR), 45(NR) in ankylosing spondylitis, Q41(RM) of brain tumors, 77(NR), 78–79(NR)
Cumulative Index
in compressive cervical myelopathy, Q25(NR) in concussion, 11(NR) in dementia, 42(NR) in epilepsy, 16(NR), 17(NR) gadolinium-enhanced, 9(NP) nephrotoxicity of, 70(NP), 90(NP), Q19(NP) in headache, 2(NR), Q37(NR) in hepatitis B, Q24(GA) in idiopathic transverse myelitis, 67(NR) in inflammatory myopathies, 61(RM) in multiple myeloma, 13–14(HO) in multiple sclerosis, 58–59(NR), 58f(NR), 60(NR) in normal pressure hydrocephalus, 47(NR), Q52(NR) in osteoarthritis, 24(RM) of osteomyelitis, 50(ID), Q39(ID) in parkinsonism, 49(NR) pituitary in central adrenal insufficiency, Q9(EN) for hyperprolactinemia, Q50(EN) of thyroid-stimulating hormone-secreting pituitary tumors, Q28(EN) in rheumatic disease, 8(RM) in rheumatoid arthritis, 17(RM), 18(RM) in seizures, 13–14(NR) in spinal cord compression, 65(NR), Q25(NR) in spondyloarthritis, 32–33(RM), Q41(RM) in stroke, 24f(NR), 24(NR) in traumatic brain injury, 10–11(NR) Magnetic resonance urography, in hematuria, 7(NP), 9t(NP) Magnetic resonance venography in dural sinus venous thrombosis, 34–35(NR), 35f(NR), Q1(NR) in pregnancy, 34–35(NR) Major depressive disorder, epilepsy and, 16(NR) Malabsorption diarrhea and, 30(GA), 31–33(GA) fat, 32(GA), 60(GA) lactose, 34(GA), 42(GA), Q51(GA) protein, 32(GA) Malabsorptive procedures, in bariatric surgery, 20t(GA), 21–22(GA) Malar erythema, 48(DM) Malaria, 61–62(ID), 61t(ID), 62t(ID), Q40(ID) erythrocytapheresis for, 41(HO) as hemolytic anemia cause, 35(HO) prevention of, 61(ID), 62t(ID) in pregnancy, Q100(ID) Malar rash, in systemic lupus erythematosus, 4t(RM), 35f(RM), 35(RM), 35t(RM) Malassezia furfur, 28(DM) Malcolm Baldrige Model for Performance Excellence, 19(GIM) Malignant melanoma. See Melanoma Mallory-Weiss tears, 74(GA) Malnutrition in chronic obstructive pulmonary disease, 19(PM) hypocalcemia in, Q75(EN) Malnutrition, protein-calorie, in cirrhosis, 70(GA) MALT lymphoma, 14–15(GA), 46(RM), 47(RM), 101(HO) Mammalian target of rapamycin (mTOR) inhibitors, 73f(ID) Mammography in cancer of unknown primary site, 104(HO) for palpable breast mass evaluation, 83(GIM) screening, 7t(GIM), 9–10(GIM), 11(GIM), 69–70(HO), Q122(HO) Mannitol challenge testing, 1(PM), 3(PM) during pregnancy, Q29(PM) Manometry esophageal, 3(GA), 4f(GA), 5f(GA) gastroduodenal, in gastroparesis, 18(GA) Mantle cell lymphoma, 103(HO), 104(HO), Q88(HO) Mantoux tuberculin skin test. See Tuberculin skin test Marfan syndrome, 74(RM), 93(CV), 94t(CV), Q60(RM), Q111(CV) Marijuana use, 17–18(GA), Q64(GA) Marjolin ulcers, 36(DM) Mastalgia, 84(GIM), Q139(GIM) Mast cell degeneration, 44(DM), 45(DM) Mastectomy, 73(HO) prophylactic bilateral, 71(HO) radical, 71(HO) Material Safety Data Sheets (MSDS), 40(PM), Q24(PM) Maturity-onset diabetes of the young (MODY), 5(EN), Q73(EN) Maximal expiratory pressure tests, 74(PM) Maximal inspiratory pressure tests, 73–74(PM), Q59(PM) Maze surgery, for atrial fibrillation, 55(CV) McMurray test, 59f(GIM), 59(GIM) Mean arterial pressure in hypertensive emergencies, Q43(PM) in shock, 77t(PM), Q106(PM) Mean corpuscular volume, in anemia, 18(HO), 19(HO) Mean sleep latency testing (MSLT), 64(PM) Measles, mumps, rubella vaccine, 12t(GIM), 15(GIM), 16(GIM) Mebendazole, for giardiasis, 71(ID) Mechanical heart valves. See Prosthetic valves Mechanical ventilation, 80–82(PM), Q18(PM) for acute respiratory distress syndrome, 71(PM), 80(PM), Q47(PM) assist/control mode of, 80(PM) atelectasis and, 72(PM) with endotracheal intubation for asthma, Q51(PM) for chronic obstructive pulmonary disease, 27(PM), 27t(PM) indications for, 73–74(PM) neuropsychiatric disorders and, 93(PM), Q3(PM) noninvasive. See Noninvasive positive pressure ventilation (NPPV) as pneumonia risk factor, 82(ID), 82t(ID), 83(ID) pressure support mode of, 80(PM) for respiratory acidosis, 32(NP) for sepsis, 83(PM), 84(PM) for severe asthma exacerbations, 75(PM), Q25(PM) synchronized intermittent mandatory ventilation (SIMV), 80(PM) weaning from, 81(PM), Q2(PM) Mechanic’s hands, 4t(RM), 50–51(DM), 59(RM) Meckel diverticula, 79(GA) Medial collateral ligament injuries, 59(GIM) Medial-lateral grind test, 59(GIM), 61(GIM)
Median nail dystrophy, 69(DM), 69f(DM) Median nerve, 56f(GIM) Mediastinal lymph node metastasis, imaging of, 5(PM), Q62(PM) Mediastinal masses, 63(PM), Q56(PM) Mediastinoscopy, 107(HO) comparison with bronchoscopy, 5(PM) Medical errors, 19–22(GIM), 21t(GIM), Q12(GIM) disclosure of, 26(GIM) medication-related, 20(GIM), Q113(GIM) sources of, 20(GIM) “Swiss cheese” model of, 19f(GIM), 19(GIM) Medical literature, interpretation of, 1–4(GIM) statistical analysis, 3–4(GIM) study design, 1–3(GIM), 2t(GIM) terminology, 3t(GIM) Medically unexplained symptoms (MUSs), 112(GIM) Medicare, 28(GIM) Medication errors, 20(GIM), Q113(GIM) Medication overuse headache, 6(NR) Medications. See also specific medications as adrenal insufficiency cause, 41t(EN) diffuse parenchymal lung disease and, 36–37(PM), 37t(PM) erectile dysfunction and, 74–75(GIM), 75t(GIM) as fever of unknown origin cause, 54(ID) as hyperprolactinemia cause, 22(EN), 23t(EN) as hypothyroidism cause, 33(EN) as low bone mass cause, 68t(EN) perioperative management of, 125(GIM), 126t(GIM), Q82(GIM) teratogenic, 86(GIM), 87t(GIM), Q32(GIM) thyrotoxic, 32–33(EN) tubular toxicity of, 45t(NP), 46–47(NP), 68t(NP) weight gain and, 70t(GIM) Mediterranean spotted fever, 64(ID) Medullary cystic kidney disease, 63t(NP), 64(NP) Medulloblastomas, 78(NR), 78t(NR) Mefloquine, as malaria prophylaxis, 62t(ID), Q100(ID) Megakaryocyte proliferation, in primary myelofibrosis, 9(HO), 10(HO) Megestrol acetate adrenal insufficiency and, Q25(EN) adrenocorticotropic hormone deficiency and, 20(EN) Meglitinides, 8t(EN) contraindication to, 11(EN) surreptitious use of, 17(EN), 17t(EN) Melanocytic nevi, 39(DM), 40(DM) Melanoma, 37–40(DM), 38f(DM), 106–107(HO), Q102(HO), Q126(HO) acral, 77f(DM) brain metastasis in, 77(NR) in darker-skinned patients, 68(DM), 77f(DM) early detection of, 1(DM) in elderly patients, 75(DM) oral, 70(DM) subungual, 68(DM), Q18(DM) superficial, Q65(DM) Melanonychia, 68(DM), 68f(DM) Melatonin, for insomnia, 44–45(GIM) Melatonin-receptor agonists, for insomnia, 44–45(GIM), 45t(GIM) Melena, 74(GA), 75(GA), 77(GA), 79(GA) Melphalan for amyloid light-chain amyloidosis, 17(HO) for multiple myeloma, 15(HO) Memantine, for Alzheimer disease, 44(NR), 44t(NR) Memory loss aging-related, 41(NR), Q30(NR) in Alzheimer disease, 42(NR), 43(NR) in frontotemporal dementia, 46(NR) MEN1. See Multiple endocrine neoplasia type 1 MEN2. See Multiple endocrine neoplasia type 2 Meniere disease, 41(GIM), Q14(GIM), Q20(GIM) Meningiomas, 78(NR), 78t(NR), 79f(NR) hypopituitarism and, 18(EN) Meningitis, 1–6(ID) in anthrax, 57(ID) bacterial, 2–6(ID) causes of, 2(ID), 2t(ID) cerebral spinal fluid analysis in, 1t(ID), 3(ID) diagnosis of, 3(ID) epidemiology of, 2–3(ID) health care-associated, 2(ID), Q96(ID) management of, 3–5(ID), 5–6t(ID), Q59(ID) pneumococcal, 2(ID), 2t(ID), 3(ID), 4(ID), 6t(ID), Q73(ID) tuberculous, Q104(ID) cryptococcal, 41(ID) in HIV/AIDS, 91(ID), Q21(ID), Q25(ID) in Lyme disease, 25(ID), 25t(ID) normal pressure hydrocephalus and, 46(NR) viral aseptic, 1(ID), 2(ID), 95(ID), Q22(ID) benign recurrent lymphocytic, Q24(ID) cerebral spinal fluid analysis in, 1(ID), 1t(ID) diagnosis of, 1–2(ID), 1t(ID) epidemiology and causes of, 1(ID) herpes simplex, 95(ID), Q22(ID), Q24(ID) Mollaret, 1(ID) West Nile virus and, 10(ID) Meningococcal immunization, 2–3(ID), 12t(GIM), 15(GIM) in HIV/AIDS patients, 88(ID), 89(ID) in transplant recipients, 77t(ID) Meningoencephalitis. See Encephalitis Menisci examination of, 59f(GIM), 59(GIM), 61(GIM) injuries to, 59(GIM) Menometrorrhagia, 90(GIM) Menopausal symptoms, tamoxifen-related, Q120(HO) Menopause urogenital symptom management in, 89(GIM), Q25(GIM) vasomotor symptom management in, 88–89(GIM), 89t(GIM), Q60(GIM) Menorrhagia, 90(GIM) in von Willebrand disease, 45(HO), 46(HO)
41
Cumulative Index
Men’s health, 74–81(GIM) acute testicular and scrotal pain, 78–79(GIM) androgen deficiency, 77(GIM), 77t(GIM), Q40(GIM) benign prostatic hyperplasia, 78(GIM), 78t(GIM), Q18(GIM), Q70(GIM) epididymal cysts, 79–80(GIM) hernia, 81(GIM) hydrocele, 79(GIM) pelvic pain, 80–81(GIM) prostatitis, 80–81(GIM), 80t(GIM) sexual dysfunction, 74–77(GIM), 75t(GIM), 76t(GIM) varicocele, 79–80(GIM) Menstrual bleeding, iron loss in, 35(HO), Q61(HO) Menstrual cycle. See also Amenorrhea; Oligomenorrhea normal function of, 56(EN) Menstrual migraine, 8(NR), Q75(NR) Mental and behavioral health, 108–116(GIM) anxiety disorders, 110–112(GIM), Q146(GIM) attention-deficit/hyperactivity disorder, 115(GIM), Q93(GIM) autism spectrum disorders, 115–116(GIM) bipolar disorder, 109(GIM), 112(GIM), Q140(GIM) depression, 108–110(GIM) anorexia nervosa and, 114(GIM) bipolar disorder and, 109(GIM), 112(GIM), Q140(GIM) chronic fatigue and, 40(GIM) in elderly patients, 119(GIM), Q99(GIM) low back pain and, 50(GIM) management of, 109(GIM), 110t(GIM), Q56(GIM) pain and, 35(GIM) postpartum, 109(GIM) screening for, 7t(GIM), 8(GIM), Q145(GIM) in terminally ill patients, 32(GIM) difficult patient encounters, 116(GIM), Q73(GIM) eating disorders, 19(GIM), 77(GIM), 113–114(GIM), Q143(GIM), Q154(GIM) intermittent explosive disorder, 112(GIM) schizophrenia, 77(GIM), 114–115(GIM), Q68(GIM) somatoform disorders, 112–113(GIM), Q105(GIM) Mentzer index, in thalassemia, 28(HO) Meperidine, for sickle cell disease, 30(HO) in pregnancy, 63(HO) Meralgia paresthetica, 58(GIM), Q155(GIM) in diabetes, 16(EN) Mercaptopurine for Crohn disease, 37f(GA), 37t(GA), Q17(GA) for ulcerative colitis, 37f(GA), 37t(GA) Meropenem, for nosocomial meningitis, Q96(ID) Mesalamine, for inflammatory bowel disease, 37t(GA) Mesenteric ischemia acute, 43–44(GA), 45(GA), Q7(GA) chronic, 45(GA), Q94(GA) Mesial temporal sclerosis, 15f(NR), 15(NR), 15t(NR), Q26(NR) Mesothelioma, 40(PM), 40t(PM), 62–63(PM) pleural effusion in, 43t(PM) Meta-analyses, 3(GIM) Metabolic bone disease, 66–73(EN) cirrhosis and, 69(GA) Metabolic disorders, in HIV/AIDS, 89–90(ID) Metabolic equivalents (METs), 125(GIM), 127f(GIM), Q168(GIM) Metabolic liver disease, 58–59(GA) Metabolic syndrome, 13(CV), 67–68(GIM), 67t(GIM), Q64(GIM) “ABCDE” approach to management of, 67–68(GIM), 68t(GIM) definition of, 3(EN) kidney stones and, 74(NP) nonalcoholic steatohepatitis and, 58(GA), Q2(GA) in polycystic ovary syndrome, 58(EN) in Turner syndrome, 57(EN) Metal allergy, 6(DM), 12(DM) Metanephrine assays, in pheochromocytoma, 50(EN) Metanephrines, in pheochromocytoma, 49(EN), 50(EN) Metaplasia, esophageal, 10–11(GA), 10f(GA) Metaproterenol, for chronic obstructive pulmonary disease, 22t(PM), 23(PM) Metastases, 67(HO) in bladder cancer, 95(HO) bone, in breast cancer, 75(HO) to the brain, 77(NR) in lung cancer, 86(HO) in breast cancer, 72(HO), 74–75(HO), 108(HO), Q109(HO) in carcinoid tumors, Q95(HO) in cervical cancer, 78(HO) in colorectal cancer, 80–81(HO), Q135(HO) differentiated from thyroid nodules, 35t(EN) to the lung, 63f(PM), 63(PM), Q84(PM) in lung cancer, 86(HO), 108(HO), Q91(HO), Q106(HO) lymphangitic, 63(PM) in melanoma, 106–107(HO), Q126(HO) in pancreatic cancer, 81(HO) in renal cancer/renal cell carcinoma, 96(HO), Q92(HO) to the spinal cord, Q77(NR) Metered-dose inhalers (MDIs) for asthma, 12(PM), 15(PM) improper use of, 12(PM), Q23(PM) for asthma exacerbations, 15(PM) for chronic obstructive pulmonary disease, 21(PM) improper use of, Q63(PM) Metformin contrast media as contraindication to, 11(EN) for diabetes mellitus prevention, 4t(EN) for hirsutism, in polycystic ovary syndrome, 58(EN), Q82(EN) toxicity of, Q57(NP) use in pregnancy, 4(EN) Methacholine challenge testing, 1(PM) Methadone, 30(GIM), 36(GIM), Q136(GIM) hypogonadism and, Q38(EN) Methamphetamines, coronary spasms and, 19(CV) Methanol poisoning, 89(PM), 89t(PM) anion gap metabolic acidosis in, 25–26(NP), 27(NP), Q7(NP) Methicillin. See also Staphylococcus aureus, methicillin-resistant for community-acquired pneumonia, 23t(ID) Methimazole for Graves disease, 30(EN)
42
teratogenicity of, Q78(EN) for thyroid storm, 39(EN) Methotrexate adverse effects of, 11(RM), 12(RM), 110(HO), Q25(RM) alcohol use/abuse and, 11(RM), 12(RM), Q25(RM) contraindication during pregnancy and lactation, 4t(DM) corticosteroids with, 10(RM) for diffuse cutaneous systemic sclerosis, Q7(RM) as hand-foot syndrome cause, 58(DM) for inflammatory bowel disease, 37f(GA), 37t(GA), 38(GA) for inflammatory myopathies, 62(RM) for polymyalgia rheumatica, 65(RM) for psoriasis, 11(DM) for psoriatic arthritis, Q18(RM) pulmonary toxicity of, 37(PM) for rheumatoid arthritis, 11(RM), 18(RM), 20(RM), Q28(RM), Q75(RM) rituximab with, 14(RM) for sarcoidosis, 54(DM), 55(DM) side effects of, 58(DM) for spondyloarthritis, 34(RM) for Takayasu arteritis, 66(RM) teratogenicity of, 11(RM), 12(RM), 21(RM), Q15(RM) tumor necrosis factor-α inhibitors with, 20(RM), Q75(RM) Methyldopa as lupus erythematosus cause, 39(RM) in pregnancy, 78–79(NP), 79t(NP), Q70(NP), Q85(NP) 3,4-Methylenedioxymethamphetamine, 90(PM) hypertension and, 34t(NP) Methylmalonic acid, in vitamin B12 deficiency, 22(HO), 23(HO), Q64(HO) Methylnaltrexone, for constipation, 41(GA) for opioid-induced constipation, Q90(GA) Methylprednisolone intra-articular injections of, 10(RM), 25(RM) for multiple sclerosis, 61–62(NR), 61(NR), Q29(NR), Q89(NR) for optic neuritis, Q29(NR) for transverse myelitis, 66(NR) Methylxanthines, for chronic obstructive pulmonary disease, 22t(PM), 23(PM), 25(PM) Metoclopramide for gastroparesis, 18(GA), 18t(GA) for migraine, in pregnancy, Q53(NR) Metoprolol, 43(NP) for arrhythmias, 51t(CV) for heart failure, 33t(CV), Q17(CV) for migraine, in pregnancy, 9(NR) in pregnancy, 108t(CV) for ST-elevation myocardial infarction, 25(CV) Metronidazole for amebiasis, 72(ID) for Clostridium difficile infections, 70(ID), 70t(ID) for giardiasis, 71(ID), 72(ID) for Helicobacter pylori infection, 15(GA) for inflammatory bowel disease, 37t(GA) Metrorrhagia, 90(GIM) Mexiletine succinate, for arrhythmias, 51t(CV) Microadenomas, pituitary, 21(EN) Microalbuminuria albumin-creatinine ratio in, 16(EN) in diabetes mellitus, 7(NP), 16(EN) in diabetic nephropathy, 54(NP), 54t(NP), Q71(NP), Q89(NP) testing for, Q33(NP) Microangiography, of pregnancy, 64(HO) Microangiopathic hemolytic anemia, 43(RM) Microangiopathy, thrombotic, 56t(NP), 61–62(NP), 62t(NP), 71(NP) post-kidney transplant, 93(NP) Microcomedones, 19t(DM) Microcytosis iron deficiency in, 21(HO), Q19(HO) in thalassemia, Q47(HO) Microscopic colitis, 30(GA), 33(GA), 38–39(GA), 39t(GA), Q89(GA) Microscopic polyangiitis, 4(RM), 63t(RM), 68(RM), 69(RM) Microscopy, urine, 5–9(NP) Microvascular disease, in diabetes mellitus, 1(EN) Midfoot pain, 62(GIM) Miglitol, 8t(EN) Migraine, 1t(NR), 5–9(NR) with aura, 5(NR), 6t(NR), 7(NR), 13t(NR), Q70(NR) aura in, 5(NR), 6t(NR), 7(NR) characteristics of, 13t(NR) chronic, 5–6(NR) clinical features of, 5–6(NR), 6t(NR) diagnosis of, 5–6(NR), 6t(NR) epidemiology of, 5–6(NR) frequency of, 5(NR) medication overuse headache and, 6(NR) menstrual, 8(NR), Q75(NR) vs. multiple sclerosis, 60t(NR) ocular/retinal, Q95(GIM) perimenopausal, 9(NR) in postconcussion syndrome, 12t(NR) in pregnancy, 8–9(NR) prevention of, 7–8(NR) vs. tension-type headache, 5(NR) treatment of acute, 6–7(NR), 7t(NR) in pregnancy, 8–9(NR), Q53(NR) without aura, 5(NR), 6t(NR), Q58(NR), Q83(NR) in women, 8–9(NR) Mild cognitive impairment, 41(NR), 43(NR), 118–119(GIM), 120(GIM), Q35(GIM), Q103(GIM) Milia, 57(DM) Miliaria, 17(DM), 17f(DM), 17t(DM), Q32(DM) Military personnel, head injuries in, 12(NR), Q56(NR) Milnacipran, for fibromyalgia, 27(RM), Q85(RM) Milrinone, for cardiogenic shock, 39t(CV) Milwaukee shoulder, Q4(RM) Mineralocorticoid excess, syndromes of, 31(NP), 32f(NP) Mineralocorticoid replacement therapy, for primary adrenal insufficiency, 43(EN) Minimal inhibitory concentration (MICs) of daptomycin, 98(ID) of telavancin, 98–99(ID)
Cumulative Index
of vancomycin, 98–99(ID) Mini-Mental State Examination (MMSE), 41(NR), 43(NR), 47(NR), 76f(NR), 118(GIM) Minocycline for acne, 20t(DM) for rheumatoid arthritis, 20(RM) Minoxidil for alopecia, 66(DM) for refractory hypertension, 84(NP) Minute ventilation, in chronic obstructive pulmonary disease, 16(PM) Mirtazapine, for pruritus, 43(DM) Miscarriage, maternal hyperthyroidism and, Q78(EN) Misoprostol, as gastroprotectant, 16(GA) Mitochondrial myopathies, 76(NR) Mitomycin for anal cancer, 81(HO) cardiotoxicity of, 104t(CV) as thrombotic thrombocytopenic purpura cause, 51(HO) Mitotane, for adrenocortical cancer, 52(EN) Mitoxantrone cardiotoxicity of, 104t(CV) for multiple sclerosis, 62t(NR), 63(NR) Mitral regurgitation, 70(CV), 72t(CV), 74t(CV), 76t(CV) acute severe, Q63(CV) aortic stenosis and, 77(CV) evaluation of, 74t(CV) ischemic, 80(CV) management of, 76t(CV), 80(CV), Q63(CV), Q67(CV) natural history of, 80(CV) pathophysiology of, 80(CV) post-myocardial infarction, 26(CV), 27(CV), 27t(CV) pulmonary hypertension in, Q86(CV) Mitral stenosis, 71(CV), 72t(CV), 74t(CV), 76(CV), 76t(CV) evaluation of, 74t(CV) management of, 76t(CV), 79(CV), Q105(CV) natural history of, 79(CV) pathophysiology of, 79(CV) rheumatic, atrial fibrillation in, 53(CV) Mitral valve(s), mechanical, 82–83(CV) Mitral valve prolapse, in Marfan syndrome, 74(RM) Mitral valve regurgitation, in Marfan syndrome, 74(RM) Mitral valve repair, 76t(CV), Q63(CV), Q86(CV) Mitral valve replacement, 76t(CV), 79(CV), 82–83(CV) Mitral valvular disease, atrial fibrillation in, 53(CV) Mixed connective tissue disease, 47–48(RM), 47t(RM), Q26(RM) Mixed cryoglobulinemia, 57–58(DM) Mixed irritable bowel syndrome, 41t(GA), 42(GA) Mixed metabolic disorders, 23–24(NP) Mixing studies, of bleeding disorders, 43(HO) Mobile cardiac outpatient telemetry units (MCOT), 12(CV) Modafinil, for multiple sclerosis-related fatigue, 63t(NR), 64(NR), Q49(NR) Modification of Diet in Renal Disease (MDRD) Study equation, 2(NP), 3t(NP), Q28(NP), Q89(NP) Modified Medical Research Council (MMRC) Dyspnea Scale, 19(PM), 20t(PM) MODY. See Maturity-onset diabetes of the young Mohs micrographic surgery, 35(DM), 36(DM), 37(DM) Mold. See also Fungal infections diffuse parenchymal lung disease and, 30(PM) Moles. See Nevi Molluscum contagiosum, 31(DM), 31f(DM), 91f(ID), 91(ID), Q68(DM) in HIV/AIDS, 61(DM) Mometasone, for chronic obstructive pulmonary disease, 22t(PM) Monoamine oxidase type B inhibitors, for Parkinson disease, 50(NR), 50t(NR) Monoclonal antibodies cardiotoxicity of, 104(CV) for colorectal cancer, 80–81(HO) indications for, 69(HO) for lymphoma, 98(HO) for multiple sclerosis, 62–63(NR), 62t(NR) for myasthenia gravis, 74(NR) toxicity of, 69(HO), 110(HO) Monoclonal gammopathy, 69(EN) Monoclonal gammopathy of undetermined significance (MGUS), 14t(HO), 15–16(HO) Monoclonal immunoglobulin deposition disease, 50t(NP), 74(NP) Monoclonal (M) proteins in monoclonal gammopathy of undetermined significance, 16(HO) in multiple myeloma, 13(HO), 14(HO), 14t(HO) Mononeuritis multiplex, 68(RM), 69(RM) Mononeuropathies, 68(NR), 70(NR), 71(NR), 71t(NR) diabetic, 16(EN) Mononucleosis, fever of unknown origin in, 53(ID) Mononucleosis-like syndrome, 86(ID), 86t(ID), Q99(ID) Mononucleosis syndrome, 61t(ID) Montelukast, for asthma, 14(PM) Montreal Cognitive Assessment, 41(NR) Mood disorders epilepsy and, 16(NR) in fibromyalgia, 26(RM), 27(RM) Moraxella catarrhalis infections, 19(ID), 25(PM) Morbilliform drug reactions, 14(DM), 15t(DM) Morning stiffness, 1(RM), 1t(RM), Q65(RM) in rheumatoid arthritis, 17(RM), 19(RM) Morphea, 45(RM), Q31(RM) Morphine, 30(GIM), 31t(GIM), Q19(GIM) for dyspnea, 25(PM) for sickle cell anemia-related pain, Q42(HO), Q51(HO) Mosquito bites, 31(DM) Mosquitoes, as dengue fever vectors, 64(ID) Motility disorders esophageal, 3–6(GA) hypertonic (spastic), 3–5(GA) hypotonic, 3(GA), 5–6(GA) gastrointestinal, vs. irritable bowel syndrome, 41(GA) Motivational interviewing, 16(GIM), 72(GIM), Q63(GIM) Motor neuron diseases, ventilatory failure in, 74(PM) Motor vehicle accidents, in older drivers, 120(GIM), Q118(GIM) Mountain sickness, acute, 69(PM), 70(PM), Q52(PM) Movement disorders, 47–57(NR) chorea, 53–54(NR) dystonia, 53(NR) hyperkinetic, 47(NR)
hypokinetic, 47(NR) myoclonus, 54(NR), 55t(NR) neuroleptic-induced, 54(NR), 56(NR) restless legs syndrome, 56–57(NR) in stroke, 29t(NR) tardive dyskinesia, 54(NR) tic disorders, 55(NR) Tourette syndrome, 55(NR) Wilson disease, 55–56(NR) Moxifloxacin for penicillin-allergic patients, Q13(ID) for tuberculosis, 35t(ID) MRI. See Magnetic resonance imaging MRSA. See Staphylococcus aureus, methicillin-resistant mTOR (mammalian target of rapamycin) inhibitors, 73f(ID) Muckle-Wells syndrome, 54(ID), 74t(RM) Mucolytic agents, for chronic obstructive pulmonary disease, 25(PM), Q85(PM) Mucormycosis, 40–41(ID) in diabetic ketoacidosis, Q65(ID) rhinocerebral, 40(ID), 41(ID) Mucosa-associated lymphoid tissue (MALT) lymphoma, 101(HO) Mucosal lesions, oral, 105(GIM), 106(GIM) Mucous membranes, oral, disorders of, 70–72(DM) Mucus gland hyperplasia, in asthma, 7(PM) Multidrug-resistant organism-related infections hospital-acquired, 83–84(ID) in transplant recipients, 75(ID) tuberculosis, 36(ID) Multiorgan failure, 82(PM) in septicemic plague, 58–59(ID) Multiple endocrine neoplasia type 1 (MEN1) acromegaly in, 25(EN) differentiated from MEN2, Q32(EN) familial hyperparathyroidism in, 62(EN) pituitary adenomas in, 21(EN), Q32(EN) three “Ps” of, 21(EN), Q32(EN) Multiple endocrine neoplasia type 2 (MEN2) calcitonin measurement in, 28(EN) differentiated from MEN1, Q32(EN) familial hyperparathyroidism in, 62(EN) hypercalcemia in, Q81(EN) medullary thyroid cancer and, 37(EN), Q34(EN) Multiple mononeuropathies, 68(NR) Multiple myeloma, 13–16(HO), 13f(HO), 14t(HO), Q13(HO), Q33(HO) acute kidney injury in, 74(NP), Q11(NP) AL amyloidosis in, 54(NP) asymptomatic, 14(HO), 15(HO) chronic tubulointerstitial disorders in, 45t(NP), 46(NP) kidney failure in, 55(NP) monoclonal gammopathy of undetermined significance and, 15–16(HO) rheumatic disease in, 6t(RM) Multiple sclerosis, 57–64(NR), 66(NR) acute exacerbations of, 61–62(NR), Q89(NR) benign, 60–61(NR) course of, 59–61(NR) diagnosis of, 58–59(NR), Q45(NR) differential diagnosis of, 59(NR), 60t(NR) epidemiology of, 57(NR) fatigue in, 58(NR), 63–64(NR), 63t(NR), Q49(NR) general health care in, 61(NR) genetic factors in, 57(NR) lifestyle modifications for, 61(NR) mobility maintenance in, 61(NR), 64(NR) pathophysiology of, 57(NR) perioperative management of, 134(GIM) pregnancy in, 61(NR) primary progressive, 59–60(NR), 61f(NR), 63(NR) pseudorelapse in, 61(NR), Q91(NR) relapse or flare of, 57–58(NR) relapsing-remitting, 59–60(NR), 61f(NR), 61(NR), 63(NR) secondary progressive, 59(NR), 61f(NR), 61(NR) signs and symptoms of, 57–58(NR) spasticity in, 58(NR), 63(NR), 63t(NR), Q63(NR) spectrum of, 57(NR) treatment of, 61–64(NR), Q29(NR), Q80(NR), Q89(NR) adverse effects of, 61–62(NR), 63(NR), Q93(NR) symptomatic management, 63–64(NR), 63t(NR) trigeminal neuralgia and, 4(NR) urinary tract infections in, 29(ID) Multiple sleep latency testing, Q12(PM) Multiple system atrophy, 49(NR), 51(NR), 52(NR) Mumps vaccine, 12t(GIM), 15(GIM), 16(GIM) Mupirocin for impetigo, 24(DM), Q6(DM) for wounds, 33(DM) Murphy sign, 71(GA) Muscle disorders. See Myopathies Muscle relaxants for achalasia, 4(GA) for irritable bowel syndrome, 42(GA) for low back pain, 52(GIM) for multiple sclerosis, 63(NR), 64(NR) for neck pain, 53(GIM) Muscle strength, impaired. See Weakness Muscle wasting, in chronic obstructive pulmonary disease, 19(PM) Muscular dystrophy, 76(NR) Musculoskeletal disorders in ankylosing spondylitis, 29t(RM) in inflammatory bowel disease-associated arthritis, 29t(RM) vs. peripheral arterial disease, 98t(CV) in psoriatic arthritis, 29t(RM) in Sjögren syndrome, 46t(RM) in systemic conditions, 5(RM), 6t(RM) in systemic lupus erythematosus, 35–36(RM), 38t(RM), 40(RM) Musculoskeletal examination, 1–2(RM) Musculoskeletal pain, 50–62(GIM) acute low back, 50–52(GIM), 51t(GIM), Q91(GIM) ankle and foot, 61–62(GIM), 61f(GIM), Q59(GIM) elbow, 56f(GIM), 56(GIM)
43
Cumulative Index
Musculoskeletal pain (continued) hip, 58f(GIM), 58(GIM) knee, 58–61(GIM), 59f(GIM), 60f(GIM) neck, 52–53(GIM), Q37(GIM), Q134(GIM) shoulder, 53–56(GIM), 54f(GIM), 54t(GIM), 55f(GIM) wrist and hand, 57(GIM) Mushroom poisoning, 65(GA), 67t(GA) Musician’s dystonia, 53(NR) Myalgia in brucellosis, 65(ID) in dengue fever, 64(ID) in influenza, 94(ID) in malaria, 61(ID), 62(ID) in systemic sclerosis, 43(RM) in viral hemorrhagic fever, 61(ID) Myasthenia gravis, 63(PM), 74(NR), Q44(NR) sleep-related hypoventilation syndromes in, 68t(PM) Myasthenic crisis, 74(PM) Myelodysplastic syndromes, 59–60(DM) Mycobacteria, rapidly growing, 38(ID) Mycobacterial infections as arthritis cause, 3(RM), 56(RM), 58(RM), 59(RM), Q50(RM) hypersensitivity pneumonitis and, 36t(PM) nontuberculous, 36–38(ID), 37t(ID) Mycobacterium avium complex infections, 37–38(ID), Q20(ID) in HIV/AIDS, 91(ID) prophylaxis for, 89(ID), 89t(ID) Mycobacterium kansasii infections, 38(ID) Mycobacterium marinum infections, 56(RM), Q50(RM) Mycobacterium tuberculosis infections, 5(NP), 46(NP), 66(NR). See also Tuberculosis as tuberculosis causal agent, 32(ID) Mycophenolate mofetil adverse effects of, 12(RM) contraindication in pregnancy, 80–81(NP) for immune (idiopathic) thrombocytopenic purpura, 49(HO) for kidney transplantation, 93t(NP) for systemic lupus erythematosus, 12(RM), 40(RM) use in transplant recipients, 72(ID), 73(ID) Mycoplasma genitalium infections, 43(ID) Mycoplasma pneumoniae infections, 19(ID), 23t(ID), 63(DM), 64(DM) Mycosis fungoides, 104(HO), Q99(HO) Myectomy, septal, for hypertrophic cardiomyopathy, 45(CV) Myelitis idiopathic transverse, 57(NR), 59(NR), 66(NR), 67f(NR) corticosteroid-resistant, 66(NR), Q9(NR) in multiple sclerosis, 58(NR), Q45(NR) in West Nile virus infections, Q19(ID) Myelodysplasia, 110(HO) in aplastic anemia, 2(HO) neutropenia in, 4(HO) thrombocytopenia in, 48(HO) Myelodysplastic syndromes, 5–6(HO), 5f(HO), 5t(HO), 6t(HO), Q49(HO) chemotherapy-related, Q131(HO) Myelofibrosis, primary, 9–10(HO), 9f(HO), Q1(HO) Myeloma. See Multiple myeloma Myeloma cast nephropathy, 74(NP) Myeloneuropathies. See Myelopathies Myelopathies, 64–67(NR) compressive, 65(NR), 66t(NR) noncompressive, 66–67(NR), Q96(NR) Myeloproliferative disorders, 6–13(HO) acute myeloid leukemia and, 10(HO) MYH-associated polyposis, 47(GA) colorectal cancer screening in, 51t(GA) Myocardial infarction anterior wall, 22–23(CV) atrial fibrillation in, 52–53(CV) chest pain in, 50(GIM) in chronic kidney disease, 86(NP) heart failure and, 26(CV), 31(CV) non-ST-elevation, 19–22(CV), 19f(CV) management of, 21f(CV), Q25(CV) as mortality cause, 29(CV) smoking cessation and, Q5(CV) treatment for, 20–22(CV), Q65(CV) in women, 29(CV) pericarditis after, 61(CV) perioperative, 125(GIM) risk factors for, Q48(CV) ST-elevation, 19–20(CV), 19f(CV), 22–28(CV) complications following, 26–27(CV) mimics of, 22(CV) as mortality cause, 29(CV) treatment for, 22–26(CV), 28(CV), Q38(CV), Q72(CV) in women, 29(CV) sulfonylureas and, 7(EN) in women, 2(CV), 29(CV) Myocardial ischemia chest pain in, 63t(CV) cocaine and, 90(PM) diabetic ketoacidosis in, 11–12(EN) echocardiography in, 64t(CV) electrocardiography in, 64t(CV) evaluation of, 32(CV) in heart failure, 32(CV) stress testing-provoked, 3(CV) Myocardial perfusion imaging, in women, 30(CV) Myocarditis acute, 40–41(CV) atrial fibrillation in, 52–53(CV) fulminant, 40(CV), 41(CV) giant cell, 41(CV) in influenza, 94(ID) in Lyme disease, 25(ID), 25t(ID), Q76(ID) nonfulminant, 41(CV) Myocardium, chemotherapy-related damage to, 104(CV), 105(CV) Myoclonic seizures, 15(NR) Myoclonus, 48t(NR), 54(NR) in atypical parkinsonism, 51(NR)
44
in Creutzfeldt-Jakob disease, 11(ID), 11t(ID), Q49(ID) differential diagnosis of, 55t(NR) posthypoxic, 54(NR), Q69(NR) Myoglobin, urine levels of, 4(NP) in pigment nephropathy, 70(NP) Myopathy, 75–77(NR) idiopathic inflammatory. See Inflammatory myopathies inflammatory, 76(NR) inflammatory. See Inflammatory myopathies inherited, 76(NR) statins and, 64(GIM), 66t(GIM) in systemic sclerosis, 43(RM) thyrotoxic, 76(NR) toxic, 77(NR), Q74(NR) vitamin D deficiency-associated, 76(NR) Myopericarditis, 65–66(CV), 65(CV), 65f(CV), Q96(CV), Q112(CV) Myositis inclusion body, 60(RM), Q71(RM) inflammatory, in systemic lupus erythematosus, 36(RM) in mixed connective tissue disease, 47t(RM) as paraneoplastic syndrome, 58(RM) statins and, 17(CV) Myotomy, laparoscopic, for achalasia, 3(GA), Q87(GA) Myxedema cutaneous, 61(DM) pretibial, 30(EN) Myxedema coma, 39–40(EN) Myxomas, 48(CV), Q27(CV) atrial, 63t(RM) N-Acetylcysteine, for chronic obstructive pulmonary disease, 25(PM), Q85(PM) Nadolol, for variceal bleeding, 63t(GA) Nail disorders in psoriatic arthritis, 4t(RM), 29t(RM), 30f(RM), 30(RM), 31(RM), Q62(RM) in systemic sclerosis, 4t(RM) Nails Beau lines of, 68(DM), 69f(DM) dermatomyositis of, 50(DM) fungal infections of, 68–69(DM), 69f(DM), 70t(DM) median dystrophy of, 69(DM), 69f(DM) Plummer, 61(DM) psoriasis of, 10(DM), 67–68(DM), 68f(DM) in thyroid disease, 61(DM) Naloxone, 73(PM), Q36(PM) for pruritus, 43(DM) Naltrexone, for pruritus, 43(DM) Naproxen, cardioprotective activity of, 10(RM) Naproxen sodium, for migraine, 7t(NR) Naratriptan, for migraine, 7t(NR) Narcotic bowel syndrome, 42(GA) NASH. See Nonalcoholic steatohepatitis Natalizumab for inflammatory bowel disease, 37f(GA), 37t(GA), 38(GA) or multiple sclerosis, 62–63(NR), 62t(NR), Q80(NR) Nateglinide, 8t(EN) National Asthma Education and Prevention Program guidelines, Q91(PM) National Cholesterol Education Program Adult Treatment Panel III (ATP III), 8(GIM), 62(GIM), 63(GIM), 63t(GIM), 64(GIM), 65(GIM), 69(GIM), Q151(GIM) National Committee for Quality Assurance (NCQA), 6(GIM) National Comprehensive Cancer Network, 9(GIM) National Institutes of Health Chronic Prostatitis Symptom Index, 80(GIM) HIV/AIDS management guidelines from, 92(ID) obesity screening guidelines from, 70(GIM) polycystic ovary syndrome definition from, 58(EN) primary hyperparathyroidism surgical treatment guideline from, 62(EN), 62t(EN) National Institutes of Health Stroke Scale, 24(NR), 25t(NR) National Kidney Foundation blood pressure target goal recommendation from, 39(NP), 43(NP), Q29(NP) hyperparathyroidism treatment guidelines from, 89(NP) urine albumin screening recommendation from, Q73(NP) National Kidney Foundation Kidney Disease Outcomes Quality Initiative, 2(NP), 6t(NP), Q73(NP) National Lung Cancer Screening Trial, 58(PM) National Osteoporosis Foundation osteopenia treatment recommendation from, 69(EN), Q10(EN) osteoporosis screening recommendation from, 67(EN), 69t(EN) osteoporosis treatment recommendation from, 71–72(EN), 71t(EN) National Prion Disease Pathology Surveillance Center, 11(ID) National Quality Forum, 26(GIM) Natriuretic peptide, B-type. See B-type natriuretic peptide Nausea, chronic, 32(GIM) Near drowning, acute respiratory distress syndrome and, 71t(PM) Nebulizers, for chronic obstructive pulmonary disease, 21(PM), 22t(PM) Neck pain, 52–53(GIM), Q37(GIM), Q134(GIM) in compressive myelopathy, 65(NR) in internal carotid artery dissection, 36(NR) in postconcussion syndrome, 12t(NR) in spinal cord disorders, 64(NR) in vertebral osteomyelitis, 52(ID) Necrobiosis, 60(DM) Necrosis acute tubular, 67–68(NP), 68f(NP), 69t(NP) hepatic, urobilinogen levels in, 5(NP) pancreatic, 24f(GA), 24(GA), 25f(GA) Nedocromil, for asthma, 13f(PM) Neer test, 54f, 54(GIM), 54t(GIM) Negative likelihood ratio (LR−), 5t(GIM) Negative predictive value (NPV), 4(GIM), 5t(GIM) Neisseria gonorrhoeae infections, 43–44(ID), 55(RM) treatment of, 45–46(ID), 45t(ID) Neisseria infections, primary immunodeficiency syndromes in, 55(ID) Neisseria meningitidis infections meningitis in, 2(ID), 2t(ID), 5t(ID), 6t(ID) neutropenia in, 4(HO) Neomycin, allergic reactions to, 33(DM) Neonatal lupus erythematosus, 40(RM) Neonatal-onset multisystem inflammatory disease, 74t(RM) Neonates, thrombocytopenia in, 63–64(HO) Neoplasms. See Cancer
Cumulative Index
Nephrectomy, for renal cell carcinoma, 96(HO), Q92(HO) Nephritic syndromes causes of, 56–62(NP), 56t(NP), 59t(NP) clinical manifestations of, 48–49(NP) in diabetic nephropathy, 53(NP) in hepatitis C-associated kidney disease, Q23(NP), Q24(NP) in postinfectious glomerulonephritis, Q60(NP) Nephritis hereditary (Alport syndrome), 64–65(NP), Q59(NP) interstitial acute, 5(NP), 70–71(NP), 71t(NP), Q15(NP), Q67(NP), Q80(NP) in Balkan nephropathy, Q68(NP) diagnosis of, 5(NP) hereditary, 45t(NP) in lithium toxicity, Q55(NP) nephrotoxins and, 85t(NP) in pregnancy, 80(NP) in systemic lupus erythematosus, 38(RM), 40(RM), Q10(RM) Nephrocalcinosis, in hypokalemic distal renal tubular acidosis, Q17(NP) Nephrogenic systemic fibrosis, 45(RM), 54(DM), Q47(DM) Nephrolithiasis. See Kidney stones Nephrons, 48(NP) Nephropathy analgesic, 45t(NP), 46–47(NP), Q68(NP) Balkan, Q68(NP) contrast-induced, 68–70(NP), 69t(NP), 70t(NP), 71(NP) diabetic, 15–16(EN), 53–54(NP), 54t(NP), Q71(NP), Q89(NP) post-kidney transplant, 93(NP) heavy metal-related, 45t(NP) HIV/AIDS-related, 55(NP) HIV-associated, 90(ID) hypertensive, Q68(NP) immunoglobulin A, 56–57(NP), 56t(NP), 69(RM), Q5(NP), Q16(NP), Q51(NP) post-kidney transplant, 93(NP) in pregnancy, Q14(NP) lead-related, 45t(NP), 47(NP) myeloma cast, 74(NP) phosphate-related, 71(NP) pigment, 70(NP) polyoma BK virus-related, 92(NP), Q72(NP) radiocontrast-related, 9(CV) Nephrotic syndromes, 1(NP) causes of, 49–53(NP), 50t(NP) focal segmental glomerulosclerosis, 49(NP), 50t(NP), 51(NP), Q16(NP) kidney-limited diseases, 49–53(NP), 50t(NP) membranous glomerulopathy, 51(NP), Q54(NP) systemic diseases, 53–56(NP), 54t(NP) clinical manifestations of, 48(NP), 49t(NP) Nephrotoxicity of immunosuppressive agents, 73(ID) of nonsteroidal anti-inflammatory drugs, Q70(HO) Nephrotoxins as acute tubular necrosis cause, 68(NP), 68t(NP), Q15(NP) avoidance in chronic kidney disease, 85(NP), 85t(NP), 86(NP) contrast media, 68–70(NP), 69t(NP), 70t(NP), 71(NP), 85(NP), 86(NP), 90(NP), Q19(NP), Q95(NP) nonsteroidal anti-inflammatory drugs, 46–47(NP), Q67(NP) Nerve ablation, for trigeminal neuralgia, 5(NR) Nesiritide, for cardiogenic shock, 39t(CV) Neuralgia postherpetic, 29(DM) trigeminal, 4–5(NR), Q95(NR) in multiple sclerosis, 63(NR) Neural tube defects, 87(GIM) efavirenz and, 93(ID) Neuraminidase inhibitors, for influenza, 95(ID) Neurilemmomas, Q56(PM) Neuritis, optic, 58(NR), 59(NR), 99(GIM), 100(GIM), Q29(NR) Neuroendocrine tumors gastrointestinal, 83–84(HO) pancreatic, 29–30(GA), 30f(GA) poorly differentiated, 105(HO) Neurofibrillary tangles, in Alzheimer disease, 44f(NR), 44(NR) Neurofibromas, 40(DM), 40f(DM) Neuroleptic malignant syndrome, 56(NR), 87(PM), Q64(NR), Q67(PM) Neuroleptics for Alzheimer disease, 45(NR) as movement disorder cause, 54(NR) for tics, 55(NR) Neurologic disorders in hypertension, 34–35(NP) in mixed connective tissue disease, 47t(RM), 48(RM) perioperative management of, 134(GIM) in rheumatoid arthritis, 19t(RM) in Sjögren syndrome, 46t(RM) in systemic lupus erythematosus, 36–37(RM), 37t(RM), 38(RM), 38t(RM) Neurologic reflexes, primitive, in dementia, 42(NR) Neuroma, Morton, 62(GIM), Q84(GIM) Neuromuscular blockade, for acute respiratory distress syndrome, 71t(PM), 72(PM) Neuromuscular disorders, 68–77(NR) amyotrophic lateral sclerosis, 73–74(NR) differential diagnosis of, 69t(NR) myopathies, 75–77(NR) neuromuscular junction disorders, 74–75(NR) peripheral neuropathies, 67–73(NR) signs and symptoms of, 69t(NR) sleep-related hypoventilation syndromes in, 68(PM), 68t(PM) Neuromuscular junction disorders, 74–74(NR) Neuromuscular weakness, respiratory complications of, 73–74(PM), 73t(PM), Q11(PM), Q59(PM), Q102(PM) Neuromyelitis optica, 57(NR), 66(NR) Neuronitis, vestibular, 41(GIM), 43(GIM), Q14(GIM) Neuro-oncology. See Brain tumors Neuropathic leg ulcers, 72(DM), 74(DM), 74f(DM), Q60(DM) Neuropathic pain, 34t(GIM), 35(GIM), Q136(GIM) in Fabry disease, 65(NP) in multiple sclerosis, 63(NR), 63t(NR) in spinal cord disorders, 64–65(NR) treatment of, 73(NR)
Neuropathy diabetic, 16(EN), 17(ID), Q67(EN) peripheral, isoniazid and, 34(ID) sensory, vs. peripheral arterial disease, 98t(CV) Neuropsychiatric disorders, after critical illness, 93(PM), 94(PM), Q3(PM) Neuropsychological evaluations, of dementia, 41–42(NR) Neurostimulation, for epilepsy, 21(NR) Neurosurgery bacterial meningitis after, 2(ID), Q96(ID) brain abscess after, 7t(ID) Neurosyphilis, 47(ID), 47t(ID) Neutropenia in acute myeloid leukemia, 11(HO) cancer treatment-related, 109–110(HO) febrile, Q124(HO) mild congenital, 4(HO), Q57(HO) in myelodysplastic syndromes, 5(HO) Neutropenia, in fever, 53(ID) Neutrophilia, 5(PM) Neutrophilic dermatoses, 58(DM), 59t(DM), 60(DM) Neutrophils, in pleural effusion, 44(PM) Nevi dysplastic, 39–40(DM), 39f(DM) halo, 40(DM), 40f(DM) melanocytic, 39(DM), 40(DM) New York Heart Association functional classification, of heart failure, 31(CV), 31t(CV), 32(CV), 34(CV), 36(CV), 36t(CV), 37(CV), 70(CV), Q24(CV), Q54(CV) in pregnancy, 106–107(CV) Niacin, 66(GIM) Nicardipine for hypertension, in stroke, 32(NR), 33(NR) for hypertensive crises, 86t(PM) Nicotine, effect on esophageal sphincters, 7(GA) Nicotinic acid, 65t(GIM), 66(GIM), 67(GIM) contraindication in fatty liver disease, Q45(EN) Nifedipine for kidney stones, 76(NP), 77(NP) in pregnancy, 79t(NP) Nikolsky sign, 46t(DM), 63(DM) Nilotinib, for chronic myeloid leukemia, 9(HO) Nimodipine, for reversible cerebral vasoconstriction syndrome, 3(NR), 4(NR) Nipah virus, 56(ID) Nissen fundoplication, 3(GA) Nitazoxanide for cryptosporidiosis, 72(ID) for giardiasis, 71(ID) Nitrates for achalasia, 4(GA) for acute coronary syndromes, 20(CV) for angina, 14(CV), 16(CV), 17(CV), 20(CV), Q70(CV) contraindication to, 20(CV) for peripartum cardiomyopathy, 107(CV) in pregnancy, 109t(CV) for ST-elevation myocardial infarction, 23(CV), 25(CV) Nitric oxide for chronic obstructive pulmonary disease, 25(PM) exhaled, measurement of, in asthma, 8(PM) Nitrites, urine levels of, 4–5(NP), 4t(NP) Nitrofurantoin, pulmonary toxicity of, 37(PM) Nitrofurantoin monohydrate macrocrystals, for cystitis, 30(ID), 30t(ID), Q36(ID) Nitroglycerin for acute coronary syndromes, 20(CV) for cardiogenic shock, 39t(CV) contraindication in ischemic stroke, 30(NR) for ST-elevation myocardial infarction, 23(CV), 25(CV) Nitroprusside contraindication in ischemic stroke, 30(NR) cyanide toxicity of, 90(PM) for hypertensive crises, 86t(PM) Nitroprusside assay, for ketones, 25(NP) Noble test, 60(GIM) Nocardiosis, in transplant recipients, 74(ID), 75(ID) Nodes Bouchard, 22f(RM), 22(RM) Heberden, 22f(RM), 22(RM) Nodules prurigo, 5(DM), 20–21(DM), 61(DM) pulmonary, Q81(HO) calcified, 56(PM), Q6(PM) ground-glass opacity, 57f(PM), 57(PM), Q64(PM), Q99(PM) imaging of, 4(PM), 5(PM), 56–57(PM), 56f(PM), 57f(PM) incidental, Q81(HO) malignancy risk evaluation of, 55–56(PM), 56t(PM), Q6(PM), Q27(PM) management of, 56–57(PM) of metastatic origin, 56(PM), 63f(PM), 63(PM), Q84(PM) in Mycobacterium avium complex infections, Q20(ID) rheumatoid arthritis and, 35(PM) spiculated, 55–56(PM), 56f(PM) rheumatoid, 18(RM), 19f(RM), 53(DM) thyroid, 35–37(EN), 35f(EN), 35t(EN), Q43(EN) benign, 35(EN), 35t(EN), 36(EN), 36t(EN) Bethesda classification of, 36(EN) fine-needle aspiration biopsy of, 35f(EN), 36(EN), 37(EN), 43(EN), Q20(EN), Q34(EN) malignant, 35(EN), 35t(EN), 36–37(EN), 36t(EN), Q34(EN) of Wegener granulomatosis, 67f(RM) Nonalcoholic fatty liver disease, 58–59(GA) Nonalcoholic steatohepatitis, 58–59(GA), Q2(GA) Noninvasive positive pressure ventilation (NPPV), 78–79(PM) for acute respiratory failure, 79(PM), Q18(PM) for chronic obstructive pulmonary disease, 26–27(PM), 27t(PM), 29(PM), Q61(PM) contraindications to, 79t(PM), Q18(PM) definition of, 78(PM) indications for, 78–79(PM) for invasive mechanical ventilation weaning, 81(PM), Q2(PM) patient selection for, 79(PM) Nonnucleoside analogue reverse transcriptase inhibitors, 93(ID), 93t(ID) Nonsteroidal anti-inflammatory drugs (NSAIDs), 29f(GIM), 29(GIM), 35(GIM) for abnormal uterine bleeding, 90(GIM) for acromioclavicular joint degeneration, 56(GIM)
45
Cumulative Index
Nonsteroidal anti-inflammatory drugs (NSAIDs) (continued) acute interstitial nephritis and, 5(NP) for adhesive capsulitis, 56(GIM) adverse effects of, 9–10(RM), 10t(RM), 11(RM), Q23(RM) for ankle pain, 61(GIM) asthma and, 11(PM) for basic calcium phosphate deposition disease, 54(RM) for cancer pain, 29(GIM), Q65(GIM) for chronic pain, Q117(GIM) colitis and, 36(GA), Q89(GA) for colorectal cancer, 52(GA), Q6(GA) contraindication in hemophilia, 45(HO) for dysmenorrhea, 91(GIM), Q131(GIM) for elbow pain, 56(GIM) enteric-coated, 16(GA) esophagitis and, 6(GA) for foot pain, 62(GIM) gastrointestinal toxicity of, 15–17(GA), 16f(GA), Q43(GA) for gout, 51(RM), 52(RM) hepatoxicity of, 70(GA) hyperkalemia and, Q44(NP) hypertension and, 34t(NP) for knee pain, 60(GIM) for low back pain, 52(GIM) membranous glomerulopathy and, 51(NP) microscopic colitis and, 39t(GA) for migraine, 6(NR), 7(NR), 7t(NR) in pregnancy, 8(NR) minimal change glomerulopathy and, Q78(NP) for mixed connective tissue disease, 48(RM) for neck pain, 53(GIM) nephrotoxicity of, 46–47(NP), 133(GIM), Q67(NP), Q70(HO) for osteoarthritis, 25(RM) overuse of, as migraine cause, 6(NR) for pelvic pain, 80(GIM), 81(GIM), 91(GIM) peptic ulcer disease and, 12–13(GA), 15–16(GA), 17(GA), 76–77(GA) for pericarditis, 66(CV), 66t(CV), 67t(CV) platelet function effects of, 52(HO), 53(HO) prerenal azotemia and, Q67(NP) for pseudogout, 53(RM), 54(RM), Q92(RM) for reactive arthritis, 34(RM) for rheumatic disease, 9–10(RM) for rheumatoid arthritis, 20(RM) for rotator cuff disorders, 55(GIM) for sarcoidosis, 75(RM) skin eruptions due to, 14(DM), 16(DM), 44(DM), 52–53(DM) for spondyloarthritis, 33(RM), 34(RM), Q21(RM) for systemic lupus erythematosus, 40(RM) toxic shock syndrome and, 16(ID) tubular toxicity of, 68t(NP), 69t(NP) use in elderly patients, 35(GIM) for wrist and hand pain, 57(GIM) Noonan syndrome, 88(CV) Norepinephrine for cardiogenic shock, 39t(CV) clinical use and physiologic effects of, 77t(PM) in hypoglycemia, 13–14(EN) Norfloxacin for spontaneous bacterial peritonitis, 63(GA) for travelers’ diarrhea, 63t(ID) for variceal bleeding, 62t(GA) Noroviruses, 71(ID) Nortriptyline, for neuropathic pain, 73(NR) Nosebleed, 105(GIM) Nosocomial infections. See Hospital-acquired infections Notalgia paresthetica, 43(DM) NPH. See Insulin, neutral protamine Hagedorn NSAIDs. See Nonsteroidal anti-inflammatory drugs (NSAIDs) Nuclear bone scans, in Paget disease of bone, 73(EN), 73f(EN) Nuclear perfusion studies dobutamine, 5t(CV) single-photon emission computed tomography, 4t(CV), 7(CV), 7f(CV), 7t(CV) for stress testing, 6(CV), 7t(CV), Q115(CV) vasodilator, 5t(CV) Nucleic acid amplification tests for Chlamydia trachomatis, 43(ID), 44(ID) for disseminated gonococcal infections, Q29(ID) for lymphogranuloma venereum, 48(ID) for tuberculosis, 34(DI) Nucleoside analogue reverse transcriptase inhibitors, 93(ID), 93t(ID) Number needed to harm (NNH), 3t(GIM), 4(GIM) Number needed to treat (NNT), 3–4(GIM), 3t(GIM), Q58(GIM) Numbness, in neuromuscular disorders, 69t(NR) Nummular dermatitis/eczema, 7(DM), 8f(DM), 14(DM) Nutrition, in critical care patients, 93(PM), Q90(PM) in burn victims, 93t(PM), Q48(PM) Nutritional deficiencies, after bariatric surgery, 22(GA), 22t(GA) Obesity, 69–74(GIM) adverse health effects of, 70(GIM), 74(GIM), Q57(GIM) bariatric surgery for, 20–23(GA), 21t(GA), 73–74(GIM), 73f(GIM), 73(GIM), 74t(GIM), Q15(GIM), Q150(GIM) complications of, 20–23(GA), 21t(GA), Q47(GA), Q67(GA) for diabetes mellitus, 4t(EN), 7(EN) malabsorptive procedures in, 20t(GA), 21–22(GA) restrictive procedures in, 20t(GA), 21(GA) Roux-en-Y procedure in, 20(GA), 20t(GA), 21–22(GA), 21f(GA) B-type natriuretic peptide in, Q11(CV) central in Cushing syndrome, 44f(EN), Q6(EN) as metabolic syndrome component, 3(EN) childhood diabetes mellitus and, 3(EN) gestational diabetes and, Q73(EN) colorectal cancer and, 46(GA), 48(GA) coronary artery disease and, 12t(CV) definition of, 69–70(GIM), 70t(GIM) diabetes mellitus and, 2(EN), 2t(EN) in children, 3(EN) surgical treatment of, 4t(EN), 7(EN)
46
end-stage liver disease and, 66–67(GA) epidemiology of, 69(GIM) erectile dysfunction in, 74(GIM) as esophageal cancer risk factor, 82(HO) evaluation of, 70(GIM) gastroesophageal reflux disease in, 7(GA) heart failure and, Q11(CV) hypertension and, 39(NP) hyperuricemia and, 48(RM) idiopathic intracranial hypertension in, 4(NR) kidney stones and, 74(NP) male hypogonadism and, Q33(EN) in metabolic syndrome, 13(CV), 58(GA), Q2(GA) obstructive sleep apnea and, 65(PM) as osteoarthritis risk factor, 22(RM), Q8(RM) as pancreatic cancer risk factor, 81(HO) screening for, 7t(GIM), 8(GIM), 70(GIM) skin disease in, 10(DM), 60(DM) treatment of, 71–74(GIM), 71f(GIM), 73f(GIM), 74t(GIM), Q51(GIM), Q150(GIM) Obesity hypoventilation syndrome, 68(PM), 68t(PM), Q69(PM) Obscure gastrointestinal bleeding, 78(GA), 79–81(GA), 79t(GA), Q36(GA), Q65(GA) Observational studies, 1–3(GIM), 2t(GIM) Obsessive-compulsive disorder, 55(NR), 111–112(GIM), 113(GIM), Q3(GIM) Obstructive acute kidney injury, 67(NP), 72(NP), Q106(NP) Obstructive lung disease invasive mechanical ventilation for, 81(PM), 82(PM) noninvasive positive pressure ventilation for, 78(PM) respiratory failure in, 75–76(PM) Obstructive sleep apnea, 65–66(PM) central sleep apnea and, 67(PM) diagnosis of, 65(PM) idiopathic interstitial pneumonia and, 33(PM) obesity hypoventilation syndrome and, 68(PM), Q69(PM) pathophysiology of, 65(PM) perioperative management of, 128–129(GIM), 129t(GIM), Q121(GIM) risk factors for, 65(PM) treatment of, 65–66(PM), 67(PM), 78(PM), Q21(PM) Obstructive uropathy, 47(NP) Occult fecal blood test, for colorectal cancer, 48–49(GA), 49t(GA), Q31(GA) Occupational lung disease, 39–42(PM), Q24(PM), Q50(PM) categories of, 39(PM) chronic obstructive pulmonary disease, 17(PM), 18t(PM) diffuse parenchymal lung disease, 30(PM) exposure history in, 39–40(PM), 40t(PM) management of, 40(PM) surveillance of, 40(PM) Occupational Safety and Health Administration (OSHA), 40(PM) Octreotide for acromegaly, 25(EN), Q83(EN) for metabolic alkalosis, Q9(NP) for prolactinomas, 25(EN) for variceal bleeding, 62t(GA) Octreotide scanning, Q70(EN) Odds ratio, 3(GIM) Odynophagia, 3(GA) Ofloxacin, for travelers’ diarrhea, 63t(ID) Ohio Valley fever. See Histoplasmosis Oil drop sign, of nail disorders, 67(DM) Oil of wintergreen, toxicity of, Q57(NP) Ointments, corticosteroid, 67(DM) Older adults anemia of kidney disease in, Q36(HO) apathetic hyperthyroidism in, 29(EN) bladder cancer in, Q111(HO) high-dose inhaled corticosteroid therapy in, 14(PM) myelodysplastic syndromes in, Q49(HO) prostate cancer in, Q84(HO) sulfonylureas’ effects on, 7(EN), 14(EN), Q53(EN), Q65(EN) thyroid function studies in, Q56(EN) vitamin B12 deficiency in, Q28(HO) Olecranon bursitis, 56(GIM), Q132(GIM) Oligoarthritis, 2Q8(RM), 22(RM) Oligodendrogliomas, 78(NR), 78t(NR) Oligomenorrhea in hyperprolactinemia, 24(EN), Q7(EN) in polycystic ovary syndrome, 58(EN) Oliguria in postinfectious glomerulonephritis, 59(NP), 60(NP), Q60(NP) in rapidly progressive glomerulonephritis, Q83(NP) Olivopontocerebellar atrophy, 52(NR) Olsalazine, for inflammatory bowel disease, 37t(GA) Omalizumab, for asthma, 13f(PM), 14(PM), Q73(PM) Omega-3 fatty acids, 65t(GIM) Omeprazole, acute interstitial nephritis and, Q15(NP) Oncology. See Cancer Oncotype DX® assay, for breast cancer treatment, 67(HO) Onychogryphosis, 69–70(DM) Onycholysis, 67(DM), 68f(DM) in psoriatic arthritis, 4t(RM), 29t(RM), 30(RM) Onychomycosis, 12(DM), 69(DM), 69f(DM), 70t(DM), 75(DM), Q18(DM), Q21(DM) Ophthalmopathy, Graves, 30(EN), 31(EN), Q8(EN) as contraindication to radioactive iodine treatment, 31(EN) Opiates central sleep apnea and, 67(PM) hyperprolactinemia and, 22(EN) hypogonadism and, Q38(EN) for sickle cell anemia, in pregnancy, 63(HO) Opioid analgesics, 29–30(GIM), 29f(GIM), 31t(GIM), 34t(GIM), 35–36(GIM) abuse of, 30(GIM), 35(GIM), 36(GIM), Q152(GIM) for cancer pain, 29–30(GIM), 31t(GIM), Q19(GIM), Q65(GIM) for chronic neuropathic pain, 34t(GIM), 35(GIM), Q136(GIM) for chronic noncancer pain, 34t(GIM), 35–36(GIM) constipation and, 30(GIM), Q90(GA) for dyspnea, Q58(PM) hepatoxicity of, 70(GA) for low back pain, 52(GIM) for migraine, 6(NR) for neck pain, 53(GIM) for neuropathic pain, 73(NR)
Cumulative Index
for osteoarthritis, 25(RM) respiratory depression and, 73(PM) toxic syndromes of, 88t(PM), Q36(PM) Opioid withdrawal, 73(PM) Opsoclonus-myoclonus, 80t(NR) Optic chiasm, pituitary tumor compression of, 21(EN), 26(EN), Q7(EN) Optic nerve fenestration, for idiopathic intracranial hypertension, 4(NR) Optic neuritis, 58(NR), Q29(NR) Oral cancer, 10(GIM), 88(HO), 105(GIM) screening for, 106(GIM) Oral contraceptives, 84(GIM), 85t(GIM) for abnormal uterine bleeding, 90(GIM) for acne, 20t(DM), 21(DM) as breast cancer risk factor, 75(HO) Budd-Chiari syndrome and, 70(GA) as cervical cancer risk factor, 78(HO) contraindication for breast cancer survivors, 74(HO) for dysmenorrhea, 90–91(GIM) as erythema nodosum cause, 55(DM), 56(DM), Q11(DM) factor V Leiden and, 53(HO) hepatic adenomas and, 67(GA), 68(GA) for hirsutism, in polycystic ovary syndrome, 58(EN), Q82(EN) hypertension and, 34t(NP) interaction with anticonvulsants, 21(NR), Q32(NR) migraine and, 8(NR), 9(NR) as ovarian cancer preventive, 75(HO) as stroke risk factor, 8(NR) in systemic lupus erythematosus, 40(RM), Q82(RM) von Willebrand disease and, Q21(HO) Oral examination, 70(DM) Oral glucose tolerance tests for acromegaly, 25(EN) for type 2 diabetes mellitus, Q24(EN) Oral hairy leukoplakia, 71(DM), 71f(DM) Oral health, 105–106(GIM) Oral hypoglycemic agents, 7(EN) Oral infections, 106(GIM) Oral melanotic macules, 70(DM) Oral ulcers, 106(GIM) Orchiectomy, radical, for testicular cancer, 93–94(HO), Q133(HO) Orchitis, 78–79(GIM) Organ transplant recipients dermatologic disease in, 1(DM), 2(DM) skin cancer in, 1(DM), 54(DM), Q23(DM) Orgasmic disorder, 82(GIM) Orlistat, 72–73(GIM) for type 2 diabetes mellitus, 4t(EN), 8t(EN) Oropharyngeal dysphagia, 1–2(GA), 1t(GA), 2(GA), 3(GA), Q79(GA) Oropharyngeal weakness, 74(PM) Oroya fever, as hemolytic anemia cause, 35(HO) Orthodeoxia-platypnea syndrome, 85(CV), 86t(CV) Orthopedic hardware, osteomyelitis and, 50(ID), 51(ID) ORYX initiative, 20(GIM) Oseltamivir, 95(ID) Osler-Weber-Rendu disease, 74(GA) Osmolal gap, urinary, 27(NP), Q7(NP), Q57(NP) Osmolality effective, 10(NP) of plasma, 10(NP) in hyponatremia, 10(NP), 11–12(NP), 11f(NP) in pregnancy, 78(NP) in toxic ingestions, Q7(NP) of urine in diabetes insipidus, 16(NP), 16t(NP), 20–21(EN), Q26(NP) in hypernatremia, 16(NP), 16t(NP) in hyponatremia, 12–13(NP) relationship with urine specific gravity, 4t(NP) Osmometers, 10(NP) Osmotic demyelination syndrome, 14(NP), Q37(NP) Osteitis fibrosis cystica, 88(NP) Osteoarthritis, 22–26(RM) calcium pyrophosphate deposition disease and, 53(RM) classification of, 22–24(RM) clinical features of, 22(RM) diagnosis of, 24(RM), Q3(RM) differential diagnosis of, 24(RM) erosive, 23(RM), 24(RM) evaluation of, 9(RM) genetic factors in, 22(RM) of the hand, 22f(RM), 22(RM), 23(RM), 24(RM), 57(GIM), Q47(RM) of the hip, 58(GIM) imaging studies in, 24(RM) of the knee, 22(RM), 23f(RM), 24(RM), 25(RM), 58(GIM), 59, Q3(RM), Q8(RM), Q13(RM), Q37(RM) management of, 24–26(RM) intra-articular injections in, 25(RM) nonpharmacologic interventions in, 24–25(RM) pharmacologic therapy in, 25(RM), Q23(RM) surgical interventions in, 25–26(RM) pathophysiology of, 22(RM) vs. peripheral arterial disease, 98t(CV) primary, 23(RM), 24(RM) vs. psoriatic arthritis, 1(RM) radiographic findings in, 8t(RM), 9(RM) risk factors for, 22(RM) secondary, 23(RM), 24(RM), Q19(RM) septic arthritis and, 54(RM) Osteodystrophy, renal, 88(NP), Q22(NP) Osteogenesis imperfecta, 73(RM) Osteomalacia, 69(GA), 72(EN), 88(NP) in nephrotic syndrome, 49t(NP) oncogenic, Q50(NP) Osteomyelitis, 49–52(ID) animal bites and, 16(ID) classification of, 49(ID) clinical manifestations of, 49(ID) in diabetic foot infections, 18(ID), 51(ID), Q53(ID) diagnosis of, 50(ID), Q39(ID) hyperbaric oxygen therapy for, 101–102(ID)
pathophysiology of, 49(ID) spinal, Q36(RM) treatment of, 50–51(ID), 101–102(ID) vertebral, 51–52(ID) Osteonecrosis bisphosphonate-related, 15(HO) of the jaw, 75(HO) of the hip, 58(GIM), Q116(GIM) in systemic lupus erythematosus, 36(RM) Osteopenia, 69(GA) in HIV/AIDS, 90(ID) hyperprolactinemia and, 23(EN) in older adults, 66(EN) treatment of, 71t(EN), Q10(EN) Osteophytes in diffuse idiopathic skeletal hyperostosis, Q57(RM) in knee osteoarthritis, Q37(RM) Osteoporosis, 69(GA), 70(GA) anticonvulsant-related, 16(NR) breast cancer therapy-related, 74(HO) in chronic kidney disease, 88(NP) corticosteroid-related, 10(RM), 11(RM), Q56(RM) in Cushing syndrome, 43(EN) epidemiology of, 66–67(EN) evaluation of, 67–69(EN), 68f(EN), 69t(EN) in HIV/AIDS, 90(ID) hyperprolactinemia and, 23(EN) idiopathic, 69(EN) in men, Q59(EN) in monoclonal gammopathy of undetermined significance, 16(HO) physiology of, 66–67(EN) prevention of, 69–72(EN), Q10(EN) screening for, 7t(GIM), 8(GIM), 9(GIM), 67(EN), 69t(EN) secondary, Q59(EN) in systemic lupus erythematosus, 36(RM), 41(RM) Ostium primum atrial septal defects, 84(CV), 85(CV), 86t(CV), Q41(CV) Ostium secundum atrial septal defects, 84(CV), 86t(CV), Q14(CV), Q101(CV) Otitis externa, 102–103(GIM), Q163(GIM) Otitis media, 102(GIM) brain abscess and, 7t(ID) Ottawa ankle and foot rules, 61f(GIM), 61(GIM) Outcome measures, of healthcare, 5–6(GIM) Outpatient antimicrobial therapy, 101(ID) Ovarian cancer, 10(GIM), 75–78(HO) BRCA gene mutations in, 70(HO), 75(HO), Q138(HO) as cancer of unknown primary site, Q141(HO) diagnosis of, 76(HO), Q100(HO) epidemiology of, 75(HO) genetic factors in, 75(HO) hyperandrogenism in, Q62(EN) monitoring and follow-up in, 77(HO), Q107(HO) Peutz-Jeghers syndrome and, 47–48(GA) polymyositis and, 62(RM) presenting as peritoneal carcinomatosis, 105(HO) prognosis of, 76t(HO) quality of life in, 77(HO) recurrent, 77(HO), Q107(HO) in remission, Q107(HO) risk factors for, 75(HO) risk reduction for, 75(HO), 76(HO) screening for, 75–76(HO) staging of, 76t(HO) supportive care in, 77(HO) survival rate in, 76t(HO) treatment of, 76t(HO), Q121(HO) chemotherapy in, 77(HO), 78(HO) second-look surgery in, 77(HO) tumor debulking surgery in, 76–77(HO), 78(HO) Overdiagnosis, 7(GIM) Overdose antidotes for, 89t(PM), 90(PM), 91t(PM) coingestions in, 88(PM), 90(PM) of drugs of abuse, 90(PM) respiratory failure in, 73(PM) of therapeutic drugs, 90(PM), 91t(PM) Oversedation, 92–93(PM) Over-the-counter medications hypertension and, Q82(NP) nephrotoxicity of, 85(NP), 85t(NP), 86(NP) Overuse injuries/syndromes, 1–2(RM), 2t(RM), 22(RM), Q59(RM) of the knee, 59–60(GIM) Overweight, 70t(GIM) Oxaliplatin for colorectal cancer, Q115(HO) for pancreatic cancer, 82(HO) Oxazolidinones, 98t(ID), 99(ID) Oxcarbazepine adverse effects of, 19t(NR), 20t(NR), 21(NR), Q85(NR) interaction with hormonal contraceptives, 21(NR) teratogenicity of, 21(NR) Oxycodone, 30(GIM), 31t(GIM) Oxygen saturation in chronic obstructive pulmonary disease, Q68(PM) pulse oximetry measurement of, 3(PM) falsely-elevated, Q57(PM) Oxygen therapy for chronic obstructive pulmonary disease, 21(PM), 26(PM), 28(PM), Q5(PM), Q63(PM), Q68(PM) for cluster headache, 10(NR), Q19(NR) for high-altitude-related illnesses, 69(PM) for pneumothorax, 46(PM) for respiratory acidosis, 32(NP) for sepsis, 83(PM) for ST-elevation myocardial infarction, 23(CV) Oxyhemoglobin saturation in hypoxemic respiratory failure, 70(PM) in inhalational injuries, 84–85(PM) Pacemakers, electronic, 36(CV), 36t(CV) for atrial fibrillation, 54(CV) biventricular, 61(CV)
47
Cumulative Index
Pacemakers, electronic (continued) electrocautery-related inhibition of, 50(CV), 61(CV) for heart block, 50t(CV) for hypertrophic cardiomyopathy, 43(CV) infection of, 61(CV), Q21(CV) for restrictive cardiomyopathy, 47(CV) Packed red blood cell transfusions, 37(HO) Paclitaxel cardiotoxicity of, 104t(CV) for melanoma, 107(HO) Paget disease of bone, 72–73(EN), 73f(EN), Q30(EN) of the breast, 59t(DM) extramammary, 59t(DM) Pain abdominal, 90(PM), 92(PM), 92t(PM) in Campylobacter infections, 67(ID) in Clostridium difficile diarrhea, 70(ID) in diabetic ketoacidosis, Q58(EN) in Escherichia coli diarrhea, 68(ID) in malaria, 61(ID), 62(ID) in pelvic inflammatory disease, 44(ID), Q26(ID) in salmonellosis, 67(ID) in typhoid fever, Q75(ID) in acute cholecystitis, 71(GA) in acute pancreatitis, 23(GA) in ankylosing spondylitis, 31(RM) in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) back in ankylosing spondylitis, 29(RM), 31(RM), 32t(RM) in spondyloarthritis, 31–32(RM), Q69(RM) in vertebral osteomyelitis, 52(ID) in bladder cancer, 94(HO) cancer, 29–30(GIM), 31t(GIM), Q19(GIM), Q65(GIM) chest, 47–49(GIM), 47–50(GIM) acute, evaluation of, Q50(CV) in acute pulmonary embolism, 63t(CV) anginal. See Angina pectoris in anthrax, 57(ID), 58(ID) in aortic dissection, 63t(CV) in aortic syndromes, 95(CV), 96(CV) cardiovascular causes of, 48–50(GIM), 48t(GIM), Q101(GIM) cocaine and, Q88(PM) differential diagnosis of, 47–49(GIM), 63t(CV) in esophageal disorders, 9(GA) gastrointestinal causes of, 49(GIM) hospitalization for, 49–50(GIM) ischemic, 19–20(CV), 63t(CV) in lung cancer, 58(PM), 84(HO), 87(HO) mediastinal masses and, 63(PM) misdiagnosis of, 47(GIM) musculoskeletal causes of, 49(GIM), Q130(GIM) in myopericarditis, Q112(CV) nonanginal, 15t(CV) noncardiac, 9(GA), Q57(GA) in pericarditis, 61(CV), 63t(CV) pleuritic, 49(GIM), 50(GIM), Q104(GIM) pulmonary causes of, 49(GIM) in pulmonary embolism, 63t(CV), Q50(CV) in supraventricular tachycardia, 55(CV) typical, 15t(CV) in women, Q28(CV) chronic in elderly patients, Q144(GIM) noncancer, 33–36(GIM), 34t(GIM), Q117(GIM) in chronic pancreatitis, 25(GA), 26(GA) in critical care patients, 92(PM), 94(PM) in diabetic neuropathy, 16(EN), Q67(EN) in epididymis-orchitis, 44(IDI), 45(ID) in esophageal disorders, 3(GA) in fibromyalgia, 26–27(RM), 27t, 27t(RM) flank in pyelonephritis, 31(ID) in urinary tract infections, 29(ID), 30(ID) in gastroesophageal reflux disease, 9(GA) groin, 58(GIM) in headache, 1(NR) in irritable bowel syndrome, 41–42(GA) joint, 1(RM), 2(RM) inflammatory vs. noninflammatory, 1(RM), 1t(RM) in osteoarthritis, 22(RM) kidney stones and, 75(NP), 76(NP) in mesenteric ischemia, 44(GA), Q7(GA), Q94(GA) musculoskeletal, 50–62(GIM) acute low back, 50–52(GIM), 51t(GIM), Q91(GIM) ankle and foot, 61–62(GIM), 61f(GIM), Q59(GIM) elbow, 56f(GIM), 56(GIM) hip, 58f(GIM), 58(GIM) knee, 58–61(GIM), 59f(GIM), 60f(GIM) neck, 52–53(GIM), Q37(GIM), Q134(GIM) shoulder, 53–56(GIM), 54f(GIM), 54t(GIM), 55f(GIM) wrist and hand, 57(GIM) neck, 52–53(GIM), Q37(GIM), Q134(GIM) in compressive myelopathy, 65(NR) in internal carotid artery dissection, 36(NR) in postconcussion syndrome, 12t(NR) in spinal cord disorders, 64(NR) in vertebral osteomyelitis, 52(ID) in necrotizing fasciitis, 14(ID), 15(ID) neuropathic, 34t(GIM), 35(GIM), Q136(GIM) in Fabry disease, 65(NP) in multiple sclerosis, 63(NR), 63t(NR) in spinal cord disorders, 64–65(NR) treatment of, 73(NR) palliative care management of, 29–30(GIM), 29f(GIM), 31t(GIM) pelvic in men, 80–81(GIM) in pelvic inflammatory disease, 44(ID), Q26(ID)
48
in women, 91–92(GIM), 91t(GIM), Q135(GIM) in peripheral arterial disease, 98(CV), 100(CV) retro-orbital pain, in dengue fever, 64(ID), Q55(ID) scrotal, 78–79(GIM) in sickle cell disease, 29–30(HO), 63(HO), Q42(HO), Q50(HO), Q52(HO), Q72(HO) in spinal cord compression, 108(HO) testicular, 78–79(GIM) in testicular cancer, 93(HO) wrist, 57(GIM) Pain assessment scales, 92(PM) Pain contracts, 36(GIM) Palliative treatment, 27–32(GIM) assessment and communication in, 29(GIM), Q36(GIM), Q89(GIM) for bladder cancer, 95(HO) for breast cancer, 75(HO) for cancer, 68(HO) hospice, 28–29(GIM) for lung cancer, 61(PM) nonhospice, 28(GIM), 29(GIM), Q76(GIM) for renal cell carcinoma, 96(HO) symptom management in, 29–32(GIM) Palpation, for joint pain evaluation, 1(RM), 2(RM) Palpitations in atrial fibrillation, 52(CV) evaluation of, 51(CV), Q33(CV) in supraventricular tachycardia, 55(CV) in ventricular tachycardia, 57(CV) Palsy, progressive supranuclear, 49(NR), 51(NR), Q76(NR) Pamidronate for hypercalcemia, 63(EN) for osteogenesis imperfecta, 73(RM) Pancoast tumors, 84–85(HO) Pancreas disorders of, 23–30(GA) sausage-shaped, 28f(GA), 28(GA) Pancreatectomy, for chronic pancreatitis, 26(GA) Pancreatic adenocarcinoma, 26–27(GA), 27f(GA), 27t(GA) Pancreatic autoantibodies, in type 1 diabetes mellitus, 2(EN), Q11(EN) Pancreatic cancer, 10(GIM), 81–82(HO) chemotherapy for, 67(HO) diagnosis of, Q74(GA) neuroendocrine tumors, 83(HO), 84(HO) Peutz-Jeghers syndrome and, 47–48(GA) Pancreatic cystic neoplasms, 28–29(GA), 28f(GA), 29t(GA) Pancreatic cysts, 28(GA), 29(GA) Pancreatic duct imaging of, 25(GA) leaks from, 24(GA) obstruction of, 26f(GA), 26(GA) papillary mucinous neoplasms of, 26(GA) Pancreatic enzyme replacement, for chronic pancreatitis, 26(GA) Pancreatic insufficiency, chronic diarrhea in, 31t(GA) Pancreatic neuroendocrine tumors, 29–30(GA), 30f(GA) Pancreatic pseudocysts, 24(GA), 25(GA) asymptomatic, 25(GA), Q22(GA) Pancreatitis acute, 23(GA), 23t(GA), 24f(GA), Q54(GA), Q86(GA) acute respiratory distress syndrome in, 71t(PM) alcoholic, 23(GA), 23t(GA), 25(GA) autoimmune, 27–28(GA), 28f(GA), Q35(GA) chronic, 25–26(GA), 25t(GA), 26f(GA) diabetes in, 5(EN) gallstone, 23(GA), 23t(GA), 25(GA) gastrointestinal bleeding in, 75(GA) hereditary, 26(GA) hypocalcemia in, 65(EN) nutrition in, 93t(PM) as pancreatic cancer risk factor, 81(HO) Pancreaticoduodenectomy, for chronic pancreatitis, 26(GA) Pancytopenia, in aplastic anemia, 2f(HO), 2(HO), Q66(HO) Panic attacks, vs. temporal lobe auras, 14(NR) Panic disorder, 110(GIM), 111(GIM), Q119(GIM) Panitumumab, 69t(HO) for colorectal cancer, 80–81(HO) Panniculitis, 55(DM) Papaverine, for acute mesenteric ischemia, 44(GA) Papillary fibroelastomas, 48(CV) Pap smear, in cervical cancer survivors, 79(HO) Papulosquamous dermatologic disease, 10–14(DM), 65(DM) Para-aminosalicylic acid, for tuberculosis, 35t(ID) Paracentesis, for ovarian cancer diagnosis, Q100(HO) Parainfluenza virus, 19(ID) Paralysis in botulism, 59(ID) in epidural abscess, 8(ID), Q66(ID) hypokalemic periodic, 17(NP) in multiple sclerosis, 58(NR) in spinal cord disorders, 65(NR) Paraneoplastic dermatoses, 46t(DM), 48(DM), 58(DM), 59t(DM) Paraneoplastic syndromes, 58(RM), 79–80(NR), 80t(NR), Q78(NR) of lung cancer, 58(PM), 59t(PM), 85(HO) of thymomas, 63(PM) vs. multiple sclerosis, 60t(NR) Parapneumonic effusions, in community-acquired pneumonia, 19(ID), 22–23(ID), Q94(ID) Parasellar masses, hyperprolactinemia in, 23t(EN) Parasitic infections. See also specific parasitic infections diarrhea in, 71–72(ID) in transplant recipients, 76(ID) Parathyroidectomy hungry bone syndrome after, 65(EN), Q42(EN) for primary hyperparathyroidism, 62(EN), 62t(EN), Q42(EN), Q54(EN) Parathyroid glands, thyroidectomy-related injury to, 65(EN) Parathyroid hormone. See also Hyperparathyroidism; Hypoparathyroidism in benign familial hypocalciuric hypercalcemia, Q47(EN) in calcium homeostasis, 59–60(EN) in chronic kidney disease-mineral bone disorder, 87–88(NP), 87f(NP) Parathyroid hormone-mediated hypercalcemia, 60–62(EN), 61t(EN), 62t(EN), Q17(EN), Q54(EN) Parathyroid hormone-related protein (PTHrP), 63(EN), Q17(EN), Q54(EN)
Cumulative Index
Parenchymal disease, in systemic lupus erythematosus, 37(RM) Parenchymal lung disease. See also Diffuse parenchymal lung disease asbestos exposure and, 40t(PM) smoking and, 35(PM) Parenchymal masses, imaging of, 5(PM) Parenteral feeding, 93(PM), 93t(PM) Paresthesias, in peripheral neuropathy, 68(NR), 69t(NR) Parkinson disease, 47–51(NR) vs. atypical parkinsonism, 50(NR), Q3(NR) compressive cervical myelopathy in, Q25(NR) compulsive behavior in, 50(NR), Q84(NR) dementia in, 42(NR) diagnosis of, 49(NR) dystonia in, 53(NR) early-stage, 50(NR) gait in, 48–49(NR), 50(NR) genetic factors in, 47–48(NR), 53(NR) idiopathic, 48(NR) juvenile, 49(NR) late-stage, 50(NR) nonmotor complications of, 49(NR), 49t(NR) perioperative management of, 134(GIM) prevalence of, 47(NR) sporadic, 47(NR) treatment of, 49–51(NR), 50t(NR) adverse effects of, 50–51(NR), Q84(NR) deep brain stimulation, 51(NR), 52t(NR), Q39(NR) pharmacologic, 49–51(NR), 50t(NR) tremor in, 48(NR), 48t(NR), 50(NR), 52(NR), 53(NR) Parkinsonism atypical, 51(NR) vs. Parkinson disease, 50(NR), Q3(NR) causes of, 48t(NR) clinical features of, 48t(NR) drug-induced, 49(NR) gait in, 46–47(NR), 52(NR) Lewy body dementia and, 46(NR) non-Parkinson disease-related, 49(NR) vascular, 49(NR) in Wilson disease, 56(NR), Q72(NR) Parkinson-plus syndromes, 49(NR), 51(NR) Paromomycin, for amebiasis, 72(ID) Paroxysmal hemicrania, 10(NR), Q35(NR) Paroxysmal nocturnal hemoglobinuria, 2(HO), 34–35(HO), Q60(HO) Paroxysmal supraventricular tachycardia, 50(CV) Partial pressure of carbon dioxide (PCO2) in asthma exacerbations, 75(PM), Q91(PM) in hypoxemic respiratory failure, 70(PM) in respiratory acidosis, 31(NP), 32(NP), 33(NP) in ventilatory respiratory failure, 72(PM) Partial pressure of oxygen/fractional concentration of oxygen in inspired gas (PO2/FIO2), in hypoxemic respiratory failure, 70(PM) Partial pressure of oxygen (PO2) in hypoxemic respiratory failure, 70(PM) pulse oximetry measurement of, 3(PM) Parvovirus B19 infection as arthritis cause, 56(RM) as polyarthritis cause, 2(RM), Q54(RM) pure red cell aplasia and, 3(HO) sickle cell disease and, 31(HO), Q35(HO) Passivity, in dementia, 42(NR) Pasteurella infections, of animal bites, 16(ID) Pasteurella multocida infections, of animal bites, 16(ID) Patch testing for allergic contact dermatitis, 6(DM), 9(DM), 10(DM), Q41(DM) in erythroderma, 65(DM) Patellofemoral pain syndrome, 59–60(GIM), Q54(GIM) Patent ductus arteriosus, 88(CV), Q100(CV) Patent foramen ovale, 83–84(CV), 83f(CV), 86t(CV) asymptomatic, Q110(CV) stroke and, 38(NR), 40t(NR) Pathergy, in Behçet disease, 71(RM) Patient-centered medical home (PCMH), 6t(GIM) Patient-controlled analgesia, for sickle cell disease, 30(HO) Patient education in fibromyalgia, 27(RM) in osteoarthritis, 24–25(RM) in rheumatoid arthritis, 21(RM) Patient Health Questionnaire (PHQ-9), 109(GIM), 119(GIM) Patient identification, 22(GIM) Patient refusal, of treatment, 25(GIM) Patients, difficult encounters with, 116(GIM), Q73(GIM) Patient safety, 19–22(GIM) health information technology and, 22(GIM) national goals for, 22(GIM) Pay for performance (P4P), 6t(GIM) PCIs. See Percutaneous coronary interventions Peak bone mass, 67(EN) Peak expiratory flow rate (PEFR), in asthma exacerbations, 15(PM), Q91(PM) Peau d’orange appearance, 13(ID), 61(DM), 73(HO) PEEP. See Positive end-expiratory pressure Peginterferon adverse effects of, 55t(GA) for hepatitis B, 55(GA), 55t(GA) for hepatitis C, 55(GA), 56t(GA), Q32(GA) Pegloticase, for gout, 52(RM) Pegvisomant, for acromegaly, 24t(EN), 25–26(EN) Pelvic adhesions, 91(GIM), 91t(GIM) Pelvic floor muscle training, 121(GIM), Q33(GIM), Q88(GIM) Pelvic inflammatory disease, 44(ID), 45t(ID), Q26(ID) Pelvic pain, chronic in men, 80–81(GIM) in women, 91–92(GIM), 91t(GIM), Q135(GIM) Pelvic varices, 91(GIM), 91t(GIM) Pemphigoid antiepiligrin, 48(DM) bullous, 46t(DM), Q56(DM) cicatricial, 46t(DM), 48(DM)
Pemphigus immunoglobulin A, 46t(DM), 48(DM) paraneoplastic, 46t(DM), 48(DM), 59t(DM) Pemphigus foliaceus, 46t(DM) Pemphigus vulgaris, 46t(DM), 47t(DM) Penicillin allergy to, Q13(ID) for bacterial meningitis, 6t(ID) for community-acquired pneumonia, 23t(ID) for syphilis, 47(ID), 47t(ID), 48(ID), Q107(ID) Penicillium marneffei infections, 65(ID), 65t(ID) Pentoxifylline for alcohol-induced liver disease, 58(GA), Q18(GA) for peripheral arterial disease, 100(CV) Peptic ulcer disease, 12–13(GA) bleeding in, 12(GA), 13(GA), 75–76(GA), 76f(GA), 77f(GA) Helicobacter pylori infection and, 12–13(GA), 14–15(GA), Q62(GA) high-risk, hospitalization for, 76, Q19 NSAIDs and, 12–13 treatment of, 75–77, 76f, 77f, Q19 Percutaneous coronary interventions, 16f(CV), 17–18(CV), 125(GIM), 127(GIM) anticoagulant therapy and, 22(CV) for chronic stable angina, 16f(CV), 17–18(CV) clopidogrel and, 26(CV) complications of, 26(CV), Q83(CV) in diabetic patients, 29(CV) facilitated, 23(CV) follow-up care for, 18–19(CV) glycoprotein IIb/IIIa inhibitors and, 21(CV) heparin and, 25–26(CV) rescue, 23(CV) for ST-elevation myocardial infarction, 23(CV), 25–26(CV), Q72(CV) Percutaneous transluminal kidney angioplasty, 42(NP) Percutaneous valvotomy, in pregnancy, 89(CV) Performance measures, 5–6(GIM), 6t(GIM) Pericardial constriction, radiation-induced, 102–103(CV), 103f(CV), Q40(CV) Pericardial disease, 61–67(CV) Pericardial effusion, 61(CV), 62t(CV), 67f(CV) in all-trans retinoic acid-induced differentiation syndrome, Q15(HO) cardiac tamponade and, 68(CV) malignant, 108–109(HO) in mixed connective tissue disease, 48(RM) in systemic sclerosis, 44–45(RM) without cardiac compression, 67–69(CV) Pericardial tamponade, 68(CV), Q50(CV) Pericardiectomy, 66(CV) for radiation-induced pericardial constriction, 102–103(CV), 103f(CV) Pericardiocentesis, for cardiac tamponade, 68(CV) Pericarditis acute, 61–65(CV) chest pain in, 49(GIM), Q39(GIM) atrial fibrillation in, 52–53(CV) autoimmune, 62t(CV), 65(CV) clinical presentation of, 61(CV), 62t–64t(CV), 65(CV) constrictive, 69–70(CV), 69t(CV), 70f(CV), Q29(CV) pleural effusion and, 44t(PM) vs. restrictive cardiomyopathy, 46(CV), 69t(CV) echocardiography in, 64t(CV), 65(CV) effusion-constrictive, 69(CV) electrocardiography in, 61(CV), 64f(CV), 64t(CV), 65(CV) management of, 65–67(CV) myocarditis and, 65–66(CV) post-myocardial infarction, 61(CV) recurrent, 65(CV), 66(CV), 67t(CV), Q26(CV) in systemic lupus erythematosus, 37(RM) transient, Q84(CV) tuberculous, 35(ID), Q37(ID) Perimenopause, migraine in, 9(NR) Perindopril, for heart failure, 33t(CV) Periodontal disease, 105(GIM), 106(GIM) Perioperative medicine, 124–134(GIM) cardiovascular, 125(GIM), 127–128(GIM), 127f(GIM), 128t(GIM) endocrine, 132–133(GIM) general recommendations for, 124–125(GIM) hematologic, 129–132(GIM) kidney disease, 133(GIM) liver disease, 133–134(GIM) neurologic disease, 134(GIM) pulmonary, 128–129(GIM), 128t(GIM) Periorificial dermatitis, 5f(DM), 19t(DM) vs, rosacea, 21–22(DM) Peripheral arterial disease, 97–101(CV) ankle-brachial index of, 97(CV), 98–99(CV), 99t(CV), Q60(CV), Q116(CV) claudication in, 99–100(CV) differential diagnosis of, 98t(CV) epidemiology of, 97(CV) evaluation of, 98–99(CV), Q4(CV) localization of, Q4(CV) management of, Q91(CV) interventional therapy in, 100–101(CV) medical therapy in, 99–100(CV) risk factor modification in, 99–100(CV) screening for, 97(CV), 98t(CV) Peripheral arterial disease, necrotizing fasciitis in, 15f(ID) Peripheral blood smears in anemia, 18(HO), 18t(HO), Q26(HO) in cold agglutinin disease, 32(HO), 33f(HO) in glucose-6-phosphate dehydrogenase deficiency, 27(HO), Q59(HO) in hereditary spherocytosis, Q41(HO) in iron-deficiency anemia, 21(HO) in microangiopathic hemolytic anemia, 33f(HO), 33(HO) in thalassemia, Q47(HO) in thrombotic thrombocytopenic purpura, 51(HO), 52(HO) in vitamin B12 deficiency, 22(HO), Q71(HO) in warm autoimmune hemolytic anemia, Q73(HO) Peripheral nervous system disorders in polyarteritis nodosa, 66(RM) in systemic lupus erythematosus, 37t(RM)
49
Cumulative Index
Peripheral neuropathies, 68–73(NR) vs. central nervous system dysfunction, 68(NR), 68t(NR) classification of, 68–69(NR) diabetic, 68(NR), 70–71(NR), 71t(NR), 73(NR) diagnosis of, 68–69(NR) differential diagnosis of, 68(NR), 69t(NR) hereditary, 71(NR) mononeuropathies, 70(NR), 71(NR), 71t(NR) paraneoplastic, 80t(NR) polyneuropathies, 68(NR), 70–73(NR), 71t(NR) Peritoneal carcinomatosis, 105(HO) Peritoneal dialysis in end-stage kidney disease, 91–92(NP), Q4(NP) pleural effusion and, 44t(PM) Peritonitis, 44 spontaneous bacterial, 63, Q3 Permethrin, for scabies, 31(DM), 32(DM) Peroxidase activity, of urine, 4(NP) Persistent vegetative state in Alzheimer disease, 43(NR) definition of, 41t(NR) Personality changes, in herpes simplex virus infections, 95(ID), 96(ID) Personalized cancer treatment, 68–69(HO), 69t(HO) Pertussis, 37(GIM) Pertussis immunization, 12t(GIM), 13(GIM), 87(GIM) Pes anserine bursitis, 2t(RM), 60(GIM), Q79(GIM) PET. See Positron emission tomography PET-CT. See Positron emission tomography-computed tomography (PET-CT) Petechiae, 51(DM) Petrolatum for atopic dermatitis, 9(DM) as basis for ointments, 3(DM) for burns, 34(DM) for hand dermatitis, 7(DM) for wounds, Q69(DM) Peutz-Jeghers syndrome, 20, 47–48 ampullary adenocarcinoma and, 73, Q21 colorectal cancer screening in, 51t Pharyngeal cancer, 88(HO), 89(HO) Pharyngitis, 104(GIM), Q161(GIM) Phenobarbital adverse effects of, 19t(NR), 21(NR) interaction with hormonal contraceptives, 21(NR) teratogenicity of, 21(NR) Phentolamine, for hypertensive crises, 86t(PM) Phenylephrine, clinical use and physiologic effects of, 77t(PM) Phenytoin adverse effects of, 18(NR), 19(NR), 19t(NR), 20t(NR), 21(NR), Q85(NR) for arrhythmias, 51t(CV) hepatoxicity of, 57, 58 interaction with hormonal contraceptives, 21(NR) in pregnancy, 109t(CV) for status epilepticus, 22(NR), Q43(NR) teratogenicity of, 21(NR) Pheochromocytoma, 42(NP), 49–50(EN), Q107(NP) α-adrenergic blocking agent therapy for, 50(EN), Q29(EN) diagnosis of, 47(EN), 48–49(EN), 49–50(EN) differentiated from benign adrenal adenomas, 47(EN) evaluation of, Q71(EN) screening for, 49t(EN) treatment of, 50(EN), Q29(EN) Philadelphia chromosome, in chronic myeloid leukemia, 8(HO) Phlebotomy for hemochromatosis, 36(HO) for polycythemia vera, 7(HO) pH monitoring, esophageal, 6, 7, Q83 Phonic tics, 55(NR) Phosphate nephrotoxicity of, 71(NP) serum disorders of, 22(NP) Phosphate deficiency. See also Hypokalemia osteomalacia in, 72(EN) Phosphate wasting, renal, 22(NP), Q50(NP) Phosphodiesterase inhibitors, 75–76(GIM), 78(GIM), Q166(GIM) Phosphodiesterase-5 inhibitors for chronic obstructive pulmonary disease, 25(PM) for pulmonary arterial hypertension, 55t(PM) Phosphodiesterase inhibitors, as contraindication to nitrates, 20(CV) Phosphodiesterase-4 inhibitors, for chronic obstructive pulmonary disease, 22t(PM), 25(PM), Q85(PM) Phosphorus homeostasis, in chronic kidney disease, 87f(NP), 87(NP) Photodamaged skin, 74f(DM). See also Sun exposure Photodermatitis, in HIV/AIDS, 61(DM) Photodynamic therapy, for acne, 21(DM) Photosensitivity in dermatomyositis, 59(RM) drug-related, 15t(DM) in HIV/AIDS, 61(DM) in systemic lupus erythematosus, 38t(RM) Phrenic nerve, 74(PM) Physical activity. See also Exercise for hypertension management, 39(NP), 40(NP) promotion of, 16(GIM) Physician-assisted suicide, 25(GIM), Q83(GIM) Physician health programs, 27(GIM) Physician Quality Reporting System (PQRS), 6t(GIM) Physicians, impaired, 27(GIM), 27t(GIM), Q124(GIM) Pica, 21(HO) Pick disease, 46(NR) Pigmented lesions. See also Hyperpigmentation; Hypopigmentation ABCDE diagnostic method for, 37(DM), 39(DM) postinflammatory, 76(DM), 76f(DM) purpura, 16–17(DM), 16f(DM) Pill-induced esophagitis, 6, 7 Pilocarpine, for Sjögren syndrome, 46(RM) Pimecrolimus, 9(DM) Pindolol, contraindication in heart failure, 33(CV) Pioglitazone, 8t(EN) contraindications to, 11(EN) Pirbuterol, for chronic obstructive pulmonary disease, 22t(PM), 23(PM)
50
Piriformis syndrome, 2t(RM), 58(GIM) Pitted keratolysis, 25–26(DM), 25f(DM), Q26(DM) Pituitary gland posterior, anatomy of, 17–18(EN) in pregnancy, 25(EN) Pituitary gland disorders, 17–26(EN) hyperprolactinemia, 22–25(EN) hypopituitarism, 18–21(EN) hypothalamic disease, 17–18(EN) pituitary tumors, 21–22(EN) hypopituitarism and, 18(EN) prolactinomas, 22–25(EN) Pituitary tumor apoplexy, 18(EN), 21–22(EN), Q14(EN) Pituitary tumors, 21-22(EN). See also Adenomas, pituitary hypopituitarism and, 18(EN) Pityriasis alba, 26–27(DM) Pityriasis rosea, 11t(DM), 13–14(DM), 13f(DM), 26–27(DM), Q70(DM) Pityriasis versicolor, 26(DM) Pivot test, 59f(GIM) Plague as bioterrorism agent, 56t(ID), 58–59(ID) bubonic, 58(ID), Q74(ID) pneumonic, 59(ID), Q74(ID) septicemic, 58–59(ID), Q74(ID) Plan-Do-Study-Act (PDSA) model, for quality improvement, 19(GIM), 20f(GIM), Q30(GIM) Plantar fasciitis, 2t(RM), 61(GIM), Q167(GIM) Plaques, amyloid, in Alzheimer disease, 43(NR), 44(NR) Plasma aldosterone-plasma renin activity ratio, Q62(NP) Plasma exchange. See Plasmapheresis Plasma osmolality, 10(NP) in hyponatremia, 10(NP), 11–12(NP), 11f(NP) in pregnancy, 78(NP) in toxic ingestions, Q7(NP) Plasmapheresis, 41–42(HO), 41t(HO), Q63(HO) for ANCA vasculitis, Q87(NP) for anti-glomerular basement membrane antibody disease, 60(NP) for fibrillary glomerulopathy, 53(NP) for Guillain-Barré syndrome, 72(NR) for Guillain-Barré syndrome-related ventilatory failure, 74(PM), Q15(PM) for hemolytic uremic syndrome, 34(HO), 51–52(HO) for immunotactoid glomerulopathy, 53(NP) for thrombotic microangiography, 62(NP) for thrombotic thrombocytopenic purpura, 34(HO), 51(HO), 52(HO) Plasma tonicity, 10(NP) Plasma volume, in pregnancy, 77(NP) Plasmodium, as malaria causal agent, 61(ID), 61t(ID), 62(ID), Q40(ID) chloroquine-resistant, 61t(ID), Q100(ID) Platelet(s), 47–53(HO) normal physiology of, 47(HO) Platelet clumping, Q30(HO) Platelet count in essential thrombocytopenia, Q54(HO) in gestational thrombocytopenia, 63(HO) in heparin-induced thrombocytopenia, 50t(HO) in immune (idiopathic) thrombocytopenic purpura, 49(HO), Q45(HO) in neonatal thrombocytopenia, 63(HO) normal, 47(HO) in pregnancy, 65(HO) Platelet deficiencies/disorders, 47-53(HO). See also Thrombocytopenia perioperative management of, 131(GIM) qualitative, 52–53(HO) Platelet Function Analyzer-100®, 52(HO) Platelet function testing, 52(HO) Platelet transfusions, 37t(HO), 38–39(HO) in aplastic anemia, 2(HO) refractoriness to, 38(HO), 39(HO) for thrombocytopenia, 52(HO), Q5(HO) Platypnea-orthodeoxia, 85(CV), 86t(CV), Q110(CV) Pleural effusions, 42–46(PM) benign asbestos, 40t(PM), 41f(PM), 41(PM), 44(PM) causes of, 43(PM), 43t(PM), Q74(PM) in community-acquired pneumonia, 19(ID), 22–23(ID), Q94(ID) in critical care patients, 74(PM) history and physical examination in, 42–43(PM) malignant, 44–45(PM), 84(HO), 108(HO), 109(HO), Q71(PM), Q106(HO) treatment of, 45–46(PM) in pancreatitis, 23 parapneumonic, 44–45(PM) treatment of, 45(PM), 46(PM), Q100(PM) in retinoic acid syndrome, Q15(HO) tuberculous, 43t(PM), 45(PM), Q14(PM) Pleural fluid analysis, 43–45(PM) chemistries of, 44–45(PM) tests for pleural malignancy, 45(PM) tests for tuberculous effusions, 45(PM), Q14(PM) transudate or exudate characterization in, 43–44(PM), 44t(PM) Pleural lung disease, 42–46(PM) asbestosis exposure and, 40t(PM), 41f(PM), 41(PM) definition of, 42(PM) management of, 45–46(PM) Pleural plaques, 41f(PM), 41(PM) Pleuritis as chest pain cause, 49(GIM), 50(GIM) in systemic lupus erythematosus, 37(RM) Plummer nail, of hyperthyroidism, 61(DM) Pneumococcal conjugate vaccines, for children, 2–3(ID) Pneumococcal immunization, in community-acquired pneumonia patients, 24(ID) Pneumococcal polysaccharide immunization, 12t(GIM), 14(GIM), 14t(GIM), 16(GIM), Q74(GIM), Q159(GIM) in chronic obstructive pulmonary disease patients, 25–26(PM), Q41(PM) in HIV/AIDS patients, 88(ID), 89(ID) in transplant recipients, 77t(ID) Pneumoconiosis, 39(PM) Pneumocystis jirovecii pneumonia, 61(DM) in HIV/AIDS, 91(ID) prevention of, 89t(ID) in transplant recipients, 72–73(ID), 74(ID), 92(ID) prevention of, 76(ID) treatment of, 99(ID), 101(ID) Pneumomediastinum, air travel and, 69(PM)
Cumulative Index
Pneumonia acute respiratory distress syndrome in, 71t(PM), 72(PM) bronchiolitis obliterans organizing, 32t(PM), Q96(PM) drug-induced, 37(PM), 37t(PM) idiopathic form of, 34(PM) chronic obstructive pulmonary disease and, 17t(PM) community-acquired, 18–24(ID) antibiotic treatment of, 98t(ID), 99(ID) bacteremic pneumococcal, Q46(ID) causes of, 20t(ID) clinical presentation of, 19(ID), 20t(ID) complications of, 22–23(ID) diagnosis of, 19–20(ID), 20t(ID) epidemiology of, 18(ID), 20t(ID) follow-up of, 23–24(ID) management of, 21t(ID), 22t(ID), 23t, (ID) 19–22(ID) Medicare quality of care indicators for, 19(ID), 22(ID), 23(ID) microbiology of, 19(ID) misdiagnosis of, 22(ID), 24(ID) outpatient treatment for, Q34(ID), Q103(ID) parapneumonic effusions in, 19(ID), 22–23(ID), Q94(ID) pneumococcal, 19(ID), 21t(ID), 23t(ID), 24(ID), Q79(ID) severe, 21(ID), 21t(ID), Q79(ID) site of care for, 18(ID), 20–21(ID), 22(ID), 23–24(ID), Q34(ID), Q46(ID), Q103(ID) cryptogenic organizing, 34(PM), Q96(PM) chest radiography in, 3(PM) diffuse, diffusing capacity for carbon monoxide in, 3(PM) eosinophilic, acute, 32t(PM) herpes simplex, 95(ID) in histoplasmosis, Q30(ID) hospital-acquired, 82–83(ID), 82t(ID) hypersensitivity, transbronchoscopic biopsy in, 5(PM) as influenza complication, 94(ID) interstitial acute, 32t(PM), 34–35(PM) idiopathic, 32–35(PM), Q72(PM) nonspecific, 34(PM) rheumatoid arthritis and, 35(PM) Legionella, 18(ID), 19(ID), 23t(ID), Q79(ID) fever of unknown origin in, 53(ID) in transplant recipients, 74(ID) neuromuscular weakness and, 73t(PM) noninvasive positive pressure ventilation in, 79t(PM) organizing amiodarone and, 37t(PM), Q16(PM) bronchiolitis, 32t(PM), 34(PM), 37(PM), 37t(PM), Q96(PM) cryptogenic, 3(PM), 34(PM), Q96(PM) transbronchoscopic biopsy in, 5(PM) Pneumocystis jirovecii, 39(GIM), 61(DM), Q64(PM) in HIV/AIDS, 89t(ID), 91(ID), 92(ID), Q64(ID) prevention of, 89t(ID) prophylaxis for, 89t(ID) in transplant recipients, 72–73(ID), 74(ID), 76(ID), 92(ID) prevention of, 76(ID) treatment of, 99(ID), 101(ID) in pneumonic plague, 59(ID) Pseudomonas aeruginosa, Q60(ID) as shoulder pain cause, 53(GIM) in transplant recipients, 72–73(ID), 74(ID), 76(ID) varicella (chickenpox) and, 96(ID) ventilator-associated, 81–82(PM), 82–83(ID), 82t(ID), Q81(ID), Q101(ID) Pneumonia Severity Index (PSI), 21(ID) Pneumonic plague, 59(ID) Pneumonitis amiodarone and, 37(PM), 37t(PM), Q16(PM) bleomycin-induced, 110(HO) drug-induced, 37(PM), 37t(PM), Q16(PM) hypersensitivity, 35–36(PM), 36t(PM), Q60(PM) acute, 32t(PM) occupational exposure and, 39(PM), Q24(PM), Q49(PM) hypersensitivity-like, 38(ID) in inflammatory myopathies, 60(RM) in lung cancer, 86(HO) radiation-induced, 37–38(PM), 110(HO) in rheumatoid arthritis, 4(RM) in systemic lupus erythematosus, 37(RM) Pneumothorax, 46(PM) air travel and, 69(PM) as chest pain cause, 49(GIM), Q50(CV), Q104(GIM) chest radiography in, 4(PM) in chronic obstructive pulmonary disease, 17t(PM) as contraindication to hyperbaric oxygen therapy, 102(ID) in obstructive lung disease, 75(PM) secondary spontaneous, Q8(PM) Podagra, 50f(RM), 51(RM) POEMS syndrome, 13(HO) Poikiloderma, 50(DM) Poison ivy, 5(DM), 6(DM) Polio immunization, in transplant recipients, 77t(ID) Polyangiitis, microscopic, 4(RM), 61(NP), 62(NP), 63t(RM), 68(RM), 69(RM) Polyarteritis nodosa, 4(RM), 63t(RM), 66(RM), 67(RM), Q22(RM), Q35(NP), Q92(NP) cardiovascular disease and, 2t(CV) hepatitis B and, 58(NP), Q20(NP) Polyarthritis, 2–3(RM) inflammatory chronic, 3t(RM) parvovirus B19-related, 2(RM), Q54(RM) in rheumatoid arthritis, 16(RM), 17(RM) Polychondritis, relapsing, 71–72(RM), 72f(RM), 72t(RM), Q45(RM) Polycystic ovary syndrome, 19(NR), 60(DM), 66(DM), Q44(EN) diagnostic criteria and management of, 58(EN) hirsutism in, 58(EN), Q82(EN) Polycythemia vera, 6–7(HO), Q6(HO) Polydipsia in diabetes mellitus, 2(EN) differentiated from diabetes insipidus, 21(EN) in hyperglycemia, 12(EN) primary, hyponatremia and, 12(NP) Polyethylene glycol, for constipation, 41 Polymenorrhagia, 90(GIM)
Polymerase chain reaction (PCR) tests in anthrax, 57(ID) in babesiosis, 27(ID) in bacterial meningitis, 3(ID) in Clostridium difficile infections, 70(ID) in genital herpes simplex virus infections, 46(ID), Q27(ID) in herpes simplex encephalitis, 9(ID), 10(ID) in herpes simplex virus infections, 95(ID) in HIV/AIDS, 88(ID) in viral meningitis, 1–2(ID) Polymyalgia rheumatica, 63t(RM), 64(RM), 65(RM) Polymyositis, 58(RM), 59(RM) cancer and, 62(RM) clinical features of, 59–60(RM) diagnosis of, Q53(RM) differential diagnosis of, 61t(RM) epidemiology of, 58(RM) lung cancer and, 59t(PM) prognosis of, 62(RM) systemic sclerosis and, 43(RM) treatment of, 62(RM) Polymyositis-scleroderma overlap syndrome, 59(RM) Polymyxins, 100(ID), 100t(ID), 101(ID) for multidrug-resistant organisms, 83–84(ID) Polyneuropathies, 68(NR), 70–73(NR) acquired, 70–71(NR) critical illness, 72–73(NR) hereditary, 70(NR), 71–72(NR) Polyoma BK virus infections, 46(NP), 92(NP), Q72(NP) in transplant recipients, 73(ID), 74(ID), 75(ID) Polypectomy colorectal cancer after, 51–52(GA), Q45(GA) gastrointestinal bleeding after, 77(GA) surveillance colonoscopy after, 51–52(GA), Q45(GA) Polypharmacy, 120–121(GIM), Q46(GIM) Polyposis familial adenomatous, 20(GA), 46–47(GA) ampullary adenocarcinoma and, 73(GA), Q21(GA) attenuated, 47(GA), 51t(GA) colorectal cancer screening in, 51t(GA) hyperplastic, 48(GA), 51t(GA) juvenile polyposis syndrome, 20(GA), 48(GA), 51t(GA) MYH-associated, 47(GA), 51t(GA) Polyps of gallbladder, Q78(GA) gastric, 19(GA), Q84(GA) fundic gland, Q84(GA) hamartomatous, 47(GA) benign juvenile, 48(GA) nasal, Samter triad and, 10(PM) Polyradiculoneuropathies, inflammatory, 71–72(NR) Polysomnography, 64(PM), 67(PM), Q12(PM) Polyuria assessment of, 15–16(NP) definition of, 15(NP) in diabetes insipidus, 21(EN) in diabetes mellitus, 2(EN) in hyperglycemia, 12(EN) Poorly differentiated carcinoma, 105(HO) Popliteal entrapment syndrome, vs. peripheral arterial disease, 98t(CV) Popliteal fossa, atopic dermatitis of, 8(DM), 9f(DM) Porphyria cutanea tarda, 57(DM), 58(DM) Porphyromonas infections, of animal bites, 16(ID) Portal vein, thrombosis of, 71 Portopulmonary hypertension, 64–65 Positive airway pressure (PAP), for obstructive sleep apnea, 66(PM) Positive end-expiratory pressure for acute respiratory distress syndrome, 80(PM), Q76(PM) for hypoxemic respiratory failure, 70(PM) for pneumonia, 72(PM) Positive likelihood ratio (LR+) 5t(GIM) Positive predictive value (PPV), 4(GIM), 5t(GIM) Positron emission tomography, 4–5(PM) with 18-fluoro-deoxyglucose tracer, 5(PM) in non-small cell lung cancer, 60(PM) Positron emission tomography-computed tomography (PET-CT), 5(PM) in coronary artery disease, 5t(CV), 8(CV) in metastatic lung cancer, 6f(PM), Q62(PM) in non-small cell lung cancer, 60(PM) in pulmonary nodules, 57f(PM), 57(PM) Positron emission tomography stress testing, 5t(CV), 7t(CV) Postconcussion syndrome, 11–12(NR), 12t(NR), 111(GIM), Q56(NR) Posterior drawer test, 59(GIM) Posterior vitreous detachment, 98(GIM) Postherpetic neuralgia, 29(DM) Post-Lyme disease syndrome, 26(ID) Posttest odds, 5t(GIM) Posttest probability, 5t(GIM) Post-transplant lymphoproliferative disease, 93(NP) Posttraumatic stress disorder (PTSD), 111(GIM), Q100(GIM) after critical illness, 93(PM) Potassium dietary intake of, 20–21(NP) esophagitis and, 6(GA) serum disorders of, 17–21(NP) Potassium chloride for hypokalemia, 19(NP) for metabolic alkalosis, 31(NP) Potassium citrate, for hypokalemia, 19(NP) Potassium-creatinine ratio, 19(NP), Q52(NP) Potassium hydroxide (KOH) test for lichen planus, 11t(DM) for nummular dermatitis, 7(DM) for onychomycosis, 69(DM) for pityriasis rosea, 11t(DM) for psoriasis, 11t(DM) for scabies, 31(DM), 32(DM) for seborrheic dermatitis, 11t(DM) for tinea, 7t(DM), 26(DM), 27(DM) Potassium restriction, for hyperkalemia, 21(NP)
51
Cumulative Index
Pott disease, 56(RM) Pramipexole, for restless legs syndrome, 57(NR) Pramlintide for type 1 diabetes mellitus, Q19(EN) for type 2 diabetes mellitus, 8t(EN) Prasugrel, for acute coronary syndromes, 21(CV) Pravastatin, 65(GIM), Q52(GIM) Prazosin, 39(NP) Preconception counseling, 86–87(GIM), 87t(GIM) Precursor cells, 1(HO) Predictive value, of diagnostic tests, 4(GIM) Prednisolone, for chronic obstructive pulmonary disease, 22t(PM) Prednisone for adrenal insufficiency, 42t(EN), 43(EN) for Bell palsy, Q23(NR) for chronic inflammatory demyelinating polyradiculoneuropathy, 72(NR) for chronic obstructive pulmonary disease, 22t(PM), Q63(PM) for giant cell arteritis, 65(RM) for Graves ophthalmopathy, Q8(EN) for kidney transplantation, 93t(NP) for migraine, in pregnancy, 8(NR) for minimal change glomerulopathy, 52–53(NP) for multiple myeloma, 15(HO) for multiple sclerosis, 61(NR) in pregnancy, 41(RM) for refractory asthma, Q23(PM) for systemic lupus erythematosus, 41(RM) use in transplant recipients, 72(ID) Preeclampsia, 63(HO), 64(HO), 64t(HO), 65(HO), 78(NP), 79–80(NP), Q14(NP), Q85(NP) gestational diabetes and, 4(EN) hyperthyroidism and, Q78(EN) in systemic lupus erythematosus, 40(RM), 41(RM) Pregabalin, 35(GIM) adverse effects of, 19t(NR), 20t(NR), 73(NR) for fibromyalgia, 27(RM) for neuropathic pain, 63(NR), 73(NR) Pregnancy acne treatment in, 21(DM), Q17(DM) acute fatty liver in, 64t(HO) alcohol abuse screening during, 17(GIM) amenorrhea in, 57(EN) anemia in, 62(HO), Q10(HO) anticonvulsants in, 19(NR), 21(NR), Q12(NR) antimalarial drugs in, 8–9(NR) in antiphospholipid syndrome, Q90(RM) asthma in, 15–16(PM), Q29(PM) calcium and vitamin D daily intake in, 66t(EN) cardiovascular changes during, 105(CV) cardiovascular disease in, 105–110(CV) aortic coarctation, 90(CV) aortic dissection, 93(CV) cyanotic heart disease, 92(CV) drug therapy during, 107–110(CV), 107t(CV), 108t(CV), 109t(CV), 110t(CV) management of, 49(CV), 107–110(CV), Q49(CV) peripartum cardiomyopathy, 107(CV) pulmonary valve stenosis, 89(CV) risk assessment for, 106–107(CV), 106t(CV) ventricular septal defects, 87(CV) chronic kidney disease in, 78(NP), 79(NP), 80(NP), Q14(NP), Q103(NP) as contraindication to bisphosphonates, 70(EN) cystitis in, 30(ID) dermatologic disease in, 4(DM), 4t(DM), 55(DM) diabetic retinopathy in, 15(EN) disease-modifying antirheumatic drug use in, 11(RM), 12(RM) drug therapy in, 4(DM), 4t(DM), 21(DM), 34(DM), 55(DM) eclampsia in, 63(HO) Eisenmenger syndrome as contraindication to, 92(CV) folate deficiency in, 23(HO), 62(HO) genital herpes simplex virus infections in, 46(ID) gestational diabetes in, 4–5(EN), Q73(EN) Graves disease treatment in, 30(EN) headache in, 2(NR) HELLP syndrome in, 63(HO), 64(HO), 64t(HO), 65(HO), Q37(HO) hepatic adenomas in, 68(GA) HIV/AIDS in antiretroviral therapy for, 94(ID), Q54(ID) testing for, 87(ID), 94(ID) hyperlipidemia management and, Q75(GIM) hyperprolactinemia in, 22(EN), Q7(EN), Q40(EN) hypertension in, 63(HO), 78–80(NP), Q14(NP), Q103(NP) treatment of, 78–79(NP), 79t(NP), Q70(NP), Q85(NP), Q97(NP) hyperthyroidism in, 34(EN), Q78(EN) hypothyroidism in, 38(EN), 39(EN), Q4(EN), Q13(EN) influenza immunization in, Q88(ID) intrahepatic cholestasis of, 68(GA), 69t(GA), Q11(GA) iron-deficiency anemia in, 62(HO) irritable bowel treatment in, 42(GA) the kidney in, 77–81(NP), Q14(NP) normal physiologic changes, 77–78(NP) liver disease in, 68–69(GA), 69t(GA), Q11(GA) magnetic resonance venography in, 34–35(NR), 36(NR) malaria prevention in, Q100(ID) medication management during, 86(GIM), 87t(GIM), Q32(GIM) microangiography in, 64(HO) migraine in, 8–9(NR) in multiple sclerosis, 61(NR) preconception counseling for, 86–87(GIM), 87t(GIM) preeclampsia in, 63(HO), 64(HO), 64t(HO), 65(HO) prolactinomas in, 24–25(EN), Q40(EN) pulmonary embolism in, Q18(HO) in rheumatoid arthritis, 16(RM), 21(RM), Q15(RM) sickle cell disease in, 63(HO), Q42(HO) silver sulfadiazine contraindication in, 34(DM) subclinical hypothyroidism and, 34(EN) surgical site infection prevention in, Q90(ID) in systemic lupus erythematosus, 40–41(RM), Q66(RM) in systemic sclerosis, 45(RM) thalassemia in, 63(HO) thrombocytopenia in, 63–65(HO), Q56(HO)
52
thyroid function and disease in, 38–39(EN) thyroid function testing in, 28(EN) toxoplasmosis in, 53(ID) urinary tract infections in, 29(ID) vaccination during, 13(GIM) varicella zoster immunization in, 97(ID) venous thromboembolism in, 65–66(HO), 65f(HO), 65t(HO), Q18(HO), Q43(HO) vulvovaginal candidiasis during, 93(GIM), Q80(GIM) Prehypertension, 38(NP), Q6(NP), Q102(NP) in pregnancy, Q14(NP) Premature atrial contractions, 50(CV), 54(CV), 57(CV) Premature delivery, maternal hyperthyroidism and, Q78(EN) Premature ejaculation, 76(GIM) Premature ventricular contractions, 50(CV), 57(CV), 58(CV) Premenstrual dysphoric disorder, 109(GIM) Preoperative risk assessment, 124(GIM) Preoperative testing, 124(GIM), Q8(GIM) Prepatellar bursitis, 60(GIM) Prescription medications, hypertension and, 34(NP), 34t(NP) Presenilin, in Alzheimer disease, 43(NR) Pressure ulcers, 123–124(GIM), 124t(GIM), Q17(GIM), Q24(GIM) Presyncope, 43(GIM) Pretest odds, 5t(GIM) Pretest probability, 5t(GIM) Prevalence, 5t(GIM) Priapism, in sickle cell disease, 31(HO), 32(HO) Primaquine, as malaria prophylaxis, 62t(ID) Primary biliary cirrhosis, 53t(GA), 60(GA), Q93(GA) in systemic sclerosis, 43(RM) Primary central nervous systems tumors, 78–79(NR), 78t(NR) Primary ovarian insufficiency, 57(EN), Q77(EN) Primary sclerosing cholangitis, 60–61(GA), 61f(GA), Q60(GA) cholangiocarcinoma and, 61, 73, Q60 liver chemistry studies in, 53t Primidone, for essential tremor, 53(NR) Primitive neurologic reflexes, in dementia, 42(NR) Prion diseases, 11–12(ID), 11t(ID) Prion protein, 11(ID), 11t(ID), 12(ID) Probenecid, for gout, 15(RM) Probiotics, for irritable bowel syndrome, 42(GA) Procainamide for arrhythmias, 51t(CV) as lupus erythematosus cause, 39(RM) in pregnancy, 109t(CV) Process measures, in the intensive care unit, 94(PM) Prochlorperazine, for migraine, 7t(NR) Proctitis, 43(ID) in lymphogranuloma venereum, 48(ID) treatment of, 45t(ID) in ulcerative colitis, 35(GA), Q38(GA) Proctocolitis, in lymphogranuloma venereum, 48(ID) Professionalism, 22–27(GIM), 23t(GIM) Progesterone challenge test, 57(EN), Q3(EN), Q77(EN) Progressive multifocal leukoencephaly, 46(NR), 62(NR), 62t(NR), Q80(NR) Progressive supranuclear palsy, 49(NR), 51(NR), Q76(NR) Prokinetics, for gastroparesis, 18(GA), 18t(GA), 19(GA) Prolactin, 17(EN), 22(EN) in female infertility, 59(EN) Prolactinomas, 21(EN), Q46(EN) hyperprolactinemia and, 22–25(EN) in pregnancy, 24–25(EN), Q40(EN) treatment of, 22(EN), 23–24(EN) Prone positioning, of acute respiratory distress syndrome patients, 71–72(PM), 71t(PM), 80(PM) Propafenone for arrhythmias, 51t(CV) in pregnancy, 109t(CV) Propionibacterium acnes infections, 2(ID), 5t(ID), 18(DM) drug-resistant, 20–21(DM) Propofol, for status epilepticus, 22(NR) Propofol-related infusion syndrome, 24(NP), Q65(NP) Propranolol for arrhythmias, 51t(CV) for essential tremor, 53(NR) for migraine, 8(NR), 9(NR), Q83(NR) in pregnancy, 9(NR) in pregnancy, 108t(CV) for variceal bleeding, 63t(GA) Propylene glycol toxicity, 26(NP) Propylthiouracil for Graves disease, 30(EN) for hyperthyroidism in pregnancy, Q78(EN) for thyroid storm, 39(EN) Prostacyclin analogues, for limited cutaneous systemic sclerosis, Q61(RM) Prostaglandins, as inflammatory pain source, 1(RM) Prostanoids, for pulmonary arterial hypertension, 55t(PM) Prostate cancer, 89–93(HO) chemoprevention of, 89–90(HO) epidemiology of, 89(HO) follow-up in, 92–93(HO), Q78(HO) metastatic, 108(HO) as mortality cause, 57(PM), 58(PM) posttreatment recurrence of, 92–93(HO) risk factors for, 89(HO) screening for, 10(GIM), Q49(GIM) testosterone replacement therapy and, 55(EN) treatment of, 90–93(HO), 92t(HO), Q84(HO), Q93(HO) Prostatectomy, 90(HO), 91(HO), 93(HO) Prostate-specific antigen (PSA), 10(GIM), 77(GIM), 90(HO), 92–93(HO), 104(HO), Q78(HO) in testosterone replacement therapy, 55t(EN) Prostatitis, 80–81(GIM), 80t(GIM), Q106(GIM) acute, 31(ID) Prosthetic joints, infections of, 57(RM), 58(RM), 80(ID), Q7(ID), Q86(RM) Prosthetic valves, 76t(CV), 79(CV), 82-83(CV), 82t(CV), Q42(CV). See also Valvular heart disease in pregnancy, anticoagulants for, 108(CV), 109(CV), 110t(CV), Q49(CV) Protease inhibitors drug interactions of, 93(ID) for HIV/AIDS, 93(ID), 93t(ID) NS3/4A adverse effects of, 56t(GA)
Cumulative Index
for hepatitis C, 55(GA), 56(GA), 56t(GA), Q32(GA) Proteases, in chronic obstructive pulmonary disease, 16(PM) Protein C, 58(HO) activated, for septic shock, 83(PM) Protein C deficiency, 53(HO), 54(HO) acquired, 55(HO) Protein-creatinine ratio in autosomal dominant polycystic kidney disease, Q100(NP) in glomerular diseases, 6–7(NP) in hematuria, Q40(NP) in nephrotic syndrome, 48(NP) in renal potassium wasting, Q52(NP) in tubulointerstitial disorders, 6–7(NP) Protein malabsorption, 32(GA) Protein restriction, for chronic kidney disease progression delay, 85(NP) Protein S, 58(HO) Protein S deficiency, 53–54(HO) acquired, 55(HO), Q34(HO) in pregnancy, 65(HO), Q34(HO) Proteinuria, 6–7(NP) in Alport syndrome, 64(NP) in anti-glomerular basement membrane antibody disease, 60(NP) in autosomal dominant polycystic kidney disease, 63(NP), 64(NP) in chronic kidney disease, 41(NP), 85(NP), 86(NP), Q73(NP) in chronic tubulointerstitial disease, 44t(NP) definition of, 6t(NP) in diabetes mellitus, 16(EN), 85(NP) in diabetic nephropathy, 54t(NP) evaluation of, Q73(NP) in Fabry disease, 65(NP) in hepatitis B virus-associated kidney disease, 56(NP) in HIV-associated nephropathy, 55(NP) in hypertension, Q86(NP) in lupus nephritis, 60(NP) in minimal change glomerulopathy, 52(NP) in multiple myeloma, 55(NP), Q11(NP) in nephritic syndrome, 49(NP) nephrotic-range, 6(NP) orthostatic, Q48(NP) in pregnancy, 77(NP) transient, 7(NP), Q48(NP) Proteus infections, 3(NP), 4–5(NP), 75(NP) of urinary tract, 29(ID), 31(ID) Prothrombin complex concentrates, 58(HO) for hemophilia, 46(HO) Prothrombin G20210A gene mutation, 53(HO) Prothrombin time, 43(HO), 44t–45t(HO) in disseminated intravascular coagulation, 46(HO) in hemophilia, Q8(HO) in thrombocytopenia, 48(HO) Proton pump inhibitors acute interstitial nephritis and, 5(NP), Q15(NP) adverse effects of, 8(GA), 10(GA) for Barrett esophagus, 10–11(GA) calcium absorption effects of, 66(EN) as Clostridium difficile infection risk factor, 69(ID) for dyspepsia, 13(GA) for gastroesophageal reflux disease, 3(GA), 8–9(GA), 10(GA), Q15(GA), Q25(GA), Q69(GA), Q83(GA) gastrointestinal bleeding and, 74(GA) as gastroprotectant, in NSAID use, 16(GA), Q43(GA) for Helicobacter pylori infection, 15(GA) interaction with atazanavir, 93(ID) low bone mass and, 68t(EN) for noncardiac chest pain, 9(GA), Q57(GA) for peptic ulcer disease, 12(GA), 75(GA) Protozoal infections, in transplant recipients, 76(ID) Proximal tubular dysfunction, glycosuria in, 4(NP) Proxy directives, 24(GIM) Prurigo nodules, 5(DM), 20–21(DM), 61(DM) Pruritic papular eruption, in HIV/AIDS, 61(DM) Pruritus, 42–44(DM) brachioradial, 43(DM), Q44(DM) in dermatomyositis, 50(DM) diffuse, 43(DM) in drug reactions, 15t(DM) in HIV/AIDS, 61(DM) in kidney disease, 53(DM) in liver disease, 53(DM) localized, 43(DM) neurogenic, 43(DM), Q66(DM) in primary biliary cirrhosis, 60(GA) in psoriasis, 10(DM) in scabies, 31(DM), 31f(DM) skin changes associated with, 5(DM) in systemic sclerosis, 42(RM) treatment of, 43(DM) in urticaria, 15t(DM), 44–45(DM) without rash, 42(DM), 43(DM), 43t(DM) Pruritus ani, 108(GIM) PSA. See Prostate-specific antigen (PSA) Pseudoachalasia, 3(GA) Pseudoaneurysms vs. arteriovenous fistula, Q83(CV) pancreatic, 74(GA) Pseudocysts, pancreatic, 24(GA), 25(GA), 29t(GA) asymptomatic, 25(GA), Q22(GA) Pseudofollicular barbae, 77(DM) Pseudogout, 10(RM), 53(RM), 54(RM), Q92(RM) Pseudohyperkalemia, 20(NP), Q44(NP) Pseudohypokalemia, 17(NP) Pseudohyponatremia, 10(NP), Q27(NP) isosmotic hyponatremia and, 11(NP) Pseudohypoparathyroidism, hypocalcemia in, 64t(EN), 65(EN) Pseudomonal infections, in burn victims, 84(PM) Pseudomonas aeruginosa infections, 24(DM) antibiotic therapy for, 99(ID), 100(ID) central line bloodstream infections in, 81(ID), 82(ID) community-acquired pneumonia in, 22t(ID), 23t(ID)
drug-resistant, Q45(ID) meningitis in, 2(ID), 5t(ID) osteomyelitis in, 49(ID) pneumonia in, Q60(ID) Pseudomonas infections, 3(NP), 55–56(RM) multidrug-resistant, in transplant recipients, 76(ID) urinary, 4–5(NP) urinary tract infections and, 29(ID) Pseudopolyps, in ulcerative colitis, 35(GA) Pseudoseizures, 17–18(NR) Pseudothrombocytopenia, Q30(HO) Pseudotumor cerebri, 4(NR), 4t(NR) Psoralen and ultraviolet A light therapy, for mycosis fungoides, 104(HO) Psoralen plus UVA (PUVA) light, for hand dermatitis, 7(DM) Psoriasis, 10f(DM), 11(DM) in ankylosing spondylitis, 29(RM) clinical features of, 10(DM) diagnosis of, 10–11(DM), 11t(DM) epidemiology of, 10(DM) of hand, 6(DM), 6f(DM), 7t(DM) of nails, 67–68(DM), 68f(DM) as pruritus cause, 42(DM) pustular, 10(DM), Q20(DM) risk factors for, 10(DM) treatment of, 11t(DM), 12f(DM) tumor necrosis factor-α-related, 34(RM) vs. rubra pilaris, 65(DM) Psoriatic arthritis, 10(DM), 27–28(RM) clinical features of, 29t(RM), 30f(RM), 30(RM), 31f(RM), 31(RM), Q62(RM) dermatologic disorders in, 4t(RM) environmental triggers of, 28(RM) in HIV/AIDS, 28(RM) joint involvement in, 30(RM) polyarthritis in, 2–3(RM), 3t(RM) radiographic findings in, 8t(RM) treatment of, Q18(RM) vs. osteoarthritis, 1(RM) Psychiatric disorders hyperprolactinemia in, 23(EN) hypoglycemia in, 17(EN), 17t(EN) in systemic lupus erythematosus, 37t(RM) Psychiatric medications, perioperative management of, 126t(GIM) Psychogenic nonepileptic seizures, 17–18(NR), Q71(NR) Psychosis in Alzheimer disease, 44(NR), 45(NR) in Lewy body dementia, 45(NR), 46(NR), Q33(NR) in Parkinson disease, 50(NR) Psychosocial stressors, coronary artery disease and, 12t(CV), 13(CV) Pterygium, 68(DM) PTHrP. See Parathyroid hormone-related protein Pubic lice, 32(DM), 32f(DM) PubMed, 4(GIM) Pull test, 52(NR), Q60(NR) Pulmonary artery catheterization, 9–10(CV), 10t(CV) Pulmonary disorders chemotherapy-related, 110(HO) radiation-related, 110(HO) skin manifestations of, 54–56(DM) Pulmonary function testing, 1–3(PM) in asthma exacerbations, 15(PM) bronchial challenge testing, 1(PM), 3(PM) diffusing capacity for carbon monoxide, 3(PM) in hypersensitivity pneumonitis, 36(PM) lung volume, 3(PM) pulse oximetry, 3(PM) in relapsing polychondritis, 72(RM), Q45(RM) in restrictive lung disease, 74(PM) 6-minute walk test, 3(PM) spirometry, 1(PM), 1t(PM), 2f(PM) Pulmonary hemorrhage syndrome, diffusing capacity for carbon monoxide in, 3(PM) Pulmonary medications, perioperative management of, 126t(GIM) Pulmonary perioperative medicine, 128–129(GIM), 128t(GIM), 129t (GIM) Pulmonary regurgitation, 72t(CV) in tetralogy of Fallot, 91(CV), Q55(CV) Pulmonary rehabilitation for chronic obstructive pulmonary disease, 26(PM), 28(PM), Q5(PM) for idiopathic interstitial pneumonia, 33(PM) Pulmonary vascular disease, 46–55(PM) acute pulmonary thromboembolism, 46–52(PM) pulmonary hypertension, 52–55(PM) Pulmonic stenosis, 72t(CV), 76(CV), 86t(CV), 88–89(CV), Q43(CV), Q78(CV) Pulse oximetry, 3(PM) in air travelers with lung disease, 69(PM), 70(PM) in asthma exacerbations, 15(PM) in carboxyhemoglobinemia, Q57(PM) in chronic obstructive pulmonary disease, 19–20(PM), Q57(PM) Pulsus paradoxus, 68(CV) Punding, Q84(NR) Pure red cell aplasia, 3f(HO), 3(HO), 3t(HO) Purine, hyperuricemia and, 48(RM), 49–50(RM) Purpura, 51–53(DM) actinic, 51(DM) Henoch-Schönlein, 53(DM), 56–57(NP), 63t(RM), 69(RM), Q42(DM), Q80(RM) immune (idiopathic) thrombocytopenic, 49–50(HO), 63–64(HO), Q23(HO), Q30(HO), Q45(HO) palpable, 1(DM), 51–52(DM), 52f(DM) palpable, in cutaneous leukocytoclastic vasculitis, 69–70(RM), 70f(RM) periorbital, 16f(HO), 16(HO) pigmented, 16–17(DM), 16f(DM) retiform, 1(DM) thrombocytopenic, in systemic lupus erythematosus, 37(RM) thrombotic thrombocytopenic, 25(HO), 34(HO), 51–52(HO), 61–62(NP), 62t(NP), 64(HO), 64t(HO), 71(NP), Q15(NP), Q55(HO) wet, 47(HO), 49(HO) Push enteroscopy, in gastrointestinal bleeding, 80(GA) Pustular psoriasis, 10(DM), Q20(DM) Pustules, as emergent skin condition, 1(DM), 2(DM) Pustulosis, acute generalized exanthematous (AGEP), 16(DM) PUVA (psoralen plus UVA) light, for hand dermatitis, 7(DM)
53
Cumulative Index
P value, 4(GIM) Pyelonephritis, 30(ID) acute, 31(ID) in autosomal dominant polycystic kidney disease, 63(NP) diagnosis of, 29(ID) outpatient management of, Q71(ID) in pregnancy, 77(NP) Pyoderma gangrenosum, 56–57(DM), 56f(DM), Q10(DM) in spondyloarthritis, 29t(RM) in ulcerative colitis, 36 Pyogenic granulomas, 41(DM), 42f(DM) Pyrazinamide, for tuberculosis, 35(ID), 35t(ID) Pyridostigmine, for myasthenia gravis, 74(NR) Pyridoxine side effects of, 35t(ID) in tuberculosis treatment, 34(ID), 36(ID) Pyroglutamic acidosis, 26(NP), Q93(NP) Pyrosis. See Heartburn Pyuria, 5(NP) in catheter-associated urinary tract infections, 78(ID), 79(ID) in cystitis, 30(ID) in nephritic syndrome, 49(NP) sterile, 5(NP) QT interval–prolonging drugs, 58–59(CV), Q73(CV) Quadriplegia, reset osmostat in, 13(NP) Quality improvement, 6(GIM) measurement of, 20(GIM) Quality improvement models, 19–20(GIM), 20f(GIM) Quality of care, for cardiovascular disease, 3(CV) Quality of life, in cancer, 68(HO) in ovarian cancer, 77(HO) Quasi-experimental study design, 1(GIM), 2t(GIM) Quinapril, for heart failure, 33t(CV) Quinidine for arrhythmias, 51t(CV) esophagitis and, 6(GA) in pregnancy, 109t(CV) Quinine, for babesiosis, 27(ID) Quinine ticlopidine, as thrombotic thrombocytopenic purpura cause, 51(HO) Rabies, encephalitis in, 9t(ID) Rabies immunization, 16(ID) “Raccoon eyes,” 16(HO) Race/ethnicity, cardiovascular disease and, 1(CV) Radial nerve, 56f(GIM) Radiation enteropathy/proctopathy, diarrhea in, 31t(GA) Radiation exposure adverse effects of hemolytic anemia, 35 (HO) thrombocytopenia, 52 (HO) cardiotoxicity of, 102–103(CV), 103t(CV), Q6(CV), Q40(CV), Q77(CV) in computed tomography, 4(PM), Q34(PM) cranial, hypopituitarism and, 18(EN) diffuse parenchymal lung disease and, 36(PM), 37–38(PM) from imaging studies, 9(CV) as pericarditis cause, 62t(CV) tricuspid valve disease and, 80–81(CV) Radiation therapy adverse effects of, 110–111(HO) breast cancer, 70(HO) lung cancer, 84(HO), 110–111(HO) for anal cancer, Q116(HO) for brain tumors, 79(NR), 107(HO), Q85(HO) for breast cancer, 71(HO), 74(HO), 75(HO), 84(HO) central hypothyroidism and, Q57(EN) for cervical cancer, 78(HO), Q108(HO) for gastric cancer, 83(HO) for head and neck cancer, 89(HO), Q94(HO) for Hodgkin lymphoma, 84(HO), 103(HO), 104(HO) for increased intracranial pressure, Q109(HO) for lung cancer, 86(HO), 87(HO), 88(HO), Q139(HO) prophylactic cranial, 88(HO), Q85(HO) for pituitary adenomas, 22(EN) for prostate cancer, 90–92(HO), Q93(HO) for rectal cancer, 80(HO) Radiculopathy cervical, 134(GIM), Q37(GIM) in diabetes mellitus, 71t(NR) low back pain in, 51(GIM), 51t(GIM), 52(GIM) lumbar, vs. peripheral arterial disease, 98t(CV) Radioactive iodine therapy for Graves disease, 31(EN) for subclinical hyperthyroidism, 33(EN) for thyroid cancer, 37–38(EN), Q23(EN) for toxic adenoma, 32(EN) for toxic multinodular goiter, 32(EN) Radioactive iodine uptake (RAIU) test, 27t(EN) contraindication in pregnancy and breastfeeding, 39(EN) in destructive thyroiditis, 30(EN), Q52(EN) in Graves disease, 28–29(EN) in hyperthyroidism, 30(EN) in thyroid nodules, 28(EN), 35f(EN), 36(EN) in thyrotoxicosis, 28(EN) Radiocontrast-related nephropathy, 9(CV) Radiography, in rheumatic disease, 7–8(RM), 8t(RM) Radioimmunoconjugates, for lymphoma, 101(HO) Radionuclide kidney clearance scanning, 2(NP), 3t(NP), 9–10(NP), Q28(NP), Q41(NP), Q90(NP) Ragged red fibers, 76f(NR) RAIU. See Radioactive iodine uptake (RAIU) test Raloxifene, 10(GIM) for breast cancer prevention, 70–71(HO) for osteoporosis, 69(EN), 70t(EN), 71(EN), Q10(EN) Raltegravir, 93(ID), 93t(ID) Ramipril, 43(NP), 85(NP), Q86(NP) for heart failure, 33t(CV) Randomized controlled trials (RCTs), 1(GIM), 2t(GIM), Q127(GIM) Range of motion, of joints, 1(RM) Ranitidine, colitis and, Q89(GA) Ranolazine, for angina, 17(CV), Q70(CV) Rapamycin, 63(NP) Rapamycin (mTOR) pathway, activation of, 38–39(PM)
54
Rapid response teams, 94(PM) Rapid shallow breathing index, 81(PM), 82(PM) Rasagiline, for Parkinson disease, 50(NR), 50t(NR) Rasburicase, 73–74(NP), Q3(NP) adverse effects of, 11–12(HO) for tumor lysis syndrome, 15(RM), Q128(HO) Rash allopurinol-related, 15(RM) anticonvulsant-related, 18(NR), 19t(NR) common, 5–18(DM) in dengue fever, Q55(ID) in dermatomyositis, 4t(RM), 59f(RM), 59(RM), 62(RM), Q73(RM) drug-induced, 54(ID) heliotrope, 21(DM), 50(DM), 50f(DM), 51(DM), Q24(DM) in Kawasaki disease, 66(RM) malar, 48(DM) in mixed connective tissue disease, 48(RM) petechial, in rickettsial infections, 28f(ID), 29(ID), 64(ID) in Rocky Mountain spotted fever, 28f(ID), 29(ID), Q87(ID) in smallpox, 58f(ID), 58(ID) in Southern tick-associated rash illness (STARI), 25t(ID), 27(ID) in syphilis, 47(ID), 48(ID) in systemic lupus erythematosus, 4t(RM), 21(DM), 35f(RM), 35(RM), 35t(RM), 38t(RM) in typhoid fever, 63(ID), Q75(ID) in varicella (chickenpox), 96(ID) “Rash that itches,” 42(DM), 42f(DM) Rathke cleft cysts, 18(EN), 22(EN), 26(EN) Raynaud phenomenon, 61(NP) in inflammatory myopathies, 59(RM) in mixed connective tissue disease, 47(RM), 47t(RM) in Sjögren syndrome, 46t(RM) in systemic sclerosis, 42(RM), 43(RM), 45(RM), Q72(RM) Reactive airways disease, stress testing and, Q107(CV) Reactive airways dysfunction syndrome (RADS), 9(PM), 84(PM) Reactive arthritis, 27–28(RM) clinical features of, 4t(RM), 29t(RM), 30–31(RM), 31f(RM) dermatologic disorders in, 4t(RM) diagnosis of, Q12(RM) enteric infections and, 5(RM) epidemiology of, 30(RM) in HIV/AIDS, 28(RM) HLA antigens in, 28(RM) polyarthritis and, 3t(RM) treatment of, 33(RM), 34(RM), Q2(RM) Recombinant human erythropoietin, 38(HO), 39(HO) Recombinant human factor VIIa, for hemophilia, 46(HO) Rectal cancer, 80(HO), 81(HO), Q79(HO) Rectal examination, in prostate cancer, 90(HO) Rectum, bleeding from, 107(GIM), Q48(GIM) Recurrent laryngeal nerve, impingement in multinodular goiter, 31(EN), Q66(EN) Referrals, for chronic obstructive pulmonary disease, 21(PM) Referrals, to hypertension specialists, 43(NP) Reflux, gastroesophageal. See Gastroesophageal reflux disease Regadenoson, in stress testing, 5t(CV) Regurgitation in gastroesophageal reflux disease, 9(GA) in rumination syndrome, 17(GA), Q68(GA) Reiter syndrome. See Reactive arthritis Relapsing polychondritis, 71–72(RM), 72f(RM), 72t(RM), Q45(RM) Relative risk, 3(GIM) Relative risk reduction (RRR), 3(GIM), 3t(GIM) Relative risk (RR), 3(GIM), 3t(GIM), Q58(GIM) Relocation test, 54t(GIM) REM sleep behavior disorder. See also Sleep disorders in Lewy body dementia, 45(NR) Renal artery stenosis, renovascular hypertension in, 41–42(NP), Q43(NP) Renal cancer/carcinoma in autosomal dominant polycystic kidney disease, 63(NP) Renal cell cancer/carcinoma, 95–96(HO), Q92(HO) in tuberous sclerosis complex, 64(NP) Renal disease. See Kidney disease Renin, 41(EN) Renin-angiotensin-aldosterone system blockers, Q12(CV) Renin-angiotensin-aldosterone system–inhibiting agents, 21(NP) teratogenicity of, 79(NP) Renin-angiotensin system regulation of, 40f(EN) in renovascular hypertension, 41(NP) Repaglinide, 8t(EN) Reperfusion therapy. See also Revascularization; Stents for ST-elevation myocardial infarction, 23(CV) for stroke, 29(NR) Repetitive injuries, as osteoarthritis cause, 22(RM) Reproduction, physiology of female, 56(EN) male, 52–53(EN) Reproductive disorders, 52–59(EN) basic concepts of, 52(EN) common features of, 52(EN) in females, 56–59(EN) in males, 53–56(EN) Reptiles, as salmonellosis vectors, 67(ID) Reset osmostat, 13(NP) Residual volume (RV), 3(PM) Respiratory depression, morphine and, 30(GIM) Respiratory disorders. See Pulmonary disorders Respiratory drive, decreased, 73(PM) Respiratory failure, 70–76(PM) in drug overdose, 73(PM) hypercarbic, nutrition in, 93t(PM) hypoxemic, 70–72(PM), Q40(PM) in immunocompromised patients, 78(PM) in pulmonary embolism, Q42(PM) ventilatory (hypercapnic), 3(PM), 72–75(PM), Q15(PM), Q61(PM), Q102(PM) in asthma, 75(PM), 76(PM), Q51(PM) in Guillain-Barré syndrome, 74(PM), Q15(PM) in myasthenia gravis, 74(PM) in neuromuscular weakness, 73–74(PM), 73t(PM), 75(PM), Q59(PM) in obstructive lung disease, 75–76(PM) in restrictive lung disease, 74–75(PM)
Cumulative Index
Respiratory muscle weakness, respiratory failure in, 74(PM), Q11(PM) Respiratory syncytial virus infections asthma and, 9(PM), 11(PM) community-acquired pneumonia in, 19(ID) Respiratory viral infections, asthma and, 9(PM), 11(PM) Restless legs syndrome, 56–57(NR), 64(NR), Q59(NR) Restrictive lung disease, 74–75(PM) extrapulmonary complications of, 74(PM) pulmonary complications of, 68(PM), 74–75(PM) sleep-related hypoventilation syndromes and, 68(PM) Restrictive procedures, in bariatric surgery, 20t(GA), 21(GA) Resynchronization therapy, cardiac, 36(CV), 37(CV), Q54(CV) Retapamulin, for wounds, 33(DM) Reteplase, for ST-elevation myocardial infarction, 25(CV), 25t(CV) Reticulocyte count, 18–19(HO) in hemolytic anemia, 26(HO) Retinal detachment, 98f(GIM), 98(GIM), Q29(GIM) Retinal disease, in rheumatic disease, 5t(RM) Retinal toxicity, of hydroxychloroquine, Q32(RM) Retinal vascular occlusion, 99f(GIM), 99(GIM) Retinitis, cytomegalovirus, 91(ID) Retinoic acid, for acute myeloid leukemia, Q15(HO) Retinoic acid–induced differentiation syndrome, Q15(HO) Retinoids. See also Isotretinoin for acne, 19t(DM), 20(DM), 20t(DM) Retinopathy diabetic, 15(EN), 15t(EN), Q1(EN) in hypertension, 35(NP) Retro-orbital pain, in dengue fever, 64(ID), Q55(ID) Retroperitoneal lymph node dissection, in testicular cancer, 94(HO) Revascularization, 125(GIM) carotid, 38(NR) coronary, 18(CV) clopidogrel and, 20–21(CV) percutaneous coronary intervention, 16f(CV), 17–19(CV) surgical, 18(CV) for peripheral arterial disease, 100–101(CV) for Takayasu arteritis, 66(RM) Reversible cerebral vasoconstriction syndrome, 3(NR), 3t(NR), Q22(NR) Revised Cardiac Risk Index (RCRI), 125(GIM), 128t(GIM), Q168(GIM) Revised Geneva Scoring Systems, for pulmonary embolism diagnosis, 47(PM), 48t(PM), Q79(PM) Reynolds risk score, for cardiovascular disease in women, 30(CV), Q45(CV) Rhabdomyolysis acute kidney injury in, Q51(NP) in hyperthermic emergencies, 86(PM), 87(PM) hypocalcemia in, 65(EN) influenza and, 94(ID) pigment nephropathy and, 70(NP), Q63(NP) in propofol-related infusion syndrome, Q65(NP) statins and, 17(CV), 66t(GIM) treatment of, Q25(NP) urine myoglobin levels in, 4(NP) Rh compatibility, 36–37(HO), 38–39(HO), Q7(HO) Rheumatic disease approach to the patient in, 1–9(RM) evaluation of, 9(RM) extra-articular manifestations of, 3–5(RM), 4t(RM), 5f(RM), 5t(RM), 6t(RM) imaging studies in, 7–8(RM), 8t(RM) inflammatory vs. noninflammatory, 1(RM), 1t(RM), Q65(RM) laboratory studies in, 6–7(RM), 7t(RM) musculoskeletal examination in, 1–2(RM) treatment of, 9–15(RM) analgesics in, 10(RM) anti-inflammatory agents in, 9–11(RM), 10t(RM) colchicine in, 10(RM) corticosteroids in, 10(RM), 10t(RM) disease-modifying antirheumatic drugs in, 11–14(RM) urate-lowering therapy in, 14–15(RM) Rheumatic fever, dermatologic disorders in, 4t(RM) Rheumatic heart disease mitral stenosis and, 79(CV) tricuspid valve disease and, 80–81(CV) Rheumatoid arthritis, 15–21(RM), 53(DM), Q10(DM) cardiovascular disease and, 2t(CV) clinical manifestations of, 3(RM), 16(RM) complications of, 18–19(RM) diagnosis of, 16–18(RM), Q9(RM), Q20(RM) Disease Activity Score in, 9(RM), 19(RM) epidemiology of, 15(RM) evaluation of, 9(RM), 16–18(RM) extra-articular manifestations of, 4(RM), 5t(RM), 18–19(RM), 19t(RM) eye disorders in, 5t(RM) genetic factors in, 15(RM) hormonal factors in, 16(RM) imaging studies in, 17(RM), 18(RM), 19(RM) joints involved in, 16(RM) of the knee, 58(GIM) lung disease in, 4(RM) management of, 19–21(RM), Q67(RM), Q75(RM) corticosteroids in, 20(RM) disease-modifying antirheumatic drugs in, 20(RM), Q28(RM), Q34(RM) nonpharmacologic, 21(RM) NSAIDs in, 20(RM) surgery in, 21(RM), Q33(RM) musculoskeletal manifestations of, 17t(RM) pathophysiology of, 15–16(RM) polyarthritis in, 2–3(RM), 3t(RM) pregnancy in, 21(RM), Q15(RM) prognosis of, 18(RM) pulmonary disease in, 35(PM) parenchymal lung disease, 31(PM) silicosis, 42(PM) radiographic findings in, 8t(RM), Q43(RM) radiographic monitoring of, 19(RM) risk factors for, 15–16(RM), Q94(RM) Stanford Health Assessment Questionnaire in, 19(RM) Rheumatoid factor, 7t(RM), 16–17(RM), 16(RM) cryoglobulins as, 69(RM) in psoriatic arthritis, 30(RM)
Rheumatologic disease, skin diseases in, 48–53(DM) Rhinitis allergic, 103–104(GIM) continuous positive airway pressure and, 66(PM), Q30(PM) cough and, 10(PM) nonallergic, 104(GIM), Q138(GIM) Rhinitis medicamentosa, 104(GIM), Q30(PM), Q138(GIM) Rhinophyma, 21(DM), 22f(DM) Rhinorrhea, 103(GIM) Rhinosinusitis, 37(GIM), Q13(GIM) Rhinovirus, asthma and, 9(PM), 11(PM) Ribavirin adverse effects of, 55t(GA) for hepatitis C, 55(GA), 56(GA), 56t(GA), Q32(GA) Richmond Agitation Sedation Scale (RASS), 92(PM) Richter transformation, in chronic lymphocytic lymphoma, 102(HO) Rickettsial infections, 25t(ID), 28f(ID), 28(ID), 61t(ID), 64–65(ID), Q87(ID) Rifabutin for Mycobacterium avium complex infections, 38(ID) for tuberculosis, 35(ID), 35t(ID) Rifampin, 100(ID), 101(ID) minimal change glomerulopathy and, Q78(NP) for Mycobacterium avium complex infections, 38(ID) for Mycobacterium kansasii infections, 38(ID) side effects of, Q44(ID) for tuberculosis, 35(ID), 35t(ID), Q37(ID), Q44(ID) Rifamycin agents, 100(ID) for tuberculosis, 35–36(ID) Rifapentine, for tuberculosis, 34(ID), 35(ID), 35t(ID) Rifaximin contraindication to, 42(GA) for hepatic encephalopathy, Q91(GA) for travelers’ diarrhea, 63(ID), 63t(ID) RIFLE criteria, for acute kidney injury, 65(NP) Right ventricular apical pacing, 50(CV) Right ventricular hypertrophy, tetralogy of Fallot and, 90(CV) Rigidity in neuroleptic malignant syndrome, 56(NR), Q64(NR) in Parkinson disease, 48(NR), 49(NR), 50(NR) in progressive supranuclear palsy, 51(NR) Rilonacept, for rheumatic disease, 13t(RM) Riluzole, for amyotrophic lateral sclerosis, 74(NR) Rimantadine, contraindication as influenza A prophylaxis, 95(ID) Ringworm. See Tinea corporis Rinne test, 100(GIM), Q20(GIM) Risedronate, for osteoporosis, 69(EN), 70(EN), 70t(EN) Risperidone, as neuroleptic malignant syndrome cause, 56(NR) Ritonavir, 93(ID), 93t(ID), Q54(ID) use in pregnancy, 94(ID) Rituximab for chronic lymphocytic leukemia, 101(HO) for cold agglutinin disease, 33(HO) for follicular lymphoma, 102(HO) for immune (idiopathic) thrombocytopenic purpura, 49(HO) immunization and, 12(RM), Q58(RM) for lymphoma, 98(HO), 101(HO) for mantle cell lymphoma, 103(HO) for rheumatic disease, 13–14(RM), 13t(RM) for systemic lupus erythematosus, 40(RM) for Waldenström macroglobulinemia, 17(HO) Rivaroxaban for atrial fibrillation, 54(CV) for pulmonary embolism, 50t(PM), 51(PM) Rivastigmine for Alzheimer disease, 44(NR), 44t(NR), 45(NR) for Lewy body dementia, 45–46(NR) Rizatriptan, for migraine, 7t(NR) RNA viruses, as viral hemorrhagic fever causal agents, 60(ID), 60t(ID) Rocky Mountain spotted fever, 25t(ID), 28f(ID), 28(ID), Q87(ID) Roflumilast for chronic obstructive pulmonary disease, 22t(PM), 25(PM), Q85(PM) contraindications to, 25(PM) Romberg test, 51(GIM), 52(NR), Q60(NR) Rome III criteria, for irritable bowel syndrome, 41–42(GA), 41t(GA), Q81(GA) Rosacea, 19t(DM), 21–22(DM), 21f(DM) vs. malar erythema, 48(DM) Rosiglitazone, 8t(EN) contraindications to, 11(EN) Rosiglitazone, cardiovascular risks of, 29(CV) Rosuvastatin, 65(GIM) Rotator cuff disorders, 54–55(GIM), 56(GIM), Q23(GIM), Q122(GIM) Rotator cuff tendinitis, 2t(RM) Rotavirus, 71(ID) Rouleaux, 13(HO) Routine care, of healthy patients, 4–19(GIM) family history, 11(GIM) genetic testing and counseling, 11–12(GIM) immunization, 12–16(GIM), 12t(GIM) lifestyle risk factors management, 16–19(GIM) screening tests, 6–11(GIM) Roux-en-Y procedure, 20(GA), 20t(GA), 21–22(GA), 21f(GA), 73f(GIM), 73(GIM), 74t(GIM), Q15(GIM) Rubella as arthritis cause, 56–57(RM) as polyarthritis cause, 2(RM) Rubella immunization, 12t(GIM), 15(GIM), 16(GIM), 87(GIM) Rubra pilaris, 64–65(DM) Rumination syndrome, 17(GA), 17t(GA), Q68(GA) Sacroiliac joint fusion, in spondyloarthritis, 32f(RM) Sacroiliitis, 58(GIM) in inflammatory bowel disease–associated arthritis, 30(RM) in spondyloarthritis, 32f(RM) Saddle nose deformity, 71–72(RM), Q45(RM) St. Louis encephalitis virus, 9t(ID) Salbutamol, for chronic obstructive pulmonary disease, 23t(PM) Salicylic acid, topical for acne, 20t(DM), 21(DM) for psoriasis, 12f(DM) Salicylate toxicity, 4(NP), 26(NP), 90(PM), 91t(PM), Q57(NP), Q66(NP) respiratory alkalosis in, 32(NP), 33(NP)
55
Cumulative Index
Saline for hypercalcemia, Q15(EN) for hyponatremia, 14(NP), 15(NP), 15t(NP), 17(NP) isotonic, for metabolic alkalosis, 31(NP), Q9(NP) for rhabdomyolysis, Q25(NP) for syndrome of inappropriate antidiuretic hormone secretion–related hyponatremia, Q69(NP) Salmeterol for asthma, 12(PM) for chronic obstructive pulmonary disease, 22t(PM) Salmonella typhi, as typhoid fever causal agent, 63(ID) Salmonellosis as bioterrorism agent, 56(ID) diarrhea in, 67–68(ID) nontyphoidal, 67(ID) osteomyelitis in, 49(ID) as reactive arthritis cause, 5(RM), 30–31(RM), 32(RM) serotypes of, 67(ID) in sickle cell anemia, 55(RM) typhoidal, 67(ID) Salpingo-oophorectomy, prophylactic, 71(HO), 75(HO), Q138(HO) Salt restriction, for hypertension management, 39(NP), 40(NP), Q1(NP) Salt wasting, cerebral, Q26(NP) Samter triad, 10(PM) Sarcoidosis, 4t(RM), 5t(RM), 54–55(DM), 65t(DM), 66(NR), 74–75(RM), 75t(RM), Q91(RM) bradycardia in, 49(CV) cardiovascular disease and, 2t(CV), 46(CV), 47t(CV), Q108(CV) chronic tubulointerstitial disorders in, 45t(NP), 46(NP) hypercalcemia in, 61t(EN), 62–63(EN), Q5(EN), Q17(EN) hypopituitarism in, 18(EN) pulmonary, 38(PM), 38t(PM), Q77(PM) chest radiography in, 3(PM), 4f(PM), 38(PM), 38t(PM), Q101(PM) false-positive PET scans in, 5(PM) transbronchoscopic biopsy in, 5(PM) Sarcoma differentiated from thyroid nodules, 35t(EN) Kaposi, 61(DM), 91–92(ID), 92f(ID) myeloid, 10(HO) Sarcomas, cardiac, 47(CV) Sarcoptes scabiei, 65(DM) Saxagliptin, 9t(EN) Scabies, 31–32(DM), 31f(DM), 42(DM), 65t(DM), Q12(DM) in immunocompromised patients, 61(DM) Scales in psoriasis, 10(DM), 10f(DM) in xerotic eczema, 7(DM), 7f(DM) Scalp psoriasis of, 10(DM), 11f(DM) seborrheic dermatitis of, 11t(DM) skin cancer of, 1(DM) tinea of, 26(DM) Scaphoid bone, fractures of, 57(GIM) Scars acne-related, 21(DM) hypertrophic, 41(DM) pruritus-related, 5(DM) wound-related, 33(DM) Schatzki rings, 2f(GA), 2(GA) Schilling test, 22–23(HO) Schirmer test, Q44(GIM) Schistocytes, 33f(HO) in anemia, 18t(HO) in thrombocytopenia, 48(HO) in thrombotic thrombocytopenic purpura, Q55(HO) Schizophrenia, 114–115(GIM), Q68(GIM) Schwannomas, 78(NR), 78t(NR) mediastinal, Q56(PM) Sciatica, 51–52(GIM), 51t(GIM) Scintigraphy, hepatobiliary, 72(GA) Scleral melt, 3(RM) Scleredema, 45(RM) Scleritis, 95(GIM) in rheumatic disease, 5t(RM) in rheumatoid arthritis, 19(RM) Sclerodactyly in mixed connective tissue disease, 47(RM), 47t(RM), 48(RM) in systemic sclerosis, 41–42(RM), 42f(RM) Scleroderma, 60(DM) esophageal hypomotility in, 5–6(GA) gastroesophageal reflux disease and, 7(GA) Scleroderma renal crisis, 43–44(RM), 45(RM), Q42(RM) Scleroderma spectrum disorders, 45(RM) Scleromyxedema, 45(RM) Sclerotherapy, endoscopic variceal, 62(GA), 62t(GA), 63t(GA) SCOFF questionnaire, for eating disorders screening, 113(GIM), 113t(GIM), 114(GIM) SCORTEN, 63(DM) Scrapes, 33–34(DM), 34f(DM) Scratching. See also Pruritus of bites, 31(DM) signs of, 5(DM) as skin lesion cause, 42f(DM) Screening, 6–11(GIM) for abdominal aortic aneurysms, 7t(GIM), 8(GIM), Q15(GIM) for alcohol abuse, 7t(GIM), 8(GIM), 9(GIM), 17–18(GIM) for bladder cancer, 7(NP) for breast cancer, 7t(GIM), 9–10(GIM), 11(GIM) for cancer, 7t(GIM), 9–10(GIM) for cervical cancer, 7t(GIM), 10(GIM), 10t(GIM), 11(GIM), Q34(GIM) for chronic kidney disease, 81–82(NP), Q41(NP), Q73(NP) for colon cancer, 7t(GIM), 11(GIM), Q48(GIM) in acromegaly, 25(EN) for coronary artery disease, 8–9(GIM) for depression, 7t(GIM), 8(GIM), Q145(GIM) for diabetes mellitus, 2(EN), 2t(EN), 7t(GIM), 8(GIM), 70(GIM) during pregnancy, 4(EN) for drug abuse, 18(GIM) for dyslipidemia, 62(GIM) for eating disorders, 113(GIM), 113t(GIM), 114(GIM) for hearing loss, 119(GIM)
56
for hepatitis B, 7t(GIM), 9(GIM), 11(GIM) for hepatitis C, 7t(GIM), 9(GIM), 11(GIM) during history and physical examination, 8(GIM) for HIV/AIDS, 87(ID), 88(ID), Q95(ID) for human immunodeficiency virus (HIV) infection, 7t(GIM), 9(GIM), 11(GIM), Q123(GIM) for infectious diseases, 7t(GIM), 9(GIM) for lung cancer, 58(PM) for obesity, 7t(GIM), 8(GIM), 70(GIM) for oral cancer, 106(GIM) for osteoporosis, 7t(GIM), 8(GIM), 9(GIM), 67(EN), 69t(EN) for pheochromocytomas, 49t(EN) for prostate cancer, 10(GIM), Q49(GIM) for sexually transmitted diseases, 7t(GIM), 9(GIM), 11(GIM), 18(GIM) for skin cancer, 1(DM), 1t(DM), Q40(DM) for urinary incontinence, 121(GIM), 122f(GIM) Scrub typhus, 64(ID) Seafood, Vibrio transmission in, 69(ID) Seasonal affective disorder, 109(GIM) Sebaceous cysts, 41–42(DM) Sebaceous hyperplasia, 40(DM), 40f(DM) Seborrheic dermatitis, 11t(DM), 14(DM), 14f(DM) Seborrheic keratoses, 39(DM), 39f(DM), 75(DM), 75f(DM), Q8(DM), Q58(DM) Sedation, anticonvulsant-related, 18(NR) Sedation, in critical care patients, 92–93(PM) care bundles for, 94t(PM) excessive, 92–93(PM) Sedative-hypnotics, for insomnia, 44(GIM), 45t(GIM) Sedatives, for Alzheimer disease, 45(NR) Sedentary life style, low bone mass in, 68t(EN) Seizure disorders, perioperative management of, 134(GIM) Seizures. See also Epilepsy absence, 14(NR) assessment of, 13–14(NR) characteristics of, 13t(NR) clinical presentations of, 14–15(NR) complex partial, 14(NR), 15(NR) convulsive, 15(NR) in dural sinus venous thromboembolism, 33(NR) in encephalitis, 8(ID), 9(ID) epidemiology of, 12–13(NR) generalized, 14–15(NR) in herpes encephalopathy, 95(ID) in hyperthermic emergencies, 86(PM), 87(PM) hypocalcemic, 64(EN) in hypotonic hyponatremia, 14(NP) imaging studies in, 16(NR) Jacksonian, 14(NR) mimics, 13t(NR) myoclonic, 15(NR) nonepileptic, 13t(NR), 17–18(NR) partial (focal), 14(NR), 15(NR) in preeclampsia, 80(NP) psychogenic nonepileptic, 17–18(NR), Q71(NR) recurrence of, 18(NR) secondarily generalized, 14(NR) simple partial, 14(NR) in status epilepticus, 22(NR) in systemic lupus erythematosus, 38(RM) tonic-clonic, 14(NR), 15(NR) Selective estrogen receptor modulators. See also Raloxifene; Tamoxifen for breast cancer, 70–71(HO) Selective immunoglobulin A deficiency, 32(GA), 55(ID), Q86(ID) Selective serotonin reuptake inhibitors (SSRIs), 109(GIM), 110t(GIM), 111(GIM), 114(GIM), 119(GIM). See also Antidepressants for Alzheimer disease, 45(NR) for fibromyalgia, 27(RM) for migraine, 7(NR) as tremor cause, 52–53(NR) Selegiline for Alzheimer disease, 44(NR) for Parkinson disease, 50(NR), 50t(NR) Selenium, for chronic pancreatitis, 26(GA) Sellar masses approach to, 21(EN) in diabetes insipidus, 18(EN) growth hormone deficiency and, 19(EN) hyperprolactinemia and, 22–23(EN), 23t(EN), Q50(EN) incidental, Q46(EN) Semen analysis, for male fertility evaluation, 55–56(EN), Q12(EN) Seminoma, 94(HO) Senna, for constipation, 41(GA) Sensitivity, of diagnostic tests, 4(GIM), 5t(GIM) Sensorimotor peripheral neuropathy, 71t(NR) Sentinel lymph node biopsy in breast cancer, 71(HO) in melanoma, 106(HO) Sepsis, 82–83(PM), Q26(PM) acute respiratory distress syndrome and, 71t(PM), 84(PM) antibiotic therapy for, 82(PM), 83t(PM) dental, brain abscess in, 7t(ID) hyperglycemia in, 83–84(PM) Sepsis syndrome, neutropenia in, 4(HO) Septal defects atrial. See Atrial septal defects ventricular. See Ventricular septal defects Septic arthritis, 54–58(RM) animal bites and, 16(ID) bacterial, 54(RM), 55–58(RM), 57t(RM), Q17(RM) clinical features of, 54(RM) diagnosis of, 54–55(RM), Q27(RM) etiology of, 55–57(RM) fungal, 3(RM), 54(RM), 56(RM), 58(RM), Q84(RM) of the knee, 58(GIM) laboratory findings in, 54–55(RM) mycobacterial, 56(RM) in osteomyelitis, 49(ID) in previously damaged joints, 54(RM), 57(RM) in prosthetic joints, 57(RM)
Cumulative Index
radiographic studies of, 54(RM) treatment of, 57–58(RM), 57t(RM) viral, 54(RM), 56–57(RM) Septicemic plague, 58–59(ID) Serial imaging, in structural heart disease, 9(CV) Seronegative spondyloarthropathies. See Spondyloarthritis Serositis in diffuse cutaneous systemic sclerosis, 41(RM) in mixed connective tissue disease, 47t(RM) in systemic lupus erythematosus, 38t(RM) Serotonin-norepinephrine reuptake inhibitors, for fibromyalgia, 27(RM), Q85(RM) Serratia marcescens infections, meningitis in, 2(ID) Sertoli cells, 52(EN), 53f(EN) Sertraline, colitis and, Q89(GA) Serum aldosterone–plasma renin ratio in adrenal incidentalomas, Q2(EN) in primary hyperaldosteronism, 51(EN), 52(EN), Q16(EN) Serum-ascites albumin gradient, 62–63(GA), Q23(GA) Serum cardiac biomarkers, 19–20(CV) Serum osmolality gap, 10(NP) Severity-of-illness scoring systems, 94–95(PM) Sex hormone–binding globulin, 52–53(EN) Sexual arousal disorder, 82(GIM) Sexual aversion disorder, 81–82(GIM), Q5(GIM) Sexual behavior risky, 18(GIM), 19(GIM) sexual contact between physician and patient, 26(GIM) Sexual behavior counseling, 18(GIM) Sexual desire disorders, 81–82(GIM), Q5(GIM), Q147(GIM) Sexual dysfunction cancer treatment–related, 110(HO) in men, 74–77(GIM), 75t(GIM), 76t(GIM), Q112(GIM), Q166(GIM) post-prostatectomy erectile dysfunction, 91(HO) in women, 81–82(GIM), 81t(GIM), 88(GIM), 89(GIM), Q5(GIM), Q147(GIM) Sexually transmitted infections, 43–49(ID) in adolescents, 18(GIM) cervicitis, 43(ID) complications of, 44(ID) Chlamydia trachomatis infections, 43(ID) genital ulcers, 46–47(ID), 46t(ID) Neisseria gonorrhoeae infections, 43–44(ID) screening for, 7t(GIM), 9(GIM), 11(GIM), 18(GIM) sexual partner evaluation in, 44(ID), 47–48(ID) syphilis, 47–48(ID) urethritis, 43(ID) complications of, 44(ID) in victims of intimate partner violence, 18–19(GIM) Sexual pain disorders, 82(GIM) Sézary syndrome, 104(HO), Q99(HO) Shawl sign, of dermatomyositis, 4t(RM), 50(DM), 59(RM) Sheehan syndrome central adrenal insufficiency in, 18(EN) hypopituitarism in, Q69(EN) Shift work sleep disorder (SWSD), 64–65(PM) Shiga-like toxin, 62(NP), 71(NP) Shiga toxin, Escherichia coli-produced, 68–69(ID), 68t(ID), Q8(ID) Shigella infections, as reactive arthritis cause, 5(RM), 30–31(RM) Shigellosis, diarrhea in, 66(ID), 66t(ID), 67(ID), Q9(ID) Shingles. See Herpes zoster Shivering, in hypothermia, 88(PM) Shock, 76–78(PM) cardiogenic, 22–23(CV), 76(PM), 77t(PM), Q39(CV) in heart failure, 38–39(CV), 39t(CV), 40(CV) post–myocardial infarction, 26(CV) distributive, 76(PM), 77t(PM) hemodynamic parameters of, 76f(PM), 76(PM) hemorrhagic, 77(PM) in hypernatremia, 17(NP) hypovolemic, 76(PM), 77t(PM) septic, 77(PM), 82–83(PM) in anthrax, 57(ID), 58(ID) treatment of, 83(PM), Q10(PM), Q26(PM), Q66(PM), Q80(PM), Q106(PM) Short-bowel syndrome, 33–34(GA), Q39(GA) Short QT syndrome, 59(CV), 59t(CV) Shoulder “frozen,” 55–56(GIM) Milwaukee, Q4(RM) overuse syndromes of, 2t(RM) rheumatoid arthritis of, 16(RM) Shoulder pain, 53–56(GIM), 54f(GIM), 54t(GIM), 55f(GIM) Shunts agitated saline contrast studies of, Q114(CV) cerebrospinal fluid in idiopathic intracranial hypertension, 4(NR) in normal pressure hydrocephalus, 47(NR) in congenital heart disease, 91–92(CV) Shy-Drager syndrome, 51(NR) Sialorrhea in neuroleptic malignant syndrome, Q64(NR) in Parkinson disease, 49(NR) Siblings, of aplastic anemia patients, 2(HO), 3(HO), Q2(HO) Sickle cell disease, 6t(RM), Q38(HO), Q42(HO) acute chest syndrome of, 30–31(HO), 32(HO), Q62(HO) anemia of, 31(HO), 63(HO) aplastic crisis in, 30t(HO), Q35(HO) infections in, 31(HO) osteomyelitis in, 49(ID) pain in, 29–30(HO), Q42(HO), Q50(HO), Q52(HO), Q72(HO) in pregnancy, 63(HO), Q42(HO) priapism in, 31(HO), 32(HO) pulmonary hypertension of, 31(HO) stroke and, 30(HO), 31(HO) Sickle cells, 29f(HO) Sickle cell syndromes, 28–31(HO), 29t(HO), 30t(HO) Sigmoidoscopy, 107(GIM), Q48(GIM) flexible for colorectal cancer, 48(GA), 49(GA), 49t(GA) contraindication to, 43(GA) Sildenafil, for pulmonary arterial hypertension, 55t(PM)
Silicosis, 42(PM), 42t(PM) accelerated, 42t(PM) acute, 42t(PM) chest radiography in, 3(PM) chronic, 42t(PM) transbronchoscopic biopsy in, 5(PM) tuberculosis and, 42(PM), Q31(PM) Silver sulfadiazine, for burns, 34(DM) Simplified Acute Physiologic Score (SAPS), 95(PM) Simvastatin, 64–65(GIM), 66(GIM), Q158(GIM) interaction with protease inhibitors, 93(ID) Single-balloon enteroscopy, in gastrointestinal bleeding, 80(GA) Single-photon emission computed tomography nuclear perfusion, 4t(CV), 7(CV), 7f(CV), 7t(CV) Sinusitis, 103(GIM), Q107(GIM) brain abscess and, 7t(ID) cough and, 10(PM) Sinus node dysfunction, 48(CV), 49(CV) Sinus symptoms, chronic obstructive pulmonary disease and, 19t(PM) Sinus tract drainage, in osteomyelitis, 49(ID) Sirolimus drug interactions of, 73(ID), Q18(ID) for kidney transplantation, 93t(NP) Sitagliptin, 9t(EN) Sitophobia, 44(GA) 6-minute walk test, 3(PM) for idiopathic interstitial pneumonia diagnosis, 33(PM) Six Sigma model, for quality improvement, 19–20(GIM) Sjögren syndrome, 46–47(RM), 98(GIM), Q44(GIM) chronic tubulointerstitial disorders in, 45t(NP), 46(NP) classification of, 47t(RM) clinical features of, 3(RM), 46t(RM), 47t(RM) cryoglobulinemic vasculitis and, Q48(RM) diagnosis of, 46(RM) epidemiology of, 46(RM) lymphoma and, 46(RM), Q74(RM) pathophysiology of, 46(RM) prognosis of, 47(RM) treatment of, 46–47(RM) Skin aging-related changes in, 74–76(DM), 74f(DM), 75f(DM) disorders. See Dermatologic disease dry. See Dry skin painful, 1(DM), 2(DM) sloughing of, 1(DM), 2(DM) Skin and soft tissue infections, 12–18(ID) animal bites, 16–17(ID) cutaneous anthrax, 57f(ID), 57(ID), 58(ID) diabetic foot infections, 17–18(ID), 51(ID) human bites, 17(ID) methicillin-resistant Staphylococcus aureus, 12–14(ID), Q56(ID) necrotizing fasciitis, 14–15(ID), 14f(ID), 15f(ID) in nontuberculous mycobacterial infections, 37(ID) rapidly growing mycobacterial, 38(ID) Skin biopsy in alopecia, 65(DM) in autoimmune blistering disease, 46(DM) in basal cell carcinoma, 35(DM) in drug reactions, 14(DM) in erythroderma, 65(DM) in lentigo maligna, Q7(DM) in lichen planus, 12(DM) in melanoma, 37–38(DM) in nephrogenic systemic fibrosis, 54(DM) in pigmented purpura, 17(DM) in psoriasis, 10(DM), 11(DM) in rosacea, 21(DM), 22(DM) in small-fiber neuropathy, 70f(NR) in stasis dermatitis, 8(DM) in warts, 20 Skin cancer, 10(GIM), 34-39(DM). See also Basal cell carcinoma; Melanoma; Squamous cell carcinoma in darker-skinned patients, 77(DM), 77f(DM) Kaposi sarcoma, 61(DM) in organ transplant recipients, 1(DM), 54(DM), Q23(DM) risk factors, 1t(DM) screening for, 1Q40(DM), 1t(DM) tumor necrosis factor-α inhibitors and, 13(RM) Skin examination, 1(DM) Skin infections. See also Dermatologic disorders bacterial, 22–26(DM) fungal, 1(DM), 26–27(DM), 68–69(DM), 69f(DM), 70t(DM) in obesity, 10(DM), 60(DM) in older persons, 75(DM), 76(DM) viral, 27–31(DM) Skin lesions. See Dermatologic disorders Skin of color. See also African Americans; Asian Americans; Asians; Hispanics dermatologic diseases of, 76–78(DM) Skin tags, 40(DM), 56(DM), 60(DM) Skip lesions, in Crohn disease, 35–36(GA) Sleep apnea. See also Obstructive sleep apnea central syndromes of, 67(PM), Q4(PM) high-altitude periodic breathing and, 69(PM), Q104(PM) chronic obstructive pulmonary disease and, 19t(PM) Sleep deprivation, 64(PM), 65(PM) Sleep-disordered breathing, neuromuscular weakness in, 73t(PM) Sleep disorders in Alzheimer disease, 43(NR), 44(NR) in fibromyalgia, 27(RM) in Lewy body dementia, 45(NR) in Parkinson disease, 49t(NR), 50(NR) in stroke, 39(NR) Sleep hygiene, 44(GIM), Q153(GIM) Sleep latency tests, 64(PM), Q12(PM) Sleep medicine, 64–68(PM) central sleep apnea syndromes, 67(PM), Q4(PM) high-altitude periodic breathing and, 69(PM), Q104(PM) excessive daytime sleepiness, 64(PM), 64t(PM), 65–66(PM), Q12(PM) obstructive sleep apnea, 65–66(PM) shift work sleep disorder, 64–65(PM) sleep-related hypoventilation syndromes, 68(PM), 68t(PM)
57
Cumulative Index
Small-fiber neuropathies, 68(NR), 69(NR), 70f(NR) in diabetes mellitus, 71(NR), 71t(NR) Small intestinal bacterial overgrowth, 31t(GA), 32f(GA), 33(GA), 33t(GA), 34(GA), Q55(GA) Small intestinal radiography, in gastrointestinal bleeding, 80(GA) Small intestine, disorders of, 30–45(GA) Small intestine cancer, Peutz-Jeghers syndrome and, 47–48(GA) Smallpox as bioterrorism agent, 56(ID), 56t(ID), 58f(ID), 58(ID) differentiated from varicella, 58(ID) eradication of, 56(ID) Smallpox immunization, 58(ID) in health care providers, Q17(ID) Smoke inhalation. See Inhalational injuries, acute Smoking, 17(GIM) abdominal aortic aneurysm and, 7t(GIM), 97(CV), Q151(GIM) aortic disease and, 93(CV) asthma and, 7(PM) bladder cancer and, 7(NP), 94(HO), Q111(HO) cervical cancer and, 78(HO) chronic obstructive pulmonary disease and, 17–18(PM), 18t(PM), 19(PM) chronic pancreatitis and, 25(GA) colorectal cancer and, 46(GA), 48(GA) coronary artery disease and, 12(CV), 12t(CV), 13(CV), Q5(CV) cough and, 37(GIM) erectile dysfunction and, 74(GIM) esophageal cancer and, 11(GA), 82(HO) gastroesophageal reflux disease and, 7(GA) as head and neck cancer cause, 88(HO) hypertension and, 35t(NP), 39(NP) implication for female contraception, 84(GIM), 86(GIM), Q164(GIM) inflammatory bowel disease and, 38(GA) low bone mass in, 68t(EN) lung cancer and, 58(PM), Q6(PM), Q87(PM) as lung cancer cause, 84(HO), 87(HO) myocardial infarction and, Q48(CV) pancreatic adenocarcinoma and, 26(GA) parenchymal lung disease and, 35(PM) peripheral arterial disease and, 99(CV), 100(CV) pneumothorax and, 46(PM) renovascular hypertension and, 41–42(NP) rheumatoid arthritis and, 21(RM), Q94(RM) sinusitis and, 103(GIM) synergistic interaction with asbestos exposure, 58(PM) Smoking cessation in cerebral aneurysm, 71t(NR), Q8871(NR) chronic cough and, 37(GIM) in chronic obstructive pulmonary disease, 18(PM), 26(PM), 27(PM), Q75(PM) counseling in, 17(GIM), 18(GIM), Q10(GIM), Q27(GIM) for diabetes mellitus prevention, 4t(EN), 6(EN) high-density lipoprotein cholesterol levels and, 67(GIM) lung cancer risk after, 58(PM), Q87(PM) in multiple sclerosis, 61(NR) in parenchymal lung disease, 35(PM) pharmacotherapy in, 17(GIM), 18(GIM) in pneumonia, 23(ID) preoperative, 27(PM) Snake bites, as hemolytic anemia cause, 35(HO) Social anxiety disorder, 111(GIM) Society of Critical Care Medicine, acute respiratory distress syndrome classification recommendation from, 70(PM) Sodium serum disorders of, 10–17(NP) serum levels of, in diabetes insipidus, 20–21(EN) Sodium bicarbonate for chronic kidney disease, Q49(NP) for diabetic ketoacidosis, 25(NP) for hyperkalemia, 21(NP) for hypokalemia, 19(NP), 19(PM) for metabolic acidosis, 84–85(NP), Q22(NP) for methanol poisoning, 26(NP) for salicylate toxicity, 26(NP), Q66(NP) for tricyclic antidepressant overdose, 91t(PM), Q28(PM) Sodium channel blockers for arrhythmias, 51t(CV) Brugada syndrome and, 59(CV) Sodium cyanide poisoning, 90(PM) Sodium nitroprusside for cardiogenic shock, 39t(CV) in pregnancy, 109t(CV) Sodium polystyrene, for hyperkalemia, Q22(NP), Q56(NP), Q74(NP) Sodium restriction, for ascites, 63(GA) Sodium thiosulfate, for calciphylaxis, 54(DM) Soft tissue infections. See Skin and soft tissue infections Solar lentigines, 41(DM) Soldiers, head injuries in, 12(NR), Q56(NR) Somatization, 50(GIM), 112(GIM), Q105(GIM) Somatoform disorders, 112–113(GIM), Q105(GIM) vs. multiple sclerosis, 60t(NR) Somatostatin, for variceal bleeding, 62t(GA) Somatostatin analogues, for acromegaly, 25(EN), 26(EN), Q83(EN) Somogyi phenomenon, Q31(EN) Sorafenib, 69t(HO) for renal cell carcinoma, 96(HO) Sorbitol-MacConkey agar, 69(ID) Sotalol for arrhythmias, 51t(CV) in pregnancy, 108t(CV) for supraventricular tachycardia, in pregnancy, 108(CV) Southern tick-associated rash illness (STARI), 25t(ID), 27(ID) Spasms coronary, 19(CV) diffuse esophageal, 4–5(GA), Q14(GA) Spasticity in compressive myelopathies, 65(NR) in multiple sclerosis, 58(NR), 63(NR), 63t(NR), Q63(NR) Specificity, of diagnostic tests, 4(GIM), 5t(GIM) Speed maneuver, 54t(GIM) Spermicides, urinary tract infections and, 30(ID) Spherocytes, 26f(HO), 26(HO), 48(HO), Q41(HO)
58
Spider bites, 32–33(DM), 33f(DM) as hemolytic anemia cause, 35(HO) Spinal cord compression, 53(GIM), 64(NR), 65(NR), 66f(NR), Q25(NR), Q37(GIM), Q40(NR) in lung cancer, 86(HO) as medical emergency, Q144(HO) metastatic, 108(HO) in multiple myeloma, 13(HO), 14(HO) Spinal cord disorders, 64-65(NR), Q77(NR). See also Myelopathies in multiple sclerosis, 58f(NR) Spinal cord injury urinary tract infections in, 29(ID) ventilatory failure in, 74(PM) Spinal stenosis, low back pain and, 51(GIM), 51t(GIM), 52(GIM) Spine. See also Cervical spine; Lumbar spine; Thoracic spine ankylosing spondylitis of, 28(RM), 29(RM), Q51f(RM) diffuse idiopathic skeletal hyperostosis of, 23–24(RM), 23f(RM) osteoarthritis of, 22(RM) osteoporotic fractures in, 36(RM), Q95(RM) Spinocerebellar atrophy disorders, 52(NR) Spinosad, for lice, 32(DM) Spiral enteroscopy, in gastrointestinal bleeding, 80(GA) Spirometry, 1(PM), 1t(PM), 2f(PM) in asthma, 8(PM), 9f(PM), 9(PM) in exacerbations, 15(PM) during pregnancy, 15(PM) in chronic obstructive pulmonary disease, 19(PM), Q1(PM), Q81(PM) in occupational lung disease surveillance, 40(PM) preoperative, 128(GIM), 129(GIM) Spironolactone for acne, 20t(DM) for chronic kidney disease, 83(NP) for heart failure, 32(CV), 33t(CV), 34–35(CV), Q36(CV) for hirsutism, in polycystic ovary syndrome, 58(EN), Q82(EN) hyperkalemia and, 21(NP) for primary hyperaldosteronism, 51(EN), 52(EN) proteinuria and, 85(NP) for refractory hypertension, Q29(NP) teratogenicity of, 4(DM), Q82(EN) Spleen. See also Splenectomy; Splenomegaly in sickle cell disease, 28(HO) Splenectomy for immune (idiopathic) thrombocytopenic purpura, 49(HO) for primary myelofibrosis, 9(HO) for thalassemia, 28(HO) Splenic vein, thrombosis of, 23–24(GA) Splenomegaly in chronic myeloid leukemia, 9(HO) in congenital hemolytic anemia, 26(HO) in hairy cell leukemia, 102(HO) in hereditary spherocytosis, 26(HO), Q41(HO) in MALT lymphoma, 101(HO) in thrombocytopenia, 47(HO), 48(HO) Spondylitis. See also Ankylosing spondylitis in inflammatory bowel disease–associated arthritis, 30(RM) Spondyloarthritis, 27–34(RM), 50(GIM) classification of, 28–31(RM) clinical features of, 29t(RM) diagnosis of, 31–33(RM), Q69(RM) environmental triggers of, 28(RM) eye disorders in, 5t(RM) genetic factors in, 28(RM) imaging studies in, 32–33(RM), 32f(RM) pathophysiology of, 28(RM) polyarthritis in, 2–3(RM), 3t(RM) treatment of, 33–34(RM), Q21(RM) Spondyloarthropathy. See Spondyloarthritis Spondylodiskitis, 51–52(ID) Spongiosis, 5(DM) Sporotrichosis, 42–43(ID), Q69(ID) Sports participation in aortic coarctation, 90(CV) in valvular heart disease, 75(CV) Spurling test, 54t(GIM) Sputum production, in chronic obstructive pulmonary disease, 20(PM), 25(PM) Squamous cell carcinoma azathioprine-related, 93(NP) cervical, 78(HO) esophageal, 11(GA) of the head and neck, 88(HO) hypercalcemia and, 63(EN) pulmonary, 57(PM), 85(HO) polypoid, 61f(PM) of the skin, 8(DM), 36–37(DM), 36f(DM), Q25(DM) in darker-skinned patients, 77f(DM) in HIV/AIDS, 61(DM) in situ (Bowen disease), 36(DM) lichen planus and, 12(DM), 70(DM) oral, 72(DM), 72f(DM) in organ transplant recipients, 1(DM), 54(DM), Q23(DM) “Squeeze” test, 61(GIM) Stanford Health Assessment Questionnaire, 19(RM) Stanozolol, contraindication in pregnancy and lactation, 4t(DM) Staphylococcal infections animal bites in, 16(ID) in burn victims, 84(PM) diabetic foot infections in, 17(ID) postinfectious glomerulonephritis and, 58(NP), 59(NP), Q51(NP) Staphylococcal scalded skin syndrome, 22(DM), 65(DM) Staphylococcus aureus, colonization with, 10(DM) Staphylococcus aureus infections, 19t(DM), 81(CV), 82(CV) abscesses, 22(DM), 23(DM), 23f(DM) arthritis in, 55(RM), 57(RM), Q27(RM) bloodstream infections in, Q10(ID) carbuncles, 22(DM) cellulitis, 22(DM) central line bloodstream infections in, 81(ID), 82(ID) community-acquired pneumonia in, 23t(ID) ecthyma, 22(DM)
Cumulative Index
erysipelas, 22(DM) folliculitis, 19t(DM), 22–23(DM), 54(DM) furuncles, 22(DM) impetigo, 22(DM) meningitis in, 2(ID), 5t(ID), 6t(ID) methicillin-resistant (MRSA), 12–14(ID), 22(DM), 24(DM), 32(DM), 33(DM) antibacterial therapy for, 97–98(ID), 98t(ID), 99(ID), 101(ID), Q84(ID), Q101(ID), Q102(ID) cellulitis in, Q84(ID), Q102(ID) community-acquired pneumonia in, 19(ID), 22(ID), 23t(ID) community-associated, 13–14(ID), Q62(ID) of human bite wounds, 17(ID) meningitis in, 6t(ID) necrotizing fasciitis in, 15(ID) skin infections in, 12(ID), 13–14(ID), 15(ID) surgical site infections in, 79(ID) in transplant recipients, 75(ID), 76(ID) osteomyelitis in, 49(ID), 50(ID), Q63(ID) pneumonia in, 94(ID) preoperative nasal decolonization of, 79–80(ID) skin infections in, 12(ID) spinal epidural abscess in, 8(ID) staphylococcal scalded skin syndrome, 22(DM) surgical site infections in, 79–80(ID) treatment of, 83(ID) vancomycin-intermediate sensitive, Q10(ID) vertebral osteomyelitis in, 52(ID) Staphylococcus epidermidis infections, meningitis in, 5t(ID), 6t(ID) Staphylococcus saprophyticus infections, of urinary tract, 29(ID) Starvation, ketone levels in, 4(NP) Stasis dermatitis, 5–6(DM), 7–8(DM), 10(DM), Q2(DM), Q64(DM) vs. cellulitis, 9t(DM) vs. pigmented purpuric dermatoses, 16–17(DM) Statins, 64–65(GIM), 65t(GIM), 68(GIM), Q52(GIM) for abdominal aortic aneurysms, 97(CV) for acute coronary syndromes, 22(CV) adverse effects of, 17(CV), 64–65(GIM), 66t(GIM), Q158(GIM) for aortic atheromas, 96(CV) cardioprotective effects of, 17(CV) coronary stents and, 19(CV) drug interactions of, Q20(CV) in heart transplant recipients, Q20(CV) lack of cardioprotective effects, 2(CV) as myopathy cause, 77(NR), 77t(NR), Q74(NR) for nonalcoholic steatohepatitis, 58–59(GA) for non–ST-elevation myocardial infarction, Q65(CV) for peripheral arterial disease, 99(CV) for stroke, 36(NR), Q62(NR), Q73(NR) use in chronic kidney disease, 86(NP), Q96(NP) use in cirrhosis, 70(GA) use in diabetes mellitus, 6(EN), Q45(EN) use in nonalcoholic steatohepatitis, 58–59(GA) Statistical analysis, 3–4(GIM) Status epilepticus, 22–23(NR) generalized convulsive, 22(NR), 23f(NR), 23(NR), Q43(NR) nonconvulsive, 22–23(NR) Steatohepatitis, nonalcoholic, 53t(GA), 58–59(GA), Q2(GA) Steatorrhea, 32(GA) Stem cell transplantation, for myeloma cast nephropathy, 74(NP) Stenotrophomonas maltophilia, 99(ID), 101(ID) Stents aspirin and, 20(CV) for coronary artery disease, 18–19(CV) bare-metal, 18–19(CV), 18t(CV), 29(CV) in diabetic patients, 29(CV) drug-eluting, 18–19(CV), 18t(CV), 29(CV), Q61(CV) for critical limb ischemia, 102(CV) for peripheral arterial disease, 100–101(CV) for radiation-induced coronary artery disease, 102(CV) for thoracic aortic aneurysms, 94(CV) Step-down therapy, for asthma, 11(PM), 13f(PM), Q9(PM) Sterilization female, 85t(GIM), 86(GIM) male, 85t(GIM) Stevens-Johnson syndrome, 16(DM), 62f(DM), 99(ID) anticonvulsant-related, 18–19(NR), 19t(NR), Q85(NR) chemotherapy-related, 58(DM) overlap with erythema multiforme, 61(DM), 62f(DM) Stiff-person syndrome, 80t(NR) Still disease, adult-onset, 3(RM), 4t(RM), 72–73(RM), 73t(RM), Q87(RM) fever of unknown origin in, 53(ID) Stings, insect, 31(DM), 32(DM), 32f(DM), 44(DM) Stomach. See also Gastric; Gastrointestinal entries disorders of, 12–23(GA) watermelon, 74(GA) Stool, blood in, 30(GA) Stool analysis Bristol Stool Form Scale for, 39f(GA), 39(GA) in chronic diarrhea, 30(GA) in colorectal cancer, 48–49(GA), 49t(GA) in diarrhea, 66(ID) DNA tests in, 48(GA), 49(GA), 49t(GA) in inflammatory bowel disease, 36(GA) Stool softeners, 41(GA) STOP-BANG questionnaire, for sleep apnea, 128–129(GIM), 129t(GIM) Stork leg deformity, 71(NR) Straight-leg raise test, 51(GIM) Strength, impaired. See Weakness Streptococcal infections of animal bites, 16(ID) diabetic foot infections in, 17(ID) group A β-hemolytic (GABHS) cellulitis treatment in, Q102(ID) infection control in, Q67(ID) skin infections in, 12(ID), 15(ID), Q67(ID) toxic shock syndrome in, 16(ID), Q67(ID) postinfectious glomerulonephritis and, 58–59(NP), Q51(NP), Q53(NP) skin infections in, 12(ID) Streptococcus agalactiae infections
meningitis in, 2(ID) necrotizing fasciitis in, 14(ID) Streptococcus infections, as arthritis cause, 55(RM) Streptococcus pneumoniae infections, 25(PM) community-acquired pneumonia in, 19(ID), 21t(ID), 23t(ID), 24(ID), Q79(ID) drug-resistant, 21t(ID), Q34(ID) meningitis in, 2(ID), 2t(ID), 3(ID), 4(ID), 6t(ID), Q73(ID) neutropenia in, 4(HO) pneumonia in, 94(ID) primary immunodeficiency syndromes in, 55(ID) in transplant recipients, 75(ID), Q92(ID) Streptococcus pyogenes infections, 23(DM) necrotizing fasciitis in, 14(ID) toxic shock syndrome in, 16(ID) Streptokinase, for ST-elevation myocardial infarction, 25t(CV) Streptomycin for pneumonic plague, 59(ID) for tuberculosis, 35t(ID) for tularemia, 60(ID) Stress, functional hypothalamic amenorrhea and, Q44(EN) Stress cardiomyopathy, 19(CV) Stress testing cardiopulmonary, 32(CV) in coronary artery disease, 3–8(CV), 4t–5t(CV), 6f(CV), 7f(CV), 7t(CV), 14(CV), 15f(CV), Q1(CV), Q115(CV) with diabetes mellitus, 28–29(CV) in diabetes mellitus, 29(CV) in heart failure, 32(CV) in hypertrophic cardiomyopathy, 41(CV) pharmacologic, 5t(CV), 6(CV), 77(CV), Q107(CV) vs. pharmacologic stress testing, 3–4(CV) in post-revascularization angina, 19(CV) preoperative, 125(GIM), Q168(GIM) in reactive airways disease, Q107(CV) in valvular heart disease, 75(CV) in women, 30(CV), Q28(CV) Striae in Cushing syndrome, 43(EN), 44f(EN) Wickham, 11(DM), 13f(DM), 70(DM), 70f(DM) Striatonigral degeneration, 51(NR) Stridor in anaphylaxis, 85(PM) in vocal cord dysfunction, 10(PM) Stroke, 24–40(NR) acute, 28–33(NR) neuroimaging in, 29(NR), 31(NR), Q7(NR) aortic atheromas and, 96(CV) atrial fibrillation and, 53–54(CV), 53t(CV) cardiogenic, 32(NR) central sleep apnea and, 67(PM) chronic obstructive pulmonary disease and, 19t(PM) complications of, prevention of, 38–39(NR) diagnosis of, 24(NR), 25t(NR), Q7(NR) differentiated from hypoglycemia, Q65(EN) disability in, 40(NR) dural sinus venous thrombosis and, 33–35(NR) dysphagia in, 39(NR) as epilepsy cause, 15(NR) hemorrhagic, 24(NR), 27(NR) acute, 32–33(NR) differentiated from ischemic stroke, 24(NR) increased intracranial pressure in, 33(NR) risk factors for, 40t(NR) hypertension management in, 30–31(NR), Q10(NR) ischemic, 24(NR) acute, 28–32(NR), 30f(NR), 30t(NR), Q17(NR), Q31(NR) in asymptomatic carotid stenosis, 40(NR) cardioembolic, 26–27(NR), 27f(NR) classification of, 26(NR) cryptogenic, 26(NR), 27(NR), Q57(NR) diagnosis of, 28–29(NR), 30f(NR) differentiated from hemorrhagic stroke, 24(NR) hemorrhagic conversion of, 39(NR) hypertension in, Q41(NR) hypopituitarism in, 18(EN) imaging studies in, 29(NR), 31(NR) prevention of, 31–32(NR), 36(NR) recurrent, 36(NR), 38–39(NR) risk factors for, 40t(NR) time of onset of, 29(NR) treatment of, 29–32(NR), 32f(NR), Q73(NR) in women, 30(CV), Q62(CV) morbidity and mortality in, 24(NR), 25(NR), Q79(NR) neurologic deficits in, 38–39(NR), 40(NR) patent foramen ovale and, 83(CV), 84(CV) perioperative, 39(NR), 134(GIM) prevention of, 69(GIM) primary, 40(NR) secondary, 36–38(NR), Q34(NR) recovery in, 40(NR), Q65(NR) recurrent, 36(NR), 38–39(NR) rehabilitation in, 40(NR), Q65(NR) respiratory depression in, 73(PM) risk factors for, 36(NR) sickle cell disease and, 30(HO), 31(HO) stroke unit admission for, 36(NR) subtypes of, 24–28(NR) in systemic lupus erythematosus, 38(RM) transient ischemic attacks and, 24–26(NR) Stroke centers and units, 36(NR), Q79(NR) Stromal tumors, gastrointestinal, 19(GA), 74(GA) Strongyloides stercoralis infections, in transplant recipients, 76(ID) Structural heart disease atrial fibrillation and, Q30(CV) diagnostic testing for, 9–10(CV), 10t(CV) pregnancy in, 106(CV) ventricular tachycardia in, 57(CV) Struvite kidney stones, 75(NP), 78t(NP) Struvite (magnesium ammonium phosphate) urinary crystals, 6t(NP)
59
Cumulative Index
Study design, 1–3(GIM), 2t(GIM) experimental studies, 1(GIM), 2t(GIM) observational studies, 1–3(GIM), 2t(GIM) validity, 1(GIM) Subacute cutaneous lupus erythematosus, Q16(RM) Subarachnoid hemorrhage. See Hemorrhage, subarachnoid Subdural hematoma, 12(NR), Q68(NR) Substance use disorders, 17-18(GIM). See also Alcohol use/abuse; Drug abuse domestic violence and, 19(GIM) in physicians, 27(GIM), 27t(GIM) Substituted judgment, 24–25(GIM), Q109(GIM) Sudden cardiac death, 13(CV), 60–61(CV) acute management of, 60–61(CV) Brugada syndrome and, 59(CV) cardiac tumors and, 47(CV) chemotherapy and, 104t(CV) in diabetes mellitus, 16(EN) epidemiology of, 60(CV) hypertrophic cardiomyopathy and, 43(CV), 44t(CV), 45(CV), 46(CV), Q94(CV) long QT interval and, 58(CV) prevention of, 36(CV) short QT syndrome and, 59(CV) ventricular tachycardia and, 57(CV) Wolff-Parkinson-White syndrome and, 56–57(CV) Sudden death, in epilepsy, 16(NR) Suicide in ankylosing spondylitis patients, 29t(RM) antiepileptic drug–related, 16(NR) bipolar disorder and, 112(GIM) with drug overdose, 90(PM) physician-assisted, 25(GIM), Q83(GIM) tramadol and, 35(GIM) Sulcus sign, 54t(GIM) Sulfa drugs, urinary crystals and, 6(NP) Sulfasalazine adverse effects of, 11(RM) for inflammatory bowel disease, 37t(GA) for inflammatory bowel disease–associated arthritis, Q30(RM) oligospermia and, 21(RM) in pregnancy, 21(RM) for reactive arthritis, Q2(RM) for rheumatoid arthritis, 11(RM), 20(RM) for spondyloarthritis, 34(RM) Sulfonylureas, 8t(EN) contraindication to, 11(EN), Q53(EN) for type 2 diabetes mellitus, 7(EN) half-life of, 7(EN) hypoglycemia and, in older patients, 14(EN), Q65(EN) myocardial infarction and, 7(EN) surreptitious use of, 17(EN), 17t(EN) toxicity of, 91t(PM) Sulfosalicylic acid (SSA) test, 3(NP) Sumatriptan for cluster headache, 10(NR) for migraine, 6(NR), 7t(NR), Q58(NR), Q70(NR) in pregnancy, 8(NR) Sunburn, as melanoma cause, 106(HO) SUNCT syndrome, 2f(NR), 10(NR) Sun exposure as actinic keratoses cause, 35(DM), 36(DM) herpes labialis–reactivating effect of, Q13(DM) lupus erythematosus–exacerbating effect of, 49–50(DM) as purpura cause, 51(DM) as skin aging cause, 74–75(DM), 74f(DM) as skin cancer cause, 1(DM), 34(DM), 37(DM) as solar lentigines cause, 41(DM) Sunitinib, 69t(HO) for gastrointestinal neuroendocrine tumors, 83(HO) for renal cell carcinoma, 96(HO) Sun protection in lupus erythematosus, 49–50(DM) for older persons, 75(DM) Superior mesenteric artery, thrombosis of, 43(GA) Superior vena cava obstruction, 44t(PM) Superior vena cava syndrome, 107(HO), Q105(HO) Supportive care, in critical care, 92–94(PM) Supranuclear palsy, progressive, 49(NR), 51(NR), Q76(NR) Suprasellar masses growth hormone deficiency and, 19(EN) hyperprolactinemia in, 22–23(EN) Supraventricular tachycardias, 50(CV), 55–57(CV), Q59(CV) Sural nerve, biopsy of, 69(NR) Surgery coronary stents and, 18–19(CV) implantable cardioverter-defibrillators and, Q71(CV) as stroke cause, 39(NR) as venous thromboembolism cause, 54(HO), 59–61(HO), Q46(HO) Surgical resection, of cancer, 67(HO) Surgical site infections, 79–80(ID) 80t(ID) in pregnancy, Q90(ID) Surrogate decision-making, 24–25(GIM) Susac syndrome, vs. multiple sclerosis, 60t(NR) Swallowing difficulty in. See Dysphagia mechanisms of, 3(GA) Swan neck deformity, 17t(RM), 18f(RM) Sweat chloride testing, Q20(PM), Q93(PM) Sweet syndrome, 10(HO), 58–60(DM), 59f(DM), Q34(DM), Q89(ID) Symblepharon, 47f(DM) Sympathomimetics hypertension and, 34t(NP) for weight loss, 72(GIM) Sympathomimetic syndromes, 88t(PM) Synchronized intermittent mandatory ventilation (SIMV), 80(PM) Syncope, 45–47(GIM) in arrhythmogenic right ventricular cardiomyopathy, Q119(CV) cardiac causes of, 46(GIM), 47(GIM), Q21(GIM), Q156(GIM) characteristics of, 13t(NR) convulsive, 17(NR), Q20(NR)
60
diagnostic evaluation of, 46–47(GIM), Q31(GIM) in elderly patients, 46(GIM), 47(GIM), Q21(GIM), Q156(GIM) management of, 47(GIM) neurocardiogenic, 45–46(GIM), 47(GIM) orthostatic, 46(GIM), 47(GIM), Q86(GIM) risk stratification of, 47(GIM) vasovagal, 17(NR), Q86(GIM) Syndrome of inappropriate antidiuretic hormone secretion, 10(NP), Q13(NP) causes of, 13t(NP) differentiated from diabetes insipidus, 21(EN) hyponatremia in, 14–15(NP), 15t(NP), Q13(NP), Q69(NP) lung cancer and, 59t(PM) serum and urinary indices in, 13t(NP) Syndrome of mineralocorticoid excess, 31(NP), 32f(NP) Syndromic surveillance, of bioterrorism-related illness, 56(ID) Synovial biopsy, in monoarticular arthritis, 2(RM) Synovial fluid analysis, 1t(RM), 8(RM), 9(RM) in septic arthritis, 54–55(RM) Synovitis, in rheumatoid arthritis, 17(RM), 18f(RM) Syphilis, 47–48(ID) latent, 47t(ID) primary, 47t(ID), Q28(ID) screening for, 7t(GIM), 11(GIM) secondary, 47(ID), 47t(ID) tertiary, 47(ID) transmission via human bite wounds, 17(ID) treatment of, 47–48(ID), 47t(ID) Systematic reviews, 3(GIM) Systemic disease, skin manifestations of, 48–61(DM) Systemic inflammatory diseases, 70–75(RM) cardiovascular disease and, 2(CV), 2t(CV) vs. multiple sclerosis, 60t(NR) myopathies. See Inflammatory myopathies vasculitis. See Vasculitis Systemic inflammatory response syndrome (SIRS), 82(PM) Systemic lupus erythematosus, 34–41(RM) anemia in, Q26(HO) antinuclear antibodies in, 6(RM) cardiovascular disease and, 2(CV), 2t(CV) chronic tubulointerstitial disorders in, 45t(NP), 46(NP) clinical features of, 35–38(RM), Q5(RM) cardiovascular, 37(RM), 38(RM) dermatologic, 4t(RM) gastrointestinal, 37–38(RM) hematologic, 37(RM) malignancy, 38(RM), Q11(RM) mucocutaneous, 35(RM), 35t(RM) musculoskeletal, 35–36(RM) neurologic, 36–37(RM), 37t(RM), 38(RM) pulmonary, 37(RM) renal, 36(RM) contraception in, 40(RM), Q82(RM) definition of, 48(DM) diagnosis of, 38–39(RM), 38t(RM), 39t(RM), Q29(RM) differential diagnosis of, 39(RM) epidemiology of, 35(RM) evaluation of, 9(RM) fever in, 3(RM) vs. fibromyalgia, 1(RM) flares of, 40(RM) follow-up in, 41(RM) glomerulonephritis in, 59–60(NP), 59t(NP), Q5(NP) immunizations in, 40(RM) membranous glomerulopathy in, 51(NP) neonatal, 40(RM) pathophysiology of, 35(RM) polyarthritis in, 2–3(RM), 3t(RM) in pregnancy, 80(NP) pregnancy in, 40–41(RM), Q66(RM) prognosis of, 41(RM) vs. rosacea, 21(DM), 22(DM) thrombotic microangiography in, 62(NP), 62t(NP) treatment of, 40(RM) Systemic sclerosis, 41–45(RM) cardiovascular disease and, 2t(CV) classification of, 41(RM) clinical features of, 42–44(RM), Q61(RM) CREST syndrome of, 4(RM), 41f(RM), 41(RM) dermatologic disorders in, 4t(RM) diagnosis of, 41–42(RM) diffuse cutaneous, 41(RM), 42(RM), Q7(RM), Q93(RM) diffuse parenchymal lung disease and, 35(PM) epidemiology of, 41(RM) limited cutaneous, 41(RM), 42(RM), Q72(RM) lung disease in, 4(RM) pathophysiology of, 41(RM) pregnancy in, 45(RM) silicosis and, 42(PM) treatment of, 42–44(RM) Systemic sclerosis sine scleroderma, 41(RM) Systemic vasculitis. See Vasculitis T3. See Triiodothyronine T4. See Thyroxine Tachycardia, 50–52(CV) in anaphylaxis, 85(PM) atrial, 57(CV) atrioventricular nodal reentrant, 56(CV), 56f(CV), Q59(CV) atrioventricular reciprocating, 56–57(CV) in cardiac tamponade, 68(CV) long-RP, 56(CV) myopathy and, 41(CV) post-bariatric surgery, 20–21(GA), Q47(GA) in pulmonary embolism, 47(PM) short-RP, 56(CV) supraventricular, 50(CV), 55–57(CV), Q59(CV) wide-complex, Q46(CV), Q104(CV) Tacrine, for Alzheimer disease, 44(NR), 44t(NR), 45(NR) Tacrolimus, 9(DM) diarrhea and, Q10(NP)
Cumulative Index
drug interactions of, 73(ID), Q18(ID) for kidney transplant recipients, 93t(NP) nephrotoxicity of, 47(NP) Tadalafil, for pulmonary arterial hypertension, 55t(PM) Takayasu arteritis, 2t(CV), 40(CV), 63t(RM), 65–66(RM), 65t(RM), 93(CV), Q46(RM), Q79(CV) Takotsubo cardiomyopathy, 19(CV), 40(CV), Q64(CV) Tamm-Horsfall mucoprotein, 5–6(NP), 46(NP), 64(NP), 74(NP) Tamoxifen, 10(GIM) adverse effects of, 72–73(HO), Q120(HO) for breast cancer, 70–71(HO), 72(HO) contraindication in breast cancer, Q86(HO) for ductal carcinoma in situ, 71(HO), Q136(HO) Tamponade, pericardial, 67–68(CV), Q50(CV) Tampons, toxic shock syndrome and, 15(ID) Tamsulosin, 76(NP), 77(NP), Q79(NP), Q81(NP) Tandem stepping test, 52(NR) Tardive akathisia, 54t(NR) Tardive dyskinesia, 54(NR), 55(NR) Tardive dystonia, 53(NR), Q82(NR) Target cells, in thalassemia, 27f(HO), 27(HO), Q47(HO) Targeted therapies, for cancer, 68–69(HO) Target lesions, of erythema multiforme, 62(DM), 62f(DM) Tarsal tunnel syndrome, 62(GIM) Tau proteins in Alzheimer disease, 43(NR) in frontotemporal dementia, 46f(NR), 46(NR) Tazarotene (topical), contraindication during pregnancy and lactation, 4t(DM), Q17(DM) Tearing, excessive, 98(GIM) Technetium-labeled nuclear scans, in gastrointestinal bleeding, 79–80(GA), Q65(GA) Telangiectasia in basal cell carcinoma, 34(DM), 35f(DM) in dermatomyositis, 50(DM) in Fabry disease, 65(NP) gastrointestinal, 74(GA) hereditary hemorrhagic, 48(GA), 74(GA) in photoaged skin, 74f(DM) in systemic sclerosis, 42(RM), 44(RM) Telaprevir, for hepatitis C, 55(GA) Telavancin, 98–99(ID), 98t(ID) Telbivudine, for hepatitis B, 55(GA), 55t(GA) Telmisartan, 85(NP) Telogen effluvium, 66(DM), Q37(DM) Temozolomide, for melanoma, 106–107(HO) Temporal artery biopsy, 2(NR) in giant cell arteritis, Q24(RM) Temporal lobe epilepsy, 15f(NR), 15(NR), 17(NR), 18f(NR) refractory, Q26(NR) Temporal lobe seizures, 14(NR) Temporomandibular disorders, 106–107(GIM), Q97(GIM) Temsirolimus, for renal cell carcinoma, 96(HO) Tender points, in fibromyalgia, 26–27(RM), 26f(RM), 27t(RM) Tendinitis, rotator cuff, 54(GIM), 55(GIM), Q122(GIM) Tendinopathy, Achilles, 61–62(GIM) Tenecteplase, for ST-elevation myocardial infarction, 25(CV), 25t(CV) Tennis elbow, 56(GIM), Q132(GIM) Tenofovir, 90(ID), 93(ID), 93t(ID) for hepatitis B, 55(GA), 55t(GA) renal tubular acidosis and, Q76(NP) Tenosynovitis animal bites and, 16(ID) de Quervain, 57(GIM), Q96(GIM) Teratogens, 15(HO), 86(GIM), 87t(GIM), 107–108(CV), 107t(CV), 108t(CV), 109t(CV), 111(CV), Q32(GIM) ACE inhibitors, 43(NP), 78–79(NP), 79t(NP), 81(NP), Q70(NP), Q97(NP) angiotensin receptor blockers, 43(NP), 78–79(NP), 79t(NP), 81(NP), Q70(NP) anticonvulsants, 19(NR), 21(NR), 22(NR), Q12(NR) antimigraine drugs, 8–9(NR) isotretinoin, 20t(DM), 21(DM) lisinopril, Q70(NP) methimazole, Q78(EN) methotrexate, 4t(DM), 11(RM) propylthiouracil, Q78(EN) spironolactone, Q82(EN) tetracyclines, 4(DM) thalidomide, 4(DM), 4t(DM) Teratomas, 63(PM) differentiated from thyroid nodules, 35t(EN) Terbutaline, for chronic obstructive pulmonary disease, 22t(PM) Teriparatide, for osteoporosis, 70(EN), 71(EN), 72(EN), Q10(EN), Q59(EN) Terlipressin for hepatorenal syndrome, 64(GA) for variceal bleeding, 62t(GA) Terminally ill patients end-of-life care for, 25(GIM), 28–29(GIM), 28f(GIM) palliative care for, 27–32(GIM) Testicular cancer, 47–48(GA), 93–94(HO), Q117(HO), Q133(HO) poorly differentiated, 105(HO) Testicular torsion, 78(GIM), 79(GIM), Q110(GIM) Testosterone bioavailable, 52(EN) free, 52(EN) assays of, 52–53(EN), Q33(EN), Q51(EN) in hyperandrogenism, Q62(EN) morning measurement of, Q51(EN) Testosterone assays, 52–53(EN), Q33(EN), Q51(EN) Testosterone deficiency, 77(GIM), 77t(GIM), Q40(GIM) in hyperprolactinemia, 23(EN) Testosterone therapy, 77(GIM), Q166(GIM) adverse effects of, 55(EN), 55t(EN) for hypogonadism, 54–55(EN), 69(EN) Testosterone-to-estrogen ratio, in gynecomastia, 56(EN), Q18(EN) Tests. See Diagnostic tests Tetanus, diphtheria, pertussis immunization, 12t(GIM), 13(GIM), 15(GIM), 16(GIM), 87(GIM) in HIV/AIDS patients, 88(ID), 89(ID) in transplant recipients, 77t(ID) Tetanus prophylaxis, 34(DM) animal bites and, 16(ID) Tetracyclines for acne, 20t(DM)
for cellulitis, 24(DM), 25(DM) esophagitis and, 6(GA) for Helicobacter pylori infection, 15(GA) for hidradenitis suppurativa, 22(DM) for purulent cellulitis, Q62(ID) teratogenicity of, 4(DM) Tetralogy of Fallot, 90–91(CV), 91f(CV) repaired, 86t(CV), 91(CV), Q55(CV) Thalassemia, 27–28(HO), 28t(HO), 29t(HO), Q31(HO), Q47(HO), Q58(HO) in pregnancy, 63(HO) Thalidomide for Behçet disease, 71(RM) contraindication during pregnancy and lactation, 4t(DM) for multiple myeloma, 15(HO) for Sweet syndrome, 60(DM) teratogenicity of, 4(DM), 4t(DM) Theophylline for asthma, 11(PM), 13f(PM), 14(PM) during pregnancy, 16(PM), Q29(PM) for chronic obstructive pulmonary disease, 22t(PM) toxicity of, 91t(PM) Therapeutic Intervention Scoring System (TISS), 95(PM) Thermoregulation, impaired, 86–87(PM), 88(PM) Thiamine deficiency after bariatric surgery, 22(GA), 22t(GA), Q67(GA) as dementia cause, 42t(NR) Thiazolidinediones, 8t(EN) cardiovascular risks of, 29(CV) contraindications to, 11(EN) Thienopyridine adenosine diphosphate, platelet function effects of, 52(HO) Thin glomerular basement membrane disease, 65(NP) Thiopurine methyltransferase deficiency, 11(RM) Thoracentesis, 108(HO), 109(HO) in parapneumonic effusions, 23(ID), Q94(ID) in pleural malignancy, 45(PM), Q71(PM) Thoracic spine, osteoporotic fractures in, Q95(RM) Thoracostomy tubes, for parapneumonic effusions, 45(PM), Q100(PM) Thorax, cardiotoxic radiation therapy to, 102–103(CV), 103t(CV), Q6(CV), Q40(CV), Q77(CV) 3 Incontinence Questions (3IQ), 121(GIM), 122f(GIM) Thrombin, 42f(HO), 42(HO) Thrombin clotting time, 43(HO) Thrombin inhibitors direct reversal of, 59t(HO) for venous thromboembolism, 56–57(HO) effect on thrombin clotting time, 43(HO) Thrombocytopenia, 4(HO), 47–52(HO) in chronic myelomonocytic leukemia, 6(HO) essential, 8(HO), Q54(HO) evaluation of, 47–49(HO), 48t(HO) in hemolytic uremic syndrome, 62(NP), Q47(NP) heparin-induced, 50–51(HO), 50t(HO), 83(CV) intracranial hemorrhage and, Q5(HO) in myelodysplastic syndromes, 5(HO) in pregnancy, 63–65(HO), Q56(HO) in splenomegaly, 46(HO) in thrombotic microangiopathy, 61(NP) Thrombocytopenic purpura, in systemic lupus erythematosus, 37(RM) Thrombocytosis in essential thrombocytopenia, 8(HO) hyperkalemia and, 20(NP) Thromboembolic disease, estrogen-containing contraceptives and, 84(GIM), 86(GIM), Q164(GIM) Thrombolysis, intra-arterial, for stroke, 30(NR) Thrombolytics contraindications to, 23(CV), 25t(CV), 51(PM), 51t(PM), Q38(CV) cryoprecipitate transfusions in, 39(HO) for pulmonary embolism, 51(PM), 51t(PM) for ST-elevation myocardial infarction, 23(CV), 25–26(CV), 25t(CV), Q38(CV) for stroke, 29–30(NR), 31–32(NR), 33(NR), 37–38(NR), Q17(NR), Q31(NR) Thrombophilia acquired, 54(HO) testing for, 55–56(HO), 56t(HO) Thrombophlebitis, superficial venous, 62(HO), Q16(HO) Thromboprophylaxis, in atrial fibrillation, 53–54(CV), 53t(CV), 55(CV) Thrombosis/thromboembolism, 53–62(HO) acquired, 54–55(HO) atrial fibrillation and, 79(CV) coronary, 19(CV) deep venous, 38(GA) hospital-acquired, 47(PM) pulmonary embolism and, 46–47(PM), 49(PM), 51–52(PM), Q94(PM) stroke and, 39(NR) dural sinus venous, 33–35(NR), Q1(NR) idiopathic, 61(HO), Q20(HO), Q24(HO) in pregnancy, Q43(HO) inherited, 53–54(HO) intracardiac, stroke and, 37(NR), 40t(NR) left ventricular, 27–28(CV) management of, 55–56(HO) perioperative deep venous, 129–130(GIM), 130t(GIM), 131t(GIM), Q28(GIM) in polycythemia vera, 7(HO) portal vein, 71(GA) in pregnancy, 65–66(HO), 65f(HO), 65t(HO), 107(CV), Q18(HO), Q43(HO) anticoagulants for, 108(CV), 110t(CV) prevention of, 55–56(HO) prosthetic valve, 82–83(CV) superior mesenteric artery, 43(GA) venous, 54–55(HO), 54(HO), Q12(HO) acute, Q29(HO) in breast cancer, Q86(HO) in cancer, 61(HO), Q53(HO) diagnosis of, 56(HO) international normalized ratio in, Q24(HO) management of, 55–56(HO), 56–59(HO) postoperative, Q46(HO) in pregnancy, 65–66(HO), 65f(HO), 65t(HO), Q18(HO), Q43(HO) prevention of, 55–56(HO), 59–61(HO), 60t(HO)
61
Cumulative Index
Thrombosis/thromboembolism (continued) recombinant human erythropoietin–related, 38(HO), 39(HO) risk factors for, 60t(HO), Q4(HO) screening for, Q20(HO) treatment of, 61–62(HO), 61t(HO), Q4(HO), Q29(HO) Thrombotic disorders. See Thrombosis/thromboembolism Thrombotic microangiography, 56t(NP), 61–62(NP), 62t(NP), 71(NP) post-kidney transplant, 93(NP) Thrombotic thrombocytopenic purpura, 25(HO), 51(HO), 52(HO), 61–62(NP), 62t(NP), 71(NP), 131(GIM), Q15(NP), Q55(HO) as microangiopathic disease cause, 34(HO), Q55(HO) overlap with hemolytic uremic syndrome, 51–52(HO) in pregnancy, 64(HO), 64t(HO) Thrush. See Candidiasis, oral Th1/Th2 response, in asthma, 7(PM) Thymomas, 63(PM) Thyroglobulin, serum measurement of, 27t(EN), 28(EN) Thyroglossal duct, cysts of, 35t(EN) Thyroid antibodies, 27t(EN), 28(EN) in hypothyroidism, 33(EN), 34(EN) in thyrotoxicosis, 29(EN) Thyroid cancer, 37–38(EN) diagnosis of, Q43(EN) differentiated from benign thyroid nodules, 35(EN), 35t(EN), 36t(EN) follicular, 37(EN) medullary, 28(EN), 62(EN), Q81(EN) multiple endocrine neoplasia type 2 and, 37(EN), Q34(EN) papillary, 37(EN), Q23(EN) poorly differentiated, 37(EN) radiation therapy–related, 110–111(HO) radioactive iodine therapy for, 37–38(EN), Q23(EN) well-differentiated, 37(EN) Thyroid disease, 61(DM) as alopecia cause, 66(DM) myasthenia gravis in, 74(NR), Q44(NR) myopathy in, 76(NR) perioperative management of, 132(GIM) Thyroidectomy hypoparathyroidism complication, Q36(EN) for multinodular goiter, Q66(EN) parathyroid gland injury or removal during, 65(EN) for thyroid cancer, 37(EN), 38(EN), Q23(EN) for thyroid nodules, 36–37(EN), Q43(EN) Thyroid emergencies, 39–40(EN) Thyroid function testing, 27–29(EN), 27t(EN) effects of nonthyroidal illness on, 38(EN) in older patients, Q56(EN) in pregnancy, 38–39(EN) Thyroid gland, physiology of, 27(EN) Thyroid gland disorders, 27–40(EN) evaluation of, 27–29(EN) functional, 29–34(EN) in pregnancy, 38–39(EN) structural, 35–37(EN) thyroid emergencies, 39–40(EN) Thyroid hormone(s). See also Thyroid-stimulating hormone; Thyrotropin-releasing hormone; Thyroxine; Thyroxine-binding hormone; Triiodothyronine deficiency of, maternal or fetal, 38(EN) exogenous exposure to, 30(EN), 30t(EN) total, 27(EN) Thyroid hormone replacement therapy, 33–34(EN), Q69(EN) for central hypothyroidism, Q80(EN) for myxedema coma, Q49(EN) Thyroiditis destructive, 32(EN), 32f(EN) Hashimoto, 33(EN), Q68(EN) multinodular goiters in, 37(EN) thyroid antibodies in, 28(EN) thyroid lymphoma in, 37(EN) postpartum, 30t(EN) radioactive iodine uptake scans in, 28(EN) silent, 32(EN) subacute, 32(EN) diagnosis of, Q52(EN) Thyroid lymphoma, diagnosis of, Q68(EN) Thyroid medications, perioperative management of, 126t(GIM) Thyroid nodules. See Nodules, thyroid Thyroid scans. See also Radioactive iodine uptake (RAIU) test contraindication in pregnancy, 39(EN) Thyroid-stimulating hormone in amiodarone-induced hypothyroidism, Q61(EN) deficiency of, 20(EN) in hypopituitarism, 19t(EN) in destructive thyroiditis, 32(EN), 32f(EN) in female infertility, 59(EN) hypothalamic production of, 17(EN) in hypothyroidism, 33(EN), 34t(EN) in myxedema coma, 40(EN) in nonthyroidal illness, 38(EN) normal range for, Q56(EN) in pregnancy, 38(EN) pregnancy and, 34(EN), Q4(EN) secretion of, 27(EN) serum level of, 27–28(EN), 27t(EN) in subclinical hyperthyroidism, 33(EN) suppression of, for thyroid cancer, 38(EN) in thyroid hormone replacement therapy, 34(EN) in thyroid nodules, 36(EN) in thyrotoxicosis, 29(EN), 29f(EN), 30(EN) Thyroid-stimulating hormone–secreting pituitary adenomas, 21(EN), 24t(EN), 26(EN), 29(EN), 30t(EN), Q28(EN) Thyroid storm, 39(EN), Q72(EN) Thyrotoxic myopathies, 76(NR) Thyrotoxicosis, 28(EN), 29–30(EN), 30t(EN) in destructive thyroiditis, 32f(EN) drug-induced, 32–33(EN) gestational, Q78(EN) in Graves disease, 30(EN) iodine exposure–induced, 31(EN)
62
low bone mass in, 68t(EN) radioactive iodine uptake scans in, 28(EN) types of, 29(EN), 29f(EN) Thyrotropin-binding inhibitory immunoglobulins, 28(EN) Thyrotropin-releasing hormone in hypothyroidism, 57(EN) secretion of, 17(EN), 27(EN) Thyroxine in central hypothyroidism, Q57(EN) in destructive thyroiditis, 32(EN), 32f(EN) in hypothyroidism, 33(EN), 34t(EN) in nonthyroidal illness, 38(EN) secretion of, 27(EN) serum level of, 27t(EN), 28(EN) in subclinical hyperthyroidism, 33(EN) in thyroid nodules, 36(EN) in thyroid-stimulating hormone deficiency, 20(EN) in thyrotoxicosis, 29f(EN) Thyroxine-binding hormone, 27(EN) Tic disorders, 48t(NR), 55(NR), Q54(NR) Tic douloureux. See Neuralgia, trigeminal Tick-borne diseases, 24–29(ID) babesiosis, 25t(ID), 27(ID), Q93(ID) coinfection among, Q93(ID) human granulocytic anaplasmosis, 25t(ID), 28(ID) human monocytic ehrlichiosis, 25t(ID), 28(ID) Lyme disease, 24–27(ID), 24f(ID), 25t(ID), 26f(ID), 27t(ID) rickettsial diseases, 25t(ID), 28f(ID), 28(ID), 61t(ID), 64–65(ID), Q87(ID) Rocky Mountain spotted fever, 25t(ID), 28f(ID), 28(ID) Southern tick-associated rash illness, 25t(ID), 27(ID) tularemia, 59–60(ID) Ticlopidine, colitis and, Q89(GA) Tidal volume, in acute respiratory distress syndrome, Q103(PM) Tigecycline, 98t(ID), 99(ID) for multidrug-resistant organisms, 83–84(ID) Tilt-table testing, for syncope, 47(GIM), Q31(GIM) Timed “Up and Go” (TUG) test, 117(GIM), Q78(GIM) TIMI risk score, 20(CV), 20t(CV), 21(CV), Q65(CV) Timolol, for migraine, 8(NR), 9(NR), Q83(NR) Tinea, 26–27(DM) vs. pityriasis rosea, 13(DM) Tinea corporis, 26(DM), 26f(DM), 65t(DM), Q53(DM) vs. nummular dermatitis, 7(DM) Tinea cruris, 26(DM) Tinea versicolor, 26–27(DM), 26f(DM), Q45(DM) Tinel sign, 62(GIM) Tinidazole, for giardiasis, 71(ID) Tinnitus, 101–102(GIM) pulsatile, 101(GIM), Q9(GIM) Tiotropium for asthma, 13–14(PM) for chronic obstructive pulmonary disease, 22t(PM), Q13(PM) TIPS. See Transjugular intrahepatic portosystemic shunt Tissue plasminogen activator, recombinant, for stroke, 29–30(NR), 32f(NR), Q15(NR), Q31(NR) contraindications to, 32t(NR) Tizanidine, for multiple sclerosis, 63(NR), 64(NR), Q63(NR) TNM classification, of cancer, 66–67(HO) Tocilizumab lipid complications of, Q34(RM) for rheumatic disease, 13t(RM) for rheumatoid arthritis, 14(RM), 20(RM) Todd paralysis, 14(NR) Toe-brachial index, 99(CV) Toenails. See Nails To Err is Human: Building a Safer Health System (Institute of Medicine), 19(GIM) Tolbutamide, 8t(EN) Tolvaptan for hyponatremia, 38(CV) for lithium toxicity, Q55(NP) Tongue, black hairy, 71–72(DM), 71f(DM) Tongue cancer, 88(HO) Tongue syndromes, 106(GIM) Tophi, 14(RM), 15(RM), 50f(RM), 52(RM) Topiramate adverse effects of, 19(NR), 19t(NR), 20t(NR), 21(NR) calcium phosphate kidney stones and, 29–30(NP) interaction with hormonal contraceptives, 21(NR) for migraine, 8(NR), 9(NR), Q75(NR), Q83(NR) teratogenicity of, 21(NR) Torsades de pointes, 51(CV), 58–59(CV) Torticollis, spasmodic, 53(NR), Q94(NR) Tositumomab, for lymphoma, 101(HO) Total hemolytic complement (CH50), 55(ID), 56(ID) Total lung capacity (TLC), 3(PM) in chronic obstructive pulmonary disease, 17f(PM) Tourette syndrome, 55(NR) Toxic epidermal necrolysis, 16(DM), 62–63(DM), 62t(DM), Q22(DM), Q36(DM) drug-related, 18–19(NR) Toxic megacolon, ulcerative colitis and, 35(GA), Q34(GA) Toxicology, 88–90(PM), 88t(PM), 89t(PM) anticholinergic syndromes, 88t(PM) antidotes, 89t(PM), 90(PM), 91t(PM) cholinergic syndromes, 88t(PM) myopathy, 77(NR), 77t(NR) opioid intoxication, 88t(PM), Q36(PM) sympathomimetic syndromes, 88t(PM) Toxic shock syndrome, 15–16(ID), 105(GIM) staphylococcal, 15(ID), 15t(ID) streptococcal, 15(ID), 16(ID) Toxoplasmosis, 53(ID) in HIV/AIDS, 91(ID), 92(ID) prophylaxis for, 89t(ID) in transplant recipients, 76(ID) Trachea, multinodular goiter impingement on, Q66(EN) Tracheal obstruction, flow-volume loops in, 2f(PM) Tracheostomy, for long-term ventilatory support, 74(PM) Trachonychia, 68f(DM) Traction alopecia, 66(DM)
Cumulative Index
Tramadol for low back pain, 52(GIM) for neuropathic pain, 73(NR) for noncancer chronic pain, 35(GIM), Q136(GIM) for osteoarthritis, Q23(RM) for rheumatic disease, 10(RM) Trandolapril, for heart failure, 33t(CV) Tranquilizers, for Alzheimer disease, 45(NR) Transferrin, in hemochromatosis, 36(HO) Transfusion-related acute lung injury, 40(HO), 41(HO) Transfusion-related circulatory overload, 40(HO) Transfusions, 36-42(HO). See also Blood transfusions; Platelet transfusions of cellular products, 36–39(HO), Q3(HO), Q14(HO) complications of, 38t(HO), 39–41(HO) of cryoprecipitate, 37t(HO), 39(HO) of erythrocytes, 5(HO), 31(HO), 36–38(HO), 37t(HO), 63(HO), Q7(HO), Q67(HO) of fresh frozen plasma, 36t(HO), 37t(HO), 39(HO), 46(HO), 58(HO) hypocalcemia in, 65(EN) indications for, 37t(HO) for intracranial bleeding, Q5(HO) of plasma products, 39(HO) of platelets, 37t(HO), 38–39(HO) Transient ischemic attacks, 24–26(NR), Q86(NR) anticoagulation therapy for, 37(NR), 38(NR), Q17(NR) characteristics of, 13t(NR) definition of, 24(NR) recurrent, 38–39(NR) Transitions in care, 20–21(GIM), 22t(GIM), Q94(GIM), Q113(GIM) Transjugular intrahepatic portosystemic shunt, 134(GIM) for Budd-Chiari syndrome, 70(GA) gastrointestinal bleeding and, 74(GA) for variceal bleeding, 62(GA) Transplant donors, infectious disease screening in, 73(ID) Transplant recipients, infections in, 72–76(ID) antirejection drugs and, 72–73(ID), 73t(ID) bacterial infections, 75(ID) fungal infections, 75–76(ID), Q105(ID) parasitic infections, 76(ID) posttransplantation infections, 73–76(ID) prevention of, 76(ID) viral infections, 75(ID) Transsphenoidal surgery, acromegaly treatment after, 25(EN), Q83(EN) Transthyretin, 27(EN) Transtubular potassium gradient (TTKG), 21(NP), Q44(NP) Transurethral resection of bladder tumors, 94(HO), 95(HO) of the prostate (TURP), 78(GIM) TRAPS, 54(ID) Trastuzumab adverse effects of, 110(HO), Q125(HO) for breast cancer, 68(HO), 73(HO), 74(HO) cardiotoxicity of, 104t(CV), 105(CV) for gastric cancer, 83(HO) Trauma as Parkinson disease risk factor, 47(NR) as psoriatic arthritis risk factor, 28(RM) as venous thromboembolism cause, 54(HO) Traumatic brain injury, 10–11(NR), 111(GIM) diabetes insipidus in, 20(EN) hypopituitarism in, 18(EN) in military personnel, 12(NR) Travelers’ diarrhea, 63–64(ID), 63t(ID) Travel medicine, 61–65(ID), 61t(ID) brucellosis, 65(ID) dengue fever, 64(ID) fungal infections, 65f(ID), 65(ID) hepatitis A, 64(ID) malaria, 61–62(ID), 61t(ID), 62t(ID), Q40(ID) rickettsial infections, 64–65(ID) travelers’ diarrhea, 61t(ID), 63–64(ID), 63t(ID), Q82(ID), Q97(ID) typhoid fever, 61t(ID), 63(ID), Q75(ID) Trazodone, for diffuse esophageal spasm, 5(GA) Treadmill stress testing. See Exercise stress testing Tremor, 48t(NR) drug-induced, 52–53(NR) essential, 52–53(NR) fragile X, 53(NR) vs. myoclonus, 54(NR) in Parkinson disease, 48(NR), 48t(NR), 50(NR), 52(NR), 53(NR) in Wilson disease, 56(NR) Tretinoin. See Retinoids Triamcinolone, intra-articular injections of, 10(RM) Triamcinolone acetonide, 3(DM) for keloids, Q50(DM) Triazole, for tinea versicolor, Q45(DM) Trichomonas vaginalis, 43(ID) Trichomoniasis, 92–93(GIM) Tricuspid regurgitation, 72t(CV), 76t(CV), Q55(CV) ventricular dysfunction and, 86(CV), Q8(CV) Tricuspid stenosis, 72t(CV) Tricuspid valve disease, 80–81(CV) Tricyclic antidepressants. See Antidepressants Trigeminal neuralgia. See Neuralgia, trigeminal Trigger finger, 2t(RM) Triglycerides, 63–64(GIM) in pleural effusions, 45(PM) Triiodothyronine in amiodarone-induced hypothyroidism, Q61(EN) in hypothyroidism, 33(EN), 34t(EN) in nonthyroidal illness, 38(EN) secretion of, 27(EN) serum levels of, 27t(EN), 28(EN) in subclinical hyperthyroidism, 33(EN) in thyroid nodules, 36(EN) in thyrotoxicosis, 29(EN), 29f(EN) Trimethoprim hyperkalemia and, Q76(NP) serum creatinine level and, 1(NP)
Trimethoprim-sulfamethoxazole for cellulitis, 24(DM), 25(DM) for cystitis, 30(ID), 30t(ID), Q36(ID) for human bites, 17(ID) for methicillin-resistant Staphylococcus aureus infections, Q56(ID) new uses for, 99(ID), 100t(ID), 101(ID) photodermatitis-exacerbating effect of, 61(DM) for Pneumocystis jirovecii pneumonia, 91(ID) for prostatitis, 31(ID) for purulent cellulitis, Q62(ID) side effects of, 100t(ID) skin eruptions due to, 14(DM), 15t(DM), 16(DM), 61(DM) for spontaneous bacterial peritonitis, 63(GA) for staphylococcal abscesses, 23(DM) use in cirrhosis, 70(GA) use in transplant recipients, 76(ID) for Wegener granulomatosis, 68(RM) Tripe palms, 59t(DM) Triptans contraindications to, 6–7(NR) for migraine, 6–7(RN), 7t(NR), Q58(NR) overuse of, as migraine cause, 6(NR) Trochanteric bursitis, 2t(RM), 58(GIM), Q76(RM) Tropheryma whipplei, 53(ID) Trophozoites, 72(ID) Troponin as cardiac biomarker, 19–20(CV) in chronic kidney disease, 86(NP) Trousseau sign, 64(EN) Trousseau syndrome, 81(HO) Tryptase, in asthma, 7(PM) Tubal ligation, 85t(GIM), 86(GIM) Tube feeding in Alzheimer disease, 73–74(NR) in stroke, 39(NR) Tuberculin skin testing, 32(ID), 33(ID), 33t(ID), 34(ID) in HIV/AIDS patients, 89(ID) in injection drug users, Q57(ID) Tuberculosis articular, 56(RM), 58(RM), Q36(RM) biologic agents and, 12(RM), 13t(RM), 14(RM) clinical manifestations of, 32(ID) diagnostic testing for, 32–34(ID), 33t(ID), 33t(ID) epidemiology of, 31–32(ID) extensively drug-resistant, 36(ID) false-positive PET scans in, 5(PM) fever of unknown origin in, 53(ID), 54(ID) in HIV/AIDS patients, 89(ID), 91(ID), 92(ID) hypercalcemia in, 61t(EN), 62–63(EN), Q5(EN) in immunocompromised patients, 39(GIM) latent, 31(ID) reactivation of, 32(ID), 75(ID) in transplant recipients, 76(ID) treatment of, 34(ID), Q2(ID) tuberculin skin testing in, 33(ID) multidrug-resistant, 36(ID) pathophysiology of, 32(ID) pleural effusion in, 43t(PM), 45(PM), Q14(PM) pleural fluid analysis in, 45(PM), Q14(PM) prevention of, 31(ID), 36(ID) primary progressive, 32(ID) prophylaxis for, 31(ID), 36(ID) in HIV/AIDS, 89t(ID) reactivation, 32(ID) in transplant recipients, 75(ID) reactivation, chest radiography in, 3(PM) screening for, Q12(ID) silicosis and, 42(PM), Q31(PM) in transplant donors, screening for, 73(ID) treatment of, 34–36(ID), 35t(ID), Q41(ID) directly observed, 36(ID) noncompliance with, 36(ID), Q41(ID) side effects of, Q44(ID) toxicity of, 35–36(ID) Tuberous sclerosis complex, 63t(NP), 64(NP), Q88(NP) Tuberous sclerosis complex (TSC) gene mutations, 38–39(PM) Tubulointerstitial disorders chronic, 44–48(NP) causes of, 45t(NP), 46–47(NP) clinical manifestations of, 44(NP), 44t(NP) diagnosis and evaluation of, 44–47(NP), 45t(NP) treatment of, 48(NP) urine protein-creatinine ratio in, 6–7(NP) Tularemia, as bioterrorism agent, 56t(ID), 59–60(ID) Tumor lysis syndrome, 15(RM), 73–74(NP), 109(HO), Q3(NP), Q128(HO) in acute lymphoblastic leukemia, 11–12(HO) in acute myeloid leukemia, 10(HO), 11(HO) Tumor lysis syndrome, hypocalcemia in, 65(EN) Tumor necrosis factor-α in adult-onset Still disease, 72(RM) in rheumatoid arthritis, 15(RM) Tumor necrosis factor-α inhibitors, 12–13(RM) adverse effects of, 12–13(RM), 39(RM) for ankylosing spondylitis, 33f(RM) for Behçet disease, 71(RM) as lupus erythematosus cause, 39(RM) for psoriasis, 11(DM) psoriasis-exacerbating effect of, 10(DM) for reactive arthritis, 34(RM) for rheumatic disease, 14(RM) for rheumatoid arthritis, 12–13(RM), 18(RM), 20(RM), Q75(RM) for spondyloarthritis, 33(RM), 34(RM) for Sweet syndrome, 60(DM) for Takayasu arteritis, 66(RM) Tumor necrosis factor receptor-associated periodic syndrome, 3(RM), 74t(RM) Tumor-necrosis factor receptor-1-associated periodic syndrome, 54(ID) Tumors. See also Cancer cardiac, 47–48(CV)
63
Cumulative Index
Turner syndrome, 57(EN), 89(CV), Q16(CV) with mosaicism, Q77(EN) TWEAK test, 17(GIM) 24-Hour urine free cortisol excretion test, for Cushing syndrome, 43(EN), 44–45(EN) Typhoid fever, 61t(ID), 63(ID), Q75(ID) Tyrosine kinase inhibitors, skin eruptions due to, 15t(DM) Uhthoff phenomenon, 58(NR), 61(NR) Ulcerative colitis chronic diarrhea in, 31t(GA) clinical manifestations of, 35(GA) colorectal cancer surveillance in, 50t(GA), Q9(GA) extraintestinal manifestations of, 36(GA), Q76(GA) risk factors for, 34(GA), 35(GA) toxic megacolon and, 35(GA), Q34(GA) vs. Crohn disease, 36(GA) Ulcers in anthrax, 57f(ID), 57(ID), 58(ID) aphthous, 70(DM), 71f(DM) in Crohn disease, 35–36(GA) in ulcerative colitis, 36(GA) arterial, 73–74(DM) atherosclerotic, 95(CV), 95f(CV), 96(CV) corneal, 95(GIM) diabetic foot, 16(EN), 17–18(ID), 51(ID) digital, in systemic sclerosis, 41–42(RM), 43(RM) gastric, corticosteroids and, 10t(RM) genital, 46–47(ID), 46t(ID) in Behçet disease, 4t(RM), 71f(RM), 71(RM), Q83(RM) chancroid, 48(ID), 48t(ID) herpetic, 46–47(ID) syphilitic, 47(ID), 48(ID) herpetic, 27–28(DM) leg, in peripheral arterial disease, 98t(CV) in lymphogranuloma venereum, 48(ID) in methicillin-resistant Staphylococcus aureus infections, 14(ID) nonhealing, hyperbaric oxygen therapy for, 102(ID) oral, 106(GIM) in Behçet disease, 4t(RM), 71f(RM), 71(RM), Q83(RM) in reactive arthritis, 31(RM) in systemic lupus erythematosus, 38t(RM) pressure, 123–124(GIM), 124t(GIM), Q17(GIM), Q24(GIM) rheumatoid vasculitis–related, 53(DM) spider bite–related, 32(DM), 32f(DM) Ulnar nerve, 56f(GIM) entrapment of, 56(GIM), Q132(GIM) Ultrafiltration, for decompensated heart failure, 38(CV) Ultrasonography for abdominal aortic aneurysm screening, 8(GIM), Q151(GIM) cardiac, in pulmonary hypertension, 53(PM) in deep venous thrombosis, 49(PM), Q94(PM) endobronchial, 5(PM) in metastatic lung cancer, 6f(PM), Q62(PM) in sarcoidosis, 38(PM) kidney, 9(NP), 9t(NP) in acute kidney injury, 67(NP), 72(NP) in chronic kidney disease, 81–82(NP), Q90(NP) in chronic tubulointerstitial disease, 44(NP), 46(NP) in hematuria, 9t(NP) in obstructive kidney injury, Q106(NP) renal, Q104(HO) in rheumatic disease, 8(RM) thyroid, in thyroid nodules, 36(EN) transrectal, in prostate cancer, 90(HO) transvaginal, in hyperandrogenism, Q62(EN) Ultraviolet light. See Sun exposure Ultraviolet light therapy for atopic dermatitis, 9(DM) for lichen planus, 12(DM) for pityriasis rosea, 14(DM) for psoriasis, 12f(DM) Underweight, 70t(GIM) United States Department of Health and Human Services, HIV/AIDS management guidelines from, 92(ID) United States Preventive Services Task Force calcium and vitamin D daily intake recommendation from, 69(EN) diabetes screening guidelines from, 2(EN) obesity management recommendations from, 72(GIM) screening recommendations from, 7(GIM), 7t(GIM), 8(GIM), 9(GIM), 10t(GIM), 11(GIM), 62(GIM), 64(GIM), 70(GIM), 106(GIM), 119(GIM), Q151(GIM) urinalysis recommendation from, 7(NP) Unna boot, 73(DM) Upper airway cough syndrome (UACS), 37(GIM), 37(GM), 38f(GIM) Upper airway disease, obstructive ventilatory failure in, 75(PM), 76(PM) Upper airway surgery, for obstructive sleep apnea, 66(PM) Upper respiratory tract infections, 103–105(GIM) cough in, 37(GIM) ear pain in, Q114(GIM) Urate crystals, 8(RM) Urate-lowering therapy, for gout, 10(RM), 14–15(RM), 51–52(RM), Q63(RM) Urease-splitting organisms, 3(NP), 75(NP) Uremia in acute kidney injury, 65(NP) as pericarditis cause, 63t(CV) platelet dysfunction in, 52(HO), 53(HO) Ureterojejunostomy, 21(NP) Ureteroscopy, of distal ureteral stones, 77(NP) Ureterosigmoidostomy, colorectal cancer and, 46(GA) Urethritis, 43(ID) complications of, 44(ID) in genital herpes simplex infections, 46(ID) gonococcal, 45t(ID), Q83(ID) in reactive arthritis, 29t(RM), 30(RM), 31(RM) treatment of, 45t(ID), Q83(ID) Urgencies/emergencies in cancer, 107–109(HO) dermatologic, 1–2(DM), 61–65(DM) Uric acid in gout, 48f(RM), 48(RM), Q79(RM) in polycythemia vera, 7(HO)
64
renal excretion of, 47(NP) in syndrome of inappropriate antidiuretic hormone secretion, 13(NP), 13t(NP) Uric acid kidney stones, 63(NP), 75(NP), 78t(NP), Q34(NP) Uric acid urinary crystals, 6t(NP) Uricase, for gout, 15(RM) Urinalysis in acute kidney injury, 66f(NP), 66(NP) in hematuria, Q18(NP) interpretation of, 2–9(NP) dipstick tests, 2–5(NP), 4t(NP) microscopy, 2(NP), 4t(NP), 5–6(NP), 5f(NP) in urinary tract infections, 29(ID) Urinary frequency, in multiple sclerosis, 63t(NR), 64(NR) Urinary incontinence. See Incontinence Urinary obstruction, acute kidney injury in, 67(NP), 72(NP), Q106(NP) Urinary tract, in pregnancy, 77(NP), 78(NP) Urinary tract infections, 29–31(ID) catheter-associated, 77–79(ID), 78t(ID), Q31(ID), Q32(ID) complicated, 29(ID), 99(ID) diagnosis of, 29–30(ID) epidemiology of, 29(ID) hematuria in, 7(NP) in kidney transplant recipients, 93(NP) management of, 30–31(ID), 30t(ID), 99(ID) microbiology of, 29(ID) in multiple sclerosis, 61(NR) nitrites in, 4–5(NP) postcoital, 30(ID), Q106(ID) recurrent, in women, 30–31(ID) uncomplicated, 29(ID) urinalysis in, 4–5(NP) Urinary urgency, in multiple sclerosis, 63t(NR), 64(NR) Urine anion gap in, 27–30(NP) brown-colored, 7(NP) microscopic analysis of, 2(NP), 4t(NP), 5–6(NP), 5f(NP) osmolal gap in, 27(NP) osmolality of in diabetes insipidus, 16(NP), 16t(NP), Q26(NP) in hypernatremia, 16(NP), 16t(NP) in hyponatremia, 12–13(NP) relationship with urine specific gravity, 4t(NP) pH of, 2–3(NP), 4t(NP) potassium excretion in, 18–19(NP) red-colored, 7(NP) specific gravity of, 2(NP), 4t(NP) relationship with urine osmolality, 4t(NP) tea-colored, 7(NP) Urine albumin-creatinine ratio, 16(EN) in chronic kidney disease, Q73(NP) in diabetic nephropathy, Q89(NP) in nephrotic syndrome, Q102(NP) Urine collection, 24-hour, Q28(NP) in chronic kidney disease, Q41(NP) in proteinuria, Q73(NP) Urine dipstick tests, 2–5(NP), 4t(NP) for urinary tract infections, 29(ID) Urine free cortisol excretion test, for Cushing syndrome, 43(EN), 44–45(EN) Urine osmolality, in diabetes insipidus, 20–21(EN) Urine output, in acute kidney injury, 66t(NP) Urine protein-creatinine ratio in autosomal dominant polycystic kidney disease, Q100(NP) in glomerular diseases, 6–7(NP) in hematuria, Q40(NP) in nephrotic syndrome, 48(NP) in tubulointerstitial disorders, 6–7(NP) Urine sodium excretion (UNa), in acute kidney injury, 66f(NP), 66(NP), 67t(NP) Urinothorax, 44t(PM) Urobilinogen, 5(NP) Uropathy, obstructive, 47(NP) Ursodeoxycholic acid, for primary biliary cirrhosis, 60(GA), Q93(GA) Urticaria, 44–45(DM), 44f(DM) acute, 44(DM), Q72(DM) in anaphylaxis, 85(PM) chronic, 44–45(DM) drug-related, 15t(DM) vasculitic, 52(DM) in vasculitis, 69(RM), Q64(RM) Ustekinumab, 14(RM) for psoriasis, 34(RM) for rheumatic disease, 13t(RM) Uterine bleeding, abnormal, 90(GIM), Q53(GIM) Uterine cancer, Peutz-Jeghers syndrome and, 47–48(GA) Uveitis, 95(GIM) anterior, Q91(RM) in Behçet disease, 70(RM) in rheumatic disease, 3(RM), 3t(RM), 5t(RM) in spondyloarthritis, 29t(RM) treatment for, 12(RM) in Wegener granulomatosis, 67(RM) Vaccines. See also Immunizations live-virus, contraindication in immunocompromised patients, 88(ID), Q14(ID) Vaginal estrogen therapy, 89(GIM), Q25(GIM) Vaginal symptoms, postmenopausal, 89(GIM), Q25(GIM) Vaginismus, 82(GIM), Q5(GIM) Vaginosis, bacterial, 92f(GIM), 92(GIM), Q111(GIM) Vagus nerve stimulation, for epilepsy, 21(NR) Valacyclovir for herpes simplex virus genital infections, 46t(ID) for herpes simplex virus infections, 96(ID), Q5(ID) for herpes zoster infections, 96(ID) Valgus stress test, 59f(GIM), 60f(GIM) Validity, threats to, 1(GIM), Q92(GIM) Valproic acid adverse effects of, 18–19(NR), 19t(NR), 20t(NR), 22(NR) hepatoxicity of, 57(GA), 58(GA) for neuropathic pain, 73(NR) teratogenicity of, 19(NR), 22(NR)
Cumulative Index
Valsalva maneuver as bradycardia cause, 49(CV) in cardiomyopathy-related heart murmurs, 41(CV), 43(CV), Q51(CV) as headache cause, 2(NR) in patent foramen ovale, 83(CV) for supraventricular tachycardia termination, 56(CV) Value, in healthcare, 5(GIM) Valvotomy balloon, for mitral stenosis, 79(CV) percutaneous, in pregnancy, 89(CV) Valvular heart disease, 70–83(CV) asymptomatic, 75(CV) diagnosis of, 71–75(CV), 72t–74t(CV) left-sided, 74t(CV) management of, 75–76(CV) pathophysiology of, 70–71(CV) prosthetic valve treatment for, 82–83(CV), 82t(CV) regurgitant severity in, 71(CV), 75(CV) in systemic lupus erythematosus, 37(RM) Valvular regurgitation acute, 76(CV) measurement of, 75f(CV) Valvuloplasty for aortic stenosis, 77(CV) balloon for aortic stenosis, 77(CV) for bicuspid aortic valve disease, 79(CV) for pulmonary valve stenosis, Q43(CV) Vancomycin for bacterial meningitis, 3–4(ID), 5t(ID), Q73(ID), Q96(ID) for Clostridium difficile infections, 70(ID), 70t(ID) for Staphylococcus aureus infections, 83(ID), Q50(ID) for Staphylococcus aureus pneumonia, Q50(ID) Vancomycin, nephrotoxicity of, 71(NP) Vancomycin-resistant organisms, antibiotic therapy for, 83(ID), 97–98(ID), 100(ID), Q101(ID) VAP. See Ventilator-associated pneumonia Vapreotide, for variceal bleeding, 62t(GA) Varenicline, 17(GIM) Variceal band ligation, for variceal bleeding, 61–62(GA), 62t(GA), 63t(GA) Varicella, 96f(ID), 96(ID) differentiated from smallpox, 58(ID) Varicella immunization, 12t(GIM), 13–14(GIM), 15(GIM), 16(GIM), 87(GIM), 96–97(ID), Q30(GA) Varicella zoster immune globulin, 97(ID), Q14(ID) Varicella-zoster virus, 96f(ID), 96(ID) Varicella-zoster virus immunization, in transplant recipients, 77t(ID) Varices, gastroesophageal, 70(GA) bleeding from, 61–62(GA), 62t(GA), 74–75(GA), 74(GA), Q75(GA) Varicocele, 79–80(GIM) Variola minor, 58(ID) Variola virus, 56t(ID), 58(ID). See also Smallpox Varus stress test, 59f(GIM), 59(GIM), 60f(GIM) Vascular disease, pulmonary. See Pulmonary vascular disease Vascular disorders end-stage liver disease and, 66–67(GA) hepatic, 70–71(GA) vs. multiple sclerosis, 60t(NR) noncompressive myelopathy and, 67(NR) in Sjögren syndrome, 46t(RM) Vascular endothelial growth factor inhibitors, 69(HO) Vascular endothelin growth factor-D (VEGF-D), in lymphangioleiomyomatosis, 39(PM) Vascular insufficiency, in Takayasu arteritis, 65(RM), 66(RM) Vasculitis, 62–70(RM) acute onset, 32t(PM) antineutrophil cytoplasmic antibodies (ANCA)-associated, 67–69(RM), Q11(NP), Q39(RM) in Behçet disease, 70–71(RM) bowel, 60(RM) cryoglobulinemic, 57(DM), 61(NP), 62(NP), 63t(RM), 69(RM), 70(RM), Q30(DM), Q48(RM) cutaneous leukocytoclastic, 69–70(RM), 70f(RM) cutaneous small vessel (CSVV), 52–53(DM) dermatologic disorders in, 4t(RM) differential diagnosis of, 63t(RM) eye disorders in, 5t(RM) large-vessel, 63t(RM), 64–66(RM) medium-sized vessel, 63t(RM), 66–67(RM) rheumatoid, 18(RM), 53(DM) small- and medium-vessel, 61(NP) small-vessel, 63t(RM), 67–70(RM) stroke and, 26(NR) urticarial, 52(DM), 69(RM), Q14(DM), Q64(RM) Vasectomy, 85t(GIM) Vasoactive agents, for cardiogenic shock, 38(CV), 39t(CV) Vasoactive intestinal polypeptide-secreting tumors, 29(GA), 29t(GA) Vasodilator nuclear perfusion, 5t(CV) Vasodilators for acute respiratory distress syndrome, 71–72(PM), 71t(PM) for chronic obstructive pulmonary disease, 25(PM) for heart failure, 33t(CV), 34–35(CV) for hypertensive crises, 86t(PM) for pulmonary hypertension, 53(PM) Vasomotor symptoms, of menopause, 88–89(GIM), 89t(GIM), Q60(GIM) Vasopressin for cardiogenic shock, 39t(CV) clinical use and physiologic effects of, 77t(PM) in pregnancy, 77(NP) Vasopressin deficiency, in hypopituitarism, 19t(EN) Vasopressin receptor antagonists for autosomal dominant polycystic kidney disease, 63(NP) for hyponatremia, 14(NP), 15t(NP), 38(CV) Vasopressors adverse effects of, 77(PM) for anaphylaxis, 85(PM) for septic shock, 83(PM), Q106(PM) for shock, 77(PM), 77t(PM), Q10(PM) Vasospasm, cerebral, 33(NR), Q36(NR) Vasospastic (Prinzmetal) angina, 16–17(CV), 19(CV) Vaughan-Williams classification, of antiarrhythmic medications, 51–52(CV), 51t(CV) Vegetarians, urine pH in, 3(NP) Vemurafenib, for melanoma, 107(HO)
Vena cava filters, for venous thromboembolism, 61–62(HO) Vena cava syndrome, 86(HO) Venipuncture, in chronic kidney disease patients, 90(NP), Q32(NP) Venlafaxine, for neuropathic pain, 73(NR) Venom, as hemolytic anemia cause, 35(HO) Venous access, catheter insertion techniques in, 81(ID) Venous insufficiency chronic, Q38(DM) in stasis dermatitis, 7–8(DM) Venous stasis, as edema cause, 50(GIM), Q22(GIM) Venous stasis dermatitis. See Stasis dermatitis Ventilation/perfusion (V/Q) lung scans in pulmonary embolism, 49(PM) in pulmonary hypertension, 53(PM), Q105(PM) Ventilator-associated lung injury, 81(PM), 82(PM) Ventilator-associated pneumonia, 81–82(PM), 82–83(ID), 82t(ID), Q81(ID), Q101(ID) Ventilators. See also Mechanical ventilation care bundles for, 94t(PM) Ventricular arrhythmias, 57–58(CV) Ventricular assist devices, 38(CV), 40(CV), 41(CV) for peripartum cardiomyopathy, 107(CV) Ventricular dysfunction in pregnancy, anticoagulants for, 110t(CV) tricuspid regurgitation and, Q8(CV) Ventricular fibrillation, 59t(CV), 60(CV), Q118(CV) Ventricular hypertrophy, 74(CV) in heart failure, 31(CV) in hypertrophic cardiomyopathy, 41(CV) Ventricular pacing, Q92(CV) Ventricular preexcitation, Q92(CV) Ventricular remodeling, 70(CV) Ventricular septal defects, 73t(CV), 84(CV), 85–88(CV), 86t(CV) asymptomatic, Q66(CV) pathophysiology of, 85–87(CV) post-myocardial infarction, 27t(CV), Q44(CV) tetralogy of Fallot and, 90(CV), 91(CV) Ventricular systolic dysfunction, in pregnancy, 107(CV) Ventricular tachycardia, 50(CV), 51(CV) catecholaminergic polymorphic, 59t(CV), 60(CV) post-myocardial infarction, 26(CV) Verapamil for arrhythmias, 51t(CV) hyperprolactinemia and, 22(EN) for hypertrophic cardiomyopathy, 43(CV) in pregnancy, 109t(CV) for restrictive cardiomyopathy, 47(CV) for reversible cerebral vasoconstriction syndrome, 3(NR), 4(NR) Verbal tics, 55(NR) Vertebral artery dissection, stroke and, 36(NR) Vertigo, 40–43(GIM) benign paroxysmal positional, 41(GIM), 42f(GIM), 43(GIM), Q14(GIM), Q20(GIM), Q98(GIM) central, 41t(GIM), 43(GIM), Q14(GIM), Q50(GIM) characteristics of, 13t(NR) peripheral, 41(GIM), 41t(GIM), 42f(GIM), 43(GIM), Q14(GIM), Q98(GIM) Very-low-density lipoprotein (VLDL) cholesterol, 63(GIM) Viability testing, 7t(CV), 8(CV) Vibrio cholerae, as bioterrorism agent, 56(ID) Vibrio vulnificus infections, necrotizing fasciitis in, 14f(ID), 14(ID) Video electroencephalography monitoring in epilepsy, 17–18(NR) in psychogenic nonepileptic seizures, Q71(NR) in status epilepticus, 23(NR) Videofluoroscopy, for oropharyngeal dysphagia, 3(GA), Q79(GA) Vigabatrin, adverse effects of, 19t(NR), 20t(NR) Vildagliptin, 9t(EN) VIPomas, 29(GA), 29t(GA) Viral disease, vs. transverse myelitis, 66(NR) Viral hemorrhagic fever, as bioterrorism agent, 56t(ID), 60–61(ID), 60t(ID) Viral infections, 94-101(ID). See also specific viruses as arthritis cause, 56–57(RM), 58(RM) cutaneous, 27–31(DM) as neutropenia cause, 4(HO) as polyarthritis cause, 2(RM) as thrombocytopenia cause, 47(HO) Virchow triad, 47f(PM), 53(HO) Virilization, hirsutism in, 58(EN) Visual acuity test, 119(GIM) Visual field deficits, pituitary tumors and, 21(EN) Visual impairment, in older adults, 119(GIM) Vital capacity (VC), in neuromuscular weakness-related respiratory failure, Q59(PM) Vitamin A, for chronic pancreatitis, 26(GA) Vitamin A deficiency after bariatric surgery, 22t(GA) in cirrhosis, 70(GA) Vitamin B12, in polycythemia vera, 7(HO) Vitamin B12 deficiency, 21–23(HO), 22f(HO), Q64(HO), Q71(HO) after bariatric surgery, 22(GA), 22t(GA), 74(GIM), 74t(GIM), Q15(GIM) anemia in, 4(HO) atrophic glossitis and, 106(GIM) dementia and, 42t(NR) vs. multiple sclerosis, 60t(NR) noncompressive myelopathy and, 67(NR) in older adults, Q28(HO) pancytopenia in, 4(HO) in small intestinal bacterial overgrowth, Q55(GA) thrombocytopenia in, 52(HO) Vitamin C deficiency, 51(DM) Vitamin D, recommended daily intake of, 66t(EN), 69(EN), Q17(EN) Vitamin D analogues, for psoriasis, 11t(DM), 12f(DM) Vitamin D deficiency after bariatric surgery, 22(GA), 22t(GA) in alcohol abuse, Q75(EN) in chronic kidney disease, 87(NP), 88(NP), 89(NP), Q101(NP) in cirrhosis, 70(GA) diagnosis of, Q22(EN) hypocalcemia in, 61f(EN), 64t(EN), 65(EN) multiple sclerosis and, 61(NR) myopathy and, 76(NR) osteomalacia in, 72(EN)
65
Cumulative Index
Vitamin D supplementation with corticosteroids, 10(RM), 11(RM) for older adults, 118(GIM), Q87(GIM) for osteoporotic fracture prevention, 69(EN) Vitamin E for Alzheimer disease, 44(NR) for chronic pancreatitis, 26(GA) for Parkinson disease, 50(NR) Vitamin E deficiency after bariatric surgery, 22t(GA) in cirrhosis, 70(GA) vs. multiple sclerosis, 60t(NR) Vitamin K antagonists, 58(HO). See also Warfarin Vitamin K deficiency, 46–47(HO), 55(HO) Vitiligo, 77–78(DM), 78f(DM) in autoimmune Graves hyperthyroidism, Q78(EN) in diabetes mellitus, 60(DM) Vocal cord dysfunction asthma and, 10(PM), 11f(PM) differentiated from asthma, 8t(PM), Q35(PM) flow-volume loops in, 10(PM), 11f(PM), Q22(PM) Vocal cord paralysis, in thyroid cancer, 35(EN) Vocal cords, paradoxical motion of, 75(PM) Vocal cord visualization, for multinodular goiter diagnosis, 37(EN) Vocal tics, 55(NR) Voglibose, 8t(EN) Volume overload in chronic kidney failure, Q58(CV) in decompensated heart failure, 38(CV) Volume resuscitation, for shock, 77(PM), 78(PM), Q10(PM) von Hippel-Lindau gene mutations, in renal cell carcinoma, 96(HO) von Willebrand disease, 45–46(HO), 52(HO), Q21(HO), Q44(HO) von Willebrand factor, 42(HO), Q44(HO) in pregnancy, 65(HO) Voriconazole for aspergillosis, 40(ID), Q108(ID) skin eruptions due to, 15t(DM) V sign, of dermatomyositis, 4t(RM), 59(RM) Vulvar dermatoses, treatment of, 3(DM) Waldenström macroglobulinemia, 13(HO), 17(HO), Q63(HO) Walk test, 6-minute, 3(PM) Warfarin adverse effects of, 58(HO), Q34(HO) for aortic atheromas, 96(CV) for atrial fibrillation, 53t(CV), 54(CV), Q52(CV) drug interactions of, 58t(HO) for dural sinus venous thrombosis, 35f(NR), 35(NR) gastrointestinal bleeding and, Q12(GA) for hypertrophic cardiomyopathy, 44(CV) international normalized ratio (INR) of, 58(HO), 61(HO), Q24(HO), Q29(HO) perioperative management of, 126t(GIM), 129–130(GIM), 131t(GIM), 132(GIM), Q142(GIM) pre- and postoperative bridging guidelines for, 60t(HO) in pregnancy, 107(CV), 108–109(CV), 110t(CV), 111(CV), Q34(HO), Q49(CV) for prosthetic valves, 82–83(CV) for pulmonary embolism, 50(PM), 50t(PM), 51(PM) reversal of, 39(HO), 58(HO), 59t(HO), Q74(HO) for stroke, 37(NR), 38(NR) teratogenicity of, 109(CV) for venous thromboembolism, 58(HO), 61(HO), Q12(HO), Q24(HO), Q29(HO) vitamin K deficiency and, 47(HO) Warts common, 30(DM), 30f(DM) flat, 30(DM), Q28(DM) genital, 30(DM), 30f(DM), 48–49(ID) Wasp stings, 31(DM) as hemolysis cause, 35(HO) Water, purification of, 63(ID) Waterborne disease cryptosporidiosis, 72(ID) giardiasis, 55(ID), 66(ID), 66t(ID), 71(ID), Q98(ID) Water deficit equation, for hypernatremia, 16–17(NP) Water deprivation test, for diabetes insipidus, 21(EN) Water intake, inadequate, hypernatremia in, 15(NP) Water loss, pure, hypernatremia and, 15(NP), 16t(NP) Water retention, in pregnancy, 78(NP) Weakness in Guillain-Barré syndrome, 72(NR) in inflammatory myopathies, 58–59(RM) intensive care unit–acquired, 93(PM) in myasthenia gravis, 74(NR) in myopathy, 76(NR), 77(NR) in peripheral neuropathy, 68(NR), 69t(NR) in rheumatoid arthritis, 17t(RM) Weaver’s bottom, 2t(RM) Weber test, 100(GIM) Wegener granulomatosis, 3(RM), 5t(RM), 61(NP), 62(NP), 63t(RM), 67–68(RM), 67f(RM), 104(GIM), Q44(RM), Q92(NP), Q138(GIM) Weight gain, medication-related, 70t(GIM) Weight loss in chronic mesenteric ischemia, 44(GA) chronic obstructive pulmonary disease and, 19(PM) in colorectal cancer, 42(GA) for diabetes mellitus control, 6–7(EN) for diabetes mellitus prevention, 4–5(EN), 4t(EN) for gastroesophageal reflux disease, 7(GA) in hyperglycemia, 12(EN) for hypertension management, 39(NP), 40(NP), Q1(NP) for nonalcoholic steatohepatitis, 58(GA), Q2(GA) for obesity control, 71(GIM), Q51(GIM) for obstructive sleep apnea, 66(PM) for osteoarthritis, 24(RM), Q8(RM) for polycystic ovary syndrome, 58(EN) in small intestinal bacterial overgrowth, Q55(GA) Weight loss surgery. See Bariatric surgery Wells Clinical Deep Venous Thrombosis Model, 57t(HO) Wells Prediction Score, for pulmonary embolism diagnosis, 47(PM), 48t(PM), Q79(PM) Wernicke-Korsakoff syndrome, 22(GA) Westermark sign, 49(PM) Western blot assay for HIV/AIDS diagnosis, 87(ID), 88(ID)
66
for Lyme disease, 25t(ID), 26(ID) Western Ontario and McMaster Universities Osteoarthritis Index, 9(RM) West Haven Criteria, for hepatic encephalopathy classification, 63(GA), 64t(GA) West Nile virus immunoglobulin M antibody test, Q19(ID) West Nile virus infection, 1(ID) encephalitis in, 8(ID), 9t(ID), 10(ID) myelitis in, Q19(ID) transfusion-related transmission of, 40(HO) Wheals, 44(DM) Wheezing in anaphylaxis, 85(PM) in asthma, 7(PM), 8(PM), 9(PM) in diffuse parenchymal lung disease, 30–31(PM) in high-altitude pulmonary edema, 69(PM) Whipple disease, 5(RM), 31t(GA), 32(GA) Whipple triad, 17(EN) Whiteheads, 18(DM) White matter lesions, in multiple sclerosis, 57(NR), 59(NR) Whitlow, herpetic, 95(ID) Whooping cough. See Pertussis Wickham striae, 11(DM), 13f(DM), 70(DM), 70f(DM) Wilson disease, 49(NR), 53(NR), 55–56(NR), 59(GA) fulminant, 59(GA), Q82(GA) as hemolysis cause, 35(HO) liver chemistry studies in, 53t(GA) parkinsonism in, 56(NR), Q72(NR) tremor in, 56(NR) Winter itch, 7(DM) Withholding/withdrawing, of treatment, 25(GIM), Q43(GIM) Wolff-Parkinson-White syndrome, 53(CV), 56–57(CV) Women’s health, 81–93(GIM) abnormal uterine bleeding, 90(GIM), Q53(GIM) breast cancer, 84(GIM) breast masses, 82–84(GIM), 83t(GIM) breast pain, 84(GIM) cardiovascular disease, 29–30(CV), Q22(CV) cardiovascular disease risk assessment, 30(CV), Q45(CV) cardiovascular disease risk management, 30(CV), Q32(CV), Q45(CV) chest pain, 15t(CV) chronic pelvic pain, 91–92(GIM), 91t(GIM) contraception, 84–86(GIM) coronary artery disease risk, 12(CV) dysmenorrhea, 90–91(GIM) hypertension treatment, 43(NP) kidney function measurement in, 1(NP) menopause, 87–89(GIM), 89t(GIM) peritoneal carcinomatosis in, 105(HO) postpartum depression, 109(GIM) preconception counseling, 86–87(GIM), 87t(GIM) premenstrual dysphoric disorder, 109(GIM) sexual dysfunction, 81–82(GIM), 81t(GIM), 88(GIM), 89(GIM), Q5(GIM), Q147(GIM) Takayasu arteritis, Q79(CV) takotsubo cardiomyopathy, 40(CV) vaginitis, 92–93(GIM) von Willebrand disease, 45(HO), 46(HO) Women’s Health Initiative, 88(GIM) Worker’s compensation, for occupational lung disease, 40(PM) World Health Organization, analgesic ladder of, 29–30(GIM), 29f(GIM), 35(GIM) World Health Organization Classification of acute myeloid leukemia, 10(HO), 10t(HO) of lymphoma, 99t(HO) of myelodysplastic syndromes, 5(HO), 5t(HO) Wound care for burns, 34(DM) for lacerations, 33–34(DM), 34f(DM), Q69(DM) Wound healing, hyperbaric oxygen therapy for, 101–102(ID) Wright stains, 5(NP) Wrinkles, corticosteroid-related, 3(DM), 3f(DM), 4(DM) Wrist overuse syndromes of, 2t(RM) rheumatoid arthritis of, 16(RM) in sarcoidosis, 75(RM) in systemic lupus erythematosus, 35–36(RM) Wrist pain, 57(GIM) Writer’s cramp, 53(NR) Xanthine oxidase inhibition, for gout, 52(RM) Xerophthalmia, 97–98(GIM), Q44(GIM) Xerosis. See Dry skin Xerostomia, 105(GIM), 106(GIM) gastroesophageal reflux disease and, 7(GA) Xerotic (asteatotic) eczema, 7(DM), 7f(DM) X-linked adrenoleukodystrophy, 67(NR) X-rays, chest. See Chest radiography Yergason test, 54(GIM), 54t(GIM), 55f(GIM) Yersinia enterocolitica, as yersiniosis causal agent, 69(ID) Yersinia infections as reactive arthritis cause, 5(RM), 30–31(RM), 32(RM) transfusion-related transmission of, 40(HO) Yersinia pestis, as plague causal agent, 56t(ID), 58–59(ID), 69(ID) Yersinia pseudotuberculosis, as yersiniosis causal agent, 69(ID) Yersiniosis, 69(ID) Zafirlukast, for asthma, 14(PM) Zaleplon, for insomnia, 44(GIM), 45t(GIM), Q153(GIM) Zanamivir, 95(ID) Zidovudine, use in pregnancy, 94(ID), Q54(ID) Zileuton for asthma, 13f(PM), 14(PM) hepatotoxicity of, 14(PM) Zinc deficiency, in cirrhosis, 70(GA) Zoledronate for hypercalcemia, 63(EN) for osteoporosis, 69(EN), 70(EN), 70t(EN) Zolmitriptan for cluster headache, 10(NR) for migraine, 7t(NR) Zolpidem, for insomnia, 44(GIM), 45t(GIM), Q153(GIM) Zonisamide, adverse effects of, 19(NR), 19t(NR), 20t(NR), Q51(NR) Zygomycosis. See Mucormycosis